In the USA and Taiwan, afatinib is approved for use in patients with distinct types of NSCLC. Afatinib is under regulatory review by the EMA and by health authorities in other countries; afatinib is not yet approved in Australia.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONFERENCE SUPPORTERS</td>
<td>2</td>
</tr>
<tr>
<td>SCHEDULE OF ACTIVITIES</td>
<td>9</td>
</tr>
<tr>
<td>WELCOME MESSAGES</td>
<td>11</td>
</tr>
<tr>
<td>IASLC AND LOCAL ORGANIZING COMMITTEE</td>
<td>11</td>
</tr>
<tr>
<td>LUNG FOUNDATION AUSTRALIA</td>
<td>12</td>
</tr>
<tr>
<td>HEALTH MINISTER NEW SOUTH WALES</td>
<td>13</td>
</tr>
<tr>
<td>LORD MAYOR OF SYDNEY</td>
<td>14</td>
</tr>
<tr>
<td>INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER</td>
<td>15</td>
</tr>
<tr>
<td>CONTACT INFORMATION</td>
<td>15</td>
</tr>
<tr>
<td>IASLC BOARD 2011-2013</td>
<td>15</td>
</tr>
<tr>
<td>IASLC BOARD 2013-2015</td>
<td>15</td>
</tr>
<tr>
<td>COMMITTEES</td>
<td>16</td>
</tr>
<tr>
<td>LOCAL ORGANIZING COMMITTEE</td>
<td>16</td>
</tr>
<tr>
<td>CORE PROGRAM COMMITTEE</td>
<td>17</td>
</tr>
<tr>
<td>INTERNATIONAL SCIENTIFIC ABSTRACT REVIEW COMMITTEE</td>
<td>18</td>
</tr>
<tr>
<td>REGISTRATION INFORMATION</td>
<td>20</td>
</tr>
<tr>
<td>PRESS AND MEDIA</td>
<td>22</td>
</tr>
<tr>
<td>PRESS CONFERENCE</td>
<td>22</td>
</tr>
<tr>
<td>MEDIA ROOM</td>
<td>22</td>
</tr>
<tr>
<td>DAILY NEWSPAPER</td>
<td>22</td>
</tr>
<tr>
<td>HIGHLIGHT OF THE DAY EBLAST</td>
<td>22</td>
</tr>
<tr>
<td>SOCIAL MEDIA (TWITTER, FACEBOOK)</td>
<td>22</td>
</tr>
<tr>
<td>ONSITE SERVICES AND GENERAL INFORMATION</td>
<td>23</td>
</tr>
<tr>
<td>EXHIBIT INFORMATION</td>
<td>28</td>
</tr>
<tr>
<td>EXHIBITOR LISTING</td>
<td>30</td>
</tr>
<tr>
<td>EXHIBIT FLOOR PLAN</td>
<td>31</td>
</tr>
<tr>
<td>AWARDS</td>
<td>32</td>
</tr>
<tr>
<td>IASLC DISTINGUISHED AWARDS</td>
<td>32</td>
</tr>
<tr>
<td>IASLC YOUNG INVESTIGATOR AWARDS</td>
<td>37</td>
</tr>
<tr>
<td>IASLC PATIENT ADVOCACY AWARDS</td>
<td>37</td>
</tr>
<tr>
<td>IASLC GLOBAL MENTORSHIP AWARD</td>
<td>37</td>
</tr>
<tr>
<td>WCLC 2013 FELLOWSHIP AWARDS</td>
<td>38</td>
</tr>
<tr>
<td>WCLC 2013 DEVELOPING NATION AWARDS</td>
<td>38</td>
</tr>
<tr>
<td>WCLC 2013 LECTURESHP AWARDS</td>
<td>39</td>
</tr>
<tr>
<td>SIMON CHAN SHANG WHAI - IASLC - LFA CANCER RESEARCH TRAVEL AWARDS</td>
<td>39</td>
</tr>
<tr>
<td>TABS</td>
<td></td>
</tr>
<tr>
<td>CONFERENCE PROGRAM</td>
<td>40</td>
</tr>
<tr>
<td>SOCIAL EVENTS</td>
<td>40</td>
</tr>
<tr>
<td>SPECIAL EVENTS AND SESSIONS</td>
<td>42</td>
</tr>
<tr>
<td>HANDS ON TRAINING SESSIONS</td>
<td>44</td>
</tr>
<tr>
<td>INDUSTRY SUPPORTED SYMPOSIA</td>
<td>45</td>
</tr>
<tr>
<td>INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS</td>
<td>46</td>
</tr>
<tr>
<td>CME ACCREDITATION INFORMATION</td>
<td>48</td>
</tr>
<tr>
<td>SCIENTIFIC PROGRAM</td>
<td>49</td>
</tr>
<tr>
<td>SATURDAY, OCTOBER 26, 2013</td>
<td>49</td>
</tr>
<tr>
<td>SUNDAY, OCTOBER 27, 2013</td>
<td>49</td>
</tr>
<tr>
<td>MONDAY, OCTOBER 28, 2013</td>
<td>53</td>
</tr>
<tr>
<td>TUESDAY, OCTOBER 29, 2013</td>
<td>73</td>
</tr>
<tr>
<td>WEDNESDAY, OCTOBER 30, 2013</td>
<td>93</td>
</tr>
<tr>
<td>POSTER SESSIONS</td>
<td>107</td>
</tr>
<tr>
<td>SUNDAY, OCTOBER 27, 2013</td>
<td>107</td>
</tr>
<tr>
<td>MONDAY, OCTOBER 28, 2013</td>
<td>111</td>
</tr>
<tr>
<td>TUESDAY, OCTOBER 29, 2013</td>
<td>139</td>
</tr>
<tr>
<td>WEDNESDAY, OCTOBER 30, 2013</td>
<td>167</td>
</tr>
<tr>
<td>AUTHOR INDEX</td>
<td>193</td>
</tr>
</tbody>
</table>

---

**Found in the FOLD OUT SECTION at the back of this program book:**

- CONVENTION CENTRE MAPS
- PROGRAM AT A GLANCE
- SESSIONS BY TRACK
- SESSION OVERVIEW
- CONFERENCE EVALUATION FORM
IASLC and the 15th World Conference on Lung Cancer would like to sincerely thank the following organizations for their generous support:

**PLATINUM SPONSOR**

- Lilly
- Boehringer Ingelheim

**SILVER SPONSOR**

- Bristol-Myers Squibb
- Roche

**BRONZE SPONSOR**

- Pfizer
- Destination NSW
- AstraZeneca
- Celgene

**SUPPORTER**

- NSW Government
- Novartis Oncology
- Life Technologies
- Teva Pharmaceuticals
- Peregrine Pharmaceuticals

**CONTRIBUTOR**

- GlaxoSmithKline
- Myriad
- Clovis Oncology
- Abbott Molecular
- City of Sydney
- Amgen Oncology
- GTx
- Astex Pharmaceuticals
IASLC and the 15th World Conference on Lung Cancer would like to sincerely thank the following organizations for providing medical educational grants:

THANK YOU

IASLC
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

CONFERENCE SECRETARIAT
International Conference Services Ltd.
Suite 2101–1177 West Hastings Street
Vancouver, BC, Canada V6E 2K3
Phone +1 604 681 2153
Fax +1 604 681 1049
Email wclc2013@icsevents.com
www.icsevents.com
Join us at World Conference on Lung Cancer 2013
October 27 - October 30 at Booth 1210 to learn more
about Immuno-Oncology research in multiple tumor types.
What if you could use the body’s own T cells to combat Lung Cancer?

With Immuno-Oncology it may be possible.

Current approaches to lung cancer treatment include radiation, surgery and chemotherapy/targeted therapy, all of which are intended to target the tumor. Through our ongoing clinical program, BMS is investigating an entirely new way to treat lung cancer by targeting the immune system. Our research is focused on transforming the way tumor cells and the immune system communicate, including checkpoint pathways; we hope to find new ways to stop lung cancer from evading the immune system, thereby restoring the body’s natural ability to fight it.

2014 REGIONAL MEETINGS

IASLC 6th Latin American Conference on Lung Cancer
AUGUST 21–23 2014 • LIMA, PERU

LALCA.IASLC.ORG

2014 CHICAGO MULTIDISCIPLINARY SYMPOSIUM in THORACIC ONCOLOGY
October 31–November 2, 2014
Chicago Marriott Downtown Magnificent Mile
Chicago, IL, USA

CO-SPONSORED BY:
ASC0
IASLC
ASTRO

www.thoracicsymposium.org

APLCC
2014 IASLC Asia Pacific Lung Cancer Conference
6 - 8 November 2014
Kuala Lumpur

www.aplcc2014.com
Onsite Registration Hours

PARKSIDE HALL 6, GROUND LEVEL

- Saturday, October 26 14:00 – 18:00
- Sunday, October 27 06:00 – 20:00
- Monday, October 28 06:00 – 17:00
- Tuesday, October 29 06:00 – 17:00
- Wednesday, October 30 06:00 – 17:00

Exhibit Hours

EXHIBITION CENTRE, HALLS 4 + 5, GROUND LEVEL

- Sunday, October 27 20:15 – 21:30 Welcome Reception
- Monday, October 28 09:30 – 16:30
- Tuesday, October 29 09:30 – 16:30
- Wednesday, October 30 09:30 – 16:30

Speaker Ready Room

PARKSIDE G04, GROUND LEVEL

- Saturday, October 26 14:00 – 18:00
- Sunday, October 27 06:00 – 20:00
- Monday, October 28 06:00 – 17:00
- Tuesday, October 29 06:00 – 17:00
- Wednesday, October 30 06:00 – 17:00

IASLC Business Meeting

Monday, October 28 07:00 – 08:00

IASLC Radiotherapy PARKSIDE AUDITORIUM, LEVEL 1

Simultaneous Translation

English > < Mandarin provided

- Novartis 07:00 – 08:00 PARKSIDE BALLROOM B, LEVEL 1
- Boehringer Ingelheim 12:15 – 13:45 BAYSIDE AUDITORIUM B, LEVEL 1
- Roche 18:00 – 19:30 PARKSIDE AUDITORIUM, LEVEL 1

Industry Supported Symposia

Sunday, October 27

- Boehringer Ingelheim 12:00 – 13:30 BAYSIDE AUDITORIUM A, LEVEL 1
- AstraZeneca 14:00 – 15:30 PARKSIDE AUDITORIUM, LEVEL 1
- Pfizer 16:00 – 17:30 PARKSIDE BALLROOM A+B, LEVEL 1

Monday, October 28

- Boehringer Ingelheim 07:00 – 08:00 PARKSIDE AUDITORIUM, LEVEL 1
- Peregrine Pharmaceuticals 07:00 – 08:00 PARKSIDE BALLROOM B, LEVEL 1
- Celgene 07:00 – 08:00 PARKSIDE BALLROOM A, LEVEL 1
- Myriad 07:00 – 08:00 PARKSIDE 110 A+B, LEVEL 1
- Lilly Oncology 12:15 – 13:45 BAYSIDE AUDITORIUM B, LEVEL 1
- Novartis 07:00 – 08:00 PARKSIDE BALLROOM B, LEVEL 1
- Roche 18:00 – 19:30 PARKSIDE AUDITORIUM, LEVEL 1

Tuesday, October 29

- IASLC Radiotherapy 07:00 – 08:00 PARKSIDE AUDITORIUM, LEVEL 1
- Boehringer Ingelheim 12:15 – 13:45 BAYSIDE AUDITORIUM B, LEVEL 1
- Roche 18:00 – 19:30 PARKSIDE AUDITORIUM, LEVEL 1
**Wednesday, October 30**

IASLC Radiotherapy  
07:00 – 08:00  
PARKSIDE AUDITORIUM, LEVEL 1

Simultaneous Translation  
English => Mandarin provided

BMS  
12:15 – 13:45  
PLENARY HALL, GROUND LEVEL

**Hands On Training Sessions**

**Sunday, October 27**

Abbott  
10:00 – 15:00  
Molecular Diagnosis of Gene Fusions by FISH for Targeted Therapy  
PARKSIDE 110 A+B, LEVEL 1

Covidien/Superdimension  
12:30 – 16:00  
Introduction to Electromagnetic Navigation Bronchoscopy  
BAYSIDE GALLERY B, LEVEL 1

**Scientific Sessions**

**Sunday, October 27**

Inaugural Cochrane Workshop  
07:30 – 12:00  
BAYSIDE 204 A+B, LEVEL 2

Chinese Alliance Against Lung Cancer Session  
07:30 – 12:00  
PARKSIDE AUDITORIUM, LEVEL 1

Simultaneous Translation  
English => Mandarin provided

Young Investigator & First Time Attendee Session  
08:00 – 11:30  
PARKSIDE BALLROOM A+B, LEVEL 1

Addiction Incorporated  
10:00 – 12:00  
Documentary Screening  
BAYSIDE AUDITORIUM B, LEVEL 1

ITONF Nursing Workshop  
12:30 – 17:00  
BAYSIDE GALLERY A, LEVEL 1

A Focus on Lung Cancer  
13:00 – 15:30  
An Interactive Consumer Forum  
BAYSIDE 204 A+B, LEVEL 2

**Progress in Lung Cancer:**  
17:30 – 18:30  
Celebrating 40 Years of IASLC and Research Progress  
PARKSIDE AUDITORIUM, LEVEL 1

**Opening Plenary Session**  
18:45 – 20:15  
PLENARY HALL, GROUND LEVEL

Welcome Reception  
20:15 – 21:30  
EXHIBIT HALL, GROUND LEVEL

**Monday, October 28 – Wednesday, October 30**

Please refer to the Program at a Glance

**Poster Sessions**

EXHIBIT HALL, GROUND LEVEL

<table>
<thead>
<tr>
<th>Poster Session 1</th>
<th>Monday, October 28</th>
</tr>
</thead>
<tbody>
<tr>
<td>Setup Time</td>
<td>08:30 – 09:30</td>
</tr>
<tr>
<td>Take Down Time</td>
<td>16:30 – 18:00</td>
</tr>
<tr>
<td>Viewing Time</td>
<td>09:30 – 16:30</td>
</tr>
<tr>
<td>Presenters in Attendance</td>
<td>09:45 – 10:30  and 15:30 – 16:15 (Networking Breaks)</td>
</tr>
</tbody>
</table>

**Poster Pick Up Counter**

EXHIBIT HALL, GROUND LEVEL, EXHIBIT INFORMATION BOOTH

<table>
<thead>
<tr>
<th>Sunday, October 27</th>
<th>20:15 – 21:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Reception</td>
<td>----------------</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Monday, October 28</th>
<th>08:00 – 16:30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, October 29</td>
<td>08:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>08:00 – 11:30</td>
</tr>
</tbody>
</table>
Welcome Message from IASLC and the Local Organizing Committee

Dear Colleague,

On behalf of the International Association for the Study of Lung Cancer (IASLC) and the Local Organizing Committee, it is a great pleasure to welcome you to the 15th IASLC World Conference on Lung Cancer (WCLC 2013) in Sydney, Australia.

In more than 150 sessions the scientific program will cover a variety of groundbreaking topics that illustrate the latest scientific and clinical developments in the field of lung cancer and thoracic oncology. The World Conference on Lung Cancer has become the premier platform not only for the presentation of new science, but also for unique networking opportunities. With delegates from more than 100 countries attending this meeting, it provides the ideal forum to discuss the latest findings, put them into context and really understand how they can affect your practice day to day.

The program includes stimulating presentations from more than 250 world renowned keynote speakers as well as more than 2,000 oral, mini oral and poster abstract presentations. Please note that each day a different set of posters will be displayed, so make sure to check out the posters in the Exhibit Hall each day.

We encourage you to participate actively in the discussions and hope the meeting helps in the exchange of information and development of new collaborations. Take advantage of the various networking opportunities the Conference offers. Join us for the Welcome Reception on Sunday evening for an opportunity to mix and mingle with friends, colleagues and exhibitors. The morning and afternoon Networking Breaks have been extended to 45 minutes in order to provide sufficient time to discuss with poster presenters their work and to network with colleagues and exhibitors. Don’t miss the Gala Dinner on Tuesday night, which will take you on an amazing journey through Australia (ticketed event, limited capacity).

Sydney offers national parks, botanic gardens, pristine waterways, green space and golden beaches in abundance. Outdoor experiences unique to Sydney include sailing on the harbour, a surf lesson at Manly or Bondi beach, climbing the Harbour Bridge, or teeing off at a golf course overlooking the Pacific Ocean. We hope you have planned some extra time in your diary to experience some of these activities.

We look forward to an inspiring, educational, and enjoyable program in vibrant and beautiful Sydney — the gateway to Australia. Thanks for joining us.

Michael Boyer & Kwun Fong | WCLC 2013 Conference Presidents
Welcome Message from Lung Foundation Australia

The Lung Foundation Australia has been working with the WCLC 2013 Conference Presidents Drs. Michael Boyer and Kwun Fong as well as the Local Organizing Committee on this Conference for the last 5 years. It has been an unforgettable journey for all of us. We are extremely proud to have supported the delivery of this premier gathering of international researchers and physicians in the field of Lung Cancer and Thoracic Oncology in beautiful Sydney, Australia and look forward to a wonderful Conference with groundbreaking scientific presentations and superb networking opportunities.

The Lung Foundation Australia strives to help Australians living with a lung disease and their carers; to generate awareness about the importance of positive lung health within the community and facilitate research to improve outcomes. The Lung Foundation Australia’s Lung Cancer National Program works with our communities to reduce the impact of lung cancer and plays a lead role in improving outcomes for patients, carers, families and in the communities we serve.

Please visit our website for more information: www.lungfoundation.com.au

William Darbishire | Chief Executive Officer

LUNG FOUNDATION 
AUSTRALIA

“When you can’t breathe... nothing else matters”™
Welcome Message from Health Minister New South Wales, Australia

On behalf of the NSW Government, I extend a warm welcome to all delegates visiting Sydney and New South Wales for the 15th World Conference on Lung Cancer.

The 15th World Conference on Lung Cancer is one of the largest international gatherings of researchers and physicians in the field of lung cancer and thoracic oncology. This is the first time this very important medical event has been held in Sydney, and it will build on the success of previous conferences held in other leading cities around the world.

Sydney is Australia’s foremost tourism and major events destination, attracting more international business, holiday and education visitors than any other city in Australia. It is also home to world leading cancer researches, and specialists.

Sydney’s physical beauty, vibrant creative energy and iconic attractions such as the Sydney Opera House and Sydney Harbour Bridge have secured its status as Australia’s global city.

I wish you all a wonderful stay in Sydney.

The Hon. Jillian Skinner MP | NSW Minister for Health
Foreword and Message of Welcome

The City of Sydney offers a warm welcome to all delegates to the 15th World Conference on Lung Cancer. We’re delighted to have you here in our city.

With its theme of Next Generation Lung Cancer Care, the conference will give leaders in the treatment of lung cancer and mesothelioma the opportunity to share their knowledge and experience with delegates from around the world, to ensure the best possible results for patients.

This is important work, and I commend you for it. Innovation and knowledge are vital to progress in medicine and science, as they are vital to the development of successful cities.

Sydney values our knowledge leaders and is proud of the work they do across a range of fields.

We’re also proud of our beautiful city, with its magnificent harbour and shoreline, generous open spaces, outstanding restaurants and lively night-time and cultural life.

I hope you will find time during your stay to explore some of our urban villages and discover some of the rich and diverse culture that makes Sydney an ever-shifting kaleidoscope of experiences.

Thank you for choosing our City to host your conference. I hope we can welcome you back here again as visitors.

Yours sincerely,

Clover Moore
Lord Mayor of Sydney
Operating and financial inquiries
John Wetherington,
Chief Operating and Finance Officer
John.wetherington@iaslc.org

General inquiries, sponsorship possibilities,
and information about educational resources
Pia Hirsch, Director of Education,
Corporate Relations and Governance
Pia.hirsch@iaslc.org

Membership, payments and
advocacy-related requests
Kristin Richeimer, Director of Membership
Kristin.richeimer@iaslc.org

Member services, including
membership applications and dues
Pamela Goens, Membership Coordinator
Pamela.goens@iaslc.org

Media inquiries
Kristal Griffith, Director of Communications
Kristal.griffith@iaslc.org

2011 – 2013
OFFICERS
President
Peter Goldstraw, UK
President Elect
Tony Mok, Hong Kong
Past President
David R. Gandara, USA
Executive Director
Paul A. Bunn, Jr., USA
Treasurer
Fred R. Hirsch, USA

2013 – 2015
OFFICERS
President
Tony Mok, Hong Kong
President Elect
David Carbone, USA
Past President
Peter Goldstraw, UK
Chief Executive Officer
Fred R. Hirsch, USA
Treasurer
David R. Gandara, USA

2013 CONFERENCE PRESIDENTS
Michael Boyer, Australia
Kwun Fong, Australia

BOARD OF DIRECTORS
Alex Adjei, USA
Hisao Asamura, Japan
David Carbone, USA
Hak Choy, USA
Carolyn Dresler, USA
Dominique Grunenwald, France
Karen Kelly, USA
Christian Manegold, Germany
Tetsuya Mitsudomi, Japan
Kazuhiko Nakagawa, Japan
Silvia Novello, Italy
Keunchil Park, South Korea
Rolf Stahel, Switzerland
Sumitra Thongprasert, Thailand
Johan Vansteenkiste, Belgium

2015 CONFERENCE PRESIDENT
Fred R. Hirsch, USA

BOARD OF DIRECTORS
Alex Adjei, USA
Carolyn Dresler, USA
Laurie Gaspar, USA
Pasi A. Janne, USA
Keith Kerr, UK
Christian Manegold, Germany
Françoise Mornex, France
Tetsuya Mitsudomi, Japan
Kazuhiko Nakagawa, Japan
Silvia Novello, Italy
Yuichiro Ohe, Japan
Solange Peters, Switzerland
Sumitra Thongprasert, Thailand
William D. Travis, USA
Yi-Long Wu, China
Committees

Local Organizing Committee

CONFERENCE PRESIDENTS

Michael Boyer
Chris O’Brien Lifehouse, Sydney Cancer Centre

Kwun Fong
University of Queensland
Thoracic Research Center, The Prince Charles Hospital

COMMITTEE

Glenda Colburn
Lung Foundation Australia

Anna Nowak
The University of Western Australia

Jenny Gearon
Lung Foundation Australia

Nick Pavlakis
Royal North Shore Hospital

David Ball
Peter MacCallum Cancer Centre

Matthew Peters
Concord Hospital

James Bishop
University of Melbourne
Victorian Comprehensive Cancer Centre

Bruce Robinson
QEII Medical Centre

David Currow
Cancer Institute NSW

Ben Solomon
Peter MacCallum Cancer Centre

Edwina Duhig
John Flynn Hospital

Emily Stone
St. Vincent’s Hospital

Beth Ivimey
Prince of Wales Hospital

Nico van Zandwijk
Bernie Banton Centre, Asbestos Diseases Research Institute

Michael Millward
Sir Charles Gairdner Hospital

Gavin Wright
East Melbourne Heart & Lung

Paul Mitchell
Austin Health

INTERNATIONAL REPRESENTATIVES

Tim Christmas
Auckland City Hospital
New Zealand

Tony Mok
The Chinese University of Hong Kong
Hong Kong
# Core Program Committee

**CHAIRS**  
Michael Boyer and Kwun Fong, Australia

<table>
<thead>
<tr>
<th>Biology</th>
<th>Imaging &amp; Screening</th>
<th>Radiation Oncology</th>
</tr>
</thead>
</table>
| Ben Solomon, Australia*  
Philip Mack, USA  
Gabriella Sozzi, Italy  
Murry Wynes, USA  
Tetsuya Mitsudomi, Japan | Kwun Fong, Australia*  
Emile Comans, Netherlands  
David Shelton, USA  
Rayleen Bowman, Australia  
Kavita Garg, USA  
Kenji Eguchi, Japan  
James Jett, USA  
Denise Aberle, USA  
John Field, UK  
Ugo Pastorino, Italy | David Ball, Australia*  
David Raben, USA  
Michael MacManus, Australia  
Quynh-Thu Le, USA  
Cecile Le Pechoux, France  
Dirk De Ruysscher, Netherlands  
Luhua Wang, China |

<table>
<thead>
<tr>
<th>Prevention/Epidemiology</th>
<th>Combined Modality</th>
<th>Surgery</th>
</tr>
</thead>
</table>
| Nico van Zandwijk, Australia*  
Janine Cataldo, USA  
Maryska Janssen-Heijnen, Australia  
Celine Mascaux, USA  
Pan-Chyr Yang, Taiwan  
Chris Amos, USA  
Mike Daube, USA | Michael Millward, Australia*  
Caro Koning, Netherlands  
Houke Klomp, Netherlands  
Dominique Grunenwald, France  
Laurie Gaspar, USA  
Kathy Albain, USA  
Pieter Postmus, Netherlands  
Keunchil Park, Korea  
Jose Belderbos, Netherlands | Gavin Wright, Australia*  
Rick Paul, Netherlands  
Royce Calhoun, USA  
Eric Lim, UK  
Hisao Asamura, Japan  
Yi Long Wu, China  
Paul de Leyn, Belgium  
Michael Weyant, USA |

<table>
<thead>
<tr>
<th>Pulmonary/Endoscopy</th>
<th>Statistics Consultants</th>
<th>Pathology</th>
</tr>
</thead>
</table>
| Matthew Peters, Australia*  
Thomas Sutedja, Netherlands  
Ken Yoneda, USA  
York Miller, USA  
Felix Herth, Germany  
Henri Colt, USA  
Chunxue Bai, China | Nick Pavlakis, Australia*  
Otilia Dalesio, Netherlands  
Anna Baron, USA  
Stefan Michiels, Belgium | Edwina Duhig, Australia*  
Erik Thunnissen, Netherlands  
Kirk Jones, USA  
Daniel Merrick, USA  
Roman Thomas, Germany  
Ming Tsao, Canada  
Pietro Nederlof, Netherlands  
Paul Waring, Australia  
Yuichi Ishikawa, Japan  
Fred Hirsch, USA |

<table>
<thead>
<tr>
<th>Supportive Care</th>
<th>Medical Oncology</th>
<th>Nurses</th>
</tr>
</thead>
</table>
| David Currow, Australia*  
Wouter Zuurmond, Netherlands  
Anna Oton, USA  
Sam Ahmedzai, UK  
Ben Slotman, Netherlands  
Reena M. George, India | Michael Boyer, Australia*  
Egbert Smit, Netherlands  
Tony Mok, Hong Kong  
Jean Charles Soria, France  
Jin Soo Lee, South Korea  
Ross Camidge, USA  
Guiseppe Giaccone, USA  
Luis Paz-Ares, Spain | Beth Ivimey, Australia*  
Mary Duffy, Australia  
Liz Darlison, UK  
Mary Hesdorffer, USA |

**Mesothelioma**  
Anna Nowak, Australia*  
Takashi Nakano, Japan  
Courtney Broaddus, USA  
Paul Baas, Netherlands  
Jessica Donington, USA  
Robert Doebbe, USA

Chair of each track are in bold  
* Members of the Local Organizing Committee
International Scientific Abstract Review Committee

Denise Aberle, USA  
Alex Adjei, USA  
Sam Ahmedzai, UK  
Kathy Albain, USA  
Chris Amos, USA  
Scott Antonia, USA  
Konstantinos Arnaoutakis, USA  
Hisao Asamura, Japan  
Paul Baas, Netherlands  
Chunxue Bai, China  
David Ball, Australia  
Anna Baron, USA  
Chandra Belani, USA  
Christine Berg, USA  
Andrea Bezjak, Canada  
Lucinda Billingham, UK  
James Bishop, Australia  
Diana Borthwick, UK  
Rayleen Bowman, Australia  
Michael Boyer, Australia  
Elisabeth Brambilla, France  
Caitlin Broderick, Australia  
Odd Terje Brustugun, Norway  
Raphael Bueno, USA  
Paul Bunn, USA  
Marc Buyse, Belgium  
Royce Calhoun, USA  
D. Ross Camidge, USA  
David Carbone, USA  
Janine Cataldo, USA  
Giovanni Ceresoli, Italy  
Chien-Jen Chen, Taiwan  
Gang Chen, China  
Lucian Chirieac, USA  
Hak Choy, USA  
Josephine Clayton, Australia  
Glenda Colburn, Australia  
Emile Comans, Netherlands  
Stacie Corcoran, USA  
Jenette Creaney, Australia  
John Crowley, USA  
Melissa Culligan, USA  
Walter Curran, USA  
David Currow, Australia  
Sanja Dacic, USA  
Liz Darlison, USA  
Hiroshi Date, Japan  
Patricia Davidson, Australia  
Dirk De Ruyscher, Belgium  
Frank Detterbeck, USA  
Anand Devaraj, UK  
Robert Doebele, USA  
Jessica Donington, USA  
Carolyn Dresler, USA  
Mary Duffy, Australia  
Edwina Duhig, Australia  
Martin Edelman, USA  
John Edwards, UK  
Kenji Eguchi, Japan  
Jeremy Erasmus, USA  
Armin Ernst, USA  
William Evans, Canada  
Corinne Faivre-Finn, UK  
Laurie Fenton Ambrose, USA  
John Field, UK  
David Fielding, Australia  
Pier Luigi Filosso, Italy  
Kwun Fong, Australia  
Jesme Fox, UK  
Anne Fraser, New Zealand  
Joseph Friedberg, USA  
David Gandara, USA  
Kavita Garg, USA  
Laurie Gaspar, USA  
Adi Gazdar, USA  
Kim Geisinger, USA  
Reena George, India  
Giuseppe Giaccone, USA  
Nicolas Girard, France  
Peter Goldstraw, UK  
Daniela Gompelmann, Germany  
Ramawamy Govindan, USA  
Inga Grills, USA  
Dominique Grunenwald, France  
Peter Hammerman, USA  
Long Hao, China  
Kazushige Hayakawa, Japan  
Roy Herbst, USA  
Felix Herth, Germany  
Mary Hesdorffer, USA  
Masahiro Hiraoka, Japan  
Fred Hirsch, USA  
Hans Hoffman, Germany  
Katsuyuki Hotta, Japan  
Soon Hin How, Malaysia  
Yasuko Ichikawa, Japan  
Takashi Ishida, Japan  
Yuichi Ishikawa, Japan  
Akira Iyoda, Japan  
Pasi Jänne, USA  
Maryska Janssen-Heijnen, Netherlands  
James Jett, USA  
Helen Jo, Australia  
Miriam Johnson, USA  
Kirk Jones, USA  
Robert Keith, USA  
Karen Kelly, USA  
Keith Kerr, UK  
Young Tae Kim, Korea  
Sonja Klebe, Australia  
Houke Klomp, Netherlands  
Ritsuko Komaki, USA  
Feng-Ming (Spring) Kong, USA  
Caro Koning, Netherlands  
Mark Kris, USA  
Noraki Kurimoto, Japan  
Frank Lagerwaard, Netherlands  
Yeul-Hur Lai, Taiwan  
Richard Lake, Australia  
Wan Lam, Canada  
Primo Lara, USA  
Quynh Le, USA  
Cecile Le Pechoux, France  
Jin Soo Lee, Korea  
Pyng Lee, Singapore  
Y C Gary Lee, Australia  
Natasha Leighl, Canada  
Yolande Lievens, Belgium
Eric Lim, UK
Lunxu Liu, China
Gilberto Lopes, Singapore
Bo Lu, USA
Fergus Macbeth, UK
Philip Mack, USA
Michael Macmanus, Australia
Christian Manegold, Germany
Lawrence Marks, USA
Celine Mascaux, Canada
Daniel Merrick, USA
Matthew Meyerson, USA
David Midithun, USA
York Miller, USA
Michael Millward, Australia
David Milhe, New Zealand
John Minna, USA
John Mitchell, USA
Paul Mitchell, Australia
Tetsuya Mitsudomi, Japan
Tony Mok, Hong Kong
Alex Molassiotis, Hong Kong
Luis Montuenga, Spain
Andre Moreira, USA
Lucy Morgan, Australia
Françoise Mornex, France
Nevin Murray, Canada
Kazuhiko Nakagawa, Japan
Takashi Nakano, Japan
Tran Van Ngoc, Vietnam
Andrew Nicholson, UK
Masayuki Noguchi, Japan
Silvia Novello, Italy
Anna Nowak, Australia
Hiroshi Onishi, Japan
Noelle O’Rourke, UK
Anna Oton, USA
Sandra O’Toole, Australia
Matthijs Oudkerk, Netherlands
Keunchil Park, Korea
Harvey Pass, USA
Ugo Pastorino, Italy
Marinus Paul, Netherlands
Nick Pavlakis, Australia
Luis Paz-Ares, Spain
Michael Peake, UK
Guiseppe Pelosi, Italy
Matthew Peters, Australia
Iver Petersen, Germany
Robert Pirker, Austria
Pieter E. Postmus, Netherlands
Allan Price, UK
Elisabeth Quoix, France
Ramon Rami-Porta, Spain
Mary Redman, USA
Ramesh Rengan, USA
Umberto Ricardi, Italy
Greg Riely, USA
Rafael Rosell, Spain
Enrico Ruffini, Italy
Valerie Rusch, USA
Prudence Russell, Australia
Tajalli Saghaie, Australia
Nagahiro Saijo, Japan
Maria Eliana San Martin, Chile
Toshiyuki Sawa, Japan
Suresh Senan, Netherlands
David Shelton, USA
Frances Shepherd, Canada
Yu Shyr, USA
Ben Slotman, Netherlands
Egbert Smit, Netherlands
Ben Solomon, Australia
Ross Soo, Singapore
Jean-Charles Soria, France
Gabriella Sozzi, Italy
Margaret Spitz, USA
Rolf Stahel, Switzerland
Daniel Steinfort, Australia
Karín Steinke, Australia
Matthew Steliga, USA
Richard Stephens, UK
Martin Stockler, Australia
Emily Stone, Australia
Alexander Sun, Canada
Tom Sutedja, Netherlands
Kate Sutherland, Australia
Kenji Suzuki, Japan
Eva Szabo, USA
Martin Tammemagi, Canada
Windfield Tan, Phillipines
Ivan Tham, Singapore
Sumitra Thongprasert, Thailand
Erik Thunnissen, Netherlands
Ka Fai To, Hong Kong
Shinichi Toyooka, Japan
William Travis, USA
Ming Tsao, Canada
Masahiro Tsuboi, Japan
Paul Ugalde, Canada
Paul Van Houtte, Belgium
Jan Van Meerbeeck, Belgium
Nico Van Zandwijk, Australia
Everett Vokes, USA
Heather Wakelee, USA
Luhua Wang, China
Paul Waring, Australia
Shun-ichi Watanabe, Japan
Neil Watkins, Australia
Walter Weder, Switzerland
Maria Werner-Wasik, USA
Michael Weyant, USA
John White, UK
Ignacio Wistuba, USA
Yi-Long Wu, China
Murry Wynes, USA
Nise Yamaguchi, Brazil
Ian Yang, Australia
Pan-Chyr Yang, Taiwan
Seiji Yano, Japan
Tokuiro Yano, Japan
Yasushi Yatabe, Japan
Patsy Yates, Australia
Ken Yoneda, USA
Jinming Yu, China
Wen Zhao Zhong, China
Caicun Zhou, China
Registration Information

Registration Counter Hours
REGISTRATION IS LOCATED IN HALL 6, PARKSIDE AT THE SYDNEY CONVENTION & EXHIBITION CENTRE.

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 26</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, October 27</td>
<td>06:00 – 20:00</td>
</tr>
<tr>
<td>Monday, October 28</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Tuesday, October 29</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>06:00 – 17:00</td>
</tr>
</tbody>
</table>

Registration Counters

Registered Delegates
- For all delegates who registered online and paid in full before arriving at the Conference

Note: All delegates who registered but have not yet paid in full please proceed to the Outstanding Payment Counter

Invited Faculty Registration
- For all invited faculty members (speakers, chairs, discussants)

Note: Abstract Presenters can pick up their materials at the Registered Delegates Counter

Exhibitor Registration
- For all Exhibitor Staff

New Registration/Self Registration
- For all delegates not yet registered for the Conference
- Self Registration only available for credit card payments

Outstanding Payments/Additional Tickets and Purchases
- For all delegates who have pre-registered but not yet (fully) paid
- For all delegates wanting to purchase additional items:
  - Gala Dinner Tickets (subject to availability)
  - MTE Session Tickets (subject to availability)
  - Virtual Meeting Pass

Sydney Information Desk
THE SYDNEY INFORMATION DESK IS LOCATED IN THE REGISTRATION AREA IN HALL 6, PARKSIDE, SYDNEY CONVENTION & EXHIBITION CENTRE.

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 26</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, October 27</td>
<td>06:00 – 20:00</td>
</tr>
<tr>
<td>Monday, October 28</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Tuesday, October 29</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>06:00 – 17:00</td>
</tr>
</tbody>
</table>

Staff will provide local information and assist with:
- Ground Transportation
- Airport Transfers
- Sightseeing Tours
- Pre- and Post Tours
- Restaurant recommendations and booking
- Local PA and Personal Concierge Services

Delegate Help Desk
THE DELEGATE HELP DESK IS LOCATED IN THE REGISTRATION AREA, HALL 6, PARKSIDE AT THE SYDNEY CONVENTION & EXHIBITION CENTRE.

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 26</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, October 27</td>
<td>06:00 – 20:00</td>
</tr>
<tr>
<td>Monday, October 28</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Tuesday, October 29</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>06:00 – 17:00</td>
</tr>
</tbody>
</table>

Staff will provide information and assistance with:
- Program related questions
- Directional assistance for Convention Centre
Registration Materials

SUPPORTED BY

Boehringer Ingelheim

Registration Materials include:
- Name Badge including barcode for tickets
- Ribbons (if applicable)
- Abstract USB Stick (not included in Accompanying Person Registration)
- Mini Pocket Program (not included in Accompanying Person Registration)
- Exhibitor Pocket Program (not included in Accompanying Person Registration)
- Delegate Bag Voucher (not included in Accompanying Person Registration)
- Addendum to Onsite Program

Delegate Bags include:
- Onsite Scientific Program including Conference Evaluation Form
- Invitation Flyers for Industry Supported Symposia
- Additional Promotional Flyers from Sponsors and Exhibitors
- IASLC Information/Folder
- Financial Disclosure Information Summary for all Faculty and Planners
- IASLC 40 Year Monograph

Name Badges

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Social Events and Exhibition.

Lost Badge/Name Changes: A $50 AUD fee applies for any reprints due to onsite name changes or lost badges.

Badge Color Identification

Delegate – Blue
- Full access to Scientific Sessions (except ticketed MTE Sessions)
- Exhibit Hall access including Networking Breaks and Welcome Reception
- Delegate Bag including all materials
- Onsite Program, Onsite Pocket Program, Exhibitor Pocket Program
- Abstract USB Stick

Single Day – Red
- Full access to Scientific Sessions (except ticketed MTE Sessions) on day of attendance
- Exhibit Hall access including Networking Breaks on day of attendance
- Delegate Bag including all materials
- Onsite Program, Onsite Pocket Program, Exhibitor Pocket Program
- Abstract USB Stick
- Welcome Reception (if Sunday is day of attendance)

Exhibitor – Green
- Exhibit Hall access including Networking Breaks and Welcome Reception
- Delegate Bag including all materials
- Onsite Program, Onsite Pocket Program, Exhibitor Pocket Program
- Abstract USB Stick

Accompanying Person – Yellow
- Exhibit Hall access including Networking Breaks and Welcome Reception
- Gala Dinner Ticket
Press and Media

Press and Media Representatives

Press and Media passes are issued to Journalists, including photographers and freelance journalists based on below requirements.

Journalists, including photographers must work exclusively for the outlet for which they are credentialed (exceptions for freelance journalists as detailed below). Journalists who use their media privileges to work for non-credentialed organizations will have their privilege revoked.

Freelance journalists, including photographers, may work for multiple publications, as long as they confirm in advance that those publications are eligible for media registration.

Press and Media Access

Pre-registered Press and Media representatives are required to check in at the Registered Delegate Counter. Non registered Press and Media representatives should proceed to the New Registration counter. Media and press credential is required to receive a Press/Media Badge.

Media Room

A MEDIA WORK ROOM IS AVAILABLE AND LOCATED IN ROOMS PARKSIDE G03 AND G02, GROUND LEVEL

|Sunday, October 27 | 07:00 – 18:00 |
|Monday, October 28 | 07:00 – 18:00 |
|Tuesday, October 29 | 07:00 – 18:00 |
|Wednesday, October 30 | 07:00 – 18:00 |

Wireless internet access, power bars and a copier are available in the Media Room to assist credentialed media representatives.

Press Conference

Monday, October 28
12:15 – 13:45
Top WCLC 2013 Abstracts
BAYSIDE 101, LEVEL 1

Press releases will be posted on the Conference website at the conclusion of each Conference day.

Social Media

Follow IASLC tweets @IASLC and #WCLC2013 as well as the IASLC Facebook account for the most up to date information on the Conference.

Daily Onsite Newspaper

SUPPORTED BY

Bristol-Myers Squibb

The daily Conference Newspaper will highlight the best presentations and will provide delegates with the latest news and opinions from the Conference. The newspaper will be available at the registration desk, in the delegate lounges in the Exhibit Hall and throughout the Sydney Convention & Exhibition Centre. The Newspaper will be available from Sunday through to Wednesday. A copy of each edition will be posted on the Conference website at the end of each Conference day.

Highlight of the Day eBlast

SUPPORTED BY

astex pharmaceuticals

Each morning (Sunday – Wednesday) the Conference will provide an update to their delegates via email highlighting the best sessions and presentations taking place that day. The eNews will also include any speaker or room updates to make sure delegates always have the most up to date information.
Onsite Services and General Information

Abstracts
Abstracts selected for presentation at WCLC are presented in Oral, Mini Oral and Poster Sessions. The top four abstracts are presented in the Presidential Symposium on Tuesday, October 29, 08:15 – 09:45.
All accepted and confirmed abstracts are published in a supplement of the Journal of Thoracic Oncology, which will be posted online on the JTO website at the conclusion of the Conference.
All accepted and confirmed abstracts are also available on the Abstract USB Stick which is handed out along with your registration kit.

Accreditation
See CME Certificate

Airport Transfers
For individual airport transfer bookings please see the SYDNEY INFORMATION DESK IN THE REGISTRATION AREA, HALL 6, GROUND LEVEL

ATM
An ATM is located in the foyer in front of the Exhibition Hall (foyer Hall 3).

Baggage Check
See coat check

Breakfast
Breakfast will be provided to all attendees of Young Investigator’s Session PARKSIDE BALLROOM A + B, LEVEL 1 Sunday, October 27 08:00 – 11:30

Use of WCLC Scientific Program Content
Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the World Conference on Lung Cancer and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced or distributed without the written permission of the International Association for the Study of Lung Cancer. Use of the WCLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the express written permission of the International Association for the Study of Lung Cancer.

Copyright
Reproduction of materials such as abstract data, posters, presentation slides, etc., requires first obtaining permission from IASLC and the listed author(s) and/or presenter(s). Photography of sessions, trade show booths, event setup, etc. is prohibited by IASLC/WCLC. The WCLC has a designated staff photographer and can provide WCLC 2013 event photography for journalists who wish to run photos of the event in their given media. Please contact Kristal Griffith, IASLC Director of Communication at kristal.griffith@iaslc.org.
IASLC Business Meeting  
BAYSIDE AUDITORIUM A, LEVEL 1  
Monday, October 28 07:00 – 08:00

Meet the Expert Sessions (ticketed)  
VARIOUS BAYSIDE ROOMS, LEVEL 1  
Every morning 07:00 – 08:00

Business Centre
The Bayside Information Desk doubles as a business centre so if you need any of those facilities during WCLC 2013 they are available from there in limited capacity.

Camera and Cell Phones
No cameras or video cameras are allowed in any event during WCLC. As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

Certificate of Attendance
International attendees can request and pick up a ‘Certificate of Attendance’ at any of the Registration Counters during regular registration hours or at the IASLC Booth in the Exhibit Hall during regular exhibit hours. In order to receive your Certificate of Attendance you have to complete the Conference evaluation form available in the back of this brochure.

CME Certificate
Delegates must complete the Conference evaluation form available in the back of this book in order to receive a CME Certificate/ Certificate of Attendance. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. Please see page 48 in this brochure for further information.

This activity is planned for AMA PRA Category 27.5 Credit(s)™.
**Emergency Procedures**

**EMERGENCY NUMBER**

5555 – using the nearby house phone
02 9282 5555 – using your mobile phone

These numbers transfer the caller to the Centre’s Security Department.

**Evaluations**

A Conference evaluation form is included in this brochure. Additional copies are available at the IASLC booth as well as registration. Please help us improve the Conference by completing your form and returning to one of the Registration Counters during the Registration Counter Hours or by email to wclc2013@icsevents.com.

**Exhibits**

The exhibits are an integral part of the experience at WCLC and will feature the latest in technology and research. THE EXHIBITS ARE LOCATED IN HALLS 4 + 5, EXHIBITION CENTRE, GROUND FLOOR AT THE SYDNEY CONVENTION & EXHIBITION CENTRE.

**First Aid**

First Aid Kits are placed throughout the Convention & Exhibition Centre. In a medical emergency, please visit one of the information desks on the Ground Level or speak to one of the security guards who are first aid trained. The emergency number to call if needed is 5555 from any of the in-house phones.

**IASLC**

**Business Meeting**

All IASLC Members are invited to attend the IASLC Business Meeting on Monday, October 28, 07:00 – 08:00 in BAYSIDE AUDITORIUM A, LEVEL 1. Breakfast will be provided.

**Booth**

Please visit the IASLC Booth (#1417) for updates on membership, society-sponsored meetings and events, and general information.

**Happy Hour**

IASLC is inviting its members to join the IASLC Happy Hour during the afternoon Networking Break on Monday and Tuesday at the IASLC Booth #1417 in the Exhibit Hall. IASLC Executives and Staff members will be available for you to learn more about the association and its important work.

**Celebrating 40 Years of the IASLC and Research Advancements**

IASLC is celebrating 40 years of the association and research advancements in lung cancer with two artwork exhibitions. The displays can be found in the Parkside Promenade Foyer, Ground Level as well as in the Parkside Foyer, Level 1.

**Internet Café**

**SUPPORTED BY**

[Boehringer Ingelheim](#)

THE INTERNET CAFÉ IS LOCATED IN THE EXHIBIT HALL ATTACHED TO THE EXHIBIT SHOWCASE THEATER. Keep in touch with home and office! Computers with internet and printers are available to delegates on a complimentary basis. The Internet Café is open during Exhibit Hall Hours. Internet sessions are limited to 15 minute per delegate.

**Lost and Found**

Lost and Found items should be returned/claimed at the Registration Counters.

**Media Room**

ROOMS PARKSIDE G03 AND G02, GROUND LEVEL ARE THE DESIGNATED MEDIA WORK ROOM. Wireless internet and a copier are available. Please see page 22 in this brochure for further information.
Mobile Application

The onsite mobile application is provided free of charge and available for most mobile devices such as iPhone, iPad, Android and Blackberry (via mobile website). The application features the full scientific program including abstracts sorted by day and time, exhibit information including floor plan and exhibitor biographies as well as general Conference and venue information. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

Newspaper

A daily Conference Newspaper will be available on Sunday, Monday, Tuesday and Wednesday. Please see page 22 in this brochure for further information.

Press

Please see page 22 in this brochure for further information.

Public Transportation

The Sydney Convention & Exhibition Centre is connected to the Metro Light Rail. Convention Stop is directly behind the Convention Centre and Exhibition Stop provides easy access to the Exhibition Halls.

Due to heavy traffic during rush hours we recommend that delegates walk from their hotel to the Convention Centre if at all possible. During rush hours it usually takes longer to travel by cab than to walk.

Recharge Bar

A recharge bar is located in the Exhibit Hall allowing delegates to power up their cell phones, iPads, laptops and other electronic devices for free. These stations will be in high demand; therefore sessions are limited to 15 minutes.

Disclaimer

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
Networking Breaks

Networking Breaks (coffee and snacks) are served in the Exhibit Hall at the following times:

Monday, October 28 09:45 –10:30 and 15:30 – 16:15
Tuesday, October 29 09:45 –10:30 and 15:30 – 16:15
Wednesday, October 30 09:45 –10:30 and 15:30 – 16:15

A dietary buffet station is available for our delegates with dietary requirements.

Restaurants

There are plenty of restaurant choices in the Darling Harbour District. The staff at the Sydney Information Desk will be happy to assist with recommendations and bookings.

Session Recordings

All oral sessions are recorded (slides and audio) and will be made available in the Virtual Meeting within 24 hours. Registered Delegates can purchase the Virtual Meeting at a discounted rate. If you purchased the Virtual Meeting at the time of registration, your login details are printed on your name badge.

Smoking

Smoking is prohibited in all areas of the Sydney Convention & Exhibition Centre.

Speaker Ready Room

ROOM PARKSIDE G04 LOCATED ON THE GROUND LEVEL BEHIND HALL 6, REGISTRATION, IS THE DESIGNATED SPEAKER READY ROOM. All Presenters are required to submit and/or preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

No session room submissions will be accepted.

Sydney Information Desk

THE SYDNEY INFORMATION DESK IS LOCATED IN THE REGISTRATION AREA, HALL 6, GROUND LEVEL. Staff will provide local information and assist with restaurant recommendations and bookings. You can also book additional tours, transfers or any other services you may require during your stay in Sydney.

Virtual Meeting

SUPPORTED BY

All audio and webcast recordings including presentations will be available in the Virtual Meeting within 24 hours. Registered Delegates can purchase the Virtual Meeting at the time of registration. If you have not yet signed up for the Virtual Meeting, but would like to do so, please proceed to the Outstanding Payment/Ticket Counter in the registration area. The Virtual Meeting is available at $50 AUD plus GST for IASLC Members and $95 AUD plus GST for non IASLC Members.

Webcast

Plenary Sessions will be video recorded and made available in the Virtual Meeting within 24 hours. For further information please see Virtual Meeting.

Wireless Internet

Free Wireless Internet will be available throughout the Sydney Convention & Exhibition Centre. To enable as many delegates as possible to take advantage of this free service, we ask you to please limit the use of the wireless internet to one mobile device per delegate.
Exhibit Information

Location

HALLS 4 + 5, EXHIBITION CENTRE, GROUND FLOOR

Exhibit Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, October 27</td>
<td>20:15 – 21:30</td>
</tr>
<tr>
<td>Monday, October 28</td>
<td>09:30 – 16:30</td>
</tr>
<tr>
<td>Tuesday, October 29</td>
<td>09:30 – 16:30</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>09:30 – 16:30</td>
</tr>
</tbody>
</table>

Exhibit Features

- Exhibit Information Booth with:
  - Information Desk
  - Show Service Provider Desk
  - Poster Pick Up Counter
  - Publication table for promotional materials or related events and organizations
- Internet Stations (attached to Showcase Theater)
- Recharge Bar
- Food & Beverage Stations including ‘Dietary Corner’
- Delegate Lounges
- Exhibit Showcase Theater
- Posters
- Indigenous Artwork Displays (Booth #2304)

Exhibit Events

- Welcome Reception
  - Sunday, October 27
  - 20:15 – 21:30
- Networking Breaks
  - Monday to Wednesday
  - 09:45 – 10:30
  - and 15:30 – 16:15

Exhibit Showcase Sessions

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, October 28</td>
<td>09:55 – 10:25</td>
</tr>
<tr>
<td></td>
<td>Boehringer Ingelheim: Spotlight Review of the Boehringer Ingelheim Oncology Portfolio</td>
</tr>
<tr>
<td></td>
<td>12:15 – 12:45</td>
</tr>
<tr>
<td></td>
<td>Caris Life Sciences: Caris Molecular Intelligence: The Lung Experience</td>
</tr>
<tr>
<td></td>
<td>15:40 - 16:10</td>
</tr>
<tr>
<td></td>
<td>Lilly Oncology: Maintenance Therapy: Experience, Patient Preferences, Discussion with Patient</td>
</tr>
</tbody>
</table>

Poster Sessions

All poster presentations have been assigned a consecutive publication number for locating the abstract/poster in this brochure, the Abstract Book and the Poster Boards in the Exhibit Hall.

<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1: Poster Session 1</td>
<td>Monday, October 28</td>
<td>09:45 – 10:30</td>
</tr>
<tr>
<td>P2: Poster Session 2</td>
<td>Tuesday, October 29</td>
<td>09:45 – 10:30</td>
</tr>
<tr>
<td>P3: Poster Session 3</td>
<td>Wed., October 30</td>
<td>09:45 – 10:30</td>
</tr>
</tbody>
</table>

Poster Display Time

<table>
<thead>
<tr>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 16:30 each day</td>
</tr>
</tbody>
</table>

Presenters in Attendance

<table>
<thead>
<tr>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>and 15:30 – 16:15 (Networking Breaks)</td>
</tr>
</tbody>
</table>

IASLC Happy Hour

- Monday and Tuesday
  - 15:30 – 16:15

Poster Sessions

- Presenter Attendance during morning and afternoon Networking Breaks
- Exhibit Showcase Sessions in the Exhibit Showcase Theater
<table>
<thead>
<tr>
<th>Biology</th>
<th>Supportive Care and Nursing</th>
</tr>
</thead>
<tbody>
<tr>
<td>PX.01  Cancer Biology</td>
<td>PX.24  Clinical Care</td>
</tr>
<tr>
<td>PX.02  Novel Cancer Genes and Pathways</td>
<td>PX.25  Nurses</td>
</tr>
<tr>
<td>PX.03  Technology and Novel Development</td>
<td></td>
</tr>
<tr>
<td>PX.04  Tumor Immunology</td>
<td></td>
</tr>
<tr>
<td>PX.05  Preclinical Models of Therapeutics/ Imaging</td>
<td></td>
</tr>
<tr>
<td>PX.06  Prognostic and Predictive Biomarkers</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>Poster Pick Up Counter</td>
</tr>
<tr>
<td>PX.07  Surgery</td>
<td>Poster Presenters who had their poster printed by the Conference, can pick up their poster at the Poster Pick Up Counter at the Exhibit Information Booth during the following times:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sunday, October 27 20:15 – 21:30 Welcome Reception</td>
</tr>
<tr>
<td></td>
<td>Monday, October 28 08:00 – 16:30</td>
</tr>
<tr>
<td></td>
<td>Tuesday, October 29 08:00 – 16:30</td>
</tr>
<tr>
<td></td>
<td>Wednesday, October 30 08:00 – 11:30</td>
</tr>
</tbody>
</table>

Radiotherapy

PX.08  Radiotherapy

Combined Modality

PX.09  Combined Modality

Medical Oncology

PX.10  Chemotherapy

PX.11  NSCLC Novel Therapies

PX.12  NSCLC Early Stage

PX.13  SCLC

Mesothelioma

PX.14  Mesothelioma

Thymoma and Other Thoracic Malignancies

PX.15  Thymoma

PX.16  Other Thoracic Malignancies

Endoscopy

PX.17  Bronchoscopy, Endoscopy

Pathology

PX.18  Pathology

Imaging and Screening

PX.19  Imaging

PX.20  Early Detection and Screening

Prevention and Epidemiology

PX.21  Diagnosis and Staging

PX.22  Epidemiology, Etiology

PX.23  Tobacco Control, Prevention and Chemoprevention

Posters Online

SUPPORTED BY

Boehringer Ingelheim

All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in the Exhibit Hall. In addition to the printed posters, each presenter is required to submit an electronic version of their poster to be made available in the ePoster online library. A link to the ePoster library is available on the Conference website at wclc.iaslc.org. The online ePoster library is searchable by posters, keywords, topics as well as authors.
# Exhibitor Listing

## Alphabetically by Company

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBOTT</td>
<td>705</td>
</tr>
<tr>
<td>ALTMAIN &amp; CHERNY</td>
<td>2207</td>
</tr>
<tr>
<td>AME PUBLISHING COMPANY</td>
<td>500</td>
</tr>
<tr>
<td>AMGEN</td>
<td>2511</td>
</tr>
<tr>
<td>APLCC - 2014 ASIA PACIFIC LUNG CANCER CONFERENCE</td>
<td>1306</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1512</td>
</tr>
<tr>
<td>Betapharma Inc</td>
<td>701</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>917</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>1210</td>
</tr>
<tr>
<td>Broncus Medical</td>
<td>505</td>
</tr>
<tr>
<td>Cancer Council Australia</td>
<td>2704</td>
</tr>
<tr>
<td>Cancer Institute NSW</td>
<td>1609</td>
</tr>
<tr>
<td>Carefusion</td>
<td>1307</td>
</tr>
<tr>
<td>Caris Life Sciences</td>
<td>2706</td>
</tr>
<tr>
<td>Celgene</td>
<td>700</td>
</tr>
<tr>
<td>Clovis Oncology</td>
<td>2708</td>
</tr>
<tr>
<td>Commonwealth Bank</td>
<td>2604</td>
</tr>
<tr>
<td>CR Kennedy</td>
<td>2605</td>
</tr>
<tr>
<td>Elekta</td>
<td>2705</td>
</tr>
<tr>
<td>Elsevier Australia</td>
<td>501</td>
</tr>
<tr>
<td>Gilupi</td>
<td>405</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>703</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>503</td>
</tr>
<tr>
<td>HPA Incorporated</td>
<td>2404</td>
</tr>
<tr>
<td>IASLC</td>
<td>1417</td>
</tr>
<tr>
<td>Indigenous Respiratory Outreach Care (IROC) Program</td>
<td>2304</td>
</tr>
<tr>
<td>Life Technologies</td>
<td>1507</td>
</tr>
<tr>
<td>Lilly Oncology</td>
<td>1200</td>
</tr>
<tr>
<td>Lung Cancer Foundation</td>
<td>2608</td>
</tr>
<tr>
<td>Median Technologies</td>
<td>1506</td>
</tr>
<tr>
<td>Mesothelioma Applied Research Foundation</td>
<td>TT419</td>
</tr>
<tr>
<td>Moga</td>
<td>TT317</td>
</tr>
<tr>
<td>Myriad Genetics Inc</td>
<td>1709</td>
</tr>
<tr>
<td>Novartis Oncology</td>
<td>1206</td>
</tr>
<tr>
<td>Peregrine Pharmaceuticals</td>
<td>702</td>
</tr>
<tr>
<td>Pfizer</td>
<td>708</td>
</tr>
<tr>
<td>Qiagen</td>
<td>1508</td>
</tr>
<tr>
<td>Roche</td>
<td>612</td>
</tr>
<tr>
<td>Rocket Medical</td>
<td>1308</td>
</tr>
<tr>
<td>Scanlan</td>
<td>1208</td>
</tr>
<tr>
<td>Sequenom, Inc</td>
<td>2606</td>
</tr>
<tr>
<td>Sydney Catalyst</td>
<td>TT519</td>
</tr>
<tr>
<td>Time Research Limited</td>
<td>1509</td>
</tr>
<tr>
<td>Varian Medical Systems</td>
<td>406</td>
</tr>
<tr>
<td>Ventana Medical Systems</td>
<td>2609</td>
</tr>
<tr>
<td>Wolters Kluwer Health</td>
<td>502</td>
</tr>
</tbody>
</table>

## Numerically by Booth Number

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>BOOTH #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilupi</td>
<td>405</td>
</tr>
<tr>
<td>Varian Medical Systems</td>
<td>406</td>
</tr>
<tr>
<td>AME PUBLISHING COMPANY</td>
<td>500</td>
</tr>
<tr>
<td>Elsevier Australia</td>
<td>501</td>
</tr>
<tr>
<td>Wolters Kluwer Health</td>
<td>502</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>503</td>
</tr>
<tr>
<td>Broncus Medical</td>
<td>505</td>
</tr>
<tr>
<td>Roche</td>
<td>612</td>
</tr>
<tr>
<td>Celgene</td>
<td>700</td>
</tr>
<tr>
<td>Beta Pharma Inc</td>
<td>701</td>
</tr>
<tr>
<td>Peregrine Pharmaceuticals</td>
<td>702</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>703</td>
</tr>
<tr>
<td>Abbott</td>
<td>705</td>
</tr>
<tr>
<td>Pfizer</td>
<td>708</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>917</td>
</tr>
<tr>
<td>Lilly Oncology</td>
<td>1200</td>
</tr>
<tr>
<td>Novartis Oncology</td>
<td>1206</td>
</tr>
<tr>
<td>Scanlan</td>
<td>1208</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>1210</td>
</tr>
<tr>
<td>APLCC - 2014 Asia Pacific Lung Cancer Conference</td>
<td>1306</td>
</tr>
<tr>
<td>Carefusion</td>
<td>1307</td>
</tr>
<tr>
<td>Rocket Medical</td>
<td>1308</td>
</tr>
<tr>
<td>IASLC</td>
<td>1417</td>
</tr>
<tr>
<td>Median Technologies</td>
<td>1506</td>
</tr>
<tr>
<td>Life Technologies</td>
<td>1507</td>
</tr>
<tr>
<td>Qiagen</td>
<td>1508</td>
</tr>
<tr>
<td>Time Research Limited</td>
<td>1509</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>1512</td>
</tr>
<tr>
<td>Cancer Institute NSW</td>
<td>1609</td>
</tr>
<tr>
<td>Myriad Genetics Inc</td>
<td>1709</td>
</tr>
<tr>
<td>Altmann &amp; Cherny</td>
<td>2207</td>
</tr>
<tr>
<td>Indigenous Respiratory Outreach Care (IROC) Program</td>
<td>2304</td>
</tr>
<tr>
<td>HPA Incorporated</td>
<td>2404</td>
</tr>
<tr>
<td>Amgen</td>
<td>2511</td>
</tr>
<tr>
<td>Commonwealth Bank</td>
<td>2604</td>
</tr>
<tr>
<td>CR Kennedy</td>
<td>2605</td>
</tr>
<tr>
<td>Sequenom, Inc</td>
<td>2606</td>
</tr>
<tr>
<td>Lung Cancer Foundation</td>
<td>2608</td>
</tr>
<tr>
<td>Ventana Medical Systems</td>
<td>2609</td>
</tr>
<tr>
<td>Cancer Council Australia</td>
<td>2704</td>
</tr>
<tr>
<td>Elekta</td>
<td>2705</td>
</tr>
<tr>
<td>Caris Life Sciences</td>
<td>2706</td>
</tr>
<tr>
<td>Clovis Oncology</td>
<td>2708</td>
</tr>
<tr>
<td>Mogu</td>
<td>TT317</td>
</tr>
<tr>
<td>Sequenom, Inc</td>
<td>2606</td>
</tr>
<tr>
<td>Lung Cancer Foundation</td>
<td>2608</td>
</tr>
<tr>
<td>Ventana Medical Systems</td>
<td>2609</td>
</tr>
<tr>
<td>Cancer Council Australia</td>
<td>2704</td>
</tr>
<tr>
<td>Time Research Limited</td>
<td>1509</td>
</tr>
<tr>
<td>Varian Medical Systems</td>
<td>406</td>
</tr>
<tr>
<td>Ventana Medical Systems</td>
<td>2609</td>
</tr>
<tr>
<td>Wolters Kluwer Health</td>
<td>502</td>
</tr>
</tbody>
</table>
Awards

IASLC Distinguished Awards

The IASLC Distinguished Award Winners will receive their awards during the Opening Plenary Session on Sunday, October 27, 18:45 – 20:15.

IASLC Scientific Award  |  David R. Gandara, USA

The IASLC Scientific Award is given to an IASLC scientist for lifetime scientific contributions in thoracic malignancy research and who has also contributed to the organization’s development.

David R. Gandara, MD, Professor of Medicine at the University of California at Davis (UC Davis) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center. He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology.

He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group (SWOG) trials. He is the principal investigator for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents.

He is chair of the SWOG Lung Committee, and a member and prior co-chair of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 300 articles, book chapters, abstracts and editorials. He is Editor-in-chief of the journal Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is a manuscript reviewer for eight additional journals.

He served as president of International Association for the Study of Lung Cancer (IASLC) from 2009 to 2011 and is on the board of directors of IASLC and was elected as treasurer in 2013. He is a prior board member and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He also is chair of the NCI-directed Lung Correlative Science Committee.

After receiving his medical degree from the University of Texas Medical Branch in Galveston, Dr. Gandara was an intern and resident at the Madigan Army Medical Center in Tacoma and a fellow at the Letterman Army Medical Center Presidio of San Francisco.
IASLC Merit Award | James R. Jett, USA

The IASLC Merit Award is given to a member of IASLC who has made an extraordinary contribution to the organization’s development.

James R. Jett, M.D. is Professor of Medicine at National Jewish Health in Denver, Colorado. Dr. Jett completed the M.D. degree at the University of Missouri, Columbia. He completed a residency in internal medicine and a fellowship in thoracic diseases at Mayo Graduate School of Medicine, and a research fellowship at the National Cancer Institute, National Institutes of Health.

He was on the consulting staff of Mayo Clinic for 28 years before moving to National Jewish Health in 2010. He has held professional memberships with numerous organizations such as the American Thoracic Society, International Association for the Study of Lung Cancer, American Society of Clinical Oncology, North Central Cancer Treatment Group, and the American College of Chest Physicians.

Dr. Jett is a consultant to the USA Food and Drug Administration. He has served in journal review and editorial activities for medical publications including the American Journal of Respiratory and Critical Care Medicine, American Journal of the Medical Sciences, Cancer, Chest, International Journal of Cancer, Lung Cancer, and New England Journal of Medicine. Dr. Jett was editor-in-chief of the Journal of Thoracic Oncology from 2006-2012.

Dr. Jett’s research interests focus on screening and early detection of lung cancer. As a principal investigator, co-investigator, and consultant, Dr. Jett’s research has been funded by the National Institutes of Health and the National Cancer Institute, and industry.
Joseph W. Cullen Award | Pieter E. Postmus, Netherlands

The Joseph W. Cullen Award is given to an IASLC scientist for lifetime scientific achievements in prevention research of thoracic malignancies.

Dr. Pieter E. Postmus is a professor of pulmonary medicine at the Free University Medical Center in Amsterdam.

Dr. Postmus has a long history of research on early detection and chemoprevention of lung cancer. He has published more than 550 articles covering many aspects of lung cancer including early detection, prevention and therapy. His research has shown the value of CT/PET scans and EBUS in lung cancer staging and the value of fluorescence bronchoscopy for following preneoplastic lesions.

Dr. Postmus served on the IASLC Staging Committee starting in 1997 and was Chair of the M-descriptors subcommittee. He was on the IASLC Board of Directors from 2003–2007 and served as Conference President for the 14th World Conference on Lung Cancer held in Amsterdam in 2011.

Dr. Postmus took a leading role in the IASLC Staging Project and spearheaded the proposals and educational publications for the M-descriptors of the TNM Classification.

He also served on the Core Program Committee for the 15th World Conference on Lung Cancer in Sydney. He received his MD from the University Groningen in The Netherlands.
Mary Matthews Award | Tetsuya Mitsudomi, Japan

The Mary J. Matthews Award is given to an IASLC scientist for lifetime scientific achievements in pathology-translational research of thoracic malignancies.

Tetsuya Mitsudomi, MD, PhD, is Professor, Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine in Osaka, Japan. Prior to this, he was the Vice Director and Chief of the Department of Thoracic Surgery, at the Aichi Cancer Center Hospital in Nagoya, Japan.

He received his medical degree and completed his doctorate training in the 1980’s at Kyushu University and spent 2 years at the National Cancer Institute, in the National Institutes of Health in the United States. His current research interests include surgical treatment of lung cancer and individualized treatment of lung cancer based on cancer genotype such as EGFR mutations or ALK translocations.

He has published more than 250 papers that have featured in international peer-reviewed journals. He has been a member of the International Association for the Study of Lung Cancer (IASLC) since 2000 and has been a Board of Director since 2011.

He is a recipient of Shinoi-Kawai Award from the Japan Lung Cancer Society (2001) and JCA–Mauvernay Award from the Japanese Cancer Association (2005).
## Previous IASLC Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>IASLC Merit Award</th>
<th>IASLC Mary Mathews Award (Pathology)</th>
<th>IASLC Joseph Cullen Award (Prevention/Early Detection)</th>
<th>IASLC Scientific Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Clifton Mountain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato/ N. Bleehen</td>
<td>Geno Saccamanno</td>
<td>Jesse Steinfield</td>
<td>Robert Ginsberg</td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td></td>
<td>Daniel C. Ihde</td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td></td>
<td>Paul van Houtte</td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry Le Chevalier</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio Scagliotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce E. Johnson/ Thomas Lynch</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John K. Field</td>
<td>Nagahiro Saijo</td>
</tr>
</tbody>
</table>
IASLC Young Investigator Awards

**2013 – 2015**

**Daniela Morales-Espinosa**  
Catalan Institute of Oncology,  
Barcelona, Spain

**Peter Choi**  
Dana-Farber Cancer Institute,  
Boston, Massachusetts, USA

**Narendra Wajapeyee**  
Yale University,  
New Haven, Connecticut, USA

**2013 – 2014**

**Patrick Forde**  
Johns Hopkins University,  
Baltimore, Massachusetts, USA

**2012 – 2014**

**Daniel Costa**  
Beth Israel Deaconess Medical Center,  
Boston, Massachusetts, USA

**Anne-Marie Baird**  
St. James Hospital,  
Dublin, Ireland

**Alex Drilon**  
Memorial Sloan Kettering Cancer Center,  
New York, USA

**Jih-Hsiang Lee**  
National Taiwan University Hospital,  
Taipei, Taiwan

**Don Nguyen**  
Yale University School of Medicine,  
New Haven, Connecticut, USA

IASLC Patient Advocacy Awards

**SUPPORTED BY**

[IASLC Patient Advocacy Award Winners](#)  
The IASLC Patient Advocacy Award Winners will receive their award during the IASLC Business Meeting on:  
Monday, October 28  
07:00 – 08:00  
BAYSIDE AUDITORIUM A, LEVEL 1

**Clifton F. Mountain Foundation**  
Merel Grey

**Lung Cancer Foundation of America**  
[www.LCFAmerica.org](http://www.LCFAmerica.org)  
Beth Ida Stern, Executive Director

**Asbestos Diseases Society of Australia Inc.**  
[www.asbestosdiseases.org.au](http://www.asbestosdiseases.org.au)  
Melinda Markey, Chief Operating Officer

**Trinidad Donoso, Chile**  
Individual Advocate

IASLC Global Mentorship Award

**Natthaya Triphuridet, Thailand**  
(Pulmonology)

O05.03: Screening of Lung Cancer by Low-Dose CT (LDCT), Digital Tomosynthesis (DT) and Chest Radiography (CR) in a High Risk Population: A Comparison of Detection Methods
**WCLC 2013 Fellowship Awards**

**SUPPORTED BY**

**Boehringer Ingelheim**

The WCLC 2013 Fellowship Award Winners will receive their award during the IASLC Business Meeting on:

Monday, October 28 07:00 – 08:00
BAYSIDE AUDITORIUM A, LEVEL 1

**Kathryn Ann Gold, USA**

MO20.02: Proteomic analysis identifies baseline PI3K/Akt pathway activation and treatment-induced suppression of mTOR signaling as determinants of response to MEK inhibition

**Vinai Gondi, USA**

O14.01: Memory preservation with conformal avoidance of the hippocampus during whole-brain radiotherapy for patients with brain metastases: Preliminary results of RTOG 0933

**Jill Everland Larsen, Australia**

O12.05: Defining the role of ZEB1 in the pathogenesis of non-small cell lung cancer (NSCLC) using immortalized human bronchial epithelial cells (HBECs)

**Yu Liu, China**

O04.07: Distinguish synchronous multiple primary lung cancers from intrapulmonary metastasis by genome sequencing

**Tatsuo Maeyashiki, Japan**

O13.02: Is the Limited Surgical Resection Appropriate for Non-Small Cell Lung Cancers More than 2 cm in a Diameter? - Proposed Surgical Indication by the Presence of Ground-glass Opacity of The Tumor on Thin-section CT scan

**Victor Daniel Martinez Zamora, Canada**

O18.01: Multi-‘omic analysis of an arsenic-associated lung squamous cell carcinoma reveals specific DNA level signatures

**Geoffrey R. Oxnard, USA**

MO15.06: A prospective internet-based study of patients with lung cancer harboring baseline EGFR T790M to identify germline carriers and characterize familial risk

---

**Tai Sun Park, Korea**

P1.10-046: Heat shock protein 70 as a predictive maker in patients with platinum-based adjuvant chemotherapy in resected non-small cell lung cancer

**Jessica C. Sieren, USA**

O05.02: Local, Surrounding and Global Features for Improved Computer Aided Diagnosis of Lung Cancer

**Anish Thomas, USA**

MO03.07: Clinical activity of sunitinib in patients with thymic carcinoma

---

**WCLC 2013 Developing Nation Awards**

**SUPPORTED BY**

**Cancer Council Australia**

The WCLC 2013 Developing Nation Award Winners will receive their award during the IASLC Business Meeting on:

Monday, October 28 07:00 – 08:00
BAYSIDE AUDITORIUM A, LEVEL 1

**Ning Cheng, China**

O18.07: A Retrospective Cohort Mortality Study in Jingchuan of China - the Largest Nickel Population in World

**Neekkan Dey, India**

MO04.01: Molecular mechanisms of cigarette smoke induced hyper-proliferation of human lung cells and its prevention

**Victor Daniel Martinez Zamora, Canada**

O18.01: Is the Limited Surgical Resection Appropriate for Non-Small Cell Lung Cancers More than 2 cm in a Diameter? - Proposed Surgical Indication by the Presence of Ground-glass Opacity of The Tumor on Thin-section CT scan

**Geoffrey R. Oxnard, USA**

MO15.06: A prospective internet-based study of patients with lung cancer harboring baseline EGFR T790M to identify germline carriers and characterize familial risk

---

**Urvashi Kaushik, India**

P2.01-002: Targeting chaperone activity and chaperone expression in human lung cancer cells sensitizes them to chemotherapy and radiotherapy

**Natalia Khranovska, Ukraine**

P2.11-039: Results from phase III trial of dendritic cell based vaccine immunotherapy in patients with -IIIA stage non-small-cell lung cancer
Yubo Liu, China
P3.05-002: Resistance to BH3 mimetic S1 in non-small cell lung cancer cells that phosphorylate Bim through ERK1/2 and lead to its proteasomal degradation

C.S. Pramesh, India
O09.07: Phase II Double-blind Randomized trial comparing POsterolateral Thoracotomy versus Nerve Sparing Thoracotomy for lung surgery (PoTNeST) - Impact of preservation of the neurovascular bundle during thoracotomy on post-operative pain

Subrata Saha, India
MO13.06: Prophylactic Cranial Irradiation for patients with Small Cell Lung Cancer with 30 Gy in 10 fractions - analysis of efficacy and subset analysis of neurocognitive impairment.

Cynthia Sternberg, Brazil
P3.01-004: Pre-clinical evaluation of Death Receptor-5 activation as a feasible option for K-ras mutant NSCLC therapy

Natthaya Triphuridet, Thailand
O05.03: Screening of Lung Cancer by Low-Dose CT (LDCT), Digital Tomosynthesis (DT) and Chest Radiography (CR) in a High Risk Population: A Comparison of Detection Methods

WCLC 2013 Lectureship Awards

The WCLC 2013 Lectureship Award Winners will receive their award before their presentation in the Abstract Session.

Dan Idhe Lectureship Award – Medical Oncology
Suresh Ramalingam, USA
O03.01: GALAXY-1: Randomized phase II study of docetaxel with or without gantetespib in advanced lung adenocarcinoma: Results in biomarker sub-groups and all adenocarcinoma patients

Robert Ginsberg Lectureship Award – Surgery
Meinoshin Okumura, Japan
MO03.01: Outcome of surgical treatment for thymic epithelial tumors based on the nationwide retrospective database of 3033 patients in Japan

Heine Hansen Lectureship Award – SCLC
Michael Seckl, UK
O21.01: A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC)

Clifton Mountain Lectureship Award – Staging
Min Kim, USA
P1.07-010: Preoperative Fluorodeoxyglucose-Positron Emission Tomography Scan with Positive N1 Disease Does Not Predict Worse Survival in Pathologic Stage II Patients

Tsuguo Naruke Lectureship Award – Surgery
Junji Yoshida, Japan
O13.01: Limited Resection Trial for Pulmonary Ground-glass Opacity Nodules: Case Selection Based on High Resolution Computed Tomography: Interim Results

Simon Chan Shang Whai - IASLC - LFA Cancer Research Travel Awards

The Simon Chan Shang Whai – IASLC – LFA Cancer Research Travel Award Winners will receive their award during the IASLC Business Meeting on:
Monday, October 28 07:00 – 08:00
BAYSIDE AUDITORIUM A, LEVEL 1

Jiayu Li, China
O01.05: EGFR wild-type NSCLC patients with high miR-200c expression can benefit from EGFR-TKI

Qixue Wang, China
MO04.08: Activation of liver X receptor induces interferon-gamma production and inhibits tumor growth

Yuanyuan Li, China
P1.01-009: The Role of Autophagy Induced by Tyrosine Kinase Inhibitors in Non-small Cell Lung Carcinoma
Social Events

Darling Harbour Fireworks (dedicated to IASLC, WCLC and lung cancer)
Saturday, October 26 21:00 – 21:30
DARLING HARBOUR, DIRECTLY IN FRONT OF THE SYDNEY CONVENTION & EXHIBITION CENTRE

Opening Plenary Session and Welcome Reception
Sunday, October 27
Opening Plenary Session 18:45 – 20:15
PLENARY HALL, EXHIBITION CENTRE, GROUND LEVEL

Welcome Reception 20:15 – 21:30
EXHIBIT HALL, EXHIBITION CENTRE, GROUND LEVEL
Inclusive with full Conference and Accompanying Person Registration.

The Opening Plenary Session will set the tone for the Conference with an official ‘Welcome to Country’ by an Elder, welcome remarks from the Conference Presidents and the IASLC President followed by a keynote presentation by The Honourable Nicola Roxon, Australia and a summary of 40 Years IASLC history by the new CEO of IASLC, Dr. Fred Hirsch, USA.

You will then move into the Exhibit Hall for the Welcome Reception with local wines and canapés, allowing you the opportunity to mix and mingle with colleagues, friends and exhibitors.

IASLC Happy Hour
Monday, October 28 and Tuesday, October 29 15:30 – 16:15
AT THE IASLC BOOTH #1417

Join IASLC Executives and Staff Members and learn more about the IASLC team and IASLC’s mission.
**Gala Dinner (limited capacity, ticketed event)**

**Tuesday, October 29**

19:15 – 23:00

**Reception**

19:15 – 20:00

FOYER PLENARY HALL, EXHIBITION CENTRE, GROUND LEVEL

**Dinner**

20:00 – 23:00

PLENARY HALL, EXHIBITION CENTRE, GROUND LEVEL

On this evening you will enjoy an amazing journey through Australia - from the bush of the Western Australia, through the iconic deserts of the Red Centre and grazing lands of Australia, along the pristine sunny beaches of the Gold Coast, amidst the lush wine valleys of New South Wales and into the dazzling nightlife of Sydney.

The evening starts off with a reception showcasing Australian produce and wines. An Australian wildlife pen is set up, giving you an interactive opportunity to get up close and personal with some of Australia’s unique and famous wildlife such as kangaroos, joeys, lizards, etc. Be sure to bring your camera!

You will then be invited into the dining hall for a night of regional cuisine, indigenous culture and live music. All your senses will be delighted as you sample the best ingredients Australia has to offer, experience a powerful and mesmerizing indigenous dance performance and ride to the rhythms of Australian classics and world’s favorite hits of all times. Don’t forget your dancing shoes as the evening is sure to capture even the slightest of hearts.

**Dress Code**

**DRESS CODE = AUSTRALIAN FORMAL**

**Tickets**

Tickets can be booked at the time of registration via the online registration form or onsite at the Ticket Counter in the registration area (subject to availability).

*Registered Delegates: $200 AUD + 10% GST*

*Friends and Guests: $200 AUD + 10% GST*
Special Events and Sessions

Sunday, October 27

07:30 – 12:00  Inaugural Cochrane Workshop (open to all WCLC Delegates)
BAYSIDE 204 A+B, LEVEL 2  Including Coffee Break

The Cochrane Collaboration is an international, independent, not-for-profit organisation of over 28,000 contributors from more than 100 countries, dedicated to making up-to-date, accurate information about the effects of health care readily available worldwide. Cochrane contributors work together to produce systematic reviews of healthcare interventions, known as Cochrane Reviews, which are published online in The Cochrane Library. If you are intending to undertake one of these high quality reviews or to update your knowledge, this is likely to be of benefit.

07:30 – 12:00  Chinese Alliance Against Lung Cancer Session (open to all WCLC Delegates)
PARKSIDE AUDITORIUM, LEVEL 1

Lung cancer continues to be an increasing problem in many parts of the world including China and the Asia-Pacific. It has been reported that only 5% of global cancer resources are spent in developing countries. This Inaugural CALC session highlights the latest research and issues in China in the context of global lung cancer knowledge and control.

★ Including Chinese Poster Display during Coffee Break
★ Including Coffee Break
Simultaneous translation English >> Mandarin provided

08:00 – 11:30  Young Investigator & First Time Attendee Session
PARKSIDE BALLROOM A+B, LEVEL 1

The Young Investigator’s Session is designed specifically for medical professionals in training and those in the early stages of their career. It will provide a unique opportunity to interact with recognized leaders in the field of lung cancer. The session will provide practical, treatment-oriented, and career-related information. If this is your first WCLC Conference don’t miss this session as it will provide you with inside information on how the Conference works and will highlight important sessions and networking opportunities you shouldn’t miss.

BREAKFAST AND A COFFEE BREAK DURING THIS SESSION ARE GENEROUSLY PROVIDED BY

Bristol-Myers Squibb

10:00 – 12:00  Addiction Incorporated – Documentary Screening (Open to Public)
BAYSIDE AUDITORIUM B, LEVEL 1

Addiction Incorporated Documentary Screening: The true story of the tobacco companies’ commitment to addicting the human brain, and how the world came to know about it. Featuring a post-screening panel discussion with Dr. Carolyn Dresler, IASLC Board Member and Dr. Mike Daube, Australia.

12:30 – 17:00  International Thoracic Oncology Nursing Forum (ITONF) Workshop
BAYSIDE GALLERY A, LEVEL 1

Meeting the Needs of Nurses...

The ITONF are delighted to present this workshop. Officially launched at the WCLC 2011 Conference in Amsterdam, ITONF aims to be an internationally recognized body of expert knowledge in thoracic
oology nursing. It provides members with leadership, a united voice, support, education and a unique forum to network internationally. This interactive workshop will provide an excellent opportunity for learning, sharing of knowledge as well as networking, and renewal of friendships. Nurses, palliative care & allied health professionals at all levels involved in the delivery of care to patients with lung cancer will find this workshop stimulating and informative. Attendance will provide the opportunity to network with others who are interested in lung cancer with outcomes from this workshop providing direction for the future work of the ITONF Steering Committee.

13:00 – 15:30  A Focus on Lung Cancer - An Interactive Consumer Forum  
BAYSIDE 204 A+B, LEVEL 2
Lung Foundation Australia is delighted to host this interactive consumer forum which will provide an unique up-close and personal event for patients, carers and their families. Attendees will hear short presentations from Dr. David Carbone on lung cancer around the world, Cancer Australia will provide a snapshot of lung cancer in Australia, other presentations will include how the diagnosis of lung cancer has changed, an update on lung cancer screening, and advances in chemotherapy biomarker driven therapies. Advocates from around the world will provide an overview of survivorship and patients powering progress. This Consumer Forum will be facilitated by a professional health journalist and provides an opportunity to be involved in an informal interactive question and answer session with some of the world’s leaders in lung cancer research, treatment, care and advocacy.

17:30 – 18:30  Progress in Lung Cancer:  
Celebrating 40 Years of IASLC and Research Progress  
PARKSIDE AUDITORIUM, LEVEL 1
In this session experts will highlight developments in different areas of lung cancer and thoracic oncology over the last 40 years.

Monday, October 28

07:00 – 08:00  IASLC Business Meeting  
BAYSIDE AUDITORIUM A, LEVEL 1
Breakfast provided. Including Award Presentations and updates on IASLC activities, future meetings, etc.

BAYSIDE 101, LEVEL 1

15:30 – 16:15  IASLC Happy Hour  
IASLC BOOTH #1417, EXHIBIT HALL, GROUND LEVEL
IASLC members and those interested in the association as well as its mission and goals are invited to join IASLC Board Members and Staff during the IASLC Happy Hour at the IASLC Booth.

Tuesday, October 29

15:30 – 16:15  IASLC Happy Hour  
IASLC BOOTH #1417, EXHIBIT HALL, GROUND LEVEL
IASLC members and those interested in the association as well as its mission and goals are invited to join IASLC Board Members and Staff during the IASLC Happy Hour at the IASLC Booth.
Hands On Training Sessions

**NOTE:** ATTENDANCE FOR REGISTERED WCLC DELEGATES ONLY

### COVIDIEN / SUPERDIMENSION HANDS ON TRAINING SESSION

**Sunday, October 27** 12:30 – 16:00

**BAYSIDE GALLERY B, LEVEL 1**

**Introduction to Electromagnetic Navigation Bronchoscopy**

The primary objective for this activity is to introduce physicians to the Superdimension Electromagnetic Navigation Bronchoscopy System. Key program components will include didactic presentations by key opinion leaders as well as hands-on planning and procedure lab exercises.

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 13:00</td>
<td>Clinical Background</td>
</tr>
<tr>
<td>13:00 – 13:30</td>
<td>Review Electromagnetic Navigation Bronchoscopy</td>
</tr>
<tr>
<td>13:30 – 15:30</td>
<td>ENB Lab Sessions, Planning Station, Navigation Station, Sampling Station, Markers for SBRT Station, Markers for Localization Station</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Business &amp; Clinical Case Studies</td>
</tr>
</tbody>
</table>

**Faculty** | Douglas Minnich MD, Thoracic Surgery, University of Alabama at Birmingham

### ABBOTT HANDS ON TRAINING SESSION

**Sunday, October 27** 10:00 – 15:00

**PARKSIDE 110 A+B, LEVEL 1**

**Molecular Diagnosis of Gene Fusions by FISH for Targeted Therapy**

Presented by Dr. Marileila Varella Garcia, USA

This interactive educational activity is directed to medical professionals aiming to discuss scoring of ALK FISH in lung cancer specimens. The session includes individual case reviews of a variety of patients.

**Learning objectives include:**

- Understand the break-apart probe design and its performance in rearrangements derived from translocations, deletions and inversions.
- Recognize typical FISH patterns supporting interpretation of negative and positive for ALK rearrangements.
- Discuss similarities and differences between ALK FISH and other FISH assays in lung cancer specimens such as ROS1 and RET.
- Learn about simplifying FISH scoring with automated image capture system.
- Identify acceptable hybridization conditions and distinguish features indicating failure of quality assessment.
- Learn about variant ALK FISH patterns that may pose interpretation challenges.
- Establish optimal pre-hybridization procedures based on histological characteristics and/or technical variables.

Abbott Molecular is proud to host this diagnostic education session. Box lunches will be available.
# Industry Supported Symposia

## Sunday, October 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 13:30</td>
<td>Symposium supported by Boehringer Ingelheim: Questions in the Treatment of NSCLC: Targeting Angiogenesis</td>
<td>BAYSIDE AUDITORIUM A, LEVEL 1</td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>Symposium supported by AstraZeneca: Future Concepts in EGFR Mutation-Positive Advanced NSCLC</td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
<tr>
<td>16:00 – 17:30</td>
<td>Symposium supported by Pfizer: Preparing for Tomorrow: Molecular Diagnostics and the Changing NSCLC Landscape</td>
<td>PARKSIDE BALLROOM A+B, LEVEL 1</td>
</tr>
</tbody>
</table>

## Monday, October 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>Symposium supported by Celgene: Tackling the Challenges of Squamous Cell NSCLC Patients</td>
<td>PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Symposium supported by Myriad: Validation of a 46-Gene Expression Signature in Early-Stage Non-Small-Cell Lung Cancer</td>
<td>PARKSIDE 110 A+B, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Symposium supported by Boehringer Ingelheim: Let’s Discuss: Optimising Treatment of Advanced NSCLC</td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Symposium supported by Peregrine Pharmaceuticals: Immune Checkpoints in the Tumor Environment: Novel Targets and the Clinical Promise of Combined Immunotherapies</td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
</tbody>
</table>

## Tuesday, October 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>Symposium supported by IASLC Radiotherapy Group: What is the Appropriate Patient Population for SBRT?</td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Simultaneous Translation English &gt;&gt; Mandarin provided</td>
<td></td>
</tr>
<tr>
<td>12:15 – 13:45</td>
<td>Symposium supported by Boehringer Ingelheim: Questions in the Treatment of NSCLC: Focus on EGFR Mutation Positive NSCLC</td>
<td>BAYSIDE AUDITORIUM B, LEVEL 1</td>
</tr>
<tr>
<td>18:00 – 19:30</td>
<td>Symposium supported by Roche: New Horizons in First-Line NSCLC Therapy</td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
</tbody>
</table>

## Wednesday, October 30

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>Symposium supported by IASLC Radiotherapy Group: What is the Appropriate Patient Population for IGRT?</td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Simultaneous Translation English &gt;&gt; Mandarin provided</td>
<td></td>
</tr>
<tr>
<td>12:15 – 13:45</td>
<td>Symposium supported by BMS: Perspectives in Lung Cancer: Is Immuno-Oncology the New Treatment Paradigm?</td>
<td>PLENARY HALL, GROUND LEVEL</td>
</tr>
</tbody>
</table>
## Information for Invited Faculty and Abstract Presenters

### Registration

**INVITED FACULTY**
Invited Faculty Registration Counter

**ABSTRACT PRESENTERS**
Registered Delegate Counter

All registration counters are located in Hall 6, Parkside, Ground Level

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 26</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, October 27</td>
<td>06:00 – 20:00</td>
</tr>
<tr>
<td>Monday, October 28</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Tuesday, October 29</td>
<td>06:00 – 17:00</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>06:00 – 17:00</td>
</tr>
</tbody>
</table>

### Speaker Ready Room

All invited speakers as well as Oral and Mini Oral Abstract Presenters are required to report to the Speaker Ready Room at least 24 hours prior to their scheduled presentation in order to upload their presentation slides or to check their previously uploaded slides.

### Oral Abstract Presenters

You will have a total of **10 minutes**; 8 minutes of presentation, followed by 2 minutes time for questions from the audience. **Time limits will be strictly enforced.**

After a set of 3–4 related abstract presentations, a Discussant (keynote speaker) will provide a brief summary of the work that has been presented, commenting on the strengths and weaknesses and placing it in the context of other research / knowledge in the relevant area.

Please be in the room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.

You are asked to prepare a PowerPoint Presentation with **maximum 10 slides** (not including title and disclosure slide).

All presenters **MUST include a statement disclosing any conflict of interest** related to your abstract as the first slide of your presentation.

---

### NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS

Computers are available to preview and upload presentations. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Ready Room, no presentation submissions will be accepted in the session rooms.
**Mini Oral Abstract Presenters**

You will have a total of **5 minutes**; 3 minutes of presentation, followed by 2 minutes time for questions from the audience. **Time limits will be strictly enforced.**

Please be in the room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.

You are asked to prepare a PowerPoint Presentation with **maximum 5 slides** (not including title and disclosure slide).

All presenters **MUST include a statement disclosing any conflict of interest** related to your abstract as the first slide of your presentation.

---

**Poster Presenters**

All Poster Presentations/Boards are located in the Exhibit Hall and each Poster Board is identified by a professionally lettered sign with the assigned Poster Number. The Poster Board Number corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Onsite Program.

**Poster Session 1**  Monday, October 28  
**Poster Session 2**  Tuesday, October 29  
**Poster Session 3**  Wednesday, October 30

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Setup Time</strong></td>
<td>08:30 – 09:30</td>
</tr>
<tr>
<td><strong>Take Down Time</strong></td>
<td>16:30 – 18:00</td>
</tr>
<tr>
<td><strong>Viewing Time</strong></td>
<td>09:30 – 16:30</td>
</tr>
<tr>
<td><strong>Presenters in Attendance</strong></td>
<td>09:45 – 10:30 and 15:30 – 16:15 (Networking Breaks)</td>
</tr>
</tbody>
</table>

---

**Poster Pick Up Counter**

EXHIBIT HALL, GROUND LEVEL, EXHIBIT INFORMATION BOOTH

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, October 27</td>
<td>20:15 – 21:30</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td></td>
</tr>
<tr>
<td>Monday, October 28</td>
<td>08:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, October 29</td>
<td>08:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, October 30</td>
<td>08:00 – 11:30</td>
</tr>
</tbody>
</table>
CME Accreditation Information

CME Accreditation

This activity is planned for AMA PRA Category 27.5 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the International Association for the Study of Lung Cancer (IASLC). IASLC is accredited by the ACCME to provide continuing medical education for physicians.

PROGRAM HIGHLIGHTS

At the 15th World Conference on Lung Cancer, the learning objectives are:

- Recommend effective tobacco control and smoking cessation
- Define regional lung cancer prevention strategies
- Define risk stratification for screening and early detection
- Identify optimal biopsy and molecular testing strategies to support individualized care
- Apply cost-effective imaging for diagnosis, staging, and follow-up
- Describe best practice multi-disciplinary management and identify barriers to its implementation
- Identify emerging technologies relevant to recent advances in treatment for lung cancer
- Define optimal symptom relief and palliation strategies for thoracic cancers
- Practice survivorship and support strategies

Disclosure Policy

All faculties participating in the continuing medical education program sponsored by the International Association for the Study of Lung Cancer (IASLC) are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s). A Disclosure statement listing or apparent conflict(s) of interest related to the content expected to disclose to the program audience has been completed by all faculties who have indicated potential relationships that could affect the objectivity of their presentation can be found in your delegate bag and on the conference website at wclc.iaslc.org. Disclosures can also be found in the supplement to the Journal of Thoracic Oncology (JTO).

CME Credits and CME Certificate

Participants must complete the Conference evaluation form and hand in at the IASLC Booth (#1417) in order to receive a certificate of CME credits. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. To obtain your certificate, simply go to the IASLC Booth (#1417) prior to leaving the Conference and hand in your completed evaluation form. The Conference evaluation form is available in the back of this book. Copies are also available at the IASLC Booth (#1417).

PRESENTATION CONTENT - FACULTY RESPONSIBILITY

Presenters warrant that nothing in their presentation is libelous or will infringe the rights of any third party. Presenters also warrant that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such materials. Upon request Presenters agree to furnish copies of said permission(s) to IASLC. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter shall indemnify IASLC for all damages, costs and expenses, including attorney’s fees, incurred by IASLC as a result of a violation of this paragraph.

CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational materials or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company.

UNLABELED USAGE STATEMENT

The information presented at the World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Some drugs or medical devices demonstrated have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice.

“Off label” uses of a drug or medical device may be described in CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e. it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the product’s approval label.

WHO SHOULD ATTEND?

The 15th World Conference on Lung Cancer will be one of the largest international gatherings of clinicians and scientists in the field of lung cancer and thoracic malignancies. Those interested in all aspects of lung cancer including surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists are encouraged to attend this conference. Also, the Conference will continue implementing special sessions for nurses, allied health professional and advocacy members.
Koala

Koalas live in eastern Australia, where the eucalyptus trees they love are most plentiful. In fact, they rarely leave these trees, and their sharp claws and opposable digits easily keep them aloft. During the day they doze, tucked into forks or nooks in the trees, sleeping for up to 18 hours.

When not asleep a koala feeds on eucalyptus leaves, especially at night. Koalas do not drink much water and they get most of their moisture from these leaves. Each animal eats a tremendous amount for its size—about two and a half pounds (one kilogram) of leaves a day. Koalas even store snacks of leaves in pouches in their cheeks.

Courtesy of nationalgeographic.com
Join IASLC

Multi-year discounts available!

**Special Offer for NEW Regular Members at WCLC** 2 years for 1 year dues (2014–2015)  
IASLC Regular Annual dues 2014  
IASLC Regular Three year *Special Rate* (2014–2016)  
IASLC Allied Professional Annual dues 2014  
IASLC Allied Professional 3-year (2014–2016)  
IASLC Developing Countries Annual dues 2014  
IASLC Developing Countries 3-year (2014–2016)  
IASLC Fellowship 2014

**Save $150 on 3-year membership**

**IASLC MEMBERSHIP BENEFITS INCLUDE**

- Collaboration with a global team of thoracic oncology experts and leaders
- Member access to *Journal of Thoracic Oncology*, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including latest in ground-breaking research and treatment of thoracic malignancies

**And much more!**  
Visit www.IASLC.org for more details.

FOR MORE INFORMATION VISIT US AT BOOTH #1417
Saturday | October 26, 2013

14:00 – 18:00 REGISTRATION OPEN
HALL 6, PARKSIDE, GROUND LEVEL

14:00 – 18:00 SPEAKER READY ROOM OPEN
PARKSIDE G04, GROUND LEVEL

Sunday | October 27, 2013

06:00 – 20:00 REGISTRATION OPEN
HALL 6, PARKSIDE, GROUND LEVEL

06:00 – 20:00 SPEAKER READY ROOM OPEN
PARKSIDE G04, GROUND LEVEL

20:15 – 21:30 EXHIBIT HALL OPEN
HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL

07:30 - 12:00 C: INAUGURAL COCHRANE WORKSHOP
BAYSIDE 204 A+B, LEVEL 2

Chairs: Ramon Rami-Porta, Spain & Fergus Macbeth, UK

07:30  C.01: INTRODUCTION TO WRITING A COCHRANE REVIEW
Fergus Macbeth, UK

07:50  C.02: WRITING A PROTOCOL
Noelle O’Rourke, UK

08:10  C.03: DEFINING A REVIEW QUESTION
Kwun Fong, Australia

08:30  C.04: SEARCHING FOR STUDIES AND SELECTING STUDIES
Virginie Westeel, France

09:10  C.05: COLLECTING DATA
Nick Pavlakis, Australia

09:30  Tea Break

10:00  C.06: ANALYSING DICHOTOMOUS DATA
Chee Khoon Lee, Australia

10:15  C.07: ANALYSING CONTINUOUS DATA
Chee Khoon Lee, Australia

10:30  C.08: ANALYSING NON-STANDARD DATA AND DESIGNS
Chee Khoon Lee, Australia

10:45  C.09: ASSESSING BIAS IN INCLUDED STUDIES
Lisa Askie, Australia

11:00  C.10: INTRODUCTION TO META-ANALYSIS
Lisa Askie, Australia

11:15  C.11: ASSESSING SMALL STUDY EFFECTS AND REPORTING BIAS
Lisa Askie, Australia

11:30  C.12: INTRODUCTION TO REVMAN
Ian Yang, Australia

11:50  C.13: FEEDBACK AND CLOSING REMARKS
Ramon Rami-Porta, Spain & Fergus Macbeth, UK
07:30 - 12:00  CALC: CHINESE ALLIANCE AGAINST LUNG CANCER SESSION

Simultaneous Translation English <-> Mandarin provided

PARKSIDE AUDITORIUM, LEVEL 1

Part 1 Chairs: Chunxue Bai, China & Yi-Long Wu, China

07:30  CALC.01: WELCOME
Chunxue Bai, China & Yi-Long Wu, China

07:40  CALC.02: KEYNOTE: EPIDEMIOLOGY AND BURDEN OF SMOKING RELATED DISEASES IN CHINA
Chunxue Bai, China

08:30  CALC.03: PATHOGENESIS AND PATHOLOGY OF NEVER SMOKING LUNG CANCER
Adi Gazdar, USA

08:50  CALC.04: SBRT FOR LUNG CANCER
Min Fan, China

09:10  CALC.05: COPD AND LUNG CANCER
Ian Yang, Australia

09:25  Morning Tea and Chinese Poster Review
Chinese Posters on display – please see page 107

Part 2 Chairs: Chunxue Bai, China & David Lam, Hong Kong

09:55  CALC.06: DIAGNOSIS OF LUNG NODULES BY CT-GUIDED LUNG BIOPSY
Yong Song, China

10:05  CALC.07: MOLECULAR SIGNATURES FOR THE ACCURATE CLASSIFICATION OF NSCLC AND NEUROENDOCRINE TUMORS AND CELL LINES
Adi Gazdar, USA

10:25  CALC.08: TARGETED THERAPIES FOR ADENOCARCINOMA, NOW AND FUTURE
Caicun Zhou, China

10:45  CALC.09: TARGETED THERAPIES FOR SCC, NOW AND FUTURE
Tony Mok, Hong Kong

11:05  CALC.10: SECOND LINE TREATMENT OF NSCLC: NEEDED TO DETECT DRIVEN GENE MUTATION STATUS
Baohui Han, China

11:15  CALC.11: MICRORNA BIOMARKERS IN LUNG CANCER
Shaohua Lu, China

11:25  CALC.12: IPF CAUSED BY EGFR-TKIS IN ASIA
Qunying Hong, China

11:35  CALC.13: NOVEL LUNG CANCER PLASMA IMMUNO-INFLAMMATORY COMPLEXES
Li Zhang, China

11:45  CALC.14: SUMMARY AND CLOSE, THANKS TO CALC, SPEAKERS AND SPONSORS
David Lam, Hong Kong & Chunxue Bai, China

Speakers of the CALC session are generously supported by Pfizer China and Destination New South Wales

08:00 - 11:30  Y: YOUNG INVESTIGATOR & FIRST TIME ATTENDEE SESSION

PARKSIDE BALLROOM A+B, LEVEL 1

Chairs: Martin Edelman, USA & Gilberto Lopes, Singapore

08:00  Breakfast

08:30  Y.1: PLANNING AN ACADEMIC CAREER IN LUNG CANCER
Natasha Leighl, Canada

08:50  Y.2: HOW TO PRESENT DATA AT A CONFERENCE
Michael Boyer, Australia

09:10  Y.3: HOW TO WRITE A GRANT APPLICATION FOR THE IASLC
Karen Kelly, USA

09:30  Y.4: HOW TO GET YOUR PAPERS PUBLISHED
James Jett, USA

09:50  Y.5: USING THE PUBLISHED LITERATURE EFFECTIVELY
Martin Stockler, Australia

10:20  Refreshment Break

Primo Lara, USA

11:00  Y.7: Q&A AND NETWORKING OPPORTUNITY WITH LONGSTANDING IASLC MEMBERS
10:00 – 12:00  ADDICTION INCORPORATED (DOCUMENTARY SCREENING)

BAYSIDE AUDITORIUM B, LEVEL 1
Chairs: Carolyn Dresler, USA & Mike Daube, Australia

10:00 – 15:00  ABBOTT HANDS ON TRAINING SESSION: MOLECULAR DIAGNOSIS OF GENE FUSIONS BY FISH FOR TARGETED THERAPY

PARKSIDE 110 A+B, LEVEL 1
Chair: Marileila Varella Garcia, USA
Lunch Boxes will be provided

Abbott Molecular

12:00 – 13:30  SYMPOSIUM SUPPORTED BY BOEHRINGER INGELHEIM: QUESTIONS IN THE TREATMENT OF NSCLC: TARGETING ANGIOGENESIS
BAYSIDE AUDITORIUM A, LEVEL 1

12:30 – 16:00  COVIDIEN/SUPERDIMENSION HANDS ON TRAINING SESSION: INTRODUCTION TO ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY

BAYSIDE GALLERY B, LEVEL 1
Chair: Douglas Minnich, USA

12:30  Clinical Background
13:00  Review Electromagnetic Navigation Bronchoscopy
13:30  ENB Lab Sessions
  • Planning Station
  • Navigation Station
  • Sampling Station
  • Markers for SBRT Station
  • Markers for Localization Station

15:30  Business & Clinical Case Studies

superDimension®

12:30 - 17:00  ITONF: INTERNATIONAL THORACIC ONCOLOGY NURSING FORUM (ITONF) WORKSHOP

BAYSIDE GALLERY A, LEVEL 1
Chair: Beth Ivimey, Australia

12:30  ITONF.01: OPENING OF WORKSHOP (ITONF UPDATE AND WORKSHOP INTRO)
Beth Ivimey, Australia

12:40  ITONF.02: PREPARING NURSES FOR THE NEXT GENERATION OF MDT LUNG CANCER CARE
Meinir Krishnasamy, Australia

13:35  ITONF.03: OUT OF THE SHADOWS INTO THE CLINIC
Janine Cataldo, USA

14:05  ITONF.04: SURVIVORSHIP - HOW DO WE DEFINE IN LUNG CANCER
Caitlin Broderick, Australia

14:30  Networking Break

15:00  ITONF.05: POSITIVE IMPACT OF SPECIALIST LUNG CANCER NURSES ON BETTER PATIENT OUTCOMES
Angela Tod, UK

15:40  ITONF.06: NON-PHARMACOLOGICAL MANAGEMENT OF BREATHLESSNESS AND COUGH IN LUNG CANCER PATIENTS
Alex Molassiotis, Hong Kong

16:20  ITONF.07: WORKSHOP CLOSE / QUESTIONS
Beth Ivimey, Australia

16:30  ITONF MEMBERS MEETING DISCUSSION
<table>
<thead>
<tr>
<th>13:00 – 15:30</th>
<th>A FOCUS ON LUNG CANCER - AN INTERACTIVE CONSUMER FORUM</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAYSIDE 204 A+B, LEVEL 1</td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>WELCOME</td>
</tr>
<tr>
<td>Glenda Colburn, Australia</td>
<td></td>
</tr>
<tr>
<td>13:05</td>
<td>STANDARDISING LUNG CANCER AROUND THE WORLD</td>
</tr>
<tr>
<td>David Carbone, USA</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>TACKLING LUNG CANCER IN AUSTRALIA - IMPROVING PATIENT OUTCOMES</td>
</tr>
<tr>
<td>Helen Zorbas, Australia</td>
<td></td>
</tr>
<tr>
<td>13:25</td>
<td>LUNG CANCER - WHERE ARE WE AT?</td>
</tr>
<tr>
<td>Henry Marshall, Australia</td>
<td></td>
</tr>
<tr>
<td>13:35</td>
<td>ADVANCES IN DIAGNOSING LUNG CANCER</td>
</tr>
<tr>
<td>13:45</td>
<td>ADVANCES IN LUNG CANCER TREATMENTS</td>
</tr>
<tr>
<td>David Carbone, USA</td>
<td></td>
</tr>
<tr>
<td>13:55</td>
<td>PATIENTS POWERING PROGRESS</td>
</tr>
<tr>
<td>Bonnie J. Addario, USA</td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>Refreshment Break</td>
</tr>
<tr>
<td>14:15</td>
<td>INTERACTIVE Q&amp;A SESSION</td>
</tr>
<tr>
<td>- WITH PANEL</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>FORUM SUMMARY FOLLOWED BY LIGHT REFRESHMENTS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14:00 – 15:30</th>
<th>SYMPOSIUM SUPPORTED BY ASTRAZENECA: FUTURE CONCEPTS IN EGFR MUTATION-POSITIVE ADVANCED NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17:30 – 18:30</th>
<th>G01: PROGRESS IN LUNG CANCER: CELEBRATING 40 YEARS OF IASLC AND RESEARCH PROGRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
<td></td>
</tr>
<tr>
<td>Chairs: Tony Mok, Hong Kong &amp; Peter Goldstraw, UK</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>G01.1: SURGERY AND STAGING</td>
</tr>
<tr>
<td>Hisao Asamura, Japan</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>G01.2: EARLY DETECTION, ETIOLOGY, EPIDEMIOLOGY, PULMONOLOGY AND RADIOLOGY</td>
</tr>
<tr>
<td>Pieter E. Postmus, Netherlands</td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>G01.3: BIOLOGY AND PATHOLOGY</td>
</tr>
<tr>
<td>Fred Hirsch, USA</td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td>G01.4: NON-SURGICAL THERAPY</td>
</tr>
<tr>
<td>Paul Bunn, Jr., USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18:45 – 20:15</th>
<th>PL01: OPENING PLENARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLENARY HALL, GROUND LEVEL</td>
<td></td>
</tr>
<tr>
<td>Chairs: Michael Boyer, Australia &amp; Kwun Fong, Australia</td>
<td></td>
</tr>
<tr>
<td>WELCOME TO COUNTRY</td>
<td></td>
</tr>
<tr>
<td>WELCOME SPEECHES AND AWARD CEREMONIES (IASLC Distinguished Awards)</td>
<td></td>
</tr>
<tr>
<td>PL01.01: 40 YEARS IASLC</td>
<td></td>
</tr>
<tr>
<td>Fred Hirsch, USA</td>
<td></td>
</tr>
<tr>
<td>PL01.02: YOU CAN TAKE ON THE TOBACCO INDUSTRY AND WIN</td>
<td></td>
</tr>
<tr>
<td>The Honourable Nicola Roxon, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>20:15 – 21:30</th>
<th>WELCOME RECEPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>★ EXHIBIT HALL, GROUND LEVEL</td>
<td></td>
</tr>
</tbody>
</table>
Boomerang

Boomerang is a curved throwing stick used chiefly by the Australian Aborigines for hunting.

A boomerang is made of roughly V-shaped hard wood, with arms slightly skewed, and the angle between the arms ranging from 90° to about 160°. Both edges are sharpened; one surface is flat, and the other slightly convex, so the boomerang blades are carved in the shape of an airfoil.

Aboriginals often paint or carve designs on boomerangs related to legends and traditions, and some continue to be used in some religious ceremonies — and clapped together, or pounded on the ground as accompaniment to songs.

Courtesy of boomerangshack.com
A free, online clinical information resource for health professionals, patients and carers.

Evidence-based and peer-reviewed, eviQ features:

- standard cancer treatment protocols
- chemotherapy dose calculator
- treatment-specific patient information sheets
- opioid conversion calculator
- clinical procedures
- health professional discussion forums
- diverse content areas, including cancer genetics, medical oncology, radiation oncology and haematology
- point-of-care education resources
- standardised reference data for Oncology Information Systems (OIS)

Access online, anytime, anywhere.

Free registration www.eviq.org.au

Working together to lessen the impact of cancer
### Monday | October 28, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:00 – 17:00</td>
<td><strong>REGISTRATION OPEN</strong>&lt;br&gt;HALL 6, PARKSIDE, GROUND LEVEL</td>
</tr>
<tr>
<td>06:00 – 17:00</td>
<td><strong>SPEAKER READY ROOM OPEN</strong>&lt;br&gt;PARKSIDE G04, GROUND LEVEL</td>
</tr>
<tr>
<td>09:30 – 16:30</td>
<td><strong>EXHIBIT HALL OPEN</strong>&lt;br&gt;HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>IASLC BUSINESS MEETING</strong>&lt;br&gt;★ BAYSIDE AUDITORIUM A, LEVEL 1&lt;br&gt;<strong>Breakfast provided (Foyer Bayside, Level 1)</strong></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>TOBACCO CONTROL: FROM PLAIN PACKAGING TO SMOKE-FREE GENERATIONS</strong>&lt;br&gt;BAYSIDE 201 - 203, LEVEL 2&lt;br&gt;<strong>Discussion: Prevention &amp; Epidemiology</strong>&lt;br&gt;<strong>Chairs: The Honourable Nicola Roxon, Australia &amp; Carolyn Dresler, USA &amp; Mike Daube, Australia</strong></td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>SYMPOSIUM SUPPORTED BY CELGENE: TACKLING THE CHALLENGES OF SQUAMOUS CELL NSCLC PATIENTS</strong>&lt;br&gt;PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>SYMPOSIUM SUPPORTED BY MYRIAD: VALIDATION OF A 46-GENE EXPRESSION SIGNATURE IN EARLY-STAGE NON-SMALL-CELL LUNG CANCER</strong>&lt;br&gt;PARKSIDE 110 A+B, LEVEL 1</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>SYMPOSIUM SUPPORTED BY BOEHRINGER INGELHEIM: LET’S DISCUSS: OPTIMISING TREATMENT OF ADVANCED NSCLC OPTIMISING TREATMENT OF ADVANCED NSCLC</strong>&lt;br&gt;PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>SYMPOSIUM SUPPORTED BY PEREGRINE PHARMACEUTICALS: IMMUNE CHECKPOINTS IN THE TUMOR ENVIRONMENT: NOVEL TARGETS AND THE CLINICAL PROMISE OF COMBINED IMMUNOTHERAPIES</strong>&lt;br&gt;PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE01: NLST – ADDITIONAL LESSONS AND FUTURE DIRECTIONS</strong>&lt;br&gt;BAYSIDE GALLERY B, LEVEL 1&lt;br&gt;<strong>Meet the Expert Session (ticketed): Imaging/Staging</strong>&lt;br&gt;Christine Berg, USA</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE02: MOUSE MODELS OF ONCOGENIC DRIVERS IN NSCLC</strong>&lt;br&gt;BAYSIDE GALLERY A, LEVEL 1&lt;br&gt;<strong>Meet the Expert Session (ticketed): Biology</strong>&lt;br&gt;Kwok-Kin Wong, USA</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE03: NEUROENDOCRINE TUMOURS OF THE LUNG</strong>&lt;br&gt;BAYSIDE 106, LEVEL 1&lt;br&gt;<strong>Meet the Expert Session (ticketed): Medical Oncology</strong>&lt;br&gt;Joel Guigay, France</td>
</tr>
</tbody>
</table>
### 07:00 – 08:00  MTE04: SUBMIT YOUR CHALLENGING CASES FOR DISCUSSION & DEBATE!

**Meet the Expert Session (ticketed): Pathology**  
BAYSIDE 105, LEVEL 1  
*Chair: Edwina Duhig, Australia*  
Speakers: Andrew Nicholson, UK & Kirk Jones, USA

### 07:00 – 08:00  MTE05: NAVIGATION BRONCHOSCOPY

**Meet the Expert Session (ticketed): Pulmonology**  
BAYSIDE 104, LEVEL 1  
Takashi Ishida, Japan

### 07:00 – 08:00  MTE06: MOLECULAR PATHOLOGY APPROACH FOR EARLY CLINICAL STAGE MESOTHELIOMA: CYTOLOGICAL DIAGNOSIS, AND REACTIVE MESOTHELIAL HYPERPLASIA

**Meet the Expert Session (ticketed): Mesothelioma**  
BAYSIDE 103, LEVEL 1  
Sonja Klebe, Australia

### 07:00 – 08:00  MTE07: CHEST WALL RECON: MATERIALS, ARTIFICIAL RIBS

**Meet the Expert Session (ticketed): Surgery**  
BAYSIDE 102, LEVEL 1  
Michael Weyant, USA

### 07:00 – 08:00  MTE08: SMOKING CESSATION

**Meet the Expert Session (ticketed): Epidemiology**  
BAYSIDE 101, LEVEL 1  
Nancy Rigotti, USA

### 08:15 – 09:45  PL02: WILL PERSONALISED THERAPIES EVER “CURE” METASTATIC NSCLC?

**Plenary Session: Biology & Medical Oncology**  
PLENARY HALL, GROUND LEVEL  
*Chairs: David Gandara, USA & Desmond Carney, Ireland*

08:15  **CHAIR INTRO**

08:20  **PL02.1: IDENTIFYING DRUGGABLE TARGETS THROUGH WHOLE GENOME SEQUENCING: TCGA**  
Matthew Meyerson, USA

08:40  **PL02.2: DARK MATTER: DEFINING ONCOGENIC DRIVERS IN THE EPIGENOME**  
Charles Rudin, USA

09:00  **PL02.3: TUMOUR HETEROGENEITY AS AN OBSTACLE TO CURE**  
Charles Swanton, UK

09:20  **PL02.4: WHAT IS CURE AND HOW CAN WE ACHIEVE THIS WITH TARGETED THERAPIES?**  
Tony Mok, Hong Kong

### 09:45 – 10:30  NETWORKING BREAK

**POSTER SESSION 1**  
- Presenters are available for questions  
- Refreshments are provided  
EXHIBIT HALL, HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL

### 09:55 – 10:25  EXHIBIT SHOWCASE SESSION: BOEHRINGER INGELHEIM: SPOTLIGHT REVIEW OF THE BOEHRINGER INGELHEIM ONCOLOGY PORTFOLIO  
EXHIBIT SHOWCASE THEATER, EXHIBIT HALL, GROUND LEVEL
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Abstract</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>001: PROGNOSTIC AND PREDICTIVE BIOMARKERS I</td>
<td>001.01: GENETIC POLYMORPHISMS OF INFLAMMATORY AND DNA REPAIR PATHWAYS, RADIATION-RELATED ESOPHAGITIS AND PNEUMONITIS IN DEFINITIVE CHEMORADIATION TREATED NON-SMALL CELL LUNG CANCER PATIENTS</td>
<td>Andrew Hope, Canada</td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
<tr>
<td>10:40</td>
<td>001.02: MICRORNA SIGNATURE PREDICTS SURVIVAL IN RESECTABLE SMALL-CELL LUNG CANCER</td>
<td>Luhua Wang, China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>001.03: BRM PROMOTER VARIANTS AND SURVIVAL OUTCOMES OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A VALIDATION STUDY IN THE NCIC CLINICAL TRIALS GROUP (NCIC-CTG) BR24 CLINICAL TRIAL</td>
<td>Sinead Cuffe, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>001.04: DISCUSSANT</td>
<td>Gabriella Sozzi, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>001.05: EGFR WILD-TYPE NSCLC PATIENTS WITH HIGH MIR-200C EXPRESSION CAN BENEFIT FROM EGFR-TKI</td>
<td>Jiayu Li, China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>001.06: DYNAMIC CHANGE IN PLASMA EGFR MUTATION DNA IN RESPONSE TO FIRST LINE THERAPY FOR ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Tony Mok, Hong Kong</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td>001.07: RANDOMIZED PROTEOMIC STRATIFIED PHASE III STUDY OF SECOND LINE ERLOTINIB (E) VERSUS CHEMOTHERAPY (CT) IN PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG CANCER (PROSE): SECONDARY ENDPOINT ANALYSIS</td>
<td>Vanessa Gregorc, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>001.08: DISCUSSANT</td>
<td>David Gandara, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>002: NSCLC - COMBINED MODALITY THERAPY I</td>
<td>002.01: GEOGRAPHIC DIFFERENCES IN THE COMBINED-MODALITY TREATMENT OF STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER: RESULTS FROM A GLOBAL PHASE III TRIAL OF TECEMOTIDE (L-BLP25)</td>
<td>Nicholas Thatcher, UK</td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
<tr>
<td>10:40</td>
<td>002.02: TECEMOTIDE (L-BLP25) IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER IN THE PHASE III START STUDY: FURTHER ENDPOINT AND EXPLORATORY BIOMARKER RESULTS</td>
<td>Paul Mitchell, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>002.03: VALUE OF ADDING ERLOTINIB TO THORACIC RADIATION THERAPY WITH CHEMOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER: A PROSPECTIVE PHASE II STUDY</td>
<td>Ritsuko Komaki, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>002.04: DISCUSSANT</td>
<td>Everett Vokes, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>002.05: MAJOR PATHOLOGIC RESPONSE (≤10% VIABLE TUMOR) FOLLOWING NEOADJUVANT CHEMOTHERAPY AS A SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH PATHOLOGICALLY DOCUMENTED STAGE IIIA (N2) LUNG ADENOCARCINOMAS</td>
<td>Jamie Chaft, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>002.06: PREDICTORS OF TRIMODALITY THERAPY USE AND OVERALL SURVIVAL IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) IN THE NATIONAL CANCER DATABASE</td>
<td>Mary Jo Fidler, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td>002.07: IS THERE A SURVIVAL BENEFIT IN PATIENTS WITH STAGE IIIA (N2) NON-SMALL CELL LUNG CANCER UNDER NEOADJUVANT CHEMOTHERAPY AND/OR RADIOTHERAPY FOLLOWED BY SURGERY ADMINISTRATION: A SYSTEMATIC REVIEW AND META-ANALYSIS</td>
<td>Yaping Xu, China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>002.08: DISCUSSANT</td>
<td>Eric Vallieres, USA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 10:30 – 12:00  O03: NSCLC - TARGETED THERAPIES I

**Oral Abstract Session: Medical Oncology**

**BAYSIDE AUDITORIUM B, LEVEL 1**

**Chairs:** Jeffrey Ross, USA  
& James Chih-Hsin Yang, Taiwan

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>O03.01</td>
<td>GALAXY-1: RANDOMIZED PHASE II STUDY OF DOCETAXEL WITH OR WITHOUT GANETESPIB IN ADVANCED LUNG ADENOCARCINOMA: RESULTS IN BIOMARKER SUB-GROUPS AND ALL ADENOCARCINOMA PATIENTS</td>
<td>Suresh Ramalingam, USA</td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>O03.02</td>
<td>RANDOMIZED PHASE-3 TRIAL (INSPIRE) OF NECITUMUMAB PLUS CISPLATIN-PEMETREXED VERSUS CISPLATIN-PEMETREXED ALONE AS FIRST-LINE THERAPY IN STAGE IV NON-SQUAMOUS NSCLC</td>
<td>Luis Paz-Ares, Spain</td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>O03.03</td>
<td>OUTCOMES OF NSCLC PATIENTS ON PHASE I TRIALS: THE IMPORTANCE OF MOLECULAR AND PATIENT SELECTION</td>
<td>Daniel Shao-Weng Tan, Singapore</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>O03.04</td>
<td>DISCUSSANT</td>
<td>Benjamin Besse, France</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>O03.05</td>
<td>ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: FINDINGS FROM THREE TRIALS OF AFATINIB IN EGFR MUTATION-POSITIVE LUNG CANCER</td>
<td>James Chih-Hsin Yang, Taiwan</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>O03.06</td>
<td>FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)</td>
<td>Jean-Charles Soria, France</td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td>O03.07</td>
<td>INVESTIGATION OF RISK FACTORS FOR DEVELOPING INTERSTITIAL LUNG DISEASE (ILD) AND POOR PROGNOSTIC FACTORS FOR ILD DEATH IN JAPANESE PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC): A FINAL ANALYSIS OF A LARGE-SCALE ERLOTINIB SURVEILLANCE STUDY (POLARSTAR)</td>
<td>Kazuyoshi Kuwano, Japan</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>O03.08</td>
<td>DISCUSSANT</td>
<td>Federico Cappuzzo, Italy</td>
<td></td>
</tr>
</tbody>
</table>

### 10:30 – 12:00  O04: MOLECULAR PATHOLOGY I

**Oral Abstract Session: Pathology**

**PARKSIDE BALLROOM A, LEVEL 1**

**Chairs:** Ignacio Wistuba, USA  
& Wendy Cooper, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>O04.01</td>
<td>IDENTIFICATION OF CD74-NRG1, A NEW RECURRENT FUSION GENE IN INVASIVE MUCINOUS LUNG ADENOCARCINOMAS OF NEVER SMOKERS</td>
<td>Lynnette Fernandez-Cuesta, Germany</td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>O04.02</td>
<td>USING NGS FOR MUTATIONAL PROFILING OF NSCLC IN THE CLINICAL SETTING</td>
<td>George Simon, USA</td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>O04.03</td>
<td>ONCOGENE MUTATIONS AND NOVEL TRANSCRIPT FUSIONS IN LUNG ADENOCARCINOMA FROM NEVER SMOKERS</td>
<td>Jin Jen, USA</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>O04.04</td>
<td>DISCUSSANT</td>
<td>Ignacio Wistuba, USA</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>O04.05</td>
<td>EPIDEMIOLOGY OF PI3K PATHWAY ALTERATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): FINDINGS FROM THE INTERNATIONAL BASALT-1 STUDY</td>
<td>Grace Dy, USA</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>O04.06</td>
<td>AN INTERNATIONAL STANDARDIZATION STUDY USING THE ALK IHC ANTIBODY D5F3 AND A SENSITIVE DETECTION KIT DEMONSTRATES HIGH CONCORDANCE BETWEEN ALK IHC AND ALK FISH AND BETWEEN EVALUATORS</td>
<td>Murry Wynes, USA</td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td>O04.07</td>
<td>DISTINGUISH SYNCHRONOUS MULTIPLE PRIMARY LUNG CANCERS FROM INTRAPULMONARY METASTASIS BY GENOME SEQUENCING</td>
<td>Yu Liu, China</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>O04.08</td>
<td>DISCUSSANT</td>
<td>Sanja Dacic, USA</td>
<td></td>
</tr>
</tbody>
</table>
10:30 – 12:00  O05: CANCER CONTROL

**Oral Abstract Session: Prevention & Epidemiology**

**BAYSIDE AUDITORIUM A, LEVEL 1**

**Chairs:** Annette McWilliams, Australia & Nico van Zandwijk, Australia

**10:30**

**O05.01:** THE DANTE TRIAL, A RANDOMIZED STUDY OF LUNG CANCER SCREENING WITH SPIRAL CT: 7-YEAR RESULTS
Maurizio Infante, Italy

**10:40**

**O05.02:** LOCAL, SURROUNDING AND GLOBAL FEATURES FOR IMPROVED COMPUTER AIDED DIAGNOSIS OF LUNG CANCER
Jessica Sieren, USA

**10:50**

**O05.03:** SCREENING OF LUNG CANCER BY LOW-DOSE CT (LDCT), DIGITAL TOMOSYNTHESIS (DT) AND CHEST RADIOGRAPHY (CR) IN A HIGH RISK POPULATION: A COMPARISON OF DETECTION METHODS
Natthaya Triphuridet, Thailand

**11:00**

**O05.04:** DISCUSSANT
Stephen Lam, Canada

**11:15**

**O05.05:** BIENNIAL LUNG CANCER SCREENING BY LOW-DOSE CT SCAN - A SIMULATION OF COST EFFECTIVENESS IN CANADA
John Goffin, Canada

**11:25**

**O05.06:** RESOURCE UTILIZATION AND COSTS OF SCREENING HIGH-RISK INDIVIDUALS FOR LUNG CANCER IN CANADA
Sonya Cressman, Canada

**11:35**

**O05.07:** COPD-BASED ELIGIBILITY INCREASES LUNG CANCER DETECTION RATE AND LOWERS OVER-DIAGNOSIS IN CT SCREENING STUDIES
Robert Young, New Zealand

**11:45**

**O05.08:** DISCUSSANT
Henry Marshall, Australia

10:30 – 12:00  O06: CANCER CONTROL AND EPIDEMIOLOGY I

**Oral Abstract Session: Prevention/Epidemiology**

**BAYSIDE 104, LEVEL 1**

**Chairs:** Carolyn Dresler, USA & Caicun Zhou, China

**10:30**

**O06.01:** LUNG CANCER RISKS, BELIEFS, AND HEALTHCARE ACCESS AMONG THE UNDERPRIVILEGED
Jean-Francois Morere, France

**10:40**

**O06.02:** STATIN USE AND REDUCED LUNG CANCER-RELATED MORTALITY
Robert Young, New Zealand

**10:50**

**O06.03:** DISCUSSANT
Matthew Steliga, USA

**11:05**

**O06.04:** THE ASSOCIATION BETWEEN HAVING A FIRST-DEGREE FAMILY HISTORY OF CANCER AND SMOKING STATUS
Hermine Poghosyan, USA

**11:15**

**O06.05:** MULTIDISCIPLINARY SMOKING CESSATION MODEL IN A SPECIALIST ONCOLOGY HOSPITAL - OUR 5 YEAR EXPERIENCE
Marliese Alexander, Australia

**11:25**

**O06.06:** FACTORS ASSOCIATED WITH SMOKING CESSATION IN PARTICIPANTS OF THE PAN CANADIAN EARLY LUNG CANCER STUDY
Grzegorz Korpanty, Canada

**11:35**

**O06.07:** DISCUSSANT
Janine Cataldo, USA

10:30 – 12:00  O07: SUPPORTIVE AND SURGICAL CARE

**Oral Abstract Session: Surgery**

**BAYSIDE GALLERY A, LEVEL 1**

**Chairs:** Melissa Culligan, USA & Kirsten Mooney, Australia

**10:30**

**O07.01:** RANDOMIZED PHASE III TRIAL OF APREPITANT COMPARED WITH DEXAMETHASONE FOR EMESIS INDUCED BY CARBOPLATIN
Koji Takeda, Japan

**10:40**

**O07.02:** THE PREFERRED AND ACTUAL LEVELS OF INVOLVEMENT IN DECISION-MAKING AMONG PATIENTS CONSIDERING ADJUVANT CHEMOTHERAPY (ACT) FOR NON-SMALL-CELL LUNG CANCER (NSCLC)
Prunella Blinman, Australia

**11:00**

**O07.04:** DISCUSSANT
Martin Stockler, Australia

**11:15**

**O07.05:** GUIDELINES TO PREPARE AND SUPPORT PATIENTS UNDERGOING A LUNG RESECTION
Vanessa Beattie, UK
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25</td>
<td>O07.06: EARLY POST-OPERATIVE AMBULATION IS FEASIBLE AND SAFE</td>
<td>Sandeep Khandhar, USA</td>
</tr>
<tr>
<td>11:35</td>
<td>O07.07: LUNG CANCER CLINICAL TRIALS AND THE INVOLVEMENT OF THE LUNG CANCER NURSE SPECIALIST</td>
<td>John McPhelim, UK</td>
</tr>
<tr>
<td>11:45</td>
<td>O07.08: DISCUSSANT</td>
<td>Hiroshi Date, Japan</td>
</tr>
</tbody>
</table>

10:30 – 12:00 **MO01: LUNG CANCER BIOLOGY - TECHNIQUES AND PLATFORMS**

**Mini Oral Abstract Session: Biology**

**BAYSIDE 204 A+B, LEVEL 2**

*Chairs: Shaohua Lu, China & Paul Waring, Australia*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MO01.01: NEXT GENERATION SEQUENCING OF CIRCULATING TUMOUR CELLS CAPTURED BY ANTIBODY-INDEPENDENT ENRICHMENT AND MATCHED PRIMARY TUMOURS/METASTASES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER</td>
<td>Richie Soong, Singapore</td>
</tr>
<tr>
<td>10:35</td>
<td>MO01.02: CIRCULATING TUMOR CELLS DETECTION AND MOLECULAR CHARACTERIZATION OF ALK(2P23)-FUSION NON-SMALL CELL LUNG CANCER</td>
<td>Patrick Ma, USA</td>
</tr>
<tr>
<td>10:40</td>
<td>MO01.03: TRANSITIONING TO NEXT GEN TESTING OF LUNG CARCINOMA</td>
<td>Daniel Merrick, USA</td>
</tr>
<tr>
<td>10:45</td>
<td>MO01.04: COMPARISON OF MICROARRAY AND RNA SEQUENCING PLATFORMS FOR PROFILING MICRORNAS IN FORMALIN-FIXED, PARAFFIN-EMBEDDED NON-SMALL CELL LUNG CANCER SPECIMENS</td>
<td>Daniel Buitrago, USA</td>
</tr>
<tr>
<td>10:50</td>
<td>MO01.05: DISCUSSANT</td>
<td>Stephen Fox, Australia</td>
</tr>
<tr>
<td>10:00</td>
<td>MO01.06: SCREENING FOR DRUGS THAT OVERCOME Gefitinib RESISTANCE IN EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER CELLS</td>
<td>Zhi Zheng, China</td>
</tr>
<tr>
<td>11:05</td>
<td>MO01.07: INHIBITION OF THE IGF-1R SIGNALING PATHWAY POTENTIATES RESPONSES TO ALK INHIBITORS IN BOTH ALK TKI NAIVE AND ALK TKI RESISTANT LUNG CANCER</td>
<td>Christine Lovly, USA</td>
</tr>
</tbody>
</table>

11:10 MO01.08: IDENTIFYING STRATEGIES FOR THE TREATMENT OF ACQUIRED EGFR TYROSINE KINASE INHIBITOR RESISTANCE | Csilla Hasovits, Australia |

11:15 MO01.09: A NOVEL MURINE XENOGRAFT MODEL USING SAMPLES OBTAINED BY EBUS-TBNA | Takahiro Nakajima, Japan |

11:20 MO01.10: INTEGRATED MOLECULAR CHARACTERIZATION OF PATIENT-DERIVED TUMOR-GRAFTS AS INNOVATIVE MODEL FOR CLINICAL MANAGEMENT OF NON-SMALL CELL LUNG CANCER | Fabrizio Tabbo, Italy |

11:25 MO01.11: DISCUSSANT | Philip Mack, USA |

10:30 – 12:00 **MO02: GENERAL THORACIC AND MINIMALLY INVASIVE SURGERY**

**Mini Oral Abstract Session: Surgery**

**PARKSIDE 110 A+B, LEVEL 1**

*Chairs: Mark Krasnik, Denmark & Michihiko Tajiri, Japan*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MO02.01: IS LOWER ZONE LYMPH NODE DISSECTION ALWAYS MANDATORY IN PATIENTS WITH LOWER LOBE LUNG CANCER?</td>
<td>Hiroyasu Ueno, Japan</td>
</tr>
<tr>
<td>10:35</td>
<td>MO02.02: SIZE DECREASE OF GROUND-GLASS NODULES SHOULD NOT BE END OF FOLLOW-UP BUT MAY BE OPTIMAL TIMING OF CURATIVE SURGERY</td>
<td>Hiroyuki Kaneda, Japan</td>
</tr>
<tr>
<td>10:40</td>
<td>MO02.03: SURGICAL INTERVENTION STRATEGY FOR POSTOPERATIVE CHYLOTHORAX AFTER LUNG RESECTION - CLINICAL ANALYSIS OF FIFTY PATIENTS WHO DEVELOPED POSTOPERATIVE CHYLOTHORAX</td>
<td>Shinsuke Uchida, Japan</td>
</tr>
<tr>
<td>10:45</td>
<td>MO02.04: SAFETY AND LONG TERM OUTCOME OF REPEATED LUNG RESECTION FOR IPSILATERAL SECOND PRIMARY LUNG CANCER</td>
<td>Masanori Tsuchida, Japan</td>
</tr>
<tr>
<td>10:50</td>
<td>MO02.05: DISCUSSANT</td>
<td>Gail Darling, Canada</td>
</tr>
<tr>
<td>11:00</td>
<td>MO02.06: PREOPERATIVE ORAL REHYDRATION IN PATIENTS UNDERGOING THORACOSCOPIC SURGERY FOR LUNG CANCERS</td>
<td>Kunihiko Terauchi, Japan</td>
</tr>
</tbody>
</table>
11:05 MO02.07: EFFECT OF OBESITY ON PERIOPERATIVE OUTCOMES AFTER ROBOTIC ASSISTED PULMONARY LOBECTOMY: RETROSPECTIVE ANALYSIS OF 227 CONSECUTIVE PATIENTS
Matthew Thau, USA

11:10 MO02.08: THE FEASIBILITY OF SINGLE-INCISION VIDEO-ASSISTED THORACOSCOPIC SURGERY IN MAJOR PULMONARY RESECTION
Hyun Koo Kim, South Korea

11:15 MO02.09: NEEDLE SCOPIC SURGERY FOR PRIMARY LUNG CANCER: REDUCED PORT SURGERY IN THORACIC SURGERY USING FINE SCOPE AND FORCEPS
Michihiko Tajiri, Japan

11:20 MO02.10: FLUOROSCOPY-ASSISTED THORACOSCOPIC RESECTION OF PULMONARY NODULES AFTER COMPUTED TOMOGRAPHY-ASSISTED BRONCHOSCOPIC METALLIC COIL MARKING
Takanori Miyoshi, Japan

11:30 MO02.12: DISCUSSANT
Morgan Windsor, Australia

10:30 – 12:00 MO03: THYMIC MALIGNANCIES
Mini Oral Abstract Session:
Surgery & Medical Oncology
BAYSIDE GALLERY B, LEVEL 1

Chairs: Frank Detterbeck, USA
& Meinoshin Okumura, Japan

10:30 MO03.01: OUTCOME OF SURGICAL TREATMENT FOR THYMIC EPITHELIAL TUMORS BASED ON THE NATIONWIDE RETROSPECTIVE DATABASE OF 3033 PATIENTS IN JAPAN
Meinoshin Okumura, Japan

10:35 MO03.02: SURGICAL OUTCOME OF PATIENTS WITH STAGE III THYMOMA IN THE JAPANESE NATIONWIDE DATABASE
Yoshito Yamada, Japan

10:40 MO03.03: RYTHMIC: A NATIONWIDE NETWORK FOR THYMIC MALIGNANCIES IN FRANCE
Nicolas Girard, France

10:45 MO03.04: ANALYSIS OF LYMPHATIC METASTASES OF THYMIC EPITHELIAL TUMORS ON JAPANESE DATABASE
Yasushi Nakagawa, Japan

10:50 MO03.05: IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME
Rossana Berardi, Italy

10:55 MO03.06: DISCUSSANT
James Huang, USA

11:10 MO03.07: CLINICAL ACTIVITY OF SUNITINIB IN PATIENTS WITH THYMIC CARCINOMA
Anish Thomas, USA

11:15 MO03.08: INCREASED GALECTIN-1 EXPRESSION IN A THYMIC EPITHELIAL TUMOR TISSUE MICROARRAY (TMA) AND GALECTIN-1 KNOCKDOWN STUDIES IN A THYMOMA CELL LINE
Jonathan Riess, USA

11:20 MO03.09: DETECTION OF HUMAN POLYOMAVIRUS 7 IN THYMOMAS
Anne-Marie Dingemans, Netherlands

11:25 MO03.10: A MULTICENTER PROSPECTIVE STUDY OF CARBOPLATIN AND PACLITAXEL FOR ADVANCED THYMIC CARCINOMA: WEST JAPAN ONCOLOGY GROUP 4207L
Junichi Shimizu, Japan

11:30 MO03.11: DISCUSSANT
Heather Wakelee, USA

12:15 – 13:45 SYMPOSIUM SUPPORTED BY LILLY ONCOLOGY: THE CONTINUOUS EVOLUTION OF TREATMENT IN ADVANCED NSCLC
PLENARY HALL, GROUND LEVEL

12:15 – 12:45 EXHIBIT SHOWCASE SESSION: CARIS LIFE SCIENCES: CARIS MOLECULAR INTELLIGENCE: THE LUNG EXPERIENCE
EXHIBIT SHOWCASE THEATER, EXHIBIT HALL, GROUND LEVEL
### 14:00 – 15:30  E01: LDCT SCREENING
**Educational Session: Imaging/Staging**
**PARKSIDE AUDITORIUM, LEVEL 1**
**Chairs: Ugo Pastorino, Italy & Hans Daniels, Netherlands**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>E01.1</td>
<td>RISK STRATIFICATION FOR LUNG CANCER SCREENING STUDIES</td>
<td>Martin Tammemagi, Canada</td>
</tr>
<tr>
<td>14:25</td>
<td>E01.2</td>
<td>VOLUMETRICS FOR NODULE ASSESSMENT</td>
<td>Matthijs Oudkerk, Netherlands</td>
</tr>
<tr>
<td>14:45</td>
<td>E01.3</td>
<td>MOLECULAR PATHOLOGY/PROFILING OF CT DETECTED NODULES</td>
<td>Wan Lam, Canada</td>
</tr>
<tr>
<td>15:05</td>
<td>E01.4</td>
<td>IMPLEMENTING SCREENING: RECOMMENDATIONS FROM THE IASLC</td>
<td>John Field, UK</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30  E02: RADIATION TOXICITY
**Educational Session: Radiation Oncology**
**BAYSIDE GALLERY A, LEVEL 1**
**Chairs: Maria Werner-Wasik, USA & Françoise Mornex, France**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>E02.1</td>
<td>CARDIAC TOXICITY OF RADIOTHERAPY</td>
<td>Lawrence Marks, USA</td>
</tr>
<tr>
<td>14:25</td>
<td>E02.2</td>
<td>RADIATION ESOPHAGITIS</td>
<td>Jose Belderbos, Netherlands</td>
</tr>
<tr>
<td>14:45</td>
<td>E02.3</td>
<td>FUNCTIONAL BIOPHYSICAL MODEL (FUNBIPM) TO PREDICT RADIATION LUNG TOXICITY</td>
<td>Feng-Ming (Spring) Kong, USA</td>
</tr>
<tr>
<td>15:05</td>
<td>E02.4</td>
<td>NEUROTOXICITY OF CRANIAL IRRADIATION</td>
<td>Alexander Sun, Canada</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30  E03: CHEMOTHERAPY FOR NSCLC
**Educational Session: Medical Oncology**
**BAYSIDE AUDITORIUM A, LEVEL 1**
**Chairs: Robert Pirker, Austria & James Bishop, Australia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>E03.1</td>
<td>MAXIMISING THE BENEFIT OF CHEMOTHERAPY FOR ADVANCED NSCLC</td>
<td>Giuseppe Giaccone, USA</td>
</tr>
<tr>
<td>14:25</td>
<td>E03.2</td>
<td>SELECTING PATIENTS FOR MAINTENANCE THERAPY</td>
<td>Luis Paz-Ares, Spain</td>
</tr>
<tr>
<td>14:45</td>
<td>E03.3</td>
<td>OPTIMAL ADJUVANT CHEMOTHERAPY: SELECTION OF PATIENTS AND AGENTS</td>
<td>Karen Kelly, USA</td>
</tr>
<tr>
<td>15:05</td>
<td>E03.4</td>
<td>LUNG CANCER IN WOMEN</td>
<td>Silvia Novello, Italy</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30  E04: LUNG CANCER PATHOLOGY CLASSIFICATION
**Educational Session: Pathology**
**PARKSIDE 110 A+B, LEVEL 1**
**Chairs: Edwina Duhig, Australia & Ming Tsao, Canada**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>E04.1</td>
<td>ADENOCARCINOMA</td>
<td>Masayuki Noguchi, Japan</td>
</tr>
<tr>
<td>14:25</td>
<td>E04.2</td>
<td>SQUAMOUS CELL CARCINOMA</td>
<td>Andrew Nicholson, UK</td>
</tr>
<tr>
<td>14:45</td>
<td>E04.3</td>
<td>LARGE CELL AND SARCOMATOID CARCINOMA</td>
<td>Keith Kerr, UK</td>
</tr>
<tr>
<td>15:05</td>
<td>E04.4</td>
<td>NEUROENDOCRINE TUMOURS</td>
<td>William Travis, USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Room/Level</td>
<td>Chairs</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>---------------------</td>
<td>-------------------------------------------</td>
</tr>
</tbody>
</table>
| 14:00 – 15:30| E05: MANAGEMENT OF PLEURAL EFFUSION (MULTIPLE CASES) | PARKSIDE BALLROOM A, LEVEL 1 | Y.C. Gary Lee, Australia & York Miller, USA | 14:00 CHAIR INTRO  
14:05 E05.1: INTRODUCTION / PRESENTATION OF CASE  
Tajalli Saghaie, Australia  
14:10 E05.2: FIRST PRESENTATION WITH LARGE EFFUSION - DIAGNOSTIC / TREATMENT PATHWAY  
Martin Phillips, Australia  
14:30 E05.3: WHAT PROCEDURE - VATS / MEDICAL PLEUROSCOPY IN A FIT PATIENT  
Pyng Lee, Singapore  
14:50 E05.4: SMALL TUBE VS LARGE TUBE - CHOICE OF SCLEROSANT  
Ken Yoneda, USA  
15:10 E05.5: TRAPPED LUNG - WHAT DO WE DO  
Paula Ugalde, Canada |
| 14:00 – 15:30| MS01: RADIATION AS A SYSTEMIC THERAPY         | BAYSIDE 201 - 203, LEVEL 2 | Bo Lu, USA & Paul Van Houtte, Belgium    | 14:00 CHAIR INTRO  
14:05 MS01.1: IMMUNOMODULATION WITH RADIOTHERAPY  
Quynh Le, USA  
14:25 MS01.2: CIRCULATING TUMOUR CELLS AS A MECHANISM OF RADIO RESISTANCE  
Michael MacManus, Australia  
14:45 MS01.3: HYPOXIA AS A CAUSE OF TREATMENT FAILURE IN NSCLC  
Odd Terje Brustugun, Norway  
15:05 MS01.4: INTEGRATION OF FUNCTIONAL AND MOLECULAR IMAGING IN RADIOTHERAPY PLANNING  
Gerard Hanna, UK |
| 14:00 – 15:30| MS02: STEM CELLS AND EPIGENETICS IN LUNG CANCER | BAYSIDE 103, LEVEL 1 | Gabriela Sozzi, Italy & John Minna, USA  | 14:00 CHAIR INTRO  
14:05 MS02.1: STEM CELLS & THE CELL OF ORIGIN OF LUNG CANCER  
Kate Sutherland, Australia  
14:25 MS02.2: TARGETING HEDGEHOG SIGNALING IN SMALL CELL LUNG CANCER  
Neil Watkins, Australia  
14:45 MS02.3: MICRO-RNA IN LUNG CANCER  
Gabriella Sozzi, Italy  
15:05 MS02.4: TARGETING EPIGENETIC CHANGES IN LUNG CANCER  
Charles Rudin, USA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Room Location</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 15:30</td>
<td><strong>MS03: THE CUTTING EDGE OF MOLECULARLY TARGETED THERAPY</strong></td>
<td>Plenary Hall, Ground Level</td>
<td>Nagahiro Saijo, Japan &amp; Heather Wakelee, USA</td>
</tr>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>MS03.1: NOVEL TARGETS IN SMALL CELL CANCER</td>
<td>Romania, Germany</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>MS03.2: NOVEL TARGETS IN SQUAMOUS CANCER</td>
<td>Peter Hammerman, USA</td>
<td></td>
</tr>
<tr>
<td>14:55</td>
<td>MS03.3: NOVEL TARGETS IN ADENOCARCINOMA</td>
<td>Matthew Meyerson, USA</td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td><strong>MS04: MESOTHELIOMA GENETICS AND NOVEL TARGETS</strong></td>
<td>Bayside 104, Level 1</td>
<td>Robert Doebele, USA &amp; Anna Nowak, Australia</td>
</tr>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>MS04.1: BAP1 GENE MUTATION AND MESOTHELIOMA PATHOGENESIS</td>
<td>Michele Carbone, USA</td>
<td></td>
</tr>
<tr>
<td>14:25</td>
<td>MS04.2: SEQUENCING THE MESOTHELIOMA GENOME - WHERE ARE WE NOW AND WHERE ARE WE GOING?</td>
<td>Raphael Bueno, USA</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>MS04.3: NEW MOLECULAR TARGETS IN MESOTHELIOMA</td>
<td>Rolf Stahel, Switzerland</td>
<td></td>
</tr>
<tr>
<td>15:05</td>
<td>MS04.4: CURRENT CLINICAL TRIALS OF TARGETED THERAPIES</td>
<td>Paul Baas, Netherlands</td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td><strong>MS05: MODERN MANAGEMENT OF NEUROENDOCRINE TUMOURS</strong></td>
<td>Bayside Gallery B, Level 1</td>
<td>Valerie Rusch, USA &amp; Yi-Long Wu, China</td>
</tr>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>MS05.1: BRONCHOPULMONARY CARCINOIDs</td>
<td>Akira Iyoda, Japan</td>
<td></td>
</tr>
<tr>
<td>14:25</td>
<td>MS05.2: COMBINED MODALITY FOR LCNEC AND ATYPICAL CARCINOIDs</td>
<td>Eric Lim, UK</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>MS05.3: MEDIASTINAL NEUROENDOCRINE TUMOURS</td>
<td>Pier Luigi Filosso, Italy</td>
<td></td>
</tr>
<tr>
<td>15:05</td>
<td>MS05.4: ADVANCES IN RADIONUCLIDE THERAPY</td>
<td>Dik Kwekkeboom, Netherlands</td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td><strong>MS06: SURGEONS AS DRIVERS OF NSCLC RESEARCH</strong></td>
<td>Bayside 105, Level 1</td>
<td>Naveed Alam, Australia &amp; Young Tae Kim, South Korea</td>
</tr>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>MS06.1: HOW DO I CONTRIBUTE TO THE IASLC STAGING PROJECTS?</td>
<td>Ramon Rami-Porta, Spain</td>
<td></td>
</tr>
<tr>
<td>14:25</td>
<td>MS06.2: CLINICAL TRIAL AND RESEARCH COOPERATION</td>
<td>Wen Zhao Zhong, China</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>MS06.3: RANDOMIZED TRIAL OF VATS VS AXILLARY THORACOTOMY FOR LOBECTOMY</td>
<td>Long Hao, China</td>
<td></td>
</tr>
<tr>
<td>15:05</td>
<td>MS06.4: INTO THE LAB: THE SURGEON AS TRANSLATIONAL RESEARCHER</td>
<td>Gavin Wright, Australia</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>14:00 – 15:30</td>
<td>MS07: EPIDEMIOLOGY AND PREVENTION</td>
<td><strong>Mini Symposium: Epidemiology and Prevention</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BAYSIDE AUDITORIUM B, LEVEL 1</td>
<td><strong>Chairs: Keunchil Park, South Korea &amp; Nico van Zandwijk, Australia</strong></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td>MS07.1: SUCCESSFUL TOBACCO CONTROL APPROACHES IN THE 21ST CENTURY</td>
<td>Matthew Steliga, USA</td>
<td></td>
</tr>
<tr>
<td>14:25</td>
<td>MS07.2: COMORBIDITY &amp; COMPETING CAUSES OF DEATH IN LUNG CANCER PATIENTS</td>
<td>Maryska Janssen-Heijnen, Netherlands</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>MS07.3: GENETIC SUSCEPTIBILITY</td>
<td>Chris Amos, USA</td>
<td></td>
</tr>
<tr>
<td>15:05</td>
<td>MS07.4: RISK PREDICTION MODELS</td>
<td>Margaret Spitz, USA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PC01: CLINICAL TRIAL DESIGN FOR DRUG DEVELOPMENT</td>
<td><strong>Pro-Con Session: Statistics</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
<td><strong>Chairs: Nise Yamaguchi, Brazil &amp; Martin Stockler, Australia</strong></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>PC01.1: CASE INTRODUCTION</td>
<td>Mary Redman, USA</td>
<td></td>
</tr>
<tr>
<td>14:10</td>
<td>PC01.2: ADAPTIVE DESIGNS: FOR J. Jack Lee, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>PC01.3: ADAPTIVE DESIGNS: AGAINST Marc Buyse, Belgium</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:40 – 16:10 EXHIBIT SHOWCASE SESSION: LILLY ONCOLOGY: MAINTENANCE THERAPY: EXPERIENCE, PATIENT PREFERENCES, DISCUSSION WITH PATIENT</td>
<td><strong>General Session: Supportive Care &amp; Nurses</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 105, LEVEL 1</td>
<td><strong>Chairs: Peter Goldstraw, UK &amp; Matthew Peters, Australia</strong></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>CHAIR INTRO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td>G02.1: PUBLIC AWARENESS OF LUNG CANCER SYMPTOMS - THE GLCC/IPSOS MORI 2013 INTERNATIONAL CONSUMER POLL</td>
<td>Jessica Elgood, Australia</td>
<td></td>
</tr>
<tr>
<td>16:36</td>
<td>G02.2: OUTCOMES FROM PUBLIC INFORMATION CAMPAIGNS</td>
<td>Jesme Fox, UK</td>
<td></td>
</tr>
<tr>
<td>16:52</td>
<td>G02.3: CLINICIANS AS ADVOCATES: RAISING PUBLIC AWARENESS OF LUNG CANCER - THE WEST JAPAN ONCOLOGY GROUP EXPERIENCE</td>
<td>Toshiyuki Sawa, Japan</td>
<td></td>
</tr>
<tr>
<td>17:08</td>
<td>G02.4: SURVIVORS AS ADVOCATES: WHAT IS POSSIBLE? - THE LUNG CANCER ALLIANCE EXPERIENCE</td>
<td>Kay Cofrancesco, USA</td>
<td></td>
</tr>
<tr>
<td>17:24</td>
<td>G02.5: HOW CLINICIANS AND PATIENTS CAN BENEFIT FROM BETTER DATA ON LUNG CANCER</td>
<td>Michael Peake, UK</td>
<td></td>
</tr>
<tr>
<td>17:40</td>
<td>G02.6: CLOSING REMARKS, INCLUDING COMMENT ON IASLC AND ADVOCACY - THE FUTURE</td>
<td>Peter Goldstraw, UK</td>
<td></td>
</tr>
</tbody>
</table>

**15:30 – 16:15 NETWORKING BREAK**

- **POSTER SESSION 1**
  - Presenters are available for questions
  - Refreshments are provided
  - EXHIBIT HALL, HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL
16:15 – 17:45  O08: PRECLINICAL THERAPEUTIC MODELS I

Oral Abstract Session: Biology
BAYSIDE AUDITORIUM A, LEVEL 1
Chairs: Celine Mascaux, Canada & Ronald Natale, USA

16:15  O08.01: A NOVEL AUTOFLAGOSOME NON-SMALL CELL LUNG CANCER VACCINE (DRIBBLES) CONTAINS SHORT-LIVED PROTEINS, DEFECTIVE RIBOSOMAL PRODUCTS, AT LEAST NINE NCI-PRIORITIZED ANTIGENS, AND AGONISTS FOR TLR 2, 3, 4, 7, AND 9
Helen Ross, USA

16:25  O08.02: CRITICAL ROLE OF CD28 COSTIMULATION IN TUMOR-TARGETED T-CELL THERAPY CLINICAL TRIAL FOR PLEURAL MALIGNANCIES
Jonathan Villena-Vargas, USA

16:35  O08.03: T-CELL IMAGING TO NON-INVASIVELY MONITOR ADOPTIVE T-CELL THERAPY FOR THORACIC MALIGNANCIES
Jonathan Villena-Vargas, USA

16:45  O08.04: DISCUSSANT
David Carbone, USA

17:00  O08.05: GENOMIC AND METABOLIC REPROGRAMMING IN MUTATED-EGFR LUNG CANCER EARLY ADAPTIVE RESISTANCE TO ESCAPE ERLOTINIB INHIBITION
Patrick Ma, USA

17:10  O08.06: COMBINING THE HSP90 INHIBITOR, AT13387, WITH CRIZOTINIB IMPROVES RESPONSE IN AN ALK-POSITIVE MODEL OF NSCLC
Nicola Wallis, UK

17:20  O08.07: PATIENT-DERIVED PRIMARY NON-SMALL CELL LUNG CARCINOMA (NSCLC) XENOGRAPHS FOR MECHANISTIC STUDIES OF RESISTANCE TO EGFR TYROSINE KINASE INHIBITOR THERAPY
Celine Mascaux, Canada

17:30  O08.08: DISCUSSANT
Giuseppe Giaccone, USA

16:15 – 17:45  O09: GENERAL THORACIC SURGERY

Oral Abstract Session: Surgery
PARKSIDE BALLROOM B, LEVEL 1
Chairs: Gail Darling, Canada & Walter Weder, Switzerland

16:15  O09.01: SITES, SYMPTOMS, CT SCAN FINDINGS AND SURVIVAL IN PATIENTS WITH RECURRENCE AFTER CURATIVE-INTENT SURGICAL RESECTION FOR STAGE I LUNG ADENOCARCINOMA
Hideki Ujiie, USA

16:25  O09.02: CLINICOPATHOLOGICAL CHARACTERISTICS AND SURGICAL RESULTS OF LUNG CANCER PATIENTS AGED UP TO 50 YEARS: THE JAPANESE LUNG CANCER REGISTRY STUDY 2004
Masayoshi Inoue, Japan

16:35  O09.03: QUALITY INDICATORS IN THORACIC SURGERY: THE IMPORTANCE OF PROCESS INDICATORS IN LUNG CANCER
Gail Darling, Canada

16:45  O09.04: DISCUSSANT
Harvey Pass, USA

17:00  O09.05: INTRAOPERATIVE AUTOSTAPLING CARTRIDGE LAVAGE CYTOLOGY IN SURGICAL RESECTION OF PULMONARY MALIGNANT TUMORS - POSSIBLE ROLE IN PREVENTING LOCAL FAILURE
Tomohiro Miyoshi, Japan

17:10  O09.06: PROGNOSTIC FACTORS FOR LONG-TERM SURVIVAL IN NON-SMALL CELL LUNG CANCER PATIENTS WITH INTERSTITIAL LUNG DISEASE
Jaehyun Jeon, South Korea

17:20  O09.07: PHASE II DOUBLE-BLIND RANDOMIZED TRIAL COMPARING POSERTEROL THORACOTOMY VERSUS NERVE SPARING THORACOTOMY FOR LUNG SURGERY (POTNEST) - IMPACT OF PRESERVATION OF THE NEUROVASCULAR BUNDLE DURING THORACOTOMY ON POST-OPERATIVE PAIN
C.S. Pramesh, India

17:30  O09.08: DISCUSSANT
Hiroshi Date, Japan
### Oral Abstract Session: Radiotherapy

**PARKSIDE 110 A+B, LEVEL 1**

**Chairs:** Hiroshi Onishi, Japan & Joe Chang, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 16:15  | **O10.01:** Exploring the Optimal Biologically Effective Dose of Stereotactic Body Radiation Therapy for Stage I Non-Small-Cell Lung Cancer - An Update  
Baosheng Li, China |
| 16:25  | **O10.02:** Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients (PTS) With Stage I Peripheral Non-Small Cell Lung Cancer  
Gregory Videtic, USA |
| 16:35  | **O10.03:** Safety of Endobronchial Implantation of Electromagnetic Fiducials for Real-Time Tracking of Lung Tumors During Radiotherapy  
Daniel Nader, USA |
| 16:45  | **O10.04:** Discussant  
Umberto Ricardi, Italy |
| 17:00  | **O10.05:** Blinded Assessment of Radiological Changes After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: Local Recurrences Versus Fibrosis  
Sashendra Senthi, Netherlands |
| 17:10  | **O10.06:** Inter-Rater Reliability of the Categorization of Late Radiographic Changes After Lung Stereotactic Body Radiation Therapy (SBRT)  
Meredith Giuliani, Canada |
| 17:20  | **O10.07:** Dose-Response Analysis of Radiation Induced Rib Fractures After SBRT for NSCLC  
Barbara Stam, Netherlands |
| 17:30  | **O10.08:** Discussant  
Suresh Senan, Netherlands |

### Oral Abstract Session: Supportive Care

**BAYSIDE GALLERY A, LEVEL 1**

**Chairs:** Beth Ivimey, Australia & Ian Olver, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
</table>
| 16:15  | **O11.01:** Wiki-Based Treatment Guidelines for Lung Cancer  
Ian Olver, Australia |
| 16:25  | **O11.02:** The “CLIC” Cough in Lung Cancer Study: The Characterisation of Cough in Lung Cancer  
Amelie Harle, UK |
| 16:30  | **O11.03:** The “CLIC” Cough in Lung Cancer Study: The Validation of Objective and Subjective Cough Assessment Tools in Lung Cancer Patients  
Amelie Harle, UK |
| 16:35  | **O11.04:** Patterns of Quality of Life, Their Characteristics and Relationship to Symptoms -- 12 Months Follow-Up in Newly Diagnosed Advanced Lung Cancer Patients  
Yeur-Hur Lai, Taiwan |
| 16:45  | **O11.05:** Discussant  
Matthew Peters, Australia |
| 17:00  | **O11.06:** The Effects of Inspiratory Muscle Training in the Management of Breathlessness in Patients with Lung Cancer: A Pilot Feasibility Randomized Trial  
Alex Molassiotis, Hong Kong |
| 17:10  | **O11.07:** Tracheobronchial Stent Insertion in the Management of Primary Lung Cancer: 5 Year Experience  
Henrietta Wilson, UK |
| 17:15  | **O11.08:** A Comparison of Tracheobronchial Stent Insertion With and Without Radiological Guidance in Patients With Advanced Primary Lung Carcinoma  
Henrietta Wilson, UK |
| 17:20  | **O11.09:** Ibandronic Acid vs. Zoledronic Acid in Lung Cancer Patients With Skeletal Metastases: How Do They Compare?  
Ioannis Dimitroulis, Greece |
| 17:30  | **O11.10:** Discussant  
Anna Oton, USA |
**16:15 – 17:45 MO04: LUNG CANCER BIOLOGY I**

**Mini Oral Abstract Session: Biology**

**BAYSIDE 103, LEVEL 1**

*Chairs: Gabriela Sozzi, Italy & David Lam, Hong Kong*

16:15  **MO04.01:** MOLECULAR MECHANISMS OF CIGARETTE SMOKE INDUCED HYPER-PROLIFERATION OF HUMAN LUNG CELLS AND ITS PREVENTION

- Neekkan Dey, India

16:20  **MO04.02:** PACLITAXEL RESISTANCE IS ASSOCIATED WITH DRUG ACCUMULATION IN INTRACELLULAR COMPARTMENTS AND PACLITAXEL-BINDING PROTEINS IN HUMAN LUNG CANCER CELL LINES

- Masanori Shimomura, Japan

16:25  **MO04.03:** CHROMOSOMAL AND MUTATIONAL ANALYSIS OF THE CISPLATIN RESISTANT PHENOTYPE IN NSCLC CELLS

- Martin Barr, Ireland

16:30  **MO04.04:** AEROSOL AZACITIDINE REDUCES METHYLATION LEVELS OF TUMOR SUPPRESSOR GENES AND PROLONGS SURVIVAL IN THE ORTHOTOPIC LUNG CANCER MODELS IN MICE

- Yiyu Zou, USA

16:35  **MO04.05:** TRACHEAL BASAL CELLS IN THE LUNG SQUAMOUS DYSPLASIA: MOVING PROXIMAL

- Robert Keith, USA

16:40  **MO04.06:** DISCUSSANT

- George Simon, USA

16:55  **MO04.07:** CHRONIC LUNG INJURY BY CONSTITUTIVE EXPRESSİON OF AID LEADS TO FOCAL ALVEOLAR REGENERATION AND CANCER

- Jiro Kitamura, Japan

17:00  **MO04.08:** ACTIVATION OF LIVER X RECEPTOR INDUCES INTERFERON-GAMMA PRODUCTION AND INHIBITS TUMOR GROWTH

- Qixue Wang, China

17:05  **MO04.09:** EXERCISE INDUCED LUNG CANCER TUMOR GROWTH SUPPRESSION VIA ACTIVATION OF PS3: MECHANISTIC FINDINGS FROM A MOUSE MODEL

- Kristin Higgins, USA

17:10  **MO04.10:** IDENTIFICATION OF BIOLOGICAL PROPERTIES OF INTRALYMPHATIC TUMOR RELATED TO THE DEVELOPMENT OF LYMPH NODE METASTASIS IN LUNG ADENOCARCINOMA

- Keisuke Kirita, Japan

17:15  **MO04.11:** THE TUMOR MICROENVIRONMENT EXPRESSION OF THE INHIBITOR OF DIFFERENTIATION-1 (ID1) IS DETERMINANT OF THE DEVELOPMENT OF LIVER METASTASIS FROM LUNG CANCER THROUGH GENE REGULATION OF TUMOR CELLS

- Ignacio Gil-Bazo, Spain

17:20  **MO04.12:** DISCUSSANT

- Neil Watkins, Australia

---

**16:15 – 17:45 MO05: PROGNOSTIC AND PREDICTIVE BIOMARKERS II**

**Mini Oral Abstract Session:** Biology & Medical Oncology

**PARKSIDE AUDITORIUM, LEVEL 1**

*Chairs: Jie Hu, China & Sandra O'Toole, Australia*

16:15  **MO05.01:** VALIDATION OF GENE EXPRESSION BIOMARKER PANELS IN NON-SMALL CELL LUNG CANCER

- Dennis Wigle, USA

16:20  **MO05.02:** OVEREXPRESSION OF FGFR1 MRNA AND PROTEIN ARE MORE FREQUENT THAN FGFR1 GENE AMPLIFICATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

- Murry Wynes, USA

16:25  **MO05.03:** A GENE EXPRESSION PLATFORM TO PREDICT BENEFIT FROM ADJUVANT EXTERNAL BEAM RADIATION IN RESECTED NON-SMALL CELL LUNG CANCER

- Ben Creelan, USA

16:30  **MO05.04:** A PROSPECTIVE STUDY OF INNOVATIVE NON-INVASIVE TOOLS TO ASSESS THE RESPONSE TO ANTI-ANGIOGENIC THERAPIES IN NON SMALL CELL LUNG CANCER PATIENTS

- Arnaud Scherpereel, France

16:35  **MO05.05:** LUNG CANCER EXPLORER (LCE): AN OPEN WEB PORTAL TO EXPLORE GENE EXPRESSION AND CLINICAL ASSOCIATIONS IN LUNG CANCER

- Yang Xie, USA

16:40  **MO05.06:** DISCUSSANT

- Rafael Rosell, Spain

16:55  **MO05.07:** NOMOGRAM COMBINING CLINICOPATHOLOGIC FACTORS AND MOLECULAR MARKERS FOR PREDICTING SURVIVAL IN PATIENTS WITH RESECTED NON-SMALL CELL LUNG CANCER

- Jianxing He, China
17:00 MO05.08: INDIVIDUALIZED SURGICAL TREATMENT FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER BASED ON MOLECULAR BIOMARKERS Qinghua Zhou, China

17:05 MO05.09: ACTIVATION OF THE CLASSICAL COMPLEMENT PATHWAY: A NOVEL BIOMARKER FOR THE EARLY DIAGNOSIS AND PROGNOSIS OF LUNG CANCER Ruben Pio, Spain

17:10 MO05.10: METFORMIN AS A RADIOSENSITIZER FOR LUNG CANCER Ildiko Csiki, USA

17:15 MO05.11: THE EFFECT OF TWO BRM PROMOTER POLYMORPHISMS ON THE RISK OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND SMALL CELL LUNG CANCER (SCLC) IN SMOKERS Sinead Cuffe, Canada

17:20 MO05.12: DISCUSSANT Thomas Lynch, USA

16:15 – 17:45 MO06: NSCLC - CHEMOTHERAPY I

16:15 MO06.01: CLINICAL FEATURES OF PATIENTS WITH NON SMALL CELL LUNG CANCER WHO HARBOR EGFR MUTATION AND PRESENT WITH MILIARY INTRAPULMONARY OR DISSEMINATED CARCINOMATOSIS Hee Joung Kim, South Korea

16:20 MO06.02: MONITORING EGFR T790M WITH PLASMA DNA IN LUNG CANCER PATIENTS TREATED WITH EGFR TYROSINE KINASE INHIBITOR IN PROSPECTIVE OBSERVATIONAL STUDY Keisuke Aoe, Japan

16:25 MO06.03: BEVACIZUMAB AND ERLOTINIB OR BEVACIZUMAB, CISPLATIN AND PEMETREXED IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER: EGFR MUTATION BASED TREATMENT ALLOCATION AND REPEAT BIOPSY AT PROGRESSION IN THE SAKK19/09 (BIOPRO) TRIAL Oliver Gautschi, Switzerland

16:30 MO06.04: A RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY GEFITINIB AS MAINTENANCE WITH GEFITINIB MONOTHERAPY IN EAST ASIAN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSQNSCLC) James Chih-Hsin Yang, Taiwan

16:35 MO06.05: DISCUSSANT Paul Mitchell, Australia

16:45 MO06.06: ORAL VINOSELBINE (NVBO) AND CISPLATIN (P) OR PEMETREXED (PEM) AND P AS FIRST-LINE CHEMOTHERAPY FOR NON SQUAMOUS (NS) METASTATIC OR LOCALLY ADVANCED NON SMALL CELL LUNG CANCER (M OR LA NSCLC): FINAL RESULTS OF A PROSPECTIVE RANDOMISED PHASE II TRIAL (NAVOTRIAL 1) Eng-Huat Tan, Singapore

16:50 MO06.07: DAILY ADMINISTRATION OF ORAL VINOSELBINE: DATA FROM A PHASE I TRIAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Rudolf Huber, Germany

16:55 MO06.08: A PHASE 2 RANDOMIZED OPEN-LABEL STUDY OF RAMUCIRUMAB (IMC 1121B; RAM) IN COMBINATION WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY IN PATIENTS (PTS) WITH RECURRENT OR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): FINAL RESULTS FROM NON-SQUAMOUS (NSQ) PTS (NCT01160744) Robert Doebele, USA

17:00 MO06.09: DISCUSSANT Robert Pirker, Austria

17:10 MO06.10: PHASE II STUDY OF BEVACIZUMAB, CISPLATIN AND DOCTAXEL PLUS MAINTENANCE BEVACIZUMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (N-SQ NSCLC) COMBINED WITH EXPLORATORY ANALYSIS OF CIRCULATING CELLS (CEC): THORACIC ONCOLOGY Ken Katono, Japan

17:15 MO06.11: A PHASE II TRIAL OF PACLITAXEL, PEMETREXED AND BEVACIZUMAB IN PATIENTS WITH UNTREATED, ADVANCED LUNG CANCERS Maria Pietanza, USA
17:20 MO06.12: EFFICACY AND SAFETY OF PACLITAXEL AND CARBOPLATIN WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSES BASED ON AGE IN THE PHASE 3 POINTBREAK AND E4599 TRIALS Corey Langer, USA

17:25 MO06.13: BEYOND: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTRE, PHASE III STUDY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) Caicun Zhou, China

17:30 MO06.14: DISCUSSANT Wilfried Eberhardt, Germany

16:15 – 17:45 MO07: NSCLC - TARGETED THERAPIES II

Mini Oral Abstract Session: Medical Oncology

BAYSIDE AUDITORIUM B, LEVEL 1

Chairs: Thomas John, Australia & Jonathan Riess, USA

16:15 MO07.01: CLINICAL BENEFIT OF CONTINUING CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER Sai-Hong Ou, USA

16:20 MO07.02: CLINICAL EXPERIENCE WITH CRIZOTINIB IN PATIENTS WITH ADVANCED ALK-REARRANGED NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES IN PROFILE 1005 AND PROFILE 1007 Daniel Costa, USA

16:25 MO07.03: CRIZOTINIB THERAPY FOR PATIENTS WITH ADVANCED ROS1-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) Sai-Hong Ou, USA

16:30 MO07.04: CLINICAL IMPLICATION OF A POPULATION PHARMACOKINETIC ANALYSIS OF XALKORI (CRIZOTINIB) IN 1,182 PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) AND 32 PATIENTS WITH OTHER SOLID TUMORS Erjian Wang, USA

16:35 MO07.05: DISCUSSANT Jean-Charles Soria, France

16:45 MO07.06: UPDATED RESULTS OF A FIRST-IN-HUMAN DOSE FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES D. Ross Camidge, USA

16:50 MO07.07: COMBINED PAN-ERBB AND ALK/ROS1/MET INHIBITION WITH DACOMITINIB AND CRIZOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): UPDATE OF A PHASE I TRIAL Giuseppe Giaconne, USA

16:55 MO07.08: THE FREQUENCY AND IMPACT OF ROS1-REARRANGEMENT ON CLINICAL OUTCOMES IN NEVER-SMOKERS WITH LUNG ADENOCARCINOMA Hye Ryun Kim, South Korea

17:00 MO07.09: FEASIBILITY AND CLINICAL IMPACT OF RE-BIOPSY IN ADVANCED NON-SMALL CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC STUDY IN REAL WORLD SETTING (GFPC STUDY 12-01) Alain Vergnogere, France

17:05 MO07.10: DISCUSSANT Nick Pavlakis, Australia

17:15 MO07.11: A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC) Siow Ming Lee, UK

17:20 MO07.12: PHASE II STUDY OF ICOTINIB AND WHOLE BRAIN RADIOTHERAPY (WBRT) IN PATIENTS WITH BRAIN METASTASES FROM NON-SMALL-CELL LUNG CANCER(NSCLC) Fan Yun, China

17:25 MO07.13: EFFICACY OF AFATINIB VS. CHEMOTHERAPY IN TREATMENT-NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBOURING ACTIVATING EGFR MUTATIONS WITH OR WITHOUT METASTATIC BRAIN DISEASE Martin Schuler, Germany

17:30 MO07.14: DISCUSSANT Myung-Ju Ahn, South Korea
16:15 – 17:45  MO08: NSCLC - EARLY STAGE

Mini Oral Abstract Session: Medical Oncology

BAYSIDE GALLERY B, LEVEL 1

Chairs: Kazuhiko Nakagawa, Japan & Jean-Yves Douillard, France

16:15  MO08.01: FIRST ANALYSIS OF TOXICITY AND TREATMENT COMPLIANCE IN CUSTOMIZED POSTOPERATIVE CHEMOTHERAPY BASED ON BRCA1 LEVELS AFTER NSCLC RESECTION: SCAT (SPANISH CUSTOMIZED ADJUVANT THERAPY) TRIAL. SPANISH LUNG CANCER GROUP/GECP
Bartomeu Massuti, Spain

16:20  MO08.02: ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP
Benjamin Besse, France

16:25  MO08.03: ADJUVANT CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER AFTER THORACOSCOPIC VERSUS OPEN LOBECTOMY
Tine Schytte, Denmark

16:30  MO08.04: PHASE 2 STUDY OF THE GI-4000 KRAS VACCINE FOLLOWING CURATIVE THERAPY IN PATIENTS WITH STAGE I-III LUNG ADENOCARCINOMA HARBORING A KRAS G12C, G12D, G12V OR G12R MUTATION
Jamie Chaft, USA

16:35  MO08.05: RESEARCH AND PROGRESS OF VASCULAR TARGETED THERAPY IN THE POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR LUNG CANCER
Zhen Zhou, China

16:40  MO08.06: DISCUSSANT
Thierry Le Chevalier, France

16:55  MO08.07: RANDOMIZED CONTROLLED PHASE III TRIAL OF ADJUVANT CHEMOIMMUNOTHERAPY WITH ACTIVATED KILLER T CELLS AND DENDRITIC CELLS IN PATIENTS WITH RESECTED PRIMARY LUNG CANCER
Hideki Kimura, Japan

17:00  MO08.08: A COST-EFFECTIVENESS ANALYSIS OF THE 15-GENE EXPRESSION SIGNATURE IN GUIDING ADJUVANT CHEMOTHERAPY IN EARLY STAGE NON-SMALL CELL LUNG CANCER BASED ON THE JBR.10 TRIAL
Kit Man Wong, Canada

17:05  MO08.09: PET-CT SCANNING DERIVED ARTIFICIAL NEURAL NETWORK CAN PREDICT MEDIASTINAL LYMPH NODES METASTASES IN NSCLC PATIENTS. PRELIMINARY REPORT
Pawel Wnuk, Poland

17:10  MO08.10: Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with pleural lavage cytology positive findings
Hiruyki Ogawa, Japan

17:15  MO08.11: THE ROLE OF AGGRESSIVE LOCAL THERAPY AND PROGNOSTIC FACTORS IN POSTOPERATIVE RECURRENT NON-SMALL CELL LUNG CANCER: IS OLIGORECURRENT STATE POTENTIAL CURABLE DISEASE?
Yoshihisa Shimada, Japan

17:20  MO08.12: DISCUSSANT
Ronan Kelly, USA

16:15 – 17:45  MO09: MESOTHELIOMA I

Mini Oral Abstract Session: Mesothelioma

BAYSIDE 204 A+B, LEVEL 2

Chairs: Kenji Suzuki, Japan & Sam Armato, USA

16:15  MO09.01: EVALUATION OF TOLERABILITY AND ANTI-TUMOR ACTIVITY OF GDC-0980, AN ORAL PI3K/MTOR INHIBITOR, ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Saoirse Dolly, UK

16:20  MO09.02: A RANDOMISED PHASE II TRIAL OF PEGYLATED ARGININE DEIMINASE IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Peter Szlosarek, UK

16:25  MO09.03: A PILOT AND FEASIBILITY TRIAL EVALUATING TWO DIFFERENT CHEMOTHERAPY REGIMENS IN COMBINATION WITH INTRAPLEURAL ADENOVIRAL-MEDIATED INTERFERON-ALPHA (SCH 721015, AD.HIFN-ALPHA2B) GENE TRANSFER FOR MALIGNANT PLEURAL MESOTHELIOMA
Peter Szlosarek, UK

16:30  MO09.04: DEFINING BAP1 SYNDROME: PRELIMINARY RESULTS FROM AN EPIDEMIOLOGIC ASCERTAINMENT STUDY
Lee Krug, USA

16:35  MO09.05: DISCUSSANT
Anna Nowak, Australia
16:45 MO09.06: MALIGNANT PLEURAL MESOTHELIOMA IN THE UK NATIONAL LUNG CANCER AUDIT: AN ANALYSIS OF 8503 CASES
John Edwards, UK

16:50 MO09.07: DISEASE AND PATIENT CHARACTERISTICS RELATED TO SURVIVAL IN A LARGE POPULATION-BASED COHORT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Anthony Linton, Australia

16:55 MO09.08: NF-KB IN CISPLATIN RESISTANCE AND AS A PROGNOSTIC MARKER IN MALIGNANT PLEURAL MESOTHELIOMA
Kenneth O’Byrne, Australia

17:00 MO09.09: DISCUSSANT
Hedy Lee Kindler, USA

17:10 MO09.10: VOLUMETRIC RESPONSE CLASSIFICATION CRITERIA IN MESOTHELIOMA
Samuel Armato III, USA

17:15 MO09.11: QUANTITATIVE CLINICAL T CLASSIFICATION CRITERIA FOR MALIGNANT PLEURAL MESOTHELIOMA
Ritu Gill, USA

17:20 MO09.12: POSTERIOR INTERCOSTAL LYMPH NODES - FIRST REPORT OF A NEW INDEPENDENT PROGNOSTIC FACTOR FOR MALIGNANT PLEURAL MESOTHELIOMA
Joseph Friedberg, USA

17:25 MO09.13: COMPARISON OF THREE RADIOGRAPHIC TUMOR VOLUME ESTIMATION TECHNIQUES FOR MALIGNANT PLEURAL MESOTHELIOMA: THEIR CORRELATION WITH EACH OTHER, ACTUAL MEASURED INTRAOPERATIVE TUMOR VOLUMES, AND SURVIVAL
Charles Simone, USA

17:30 MO09.14: DISCUSSANT
Anne Tsao, USA

16:45 – 17:45 MO10: MOLECULAR PATHOLOGY II

16:20 MO10.02: UPDATE GENOTYPING NON-SMALL CELL LUNG CANCER (NSCLC) IN LATIN AMERICA: LATIN-AMERICAN CONSORTIUM FOR THE INVESTIGATION OF LUNG CANCER (CLICAP)
Claudio Martin, Argentina

16:25 MO10.03: DECREASED KRAS AND INCREASED HER2 OR PI3K MUTATIONS PREVALENCE IN THE FRENCH EMIGRANT POPULATION FROM AFRICAN CONTINENT IN LUNG ADENOCARCINOMA METASTATIC CANCER
Mohamed Bouchahda, France

16:30 MO10.04: HIGH THROUGHPUT PARALLEL AMPLICON SEQUENCING OF COMMON DRIVER MUTATIONS FROM FFPE LUNG CANCER SAMPLES IN MOLECULAR PATHOLOGICAL ROUTINE DIAGNOSTICS FOR A REGIONAL HEALTH CARE PROVIDER NETWORK
Lukas Heukamp, Germany

16:35 MO10.05: DISCUSSANT
Keith Kerr, UK

16:45 MO10.06: INTERTUMOUR HETEROGENEITY REVEALED BY INTEGRATIVE ANALYSIS OF TARGETED SOMATIC MUTATION PROFILING AND WHOLE GENOME COPY-NUMBER ALTERATIONS IN NON-SQUAMOUS NON-SMALL CELL LUNG CARCINOMAS
Daniel Shao-Weng Tan, Singapore

16:50 MO10.07: ALK IMMUNOHISTOCHEMISTRY AND FLUORESCENCE IN-SITU HYBRIDIZATION IN LUNG ADENOCARCINOMAS FROM THE ETOP LUNGSCAPE TUMOUR COHORT
Yuichi Ishikawa, Japan

16:55 MO10.08: GENOMIC ALTERATIONS IN PULMONARY CARCINOID TUMORS
Dennis Wigle, USA

17:00 MO10.09: DISCUSSANT
Yoo Jin Jung, South Korea

17:10 MO10.10: DETECTION OF RET FUSIONS BY FISH INUNSELECTED NSCLC
Marileila Varella-Garcia, USA

17:15 MO10.11: GENETIC POLYMORPHISMS OF TERT AND TP63 GENES ARE ASSOCIATED WITH EXON 18 AND EXON 21 MUTATIONS OF EGFR IN ADENOCARCINOMA OF THE LUNG
Roman Thomas, Germany

17:20 MO10.12: ROS1 FUSIONS DIAGNOSED by BREAK-APART FISH IN NSCLC
Marileila Varella-Garcia, USA

17:25 MO10.13: DISCUSSANT
Yi Wang, China
16:15 – 17:45  MO11: SCREENING AND EPIDEMIOLOGY

Mini Oral Abstract Session:
Imaging & Screening/Prevention & Epidemiology

BAYSIDE 201 - 203, LEVEL 2

Chairs: Paul Zimmerman, Australia & Jeffrey Bowden, Australia

16:15 MO11.01: POSITRON EMISSION TOMOGRAPHY IN LUNG CANCER SCREENING: SIX-YEAR RESULTS
Giulia Veronesi, Italy

16:20 MO11.02: VALIDATION OF ELECTRONIC NOSE EXHALED BREATH VOC PROFILE IN DISCRIMINATING BETWEEN SUBJECTS WITH EARLY STAGE LUNG CANCER AND HEALTHY NEVER SMOKERS
Annette Dent, Australia

16:25 MO11.03: THE NATURAL HISTORY AND SCREEN-DETECTABILITY OF LUNG CANCER: ESTIMATES FROM NLST AND THE PLCO
Kevin Ten Haaf, Netherlands

16:30 MO11.04: LUNG CANCER RISK MEDIATED THROUGH SUSCEPTIBILITY TO COPD: PRELIMINARY RESULTS FROM A SUB-ANALYSIS OF THE NLST
Raewyn Hopkins, New Zealand

16:35 MO11.05: DISCUSSANT
Matthijs Oudkerk, Netherlands

16:45 MO11.06: MINORITY STATUS AS A STRONG PREDICTOR OF HEALTH DISPARITIES: A GLOBAL PERSPECTIVE
Malcolm Brock, USA

16:50 MO11.07: EXPLORING DISPARITIES IN HEALTH CARE OUTCOMES IN MINORITY POPULATIONS WITH SMALL (SCLC) AND NON-SMALL CELL LUNG CANCERS (NSCLC)
Luis Raez, USA

16:55 MO11.08: THE IMPORTANCE OF A REGIMEN OF SCREENING TO MAXIMIZE EARLY DIAGNOSIS AND TREATMENT OF LUNG CANCER
Claudia Henschke, USA

17:00 MO11.09: CT SCREENING FOR LUNG CANCER: DEFINITION OF POSITIVE TEST RESULT IN THE NATIONAL LUNG SCREENING TRIAL CT COHORT COMPARED WITH I-ELCAP
Rowena Yip, USA

17:05 MO11.10: DISCUSSANT
Rayleen Bowman, Australia

17:15 MO11.11: IL-11 AND CCL-1: NOVEL PROTEIN DIAGNOSTIC BIOMARKERS OF LUNG ADENOCARCINOMA IN BRONCHOALVEOLAR LAVAGE (BAL)
Luis Paz-Ares, Spain

17:20 MO11.12: IDENTIFICATION OF PROTEIN BIOMARKERS IN BRONCHOALVEOLAR LAVAGE (BAL) FLUID TO IMPROVE THE DETECTION OF LUNG CANCER FROM BENIGN LUNG NODULE
Qing Kay Li, USA

17:25 MO11.13: LOW SELENIUM SERUM LEVEL IS A GOOD PRESELECTION FACTOR FOR PATIENTS INVITED FOR LOW DOSE CHEST CT LUNG CANCER SCREENING
Tomasz Grodzki, Poland

17:30 MO11.14: DISCUSSANT
Stephen Lam, Canada

18:00 – 19:30 SYMPOSIUM SUPPORTED BY ROCHE: HITTING THE HIGH NOTES IN NSCLC THERAPY
PARKSIDE AUDITORIUM, LEVEL 1
Gum Blossom

Eucalypts, or Gum trees, are the Australian trees – as much a part of the landscape as far horizons and sweeping plains. Yet most eucalypts aren’t the giant, gnarled trees that come to mind. There are more than 900 species, and their bark, leaves, flowers and fruit (gumnuts) come in endless combinations of size, form, texture and colour.

Although they’re endemic to Australia and a few islands immediately to the north, many eucalypt species are cultivated in tropical and temperate regions elsewhere for a variety of uses.

Courtesy of australiangeographic.com.au
The PEARL study (NCT01853878): PRAME as Adjuvant immunotherapy in Resected Non-Small Cell Lung Cancer (NSCLC), is a double-blind randomized Phase II clinical study to assess the clinical efficacy of the PRAME Cancer immunotherapeutic* as adjuvant therapy in patients with resected PRAME-positive, Stage IA-T1b, IB, II or IIIA Non-Small Cell Lung Cancer (NSCLC). PRAME (PReferentially expressed Antigen of MElanoma), is a widely expressed tumor antigen that has limited expression at low levels in normal cells. PRAME antigen is expressed by 66% of NSCLC1.

**MAIN INCLUSION CRITERIA**
- Pathological proven stage IAT1b, IB, II or IIIA NSCLC
- Completely resected
- PRAME-positive tumor (to be tested**)
- Patient may or may not receive appropriate chemotherapy in the adjuvant setting

**Resected PRAME-positive Stage IAT1b-IIIA NSCLC**

- **No Chemotherapy**
  - Randomization 2:1
  - PRAME Cancer Immunotherapeutic
  - Placebo

- **Chemotherapy**
  - Up to 4 cycles of chemotherapy
  - Randomization 2:1
  - PRAME Cancer Immunotherapeutic
  - Placebo

13 injections over 27 months

Primary Endpoint: Disease-free Survival

*PRAME cancer immunotherapeutic is an investigational compound and is not approved for use in Australia or any market at this time.
**PRAME will be tested in a central laboratory
For more information, contact: GlaxoSmithKline Vaccines, 89, rue de l’Institut, 1330 Rixensart, Belgium.
### Tuesday | October 29, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 06:00 – 17:00 | **REGISTRATION OPEN**  
HALL 6, PARKSIDE, GROUND LEVEL                                        |
| 06:00 – 17:00 | **SPEAKER READY ROOM OPEN**  
PARKSIDE G04, GROUND LEVEL                                               |
| 09:30 – 16:30 | **EXHIBIT HALL OPEN**  
HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL                             |
| 07:00 – 08:00 | **SYMPOSIUM SUPPORTED BY NOVARTIS: UP CLOSE AND PERSONAL: FUTURE TARGETED STRATEGIES IN NSCLC**  
PARKSIDE BALLROOM B, LEVEL 1                                               |
| 07:00 – 08:00 | **SYMPOSIUM SUPPORTED BY IASLC RADIOTHERAPY GROUP: WHAT IS THE APPROPRIATE PATIENT POPULATION FOR SBRT?**  
Simultaneous Translation  
English <-> Mandarin provided  
PARKSIDE AUDITORIUM, LEVEL 1                                              |
| 07:00 – 08:00 | **HOD1: MONDAY’S HIGHLIGHTS OF THE DAY - RADIOLOGY AND SURGERY**  
Chair: Jack Roth, USA                                                       |
| 07:30       | **HOD1.2: INTERVENTIONS, RADIOTHERAPY AND SURGERY**  
Masahiro Tsuboi, Japan                                                    |
| 07:00 – 08:00 | **HOD2: MONDAY’S HIGHLIGHTS OF THE DAY - MEDICAL ONCOLOGY, BIOLOGY AND PATHOLOGY**  
Chair: Robert Pirker, Austria                                              |
| 07:00       | **HOD2.1: MEDICAL ONCOLOGY**  
Martin Edelman, USA                                                        |
| 07:20       | **HOD2.2: MEDICAL ONCOLOGY AND BIOLOGY**  
Primo Lara, USA                                                            |
| 07:40       | **HOD2.3: PATHOLOGY**  
Elisabeth Brambilla, France                                                |
| 07:00 – 08:00 | **MTE09: COST EFFECTIVENESS OF CT SCREENING**  
Meet the Expert Session (ticketed): Imaging & Screening  
BAYSIDE 101, LEVEL 1                                                       |
| 07:00 – 08:00 | **MTE10: RECIST AND PERCIST CRITERIA FOR RESPONSE TO THERAPY**  
Meet the Expert Session (ticketed): Imaging & Screening  
BAYSIDE 102, LEVEL 1                                                       |
| 07:00       | **HOD1.1: RADIOThERAPY**  
Maria Werner-Wasik, USA                                                   |
| 07:30       | **HOD1.2: INTERVENTIONS, RADIOTHERAPY AND SURGERY**  
Masahiro Tsuboi, Japan                                                    |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE11: HOW DO PDXS HELP US IN THE CLINIC</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Biology</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 103, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Philip Mack, USA</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE12: THE NEW ADENOCARCINOMA CLASSIFICATION EXPLAINED</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Medical Oncology</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Gregory Riely, USA</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE13: AIRWAY STENTING - RIGID AND FIBREOPTIC TECHNIQUES</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Pulmonology</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 105, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Armin Ernst, USA</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE14: SECOND LINE CHEMOTHERAPY IN MESOTHELIOMA - WHAT IS THE BEST EVIDENCE?</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Mesothelioma</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 106, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Giovanni Ceresoli, Italy</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE15: SURGERY FOR COMPLICATIONS OF SURGERY</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Surgery</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE GALLERY A, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Young Tae Kim, South Korea</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE16: OPTIMIZING THORACIC RADIATION DOSE SCHEDULE IN COMBINED MODALITY THERAPY IN STAGE III NSCLC</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Combined Modality</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE GALLERY B, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Hak Choy, USA</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE17: NURSING GOES GLOBAL - MEETING THE CHALLENGES POSED BY MESOTHELIOMA</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Nursing/Mesothelioma</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 201 - 203, LEVEL 2</td>
</tr>
<tr>
<td></td>
<td><em>Chair: Beth Ivimey, Australia</em></td>
</tr>
<tr>
<td></td>
<td>07:00 CHAIR INTRO</td>
</tr>
<tr>
<td></td>
<td>07:05 MTE17.1: THE DRIVING FORCE OF SOCIAL NETWORKING</td>
</tr>
<tr>
<td></td>
<td>Mary Hesdorffer, USA</td>
</tr>
<tr>
<td></td>
<td>07:20 MTE17.2: PREPARING TO MEET THE GROWING NEED</td>
</tr>
<tr>
<td></td>
<td>Liz Darlison, UK</td>
</tr>
<tr>
<td></td>
<td>07:35 MTE17.3: SURGICAL OPTIONS AND GLOBAL DIFFERENCES</td>
</tr>
<tr>
<td></td>
<td>Jocelyn McLean, Australia</td>
</tr>
<tr>
<td></td>
<td>07:50 MTE17.4: DISCUSSION</td>
</tr>
<tr>
<td>07:00 – 08:00</td>
<td><strong>MTE21A: GENOMICS IN LUNG CANCER</strong></td>
</tr>
<tr>
<td></td>
<td>Meet the Expert Session (ticketed): Pathology</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 204 A+B, LEVEL 2</td>
</tr>
<tr>
<td></td>
<td>Roman Thomas, Germany</td>
</tr>
</tbody>
</table>
08:15 – 09:45  PL03: PRESIDENTIAL SYMPOSIUM INCLUDING TOP RATED ABSTRACTS

## Plenary Session

**PLENARY HALL, GROUND LEVEL**

**Chairs:** Michael Boyer, Australia & Kwun Fong, Australia

- **08:15**  PL03.01: LUNG CANCER PROBABILITY IN SUBJECTS WITH CT-DETECTED PULMONARY NODULES
  Nanda Horeweg, Netherlands

- **08:27**  PL03.02: DISCUSSANT
  Christine Berg, USA

- **08:37**  PL03.03: MESOVATS: A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL OF VIDEO ASSISTED THORACOSCOPIC PLEURECTOMY VERSUS TALC PLEURODESIS IN MALIGNANT PLEURAL MESOTHELIOMA
  Robert Rintoul, UK

- **08:49**  PL03.04: DISCUSSANT
  Valerie Rusch, USA

- **08:59**  PL03.05: AN INTERGROUP RANDOMIZED PHASE III COMPARISON OF STANDARD-DOSE (60 GY) VERSUS HIGH-DOSE (74 GY) CHEMORADIOThERAPY (CRT) +/- CETUXIMAB (CETUX) FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS ON CETUX FROM RTOG 0617
  Gregory Masters, USA

- **09:11**  PL03.06: DISCUSSANT
  Jacek Jassem, Poland

- **09:21**  PL03.07: TREATMENT WITH THERAPIES MATCHED TO ONCOGENIC DRIVERS IMPROVES SURVIVAL IN PATIENTS WITH LUNG CANCERS: RESULTS FROM THE LUNG CANCER MUTATION CONSORTIUM (LCMC)
  Mark Kris, USA

- **09:33**  PL03.08: DISCUSSANT
  Ben Solomon, Australia

### 09:45 – 10:30 NETWORKING BREAK

**POSTER SESSION 2**

- Presenters are available for questions
- Refreshments are provided

EXHIBIT HALL, HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL

10:30 – 12:00  GR02: IS THERE A ROLE FOR THE THORACIC ONCOLOGY NURSE IN ENSURING PATIENTS WITH AN ADVANCED LUNG CANCER HAVE ACCESS TO EARLY PHASE CLINICAL TRIALS?

**Grand Rounds Session: Nursing**

**BAYSIDE GALLERY A, LEVEL 1**

**Chairs:** Caitlin Broderick, Australia & Mary Hesdorffer, USA

- **10:30**  CHAIR INTRO

- **10:35**  GR02.1: AFFIRMATIVE
  Patsy Yates, Australia

- **10:50**  GR02.2: AFFIRMATIVE
  John White, UK

- **11:05**  GR02.3: NEGATIVE
  Melissa Culligan, USA

- **11:20**  GR02.4: NEGATIVE
  Yeur-Hur Lai, Taiwan

- **11:35**  GR02.5: DISCUSSION

10:30 – 12:00  O12: LUNG CANCER BIOLOGY II

**Oral Abstract Session: Biology**

**PARKSIDE 110 A+B, LEVEL 1**

**Chairs:** Yoichi Nakanishi, Japan & Ben Solomon, Australia

- **10:30**  O12.01: PROSPECTIVE ISOLATION OF HUMAN LUNG STEM/PROGENITOR CELLS AND THEIR ROLE IN THE INITIATION OF LUNG CANCER: RESULTS FROM THE LUNG CANCER MUTATION CONSORTIUM (LCMC)
  Mark Kris, USA

- **10:40**  O12.02: PATHWAY ANALYSIS OF GENE EXPRESSION PROFILES THAT DISTINGUISH PERSISTENT FROM REGRESSIVE BRONCHIAL DYSPLASIA INDICATE SYNERGISTIC ROLE FOR POLO-LIKE KINASE 1 (PLK1) AND EPOXIDE HYDROLASE 3 (EPH3) IN MALIGNANT PROGRESSION
  Daniel Merrick, USA

- **10:50**  O12.03: PSEUDOGENES AS MIRNA SPONGES IN NON-SMALL CELL LUNG CANCER
  Greg Stewart, Canada

- **11:00**  O12.04: DISCUSSANT
  Kate Sutherland, Australia
11:15  O12.05: DEFINING THE ROLE OF ZEB1 IN THE PATHOGENESIS OF NON-SMALL CELL LUNG CANCER (NSCLC) USING IMMORTALIZED HUMAN BRONCHIAL EPITHELIAL CELLS (HBECs)
    Jill Larsen, USA
11:25  O12.06: HEDGEHOG/GLI PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION IN NON-SMALL CELL LUNG CANCER
    Michael Mann, USA
11:35  O12.07: PULMONARY FIBROBLASTS INCREASE EMT SIGNALING AND DECREASE SENSITIVITY TO CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER CELLS VIA TGF-BETA AND IL-6 SIGNALING
    Yasushi Shintani, Japan
11:45  O12.08: DISCUSSANT
    John Minna, USA

11:25  O13.06: VIO-SOFT-COAGULATION FOR REPAIR OF AIR LEAK FROM DISSECTED INTERSEGMENTAL PLANE DURING THORACOSCOPIC SEGMENTECTOMY
    Atsushi Watanabe, Japan
11:35  O13.07: PREOPERATIVE PREDICTIVE FACTORS OF NODEAL METASTASIS IN PATIENTS WITH CT1 LUNG CANCER
    Xue-Ning Yang, China
11:45  O13.08: DISCUSSANT
    Naveed Alam, Australia

10:30 – 12:00  O13: LIMITED RESECTIONS

Oral Abstract Session: Surgery
BAYSIDE 204 A-B, LEVEL 2

**Chairs: Gavin Wright, Australia & Kemp Kernstine, USA**

10:30  O13.01: LIMITED RESECTION TRIAL FOR PULMONARY GROUND-Glass OPAcity NODULES: CASE SELECTION BASED ON HIGH RESOLUTION COMPUTED TOMOGRAPHY: INTERIM RESULTS
    Junji Yoshida, Japan
10:40  O13.02: IS THE LIMITED SURGICAL RESECTION APPROPRIATE FOR NON-SMALL CELL LUNG CANCERS MORE THAN 2 CM IN A DIAMETER?
    - PROPOSED SURGICAL INDICATION BY THE PRESENCE OF GROUND-Glass OPAcity OF THE TUMOR ON THIN-SECTION CT SCAN
    Tatsuo Maeyashi, Japan
10:50  O13.03: SURVIVAL OF 1963 LOBECTOMY-TOLERABLE PATIENTS WHO UNDERWENT LIMITED RESECTION FOR CTAGE I NON-SMALL CELL LUNG CANCER
    Motoki Yano, Japan
11:00  O13.04: DISCUSSANT
    Hisao Asamura, Japan
11:15  O13.05: OUTCOMES OF SUBLOBAR RESECTION VERSUS LOBECTOMY FOR NON SMALL CELL LUNG CANCER (NSCLC) WITH IPF
    Dong Kwan Kim, South Korea
11:25  O13.06: VIO-SOFT-COAGULATION FOR REPAIR OF AIR LEAK FROM DISSECTED INTERSEGMENTAL PLANE DURING THORACOSCOPIC SEGMENTECTOMY
    Atsushi Watanabe, Japan
11:35  O13.07: PREOPERATIVE PREDICTIVE FACTORS OF NODEAL METASTASIS IN PATIENTS WITH CT1 LUNG CANCER
    Xue-Ning Yang, China
11:45  O13.08: DISCUSSANT
    Naveed Alam, Australia

10:30 – 12:00  O14: RADIOThERAPY - TOxICITY AND CLINICAL TRIALS

Oral Abstract Session: Radiotherapy
PARKSIDE BALLROOM A, LEVEL 1

**Chairs: Gary Pratt, Australia & Shalini Vinod, Australia**

10:30  O14.01: MEMORY PRESERVATION WITH CONFORMAL AVOIDANCE OF THE HIPPOCAMPUS DURING WHOLE-BRAIN RADIOTHERAPY FOR PATIENTS WITH BRAIN METASTASES: PRELIMINARY RESULTS OF RTOG 0933
    Vinai Gondi, USA
10:40  O14.02: VERTEbral FRACTURES IN NSCLC PATIENTS TREATED WITH IMRT AND CONCURRENT CHEMOTHERAPY
    Chun Chen, Netherlands
10:50  O14.03: USING GENERALIZED EQUIvALENT UNIFORM DOSE (GEUD) TO MODEL VOLUME EFFECTS FOR BRACHIAL PLEXOPATHY AFTER HIGH-DOSE STEREOTACTIC BODY RADIATION THERAPy (SBRT)
    Shaun Din, USA
11:00  O14.04: DISCUSSANT
    Françoise Mornex, France
11:15  O14.05: EFFECT OF POSTOPERATIVE 3D-CONFORMAL RADIOTHERAPy (3DCRT) FOR PATIENTS WITH PIiA-N2 NON-SMALL-CELL LUNG CANCER (NSCLC) AFTER COMPLETE RESECTION AND ADJUvANT CHEMOTHERAPy: INTERIM ANALYSIS OF A PROSPECTIvE PHASE III STUDy
    Zhouguang Hui, China
11:25  O14.06: INvESTIGATION OF A PATIENT REPORTED OUTCOME (PRO) TOOL TO ASSESS RADIOTHERAPy-RELATED TOxICITy IN PATIENTS WITH LUNG CANCER
    Marianna Christodoulou, Uk
11:35 O14.07: IDEAL CRT: ISOOTIC DOSE ESCALATION AND ACCELERATION IN LUNG CANCER CHEMORADIOThERAPY - A PHASE I/II TRIAL OF CONCURRENT CHEMORADIATION WITH DOSE-ESCALATED RADIOTHERAPY IN PATIENTS WITH STAGE II OR STAGE III NON-SMALL CELL LUNG CANCER
David Landau, UK

11:45 O14.08: DISCUSSANT
Shalini Vinod, Australia

10:30 – 12:00 O15: NSCLC - CHEMOTHERAPY II

Oral Abstract Session: Medical Oncology

BAYSIDE AUDITORIUM A, LEVEL 1

Chairs: Gary Richardson, Australia & John Heymach, USA

10:30 O15.01: EVALUATION OF A “WATCH AND WAIT” APPROACH FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED NON-SMALL CELL LUNG CANCER IN A DIVERSE COMMUNITY POPULATION
Krista Noonan, Canada

10:40 O15.02: THE SPANISH LUNG CANCER GROUP (SCLG) BRCA1-RAP80 EXPRESSION CUSTOMIZATION (BREC) RANDOMIZED PHASE III TRIAL OF CUSTOMIZED CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH WILD-TYPE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
(RCT00617656/GECP-BREC)
Rafael Rosell, Spain

10:50 O15.03: PHASE III, RANDOMIZED, MULTICENTER STUDY COMPARING IN ELDERLY PATIENTS (\geq 70 YEARS) WITH STAGE IV NON-SMALL-CELL LUNG CANCER (NSCLC) A STANDARD STRATEGY OF TREATMENT ALLOCATION (CARBOPLATIN BASED BIOTHERAPY OR MONOTHERAPY WITH DOCEТАXEL) BASED ON PERFORMANCE STATUS (PS) AND AGE WITH AN EXPERIMENTAL STRATEGY ALLOCATING THE SAME CHEMOTHERAPIES OR BEST SUPPORTIVE CARE (BSC) ACCORDING TO A COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) - STUDY ESOGIA-GFPC-GECP 08-02
Romain Corre, France

11:00 O15.04: DISCUSSANT
Rogerio Lilenbaum, USA

11:15 O15.05: RANDOMIZED PHASE III TRIAL OF S-1 PLUS CISPLATIN VERSUS DOCEТАXEL PLUS CISPLATIN FOR ADVANCED NON-SMALL-CELL LUNG CANCER (TCOG0701): SUBGROUP ANALYSIS
Osamu Ishimoto, Japan

11:25 O15.06: RANDOMIZED PHASE III TRIAL OF GEMCITABINE (G)/CARBOPLATIN (C) WITH OR WITHOUT INIPARIB (I) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED STAGE IV SQUAMOUS LUNG CANCER
David Spigel, USA

11:00 O15.07: DISCUSSANT
Jin Soo Lee, South Korea

10:30 – 12:00 O16: NSCLC - TARGETED THERAPIES III

Oral Abstract Session: Medical Oncology

PARKSIDE AUDITORIUM, LEVEL 1

Chairs: Heather Wakelee, USA & Lucio Crino, Italy

10:30 O16.01: IMPACT OF TUMOR BURDEN ON THE OVERALL SURVIVAL ANALYSIS OF THE LUME-LUNG 1 STUDY: A RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL OF NINTEDANIB (BIBF 1120) + DOCEТАXEL IN NSCLC PATIENTS PROGRESSING AFTER FIRST-LINE CHEMOTHERAPY
Martin Reck, Germany

10:40 O16.02: EFFICACY OF STANDARD CARE FOR SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) BY KRAS MUTATION STATUS: OBSERVATIONS ON MEK INHIBITOR ENHANCEMENT OF CHEMOTHERAPY
Pasi Janne, USA

10:50 O16.03: COST-UTILITY ANALYSIS OF FIRST-LINE TREATMENT WITH ERLOTINIB VERSUS CHEMOTHERAPY IN EGFR-MUTANT ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): ECONOMIC ANALYSIS OF EURTAC TRIAL
Alain Vergnenegre, France

11:00 O16.04: DISCUSSANT
James Chih-Hsin Yang, Taiwan
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td>O16.05</td>
<td>EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES (PROS) WITH CRIZOTINIB VERSUS CHEMOTHERAPY IN ASIAN PATIENTS IN A PHASE III STUDY OF PREVIOUSLY TREATED ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Makoto Nishio, Japan</td>
</tr>
<tr>
<td></td>
<td>O16.06</td>
<td>A PHASE 1 DOSE ESCALATION STUDY OF A NEW ALK INHIBITOR, CH5424802/RO5424802, IN ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO HAVE FAILED CRIZOTINIB (AF-002.JG/NP28761, NCT01588028)</td>
<td>Shirish Gadgeel, USA</td>
</tr>
<tr>
<td></td>
<td>O16.07</td>
<td>CONSISTENT THERAPEUTIC EFFICACY OF CH5424802/RO5424802 IN BRAIN METASTASES AMONG CRIZOTINIB-REFRACTORY ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN AN ONGOING PHASE I/II STUDY (AF-002.JG/NP28761, NCT01588028)</td>
<td>Sai-Hong Ou, USA</td>
</tr>
<tr>
<td></td>
<td>O16.08</td>
<td>DISCUSSANT</td>
<td>D. Ross Camidge, USA</td>
</tr>
<tr>
<td>11:25</td>
<td>O16:05</td>
<td>ACCURACY AND INTEROBSERVER AGREEMENT IN IDENTIFYING HISTOLOGIC SUBTYPES IN STAGE I LUNG ADENOCARCINOMAS ≤3 CM USING FROZEN SECTION</td>
<td>Yi-Chen Yeh, Taiwan</td>
</tr>
<tr>
<td>11:25</td>
<td>O16:06</td>
<td>TUMOR BUDDING AND NUCLEAR GRADE, BUT NOT HISTOLOGIC SUBTYPE, ARE SIGNIFICANT PROGNOSTIC FACTORS, INDEPENDENT OF TNM STAGE, IN PATIENTS WITH LUNG SQUAMOUS CELL CARCINOMA</td>
<td>Kyuichi Kadota, USA</td>
</tr>
<tr>
<td>11:35</td>
<td>O16:07</td>
<td>PREVALENCE, MORPHOLOGY AND NATURAL HISTORY OF FGFR1-AMPLIFIED LUNG CANCER DETECTED BY FISH AND SISH</td>
<td>Prudence Russell, Australia</td>
</tr>
<tr>
<td></td>
<td>O16:08</td>
<td>DISCUSSANT</td>
<td>Wendy Cooper, Australia</td>
</tr>
</tbody>
</table>

10:30 – 12:00 O18: CANCER CONTROL AND EPIDEMIOLOGY II

Oral Abstract Session: Prevention & Epidemiology

BAYSIDE 103, LEVEL 1

Chairs: Margaret Spitz, USA & Louis Irving, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>O18:01</td>
<td>MULTI-OMIC ANALYSIS OF AN ARSENIC-ASSOCIATED LUNG SQUAMOUS CELL CARCINOMA REVEALS SPECIFIC DNA LEVEL SIGNATURES</td>
<td>Victor Martinez Zamora, Canada</td>
</tr>
<tr>
<td>10:40</td>
<td>O18:02</td>
<td>IMPACTS OF ENVIRONMENTAL TOBACCO SMOKE ON EGFR MUTATIONS AND ALK REARRANGEMENTS IN NEVER SMOKERS WITH NON-SMALL CELL LUNG CANCER: ANALYSES ON A PROSPECTIVE MULTINATIONAL ETS REGISTRY</td>
<td>Akihito Kubo, Japan</td>
</tr>
<tr>
<td>10:50</td>
<td>O18:03</td>
<td>THE BIOCAST / IFCT-1002 STUDY: A COMPREHENSIVE OVERVIEW OF DEMOGRAPHIC, RISK EXPOSURE AND SOMATIC MUTATIONS OF NON-SMALL CELL LUNG CANCER OCCURRING AMONG FRENCH NEVER SMOKERS</td>
<td>Sebastien Couraud, France</td>
</tr>
<tr>
<td>11:00</td>
<td>O18:04</td>
<td>IMPACT OF PASSIVE SMOKING ON MOLECULAR PATTERN IN NEVER SMOKERS WITH NON-SMALL CELL LUNG CANCER: FINDINGS FROM THE BIOCAST / IFCT-1002 STUDY</td>
<td>Sebastien Couraud, France</td>
</tr>
</tbody>
</table>
11:10 O18.05: DISCUSSANT
Pierre Massion, USA

11:25 O18.06: VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS
Kim-Son Nguyen, USA

11:35 O18.07: A RETROSPECTIVE COHORT MORTALITY STUDY IN JINGCHUAN OF CHINA - THE LARGEST NICKEL POPULATION IN THE WORLD
Ning Cheng, China

11:45 O18.08: DISCUSSANT
Chris Amos, USA

10:30 – 12:00 O19: SUPPORT AND PALLIATION I

Oral Abstract Session: Supportive Care & Nurses
BAYSIDE 104, LEVEL 1

Chairs: Yuh-Min Chen, Taiwan & Jane Ingham, Australia

10:30 O19.01: HEALTH INFORMATICS AND ONCOLOGY IN GLOBAL HEALTH: A PILOT PROGRAM IN AFFORDABLE NETWORK TECHNOLOGIES IN HAITI
Pierre Theodore, USA

10:40 O19.02: DEVELOPING GUIDANCE FOR THE SUPPORTIVE AND PALLIATIVE CARE OF LUNG CANCER AND MESOTHELIOMA PATIENTS AND THEIR CARERS
Angela Richardson, UK

10:50 O19.03: PERCEPTIONS AND ATTITUDES TO EARLY INTEGRATION OF PALLIATIVE CARE FOR PATIENTS WITH INCURABLE LUNG CANCER
Linda Mileshkin, Australia

11:00 O19.04: DISCUSSANT
Jane Phillips, Australia

11:15 O19.05: GUIDANCE FOR THE ASSESSMENT OF PATIENTS FOLLOWING PALLIATIVE RADIOTHERAPY FOR LUNG CANCER
Diana Borthwick, UK

11:25 O19.06: A RETROSPECTIVE STUDY INTO THE IMPACT PALLIATIVE CARE INTERVENTION HAD ON PLACE OF DEATH FOR PATIENTS DIAGNOSED WITH NON-SMALL CELL LUNG CANCER BETWEEN 2006 AND 2011 IN THE ILLAWARRA SHOALHAVEN LOCAL HEALTH DISTRICT
June Rose, Australia

11:35 O19.07: RESOURCE UTILIZATION IN THE LAST THREE MONTHS OF LIFE BY LUNG CANCER PATIENTS IN THE HAMILTON-NIAGARA-HALDIMAND-BRANT LOCAL HEALTH INTEGRATION NETWORK (LHIN)
Peter Ellis, Canada

11:45 O19.08: DISCUSSANT
Richard Chye, Australia

10:30 – 12:00 MO12: PROGNOSTIC AND PREDICTIVE BIOMARKERS III

Mini Oral Abstract Session: Biology & Medical Oncology
PARKSIDE BALLROOM B, LEVEL 1

Chairs: Baohui Han, China & Martin Edelman, USA

10:30 MO12.01: NOVEL MECHANISMS OF SENSITIVITY AND ACQUIRED RESISTANCE TO HSP90 INHIBITION BY GANETESPIB
Sara Busacca, UK

10:35 MO12.02: ASSOCIATION BETWEEN GENE EXPRESSION PROFILES AND CLINICAL OUTCOME OF PEMETREXED-BASED TREATMENT IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: EXPLORATORY RESULTS FROM A PHASE II STUDY
Keith Kerr, UK

10:40 MO12.03: BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
Li Zhang, China

10:45 MO12.04: BIOMARKER ANALYSIS OF NCIC CLINICAL TRIALS GROUP IND.196, A PHASE I STUDY OF ERLOTINIB PLUS FORETINIB IN ADVANCED PRETREATED NON-SMALL CELL LUNG CANCER PATIENTS
Natasha Leighl, Canada

10:50 MO12.05: A NEW BIOMARKER HEAT SHOCK PROTEIN 90 ALPHA AS THERAPEUTIC MONITOR AND PREDICTOR FOR LUNG CANCER PATIENTS
Yuankai Shi, China

10:55 MO12.06: DISCUSSANT
Vassiliki Papadimitrakopoulou, USA
11:10 MO12.07: THE PREVALENCE OF MET EXPRESSION BY IMMUNOHISTOCHEMISTRY (IHC) IN THE METLUNG (OAM4971G) TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY WITH ERLOTINIB + ONARTUZUMAB (METMAB) VS ERLOTINIB + PLACEBO IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (NSCLC) Martin Edelman, USA

11:15 MO12.08: HEPATOCYTE GROWTH FACTOR (HGF) SERUM LEVELS PREDICT FOR OUTCOME IN PATIENTS WITH SMALL CELL LUNG CARCINOMA (SCLC) Edurne Arriola, Spain

11:20 MO12.09: BIM DELETION POLYMORPHISM IN ASIAN AND TREATMENT OUTCOME TO CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER Jih-Hsiang Lee, Taiwan

11:25 MO12.10: ANALYSIS OF BIM DELETION POLYMORPHISM IN CHINESE PATIENTS WITH NSCLC Jia Zhong, China

11:30 MO12.11: THE PREDICTIVE ROLE OF COMMON BIM DELETION POLYMORPHISM AND BIM EXPRESSION ON THE EGFR-TKI THERAPY IN NEVER-SMOKING LUNG ADENOCARCINOMA Ji-Youn Han, South Korea

11:35 MO12.12: DISCUSSANT Alex Adjei, USA

10:30 – 12:00 MO13: SCLC I

Mini Oral Abstract Session: Medical Oncology

BAYSIDE 201 - 203, LEVEL 2

Chairs: Chong Kin Liam, Malaysia & Edgardo Santos, USA

10:30 MO13.01: DISEASE CONTROL RATE AT 8 WEEKS PREDICTS SUBSEQUENT SURVIVAL IN PLATINUM-TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC): A PATIENT LEVEL ANALYSIS OF SWOG TRIALS Primo Lara, USA

10:35 MO13.02: AGE AS A PROGNOSTIC FACTOR IN SMALL CELL LUNG CANCER. A POOLED ANALYSIS OF RANDOMIZED CLINICAL TRIALS FROM THE MANCHESTER LUNG CANCER GROUP (MLCG) AND THE UK MEDICAL RESEARCH COUNCIL CLINICAL TRIALS UNIT (MRC CTU) Paul Wheatley-Price, Canada

10:40 MO13.03: DURATION OF THORACIC RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY IS IMPORTANT FOR OUTCOME OF PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER (L-SCLC) Ritsuko Komaki, USA

10:45 MO13.04: A PHASE II TRIAL OF SECOND LINE PAZOPANIB IN SMALL CELL LUNG CANCER (SCLC) PATIENTS: PRELIMINARY RESULTS IN PATIENTS WITH SENSITIVE DISEASE Athanasios Kotsakis, Greece

10:50 MO13.05: DISCUSSANT Michael Millward, Australia

10:55 MO13.06: PROPHYLACTIC CRANIAL IRRADIATION FOR PATIENTS WITH SMALL CELL LUNG CANCER WITH 30 GY IN 10 FRACTIONS - ANALYSIS OF EFFICACY AND SUBSET ANALYSIS OF NEUROCOGNITIVE IMPAIRMENT Subrata Saha, India

11:10 MO13.07: SURVIVAL OF SMALL CELL LUNG CANCER PATIENTS UNDERGOING LUNG RESECTION IN ENGLAND 1998-2009 Margreet Luchtenborg, UK

11:15 MO13.08: A PILOT STUDY OF ADJUVANT CHEMOTHERAPY WITH IRINOTECAN AND CISPLATIN FOR COMPLETELY RESECTED HIGH GRADE PULMONARY NEUROENDOCRINE CARCINOMA (LARGE CELL NEUROENDOCRINE CARCINOMA AND SMALL CELL LUNG CANCER) Hirotugu Kenmotsu, Japan

11:20 MO13.09: SMALL CELL LUNG CANCER IN DAILY PRACTICE; SCOT REGISTRY (SMALL CELL LUNG CANCER TREATMENT AND OUTCOME) Pieter E. Postmus, Netherlands

11:25 MO13.10: PROSPECTIVE MOLECULAR EVALUATION OF SMALL CELL LUNG CANCER (SCLC) UTILIZING THE COMPREHENSIVE MUTATION ANALYSIS PROGRAM AT MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC) Maria Pietanza, USA

11:30 MO13.11: DISCUSSANT Mary O’Brien, UK
10:30 – 12:00 MO14: MESOTHELIOMA II - SURGERY AND MULTIMODALITY

Mini Oral Abstract Session: Mesothelioma

BAYSIDE GALLERY B, LEVEL 1

**Chairs:** Eric Lim, UK & Brian McCaughan, Australia

10:30 MO14.01: THE IMPACT OF MACROSCOPIC COMPLETE RESECTION RADICAL PLEURECTOMY FOR MESOTHELIOMA ON PULMONARY FUNCTION
Joseph Friedberg, USA

10:35 MO14.02: 16 YEAR EXPERIENCE OF ROUTINE LAPAROSCOPY AND SELECTIVE CONTRALATERAL THORACOSCOPIC STAGING FOR MALIGNANT PLEURAL MESOTHELIOMA
Joseph Friedberg, USA

10:40 MO14.03: META-ANALYSIS OF EXTRAPLEURAL PNEUMONECTOMY VERSUS RADICAL PLEURECTOMY FOR PATIENTS WITH RESECTABLE MALIGNANT PLEURAL MESOTHELIOMA
Christopher Cao, Australia

10:45 MO14.04: CURRENT EVIDENCE OF PLEURECTOMY IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA
Christopher Cao, Australia

10:50 MO14.05: INTRACAVITARY CISPLATIN-FIBRIN CHEMOTHERAPY AFTER RESECTION FOR MALIGNANT PLEURAL MESOTHELIOMA PATIENTS (INFLUENCE-MESO) - PRELIMINARY RESULTS
Isabelle Opitz, Switzerland

10:55 MO14.06: DISCUSSANT
Brian McCaughan, Australia

11:10 MO14.07: ELEVATED TUMOUR EXPRESSION OF MIR-210 IS ASSOCIATED WITH SHORT SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS UNDERGOING EXTRAPLEURAL PNEUMONECTOMY
Michaela Kirschner, Australia

11:15 MO14.08: VALIDATION OF A STAGE-INDEPENDENT PRE-OPERATIVE RISK ASSESSMENT ALGORITHM FOR PATIENTS CONSIDERING SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA
William Richards, USA

11:20 MO14.09: 5-YEAR EXPERIENCE WITH ACCELERATED INDUCTION HYPOFRACTIONATED HEMITHORACIC INTENSITY MODULATED RADIATION THERAPY (IMRT) FOLLOWED BY EXTRAPLEURAL PNEUMONECTOMY (EPP) FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Marc De Perrot, Canada

11:25 MO14.10: EVIDENCE FOR CONSIDERING HIGH-DOSE HEMITHORACIC INTENSITY-MODULATED RADIATION THERAPY AS AN ALTERNATIVE TO EXTRAPLEURAL PNEUMONECTOMY IN PATIENTS WITH LOCALISED MALIGNANT PLEURAL MESOTHELIOMA
Malcolm Feigen, Australia

11:30 MO14.11: SAFETY OF HEMITHORACIC PLEURAL INTENSITY-MODULATED RADIATION THERAPY (IMRT) FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM) IN THE MULTIMODALITY SETTING: INTERIM ANALYSIS OF A PHASE II STUDY
Andreas Rimner, USA

John Cho, Canada

11:40 MO14.13: DISCUSSANT
Mo Mo Tin, Australia

12:15 – 13:45 SYMPOSIUM SUPPORTED BY BOEHRINGER INGELHEIM: QUESTIONS IN THE TREATMENT OF NSCLC: FOCUS ON EGFR MUTATION-POSITIVE NSCLC

BAYSIDE AUDITORIUM B, LEVEL 1

**Educational Session: Imaging & Staging**

BAYSIDE 204 A+B, LEVEL 2

**Chairs:** Rayleen Bowman, Australia & Windfield Tan, Philippines

14:00 CHAIR INTRO

14:05 E07.1: TNM CLASSIFICATION WITH IMAGE GUIDED INTERVENTIONS SUCH AS EBUS / EUS
Felix Herth, Germany
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:25</td>
<td>E07.2</td>
<td>IMAGE INTERPRETATION AND NEW ADENOCARCINOMA -CLASSIFICATION</td>
<td>Kavita Garg, USA</td>
<td>BSIDE GALLERY A, LEVEL 1</td>
</tr>
<tr>
<td>14:45</td>
<td>E07.3</td>
<td>IASLC STAGING PROJECTS UPDATE</td>
<td>Ramon Rami-Porta, Spain</td>
<td>BSIDE GALLERY A, LEVEL 1</td>
</tr>
<tr>
<td>15:05</td>
<td>E07.4</td>
<td>PET/CT/MRI FOR DIAGNOSIS AND STAGING OF NON-SMALL CELL LUNG CANCER</td>
<td>Yasuko Ichikawa, Japan</td>
<td>BSIDE GALLERY A, LEVEL 1</td>
</tr>
<tr>
<td>14:00</td>
<td>E08.1</td>
<td>SCREENING / EARLY DETECTION OF CENTRAL MALIGNANCY</td>
<td>Annette McWilliams, Australia</td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>E08.2</td>
<td>DEFINING THE PATHOLOGY - DYSPLASIA / CA INSITU / INVASIVE MALIGNANCY</td>
<td>Erik Thunnissen, Netherlands</td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>E08.3</td>
<td>ENDOBRONCHIAL INTERVENTIONS (PDT/Cryo/SURGERY)</td>
<td>Daniela Gompelmann, Germany</td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>E08.4</td>
<td>RT APPROACHES FOR EARLY STAGE CENTRAL TUMOURS</td>
<td>Frank Lagerwaard, Netherlands</td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td>14:00</td>
<td>E09.1</td>
<td>PRECLINICAL MODELS FOR LUNG CANCER PREVENTION</td>
<td>Luis Montuenga, Spain</td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>E09.2</td>
<td>CLINICAL CHEMOPREVENTION STUDIES: PAST, PRESENT AND FUTURE</td>
<td>Robert Keith, USA</td>
<td>BAYSIDE 104, LEVEL 1</td>
</tr>
<tr>
<td>14:45</td>
<td>E09.3</td>
<td>STUDY DESIGN AND RESPONSE ASSESSMENT IN CHEMOPREVENTION TRIALS</td>
<td>Eva Szabo, USA</td>
<td>BSIDE GALLERY A, LEVEL 1</td>
</tr>
<tr>
<td>15:05</td>
<td>E09.4</td>
<td>NEW BIOMARKERS FOR CHEMOPREVENTION STUDIES</td>
<td>Celine Mascaux, Canada</td>
<td>BSIDE GALLERY A, LEVEL 1</td>
</tr>
<tr>
<td>14:00</td>
<td>GR01.1</td>
<td>SURGERY FOR N2 DISEASE: WHERE TO AND WHEN TO NOW?</td>
<td>Masahiro Tsuboi, Japan</td>
<td>PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td>14:05</td>
<td>GR01.2</td>
<td>WHERE DOES T3 END AND T4 BEGIN?</td>
<td>Valerie Rusch, USA</td>
<td>PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td>14:25</td>
<td>GR01.3</td>
<td>ROLE OF NEOADJUVANT AND ADJUVANT THERAPIES</td>
<td>Shun-ichi Watanabe, Japan</td>
<td>PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td>14:45</td>
<td>GR01.4</td>
<td>MULTIPLE PRIMARIES, SATELLITES OR INTRAPULMONARY METASTASES?</td>
<td>Royce Calhoun, USA</td>
<td>PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td>14:00</td>
<td>MS08.1</td>
<td>IS SABR SAFE FOR CENTRAL DISEASE?</td>
<td>Andrea Bezjak, Canada</td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
<tr>
<td>14:05</td>
<td>MS08.2</td>
<td>COMBINING SABR AND TARGETED AGENTS</td>
<td>Ramesh Rengan, USA</td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
<tr>
<td>14:25</td>
<td>MS08.3</td>
<td>SABR FOR OLIGOMETASTATIC DISEASE?</td>
<td>Billy Loo, USA</td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
<tr>
<td>14:45</td>
<td>MS08.4</td>
<td>DOSE CONSTRAINTS IN SABR</td>
<td>Masahiro Hiraoka, Japan</td>
<td>PARKSIDE BALLROOM B, LEVEL 1</td>
</tr>
</tbody>
</table>
### 14:00 – 15:30 MS09: IMMUNE THERAPIES FOR LUNG CANCER

**Mini Symposium: Medical Oncology / Biology**

**BAYSIDE AUDITORIUM A, LEVEL 1**

*Chairs: David Carbone, USA & Bruce Robinson, Australia*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS09.1: BIOLOGY OF THE B7 FAMILY MEMBERS (CTLA4, PD1, PDL1)</strong></td>
</tr>
<tr>
<td></td>
<td>Scott Antonia, USA</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS09.2: TREATMENT TARGETING PD1/PDL1 AND TOXICITY</strong></td>
</tr>
<tr>
<td></td>
<td>Julie Brahmer, USA</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS09.3: TREATMENT TARGETING CTLA4 EFFICACY AND TOXICITY</strong></td>
</tr>
<tr>
<td></td>
<td>Thomas Lynch, USA</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS09.4: LUNG CANCER VACCINES</strong></td>
</tr>
<tr>
<td></td>
<td>Johan Vansteenkiste, Belgium</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30 MS10: BEYOND LUNG CANCER - THE PATHOLOGY OF INTRA-THORACIC MIMICS

**Mini Symposium: Pathology**

**BAYSIDE GALLERY B, LEVEL 1**

*Chairs: Gang Chen, China & Yuichi Ishikawa, Japan*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS10.1: METASTASES TO LUNG AND DIFFERENTIAL DIAGNOSIS</strong></td>
</tr>
<tr>
<td></td>
<td>Ka Fai To, Hong Kong</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS10.2: SALIVARY GLAND TUMOURS AND LYMPHOEPITHELIOMA-LIKE CARCINOMA</strong></td>
</tr>
<tr>
<td></td>
<td>Lucian Chirieac, USA</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS10.3: PLEURAL NEOPLASMS</strong></td>
</tr>
<tr>
<td></td>
<td>Sonja Klebe, Australia</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS10.4: PULMONARY SARCOMAS</strong></td>
</tr>
<tr>
<td></td>
<td>Iver Petersen, Germany</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30 MS11: NEXT GENERATION TECHNOLOGY FOR DETECTION AND TREATMENT OF LUNG CANCER

**Mini Symposium: Pathology/Biology**

**BAYSIDE AUDITORIUM B, LEVEL 1**

*Chairs: Shinichi Toyooka, Japan & Tran Van Ngoc, Vietnam*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS11.1: NEXT GENERATION SEQUENCING</strong></td>
</tr>
<tr>
<td></td>
<td>Ramaswamy Govindan, USA</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS11.2: VALIDATING PLATFORMS FOR ROUTINE CLINICAL USE</strong></td>
</tr>
<tr>
<td></td>
<td>Paul Waring, Australia</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS11.3: THE ROLE OF CURRENT PATHOLOGIC TECHNIQUES IN THE NEXT GEN WORLD</strong></td>
</tr>
<tr>
<td></td>
<td>Ignacio Wistuba, USA</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS11.4: REPORTING AND INTERPRETING MOLECULAR RESULTS</strong></td>
</tr>
<tr>
<td></td>
<td>Ming Tsao, Canada</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30 MS12: LOCO-REGIONAL MANAGEMENT OF MPM

**Mini Symposium: Mesothelioma**

**BAYSIDE 103, LEVEL 1**

*Chairs: Hans Hoffman, Germany & Takashi Nakano, Japan*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:04</td>
<td><strong>MS12.1: HOW HAS THE 'MARS' TRIAL AFFECTED THE SURGICAL APPROACH TO MPM?</strong></td>
</tr>
<tr>
<td></td>
<td>John Edwards, UK</td>
</tr>
<tr>
<td>14:27</td>
<td><strong>MS12.2: PLEURECTOMY DECORTICATION VS. EXTRAPLEURAL PNEUMONECTOMY</strong></td>
</tr>
<tr>
<td></td>
<td>Jessica Donington, USA</td>
</tr>
<tr>
<td>14:50</td>
<td><strong>MS12.3: PERI-OPERATIVE RADIOTHERAPY: CURRENT DATA AND STATE OF THE ART</strong></td>
</tr>
<tr>
<td></td>
<td>Allan Price, UK</td>
</tr>
<tr>
<td>15:10</td>
<td><strong>MS12.4: ADJUVANT INTRACAVITARY TREATMENTS IN MESOTHELIOMA</strong></td>
</tr>
<tr>
<td></td>
<td>Joseph Friedberg, USA</td>
</tr>
</tbody>
</table>
14:00 – 15:30 **MS13: STATISTICS OF PERSONALISED MEDICINE**

**Mini Symposium: Statistics**

PARKSIDE 110 A+B, LEVEL 1

**Chairs: May Redman, USA & John Crowley, USA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:05</td>
<td>MS13.1: A REVIEW OF RANDOMISED TRIALS IN LUNG CANCER</td>
</tr>
<tr>
<td></td>
<td>Richard Stephens, UK</td>
</tr>
<tr>
<td>14:25</td>
<td>MS13.2: CLINICAL TRIAL DESIGNS FOR BIOMARKER DRIVEN THERAPIES IN ADVANCED DISEASE</td>
</tr>
<tr>
<td></td>
<td>Roy Herbst, USA</td>
</tr>
<tr>
<td>14:45</td>
<td>MS13.3: CLINICAL TRIAL DESIGNS FOR BIOMARKER DRIVEN THERAPIES IN EARLY DISEASE (ADJUVANT)</td>
</tr>
<tr>
<td></td>
<td>Giorgio Scagliotti, Italy</td>
</tr>
<tr>
<td>15:05</td>
<td>MS13.4: THE FUTURE OF RCTS IN THE MOLECULAR ERA?</td>
</tr>
<tr>
<td></td>
<td>David Gandara, USA</td>
</tr>
</tbody>
</table>

14:00 – 15:30 **MS14: INTERFACE BETWEEN DISEASE MODIFYING TREATMENT AND PALLIATION**

**Mini Symposium: Supportive Care**

BAYSIDE 105, LEVEL 1

**Chairs: Lucy Morgan, Australia & Beth Ivimey, Australia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:05</td>
<td>MS14.1: SLIDING SLOPE BETWEEN CURE AND PALLIATION: LOCAL CURE IN DISSEMINATED DISEASE</td>
</tr>
<tr>
<td></td>
<td>Ben Slotman, Netherlands</td>
</tr>
<tr>
<td>14:25</td>
<td>MS14.2: DECISION MAKING; WHEN TO STOP DISEASE MODIFYING TREATMENT</td>
</tr>
<tr>
<td></td>
<td>Christian Manegold, Germany</td>
</tr>
<tr>
<td>14:45</td>
<td>MS14.3: END OF LIFE DISCUSSIONS - EVIDENCE-BASED COMMUNICATION</td>
</tr>
<tr>
<td></td>
<td>Josephine Clayton, Australia</td>
</tr>
<tr>
<td>15:05</td>
<td>MS14.4: TRANSITION TO END OF LIFE CARE</td>
</tr>
<tr>
<td></td>
<td>Christos Karapetis, Australia</td>
</tr>
</tbody>
</table>

14:00 – 15:30 **MS15: EXTENDING THE LIMITS OF COMBINED MODALITY TREATMENT FOR NSCLC**

**Mini Symposium: Combined Modality**

BAYSIDE 201 - 203, LEVEL 2

**Chairs: Mary O’Brien, UK & Ivan Tham, Singapore**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:04</td>
<td>MS15.1: TARGETED THERAPY IN COMBINED MODALITY THERAPY FOR INTRATHORACIC NSCLC WITH ACTIVATING MUTATIONS</td>
</tr>
<tr>
<td></td>
<td>Egbert Smit, Netherlands</td>
</tr>
<tr>
<td>14:27</td>
<td>MS15.2: DOSE ESCALATION OF RADIATION IN COMBINED MODALITY THERAPY OF NSCLC</td>
</tr>
<tr>
<td></td>
<td>Suresh Senan, Netherlands</td>
</tr>
<tr>
<td>14:50</td>
<td>MS15.3: MANAGEMENT OF PATIENTS WITH OLIGOMETASTATIC/RESECTABLE STAGE IV NSCLC</td>
</tr>
<tr>
<td></td>
<td>Lunxu Liu, China</td>
</tr>
<tr>
<td>15:10</td>
<td>MS15.4: SURGERY AFTER INDUCTION CHEMO/RADIATION THERAPY</td>
</tr>
<tr>
<td></td>
<td>Walter Weder, Switzerland</td>
</tr>
</tbody>
</table>

14:00 – 15:30 **PC02: EGFR AS A TARGET IN EARLY STAGE DISEASE**

**Pro-Con Session: Medical Oncology**

PARKSIDE AUDITORIUM, LEVEL 1

**Chairs: Nick Pavlakis, Australia & Jin Soo Lee, South Korea**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>CHAIR INTRO</td>
</tr>
<tr>
<td>14:05</td>
<td>PC02.1: INTRODUCTION: DETECTION OF EGFR MUTATIONS</td>
</tr>
<tr>
<td></td>
<td>Fred Hirsch, USA</td>
</tr>
<tr>
<td>14:20</td>
<td>PC02.2: PRO: PATIENTS WITH EGFR MUTATIONS SHOULD RECEIVE ADJUVANT EGFR TKIS</td>
</tr>
<tr>
<td></td>
<td>Kazuhiko Nakagawa, Japan</td>
</tr>
<tr>
<td>14:40</td>
<td>PC02.3: CON: PATIENTS WITH EGFR MUTATIONS SHOULD NOT RECEIVE ADJUVANT EGFR TKIS</td>
</tr>
<tr>
<td></td>
<td>Chong Kin Liam, Malaysia</td>
</tr>
<tr>
<td>15:00</td>
<td>PC02.4: ADJUDICATION AND DISCUSSION</td>
</tr>
<tr>
<td></td>
<td>Mark Kris, USA</td>
</tr>
</tbody>
</table>
### 15:30 – 16:15 NETWORKING BREAK

**POSTER SESSION 2**
- Presenters are available for questions
- Refreshments are provided

EXHIBIT HALL, HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL

### 16:15 – 17:45 O20: STAGING AND ADVANCED DISEASE

**Oral Abstract Session: Surgery**

PARKSIDE 110 A+B, LEVEL 1

**Chairs:** Paula Ugalde, Canada & Sai Yendamuri, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td><strong>O20.01:</strong> TRANSCERVICAL EXTENDED MEDIASTINAL LYMPHADENECTOMY (TEMLA) IS SUPERIOR TO PET/CT FOR RESTAGING OF THE MEDIASTINUM AFTER NEOADJUVANT THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC) Sai Yendamuri, USA</td>
</tr>
<tr>
<td>16:25</td>
<td><strong>O20.02:</strong> A NOVEL NODAL CLASSIFICATION FOR RESECTED NON-SMALL CELL LUNG CANCER: COMPARISON BETWEEN LOCATION-BASED AND NUMBER-BASED SYSTEMS Junji Ichinose, Japan</td>
</tr>
<tr>
<td>16:35</td>
<td><strong>O20.03:</strong> LOBE-SPECIFIC LYMPHADENECTOMY PROTOCOL FOR NON-SMALL CELL LUNG CANCER PRESENTING AS A SOLITARY PULMONARY NODULE Xue-Ning Yang, China</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>O20.04:</strong> DISCUSSANT Paul De Leyn, Belgium</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>O20.05:</strong> PROGNOSIS AND OUTCOME AFTER SURGICAL RESSECTION OF SOLITARY BRAIN METASTASIS IN 82 NSCLC PATIENTS: A SINGLE INSTITUTION EXPERIENCE Oleg Pikin, Russia</td>
</tr>
<tr>
<td>17:10</td>
<td><strong>O20.06:</strong> SURGICAL TECHNIQUES AND RESULTS OF RECONSTRUCTION OF THE PULMONARY ARTERY FOR PATIENTS WITH CENTRAL NON-SMALL CELL LUNG CANCER Qianli Ma, China</td>
</tr>
</tbody>
</table>

### 16:15 – 17:45 O21: SCLC II

**Oral Abstract Session: Medical Oncology**

PARKSIDE BALLROOM B, LEVEL 1

**Chairs:** Myung-Ju Ahn, South Korea & Primo Lara, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td><strong>O21.01:</strong> A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) Michael Seckl, UK</td>
</tr>
<tr>
<td>16:25</td>
<td><strong>O21.02:</strong> PHASE III TRIAL COMPARING IRINOTECAN PLUS CISPLATIN (IP) WITH ETOPOSIDE PLUS CISPLATIN (EP) IN KOREAN PATIENTS WITH EXTENSIVE DISEASE (ED) SMALL CELL LUNG CANCER (SCLC) Dong-Wan Kim, South Korea</td>
</tr>
<tr>
<td>16:35</td>
<td><strong>O21.03:</strong> N-0923, A RANDOMIZED DOUBLE-BLIND PHASE II STUDY OF THE SENECA VALLEY VIRUS (NTX-010) VS PLACEBO FOR PATIENTS WITH EXTENSIVE STAGE SCLC (ES-SCLC) WHO WERE STABLE OR RESPONDING AFTER AT LEAST 4 CYCLES OF PLATINUM-BASED CHEMOTHERAPY: ALLIANCE (NCCCTG) STUDY Julian Molina, USA</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>O21.04:</strong> DISCUSSANT Nevin Murray, Canada</td>
</tr>
<tr>
<td>17:00</td>
<td><strong>O21.05:</strong> A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC) Bonnie Glisson, USA</td>
</tr>
<tr>
<td>17:10</td>
<td><strong>O21.06:</strong> MLN8237 (ALISERTIB), A SELECTIVE AURORA A KINASE (AAK) INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC): PHASE 2 RESULTS Libor Havel, Czech Republic</td>
</tr>
</tbody>
</table>
### 16:15 – 17:45 O22: MESOTHELIOMA III

**Oral Abstract Session: Mesothelioma**

**BAYSIDE GALLERY A, LEVEL 1**

*Chairs: Paul Baas, Netherlands & Rabab Gafaar, Egypt*

16:15 **O22.01:** NEXT GENERATION SEQUENCING IN MALIGNANT PLEURAL MESOTHELIOMA: PRELIMINARY DATA FROM A RETROSPECTIVE COHORT OF 123 PATIENTS

Giorgio Scagliotti, Italy

16:25 **O22.02:** CD8 T-CELL INFILTRATION AND TUMOR IL-7R EXPRESSION ARE INDEPENDENT PROGNOSTIC FACTORS IN EPITHELIOID MALIGNANT PLEURAL MESOTHELIOMA

Hideki Ujiie, USA

16:35 **O22.03:** DURABLE CANCER REGRESSIONS IN CHEMOTHERAPY REFRACTORY MESOTHELIOMA PATIENTS WITH THE ANTI-MESOTHELIN IMMUNOTOXIN SS1P AND HOST IMMUNE DEPLETION WITH PENTOSTATIN (P) AND CYCLOPHOSPHAMIDE (C)

Raffit Hassan, USA

16:45 **O22.04:** DISCUSSANT

TBA

17:00 **O22.05:** EXPOSURE-RESPONSE RELATIONSHIP OF AMATUXIMAB (AMA) IN COMBINATION WITH PEMETREXED AND CISPLATIN (P/C) IN PATIENTS WITH UNRESECTABLE PLEURAL MESOTHELIOMA

Julia Maltzman, USA

17:10 **O22.06:** QUALITY OF LIFE MEASUREMENT PARALLEL CHANGES IN PULMONARY FUNCTION IN PATIENTS UNDERGOING PLEURECTOMY AND DECORTICATION FOR MALIGNANT PLEURAL MESOTHELIOMA

Wickii Vigneswaran, USA

17:20 **O22.07:** DOES SURGERY IMPROVE SURVIVAL OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA? A MULTICENTER RETROSPECTIVE ANALYSIS OF 1365 CONSECUTIVE PATIENTS

Andrea Bille, Italy

17:30 **O22.08:** DISCUSSANT

Raffit Hassan, USA

### 16:15 – 17:45 O23: IMAGING AND SCREENING

**Oral Abstract Session: Imaging & Screening**

**BAYSIDE 201 - 203, LEVEL 2**

*Chairs: James Jett, USA & Yong Song, China*

16:15 **O23.01:** VOLUME DOUBLING TIME MEASUREMENT OF PULMONARY NODULES: COMPARISON BETWEEN 2D- AND 3D-METHODS

Daisuke Morimoto, Japan

16:25 **O23.02:** POSITRON EMISSION TOMOGRAPHY (PET) IN LUNG CANCER SCREENING - FINAL RESULTS AFTER A 5 YEAR SCREENING PROGRAMME

Haseem Ashraf, Denmark

16:35 **O23.03:** METABOLIC IMAGING BASED PROGNOSTIC MODEL FOR PREDICTING SURVIVAL OF PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER

Seung Hyup Hyun, South Korea

16:45 **O23.04:** IMPROVED INTEROBSERVER AGREEMENT WITH PERCIST 1.0, COMPARED TO A QUALITATIVE METHOD FOR EARLY RESPONSE EVALUATION USING FDG-PET/CT IN NSCLC

Joan Fledelius, Denmark

16:55 **O23.05:** DISCUSSANT

TBA

17:10 **O23.06:** DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING AT 3.0-T VERSUS FLUORINE 18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR DETECTION OF PULMONARY MALIGNANT TUMORS

Xing Tang, China

17:20 **O23.07:** COMPARISON OF DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING VERSUS F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY IN THE ASSESSMENT OF N2 LYMPH NODE METASTASIS DUE TO NON-SMALL CELL LUNG CANCER

Erkan Yilmaz, Turkey
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 – 17:45</td>
<td><strong>O24: CANCER CONTROL AND EPIDEMIOLOGY III</strong></td>
<td></td>
</tr>
<tr>
<td>Oral Abstract Session: Prevention &amp; Epidemiology</td>
<td>BAYSIDE 103, LEVEL 1</td>
<td></td>
</tr>
<tr>
<td>Chairs: Nico van Zandwijk, Australia &amp; Ping Yang, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>O24.01: LUNG CANCER RISK ATTRIBUTABLE TO OCCUPATION: IN A CASE CONTROL STUDY IN BLACK SOUTH AFRICANS 2001-2008</td>
<td>Cornelius Nattey, South Africa</td>
</tr>
<tr>
<td>16:25</td>
<td>O24.02: LUNG CANCER IN SOUTH EAST SCOTLAND, ARE WE STILL MAKING PROGRESS?</td>
<td>Sara Erridge, UK</td>
</tr>
<tr>
<td>16:35</td>
<td>O24.03: LUNG CANCER INCIDENCE TRENDS AMONG ASIAN-AMERICAN ETHNIC POPULATIONS IN THE UNITED STATES, 1990-2010</td>
<td>Manali Patel, USA</td>
</tr>
<tr>
<td>16:45</td>
<td>O24.04: RISK OF SECOND PRIMARY LUNG CANCER (SPLC) IN PATIENTS (PTS) WITH PREVIOUSLY TREATED LUNG CANCER: ANALYSIS OF THE SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER) DATA</td>
<td>Antoinette Wozniak, USA</td>
</tr>
<tr>
<td>16:55</td>
<td>O24.05: THE IMPACT OF BODY MASS INDEX ON SURVIVAL IN STAGE 3 AND 4 LUNG CANCER</td>
<td>Kit Man Wong, Canada</td>
</tr>
<tr>
<td>17:05</td>
<td>O24.06: DISCUSSANT</td>
<td>Ian Olver, Australia</td>
</tr>
</tbody>
</table>

| 16:15 – 17:45 | **O25: STIGMA AND NIHILISM** |                                                                          |
| Oral Abstract Session: Nurses | BAYSIDE GALLERY B, LEVEL 1 |                                                                          |
| Chairs: Janine Cataldo, USA & Sue Sinclair, Australia |                                                                          |                                                                          |
| 16:15 | O25.01: RELIABILITY OF AND CORRELATES WITH A MEASURE OF LUNG CANCER STIGMA IN NORWEGIAN PATIENTS WHO UNDERWENT LUNG CANCER SURGERY | Trine Oksholm, Norway                                                  |

| 16:25 | O25.02: THE SOCIAL STIGMA OF LUNG CANCER: DEATH ANXIETY AND HEALTH BELIEFS AS ANTECEDENT VARIABLES | Tabitha Frew, Australia                                                 |
| 16:35 | O25.03: THE UNIQUE CONTRIBUTION OF LUNG CANCER STIGMA TO PATIENT QUALITY OF LIFE | Janine Cataldo, USA                                                    |
| 16:45 | O25.04: LUNG CANCER STIGMA, ANXIETY, DEPRESSION AND SYMPTOM SEVERITY | Janine Cataldo, USA                                                    |
| 16:55 | O25.05: STIGMA AND NIHILISM IN LUNG CANCER: THE PERSPECTIVE OF AUSTRALIAN HEALTH PROFESSIONALS AND CONSUMERS | Sue Sinclair, Australia                                               |
| 17:05 | O25.06: ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY DIRECTED PLEURAL TATTOO TO AID SURGICAL RESECTION OF PERIPHERAL PULMONARY LESION | Jun Hoe Tay, Australia                                                |
| 17:15 | O25.07: PANEL DISCUSSION WITH CHAIRS AND SPEAKERS |                                                                          |

<p>| 16:15 – 17:45 | <strong>O26: SUPPORT AND PALLIATION II</strong> |                                                                          |
| Oral Abstract Session: Supportive Care &amp; Nurses | BAYSIDE 104, LEVEL 1 |                                                                          |
| Chairs: John White, UK &amp; Yeur-Hur Lai, Taiwan |                                                                          |                                                                          |
| 16:15 | O26.01: THE IMPACT OF THE LUNG CANCER CLINICAL NURSE SPECIALIST ON ACCESS TO ANTI-CANCER TREATMENT | Angela Tod, UK                                                        |
| 16:25 | O26.02: UNDERSTANDING THE VALUE OF LUNG CANCER NURSE SPECIALISTS | John White, UK                                                        |
| 16:35 | O26.03: IS EARLY INTEGRATION OF PALLIATIVE CARE FOR PATIENTS WITH INCURABLE LUNG CANCER ACCEPTABLE TO AUSTRALIAN HEALTHCARE PROFESSIONALS? | Linda Mileskikhin, Australia                                          |
| 16:45 | O26.04: DISCUSSANT | Mary Duffy, Australia                                                  |
| 17:00 | O26.05: PATTERNS OF CARE IN PALLIATIVE RADIOTHERAPY DELIVERY IN ADVANCED LUNG CANCER: HOW HAS THIS INFLUENCED THE DEVELOPMENT OF A PALLIATIVE RADIOTHERAPY RAPID ASSESSMENT CLINIC (PRRAC)? | Kathy Pope, Australia                                                 |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 17:10 | O26.06: IMPACT OF GERIATIC ASSESSMENT ON TREATMENT DECISIONS IN OLDER LUNG CANCER PATIENTS  
Leen Vanacker, Belgium |
| 17:20 | O26.07: TOWARDS CANCER REHABILITATION AT HOME DESIGN OF A TELE-REHABILITATION SERVICE FOR LUNG CANCER PATIENTS  
Josien Timmerman, Netherlands |
| 17:30 | O26.08: DISCUSSANT  
Patsy Yates, Australia |

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>MO15: NOVEL GENES AND PATHWAYS</td>
</tr>
<tr>
<td></td>
<td>PARKSIDE BALLROOM A, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Chairs: Yuichiro Ohe, Japan &amp; Glen Reid, Australia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:15 | MO15.01: PATHWAY ACTIVATION MAPPING OF KRAS WILD TYPE AND MUTATED ADENOCARCINOMAS OF THE LUNG: NEW IMPLICATIONS FOR PATIENT STRATIFICATION FOR MAP KINASE PATHWAY INHIBITION  
Elisa Baldelli, USA |
| 16:20 | MO15.02: IMPACT OF CO-OCCURRING GENETIC EVENTS ON THE SIGNALING LANDSCAPE OF KRAS-MUTANT LUNG ADENOCARCINOMA  
Ferdinandos Skoulidis, USA |
| 16:25 | MO15.03: DECIPHERING THE RASSF1A SIGNALLING PATHWAY IN LUNG CANCER CELLS REVEALS A METASTASIS-SUPPRESSOR ROLE THROUGH YAP-DEPENDENT EPITHELIAL-MESENCHYMAL TRANSITION (EMT)  
Gerard Zalcman, France |
| 16:30 | MO15.04: LOSS OF TUMOR SUPPRESSOR HIC1 ACCELERATES THE PROGRESSION OF LUNG ADENOCARCINOMA INDUCED BY ONCOGENIC KRAS  
Anette Szczepny, Australia |
| 16:35 | MO15.05: ONCOGENIC ARAF MUTATION IN LUNG ADENOCARCINOMA  
David Carbone, USA |
| 16:40 | MO15.06: A PROSPECTIVE INTERNET-BASED STUDY OF PATIENTS WITH LUNG CANCER HARBORING BASELINE EGFR T790M TO IDENTIFY GERMLINE CARRIERS AND CHARACTERIZE FAMILIAL RISK  
Geoffrey Oxnard, USA |
| 16:45 | MO15.07: DISCUSSANT  
Gregory Riely, USA |
| 17:00 | MO15.08: KDR (VEGFR-2) COPY NUMBER GAINS AND MUTATIONS ARE TARGETABLE ALTERATIONS IN NON-SMALL CELL LUNG CANCER  
John Heymach, USA |
### 16:15 – 17:45 MO16: PROGNOSTIC AND PREDICTIVE BIOMARKERS IV

**Mini Oral Abstract Session: Biology & Medical Oncology**

**PARKSIDE AUDITORIUM, LEVEL 1**

**Chairs:** Shinichi Toyooka, Japan & James Chih-Hsin Yang, Taiwan

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>MO16.01: DIFFERENT MICRO-RNA EXPRESSION IN LUNG ADENOCARCINOMA WITH MOLECULAR DRIVER EVENTS</td>
<td>Lorenza Landi, Italy</td>
</tr>
<tr>
<td>16:20</td>
<td>MO16.02: TUMOR AND STROMA TREG MARKERS IN RESECTABLE NSCLC</td>
<td>Eloisa Jantus Lewintre, Spain</td>
</tr>
<tr>
<td>16:25</td>
<td>MO16.03: CYTOPLASMIC ERβ EXPRESSION PREDICTS POORLY EFFICACY AND SURVIVAL OF EGFR-TKI IN EGFR MUTANT NSCLC</td>
<td>Zhijie Wang, China</td>
</tr>
<tr>
<td>16:30</td>
<td>MO16.04: ANALYSIS OF HER2 AMPLIFICATION IN NON-SMALL CELL LUNG Cancers (NSCLCs) WITH ACQUIRED RESISTANCE (AR) TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS (TKIs)</td>
<td>Sarah Goldberg, USA</td>
</tr>
<tr>
<td>16:35</td>
<td>MO16.05: DISCUSSANT</td>
<td>Thomas John, Australia</td>
</tr>
<tr>
<td>16:50</td>
<td>MO16.06: CLINICAL, STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF EGFR EXON 20 INSERTION MUTATIONS IN LUNG CANCER</td>
<td>Daniel Costa, USA</td>
</tr>
</tbody>
</table>

### 16:15 – 17:45 MO17: RADIOTHERAPY I: STEREOTACTIC ABLATIVE BODY RADIOThERAPY

**Mini Oral Abstract Session: Radiotherapy**

**BAYSIDE 204 A+B, LEVEL 2**

**Chairs:** Matijaz Zwitter, Slovenia & Shalini Vinod, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>MO17.01: RESPONSE ASSESSMENT OF STEREOTACTIC ABLATIVE BODY RADIOThERAPY (SABR) FOR PULMONARY METASTASES: UTILITY OF 4D-FDG-PET AND CT PERFUSION</td>
<td>Shankar Siva, Australia</td>
</tr>
<tr>
<td>16:20</td>
<td>MO17.02: RADICAL RADIOTHERAPY FOR NON-SMALL CELL LUNG CANCER - IS IT THE END FOR 2 GRAY PER FRACTION?</td>
<td>Noelle O'Rourke, UK</td>
</tr>
<tr>
<td>16:25</td>
<td>MO17.03: INCIDENTAL PROPHYLACTIC NODAL IRRADIATION AND PATTERNS OF NODAL RELAPSE IN INOPERABLE EARLY STAGE NSCLC PATIENTS TREATED WITH SBRT: A CASE-MATCHED ANALYSIS</td>
<td>Louis Lao, New Zealand</td>
</tr>
<tr>
<td>16:30</td>
<td>MO17.04: ENDOBRONCHIAL FIDUCIAL MARKER SAFETY AND STABILITY</td>
<td>Daniel Nader, USA</td>
</tr>
<tr>
<td>16:35</td>
<td>MO17.05: RECURRENT, SURVIVAL, AND TOXICITY AFTER STEREOTACTIC LUNG RADIOTherapy (SBRT) FOR CENTRAL VERSUS PERIPHERAL STAGE I NON-SMALL CELL LUNG CANCERS (NSCLC): RESULTS FROM AN INTERNATIONAL COLLABORATIVE RESEARCH GROUP</td>
<td>Maria Werner-Wasik, USA</td>
</tr>
</tbody>
</table>

**SCIENTIFIC PROGRAM**

**WCLC.IASLC.ORG | 15th WORLD CONFERENCE ON LUNG CANCER FINAL SCIENTIFIC PROGRAM**

**17:05 MO15.09: AMPLIFICATION OF YEATS4, A NOVEL ONCOGENE IN NSCLC, INHIBITS THE P53 PATHWAY AND INCREASES RESISTANCE TO CISPLATIN**

Larissa Pikor, Canada

**17:10 MO15.10: ELF3 IS A NOVEL ONCOGENE FREQUENTLY ACTIVATED BY GENETIC AND EPIGENETIC MECHANISMS IN LUNG ADENOCARCINOMA**

Katey Enfield, Canada

**17:15 MO15.11: USING SYNTHETIC LETHAL SCREENING TO IDENTIFY THERAPEUTIC TARGETS FOR INNATELY PLATINUM RESISTANT LUNG CANCER**

Kieren Marini, Australia

**17:20 MO15.12: DISCUSSANT**

Pan-Chyr Yang, Taiwan

**16:55 MO16.07: HIGHER FREQUENCY OF GENETIC ABERRATIONS IN KRAS- THAN IN EGFR-MUTATED NSCLCS. A NEXT-GENERATION SEQUENCING STUDY ON 96 SAMPLES**

Odd Terje Brustugun, Norway

**17:00 MO16.08: CYTOLOGY SAMPLES (S) FOR EGFR, KRAS AND ALK TESTING IN NON-SMALL-CELL LUNG CANCER (NSCLC)**

Enric Carcereny, Spain

**17:05 MO16.09: PATTERNS OF METASTASIS AND SURVIVAL IN PATIENTS WITH PI3K-ABERRANT AND FGFR1 AMPLIFIED STAGE IV SQUAMOUS CELL LUNG CANCERS (SCCLCS)**

Paul Paik, USA

**17:10 MO16.10: DISCUSSANT**

John Minna, USA

**17:05 – 17:45 MO16: PROGNOSTIC AND PREDICTIVE BIOMARKERS IV**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:40</td>
<td>MO17.06</td>
<td>DISCUSSANT</td>
<td>Matthew Hatton, UK</td>
</tr>
<tr>
<td>16:55</td>
<td>MO17.07</td>
<td>THE COST OF STEREOTACTIC BODY RADIOTHERAPY IN EARLY-STAGE LUNG CANCER: A MULTICENTER COST-INFORMATION</td>
<td>Yolande Lievens, Belgium</td>
</tr>
<tr>
<td>17:00</td>
<td>MO17.08</td>
<td>TCP MODELING IN STEREOTACTIC BODY RADIOTHERAPY FOR EARLY STAGE NON SMALL CELL LUNG CANCER: IS A DOSE-VOLUME EFFECT PRESENT?</td>
<td>Heike Peulen, Netherlands</td>
</tr>
<tr>
<td>17:05</td>
<td>MO17.09</td>
<td>DOSIMETRIC PREDICTORS OF ESOPHAGEAL TOXICITY AFTER STEREOTACTIC BODY RADIOTHERAPY FOR CENTRAL LUNG TUMORS</td>
<td>Abraham Wu, USA</td>
</tr>
<tr>
<td>17:10</td>
<td>MO17.10</td>
<td>LATE RADIOLOGIC CHANGE AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY FOR EARLY STAGE LUNG CANCER: A COMPARISON BETWEEN FIXED-BEAM VERSUS ARC DELIVERY TECHNIQUES</td>
<td>Sashendra Senthi, Netherlands</td>
</tr>
<tr>
<td>17:15</td>
<td>MO17.11</td>
<td>STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR CENTRALLY LOCATED EARLY-STAGE OR ISOLATED PARENCHYMAL RECURRENCES OF NON-SMALL CELL LUNG CANCER (NSCLC): HOW TO FLY IN A “NO FLY ZONE”</td>
<td>Joe Chang, USA</td>
</tr>
<tr>
<td>17:20</td>
<td>MO17.12</td>
<td>DISCUSSANT</td>
<td>Sue Yom, USA</td>
</tr>
</tbody>
</table>

16:15 – 17:45 MO18: NSCLC - TARGETED THERAPIES IV

**Mini Oral Abstract Session: Medical Oncology**

*Bayside Auditorium B, Level 1*

**Chairs: Leora Horn, USA & Juergen Wolf, Germany**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15</td>
<td>MO18.01</td>
<td>AN ANALYSIS OF THE RELATIONSHIP OF CLINICAL ACTIVITY TO BASELINE EGFR STATUS, PD-L1 EXPRESSION AND PRIOR TREATMENT HISTORY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PD-L1 BLOCKADE WITH MPDL3280A (ANTI-PDL1)</td>
<td>Leora Horn, USA</td>
</tr>
<tr>
<td>16:20</td>
<td>MO18.02</td>
<td>PRELIMINARY CLINICAL SAFETY AND ACTIVITY OF MK-3475 MONOTHERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Edward Garon, USA</td>
</tr>
<tr>
<td>16:25</td>
<td>MO18.03</td>
<td>NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): OVERALL SURVIVAL AND LONG-TERM SAFETY IN A PHASE 1 TRIAL</td>
<td>Julie Brahmer, USA</td>
</tr>
<tr>
<td>16:30</td>
<td>MO18.04</td>
<td>MUC1-TARGETED DENDRITIC CELL-BASED VACCINES IN PATIENTS WITH STANDARD TREATMENTS-REFRACTORY NON-SMALL-CELL LUNG CANCER</td>
<td>Koji Teramoto, Japan</td>
</tr>
<tr>
<td>16:35</td>
<td>MO18.05</td>
<td>DISCUSSANT</td>
<td>Peter Ellis, Canada</td>
</tr>
<tr>
<td>16:45</td>
<td>MO18.06</td>
<td>BATTLE-2 PROGRAM: A BIOMARKER-INTEGRATED TARGETED THERAPY STUDY IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Vassiliki Papadimitrakopoulou, USA</td>
</tr>
<tr>
<td>16:50</td>
<td>MO18.07</td>
<td>THE NETWORK GENOMIC MEDICINE: A PROSPECTIVE COMPREHENSIVE MOLECULAR SCREENING NETWORK FOR NSCLC</td>
<td>Marc Bos, Germany</td>
</tr>
<tr>
<td>16:55</td>
<td>MO18.08</td>
<td>PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCER (SCCA)</td>
<td>Vassiliki Papadimitrakopoulou, USA</td>
</tr>
<tr>
<td>17:00</td>
<td>MO18.09</td>
<td>DISCUSSANT</td>
<td>Julie Brahmer, USA</td>
</tr>
<tr>
<td>17:10</td>
<td>MO18.10</td>
<td>ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH PEMETREXED IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS</td>
<td>Jaafar Bennouna, France</td>
</tr>
<tr>
<td>17:15</td>
<td>MO18.11</td>
<td>ORAL MEK1/MEK2 INHIBITOR TRAMETINIB (GSK1120212) IN COMBINATION WITH DOCETAXEL IN A PHASE 1/1B TRIAL INVOLVING KRAS-MUTANT AND WILD-TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY AND BIOMARKER RESULTS</td>
<td>Jaafar Bennouna, France</td>
</tr>
</tbody>
</table>
17:20  MO18.12: IMPACT OF KRAS CODON SUB-TYPES IN A PHASE II SECOND-LINE TRIAL IN KRAS-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) OF SELUMETINIB PLUS DOCETAXEL VERSUS DOCETAXEL ALONE
Paul Smith, UK

17:25  MO18.13: DISCUSSANT
Edward Kim, USA

18:00 – 19:30  SYMPOSIUM SUPPORTED BY ROCHE: NEW HORIZONS IN FIRST-LINE NSCLC THERAPY
PARKSIDE AUDITORIUM, LEVEL 1

19:15 – 20:00  GALA DINNER RECEPTION
(Ticketed Event)
★ PLENARY HALL FOYER, GROUND LEVEL

20:00 – 23:00  GALA DINNER
(Ticketed Event)
★ PLENARY HALL, GROUND LEVEL
Didgeridoo

The Didgeridoo is a wind instrument thought to have originated in Arnhem Land, Northern Territory, Australia. Researchers have suggested it may be the world’s oldest musical instrument, over 40,000 years old.

It has been suggested that the Didgeridoo was an adaptation of traded instruments from India and/or Asia, this is possibly why it was mainly used by coastal tribes of the far North of Australia.

Traditionally didgeridoos were made from eucalyptus tree trunks and limbs hollowed out, while still living, by termites, (a small insect like an ant but a relative of the cockroach) or from bamboo in the far north of Australia.

Courtesy of didgeridoobreath.com
WHO'S LEADING THE WAY IN TREATMENT RESISTANCE

OncoGeneX

www.HaveYouMetResistance.com

© 2013 OncoGenex Pharmaceuticals, Inc. All rights reserved. OGXI-082013-001
**Wednesday | October 30, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>06:00 – 17:00</td>
<td>REGISTRATION OPEN</td>
</tr>
<tr>
<td></td>
<td>HALL 6, PARKSIDE, GROUND LEVEL</td>
</tr>
<tr>
<td>06:00 – 17:00</td>
<td>SPEAKER READY ROOM OPEN</td>
</tr>
<tr>
<td></td>
<td>PARKSIDE G04, GROUND LEVEL</td>
</tr>
<tr>
<td>09:30 – 16:30</td>
<td>EXHIBIT HALL OPEN</td>
</tr>
<tr>
<td></td>
<td>HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>SYMPOSIUM SUPPORTED BY IASLC RADIOOTHERAPY GROUP: WHAT IS THE APPROPRIATE PATIENT POPULATION FOR IGRT?</td>
</tr>
<tr>
<td></td>
<td>Simultaneous Translation English &gt;&gt; Mandarin provided</td>
</tr>
<tr>
<td></td>
<td>PARKSIDE AUDITORIUM, LEVEL 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>HOD3: TUESDAY’S HIGHLIGHTS OF THE DAY - SURGERY, STAGING, IMAGING AND PULMONARY</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE AUDITORIUM A, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Chair: Walter Weder, Switzerland</td>
</tr>
<tr>
<td>07:00</td>
<td>HOD3.1: SURGERY AND STAGING</td>
</tr>
<tr>
<td></td>
<td>Hiroshi Date, Japan</td>
</tr>
<tr>
<td>07:30</td>
<td>HOD3.2: IMAGING AND PULMONARY (2 DAY COVERAGE)</td>
</tr>
<tr>
<td></td>
<td>Pieter E. Postmus, Netherlands</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>HOD4: TUESDAY’S HIGHLIGHTS OF THE DAY - MEDICAL ONCOLOGY, BIOLOGY, RADIOOTHERAPY AND COMBINED MODALITY</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE AUDITORIUM B, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Chair: John Heymach, USA</td>
</tr>
<tr>
<td>07:00</td>
<td>HOD4.1: MEDICAL ONCOLOGY AND BIOLOGY</td>
</tr>
<tr>
<td></td>
<td>Suresh Ramalingam, USA</td>
</tr>
<tr>
<td>07:30</td>
<td>HOD4.2: RADIOOTHERAPY AND COMBINED MODALITY</td>
</tr>
<tr>
<td></td>
<td>Andrea Bezjak, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>MTE18: PET-CT FOR STAGING, JUDGING RESPONSE TO THERAPY, RESTAGING</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 101, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Jeremy Erasmus, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>MTE19: BIOLOGY AND TREATMENT OF THYMOMA / THYMIC CARCINOMA</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 102, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Nicolas Girard, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00 – 08:00</td>
<td>MTE20: PATHOLOGY OF MESOTHELIOMA</td>
</tr>
<tr>
<td></td>
<td>BAYSIDE 103, LEVEL 1</td>
</tr>
<tr>
<td></td>
<td>Victor Roggli, USA</td>
</tr>
</tbody>
</table>
07:00 – 08:00 MTE21: GENOMICS IN LUNG CANCER

**NOTE:** THIS SESSION IS FULL, NO MORE TICKETS ARE AVAILABLE. THE SESSION WILL BE REPEATED ON TUESDAY, OCTOBER 29, 07:00 – 08:00 (MTE21A).

Meet the Expert Session (ticketed): Pathology

BAYSIDE 104, LEVEL 1
Roman Thomas, Germany

07:00 – 08:00 MTE22: A PRACTICAL APPROACH TO THE INCIDENTAL PULMONARY NODULE

Meet the Expert Session (ticketed): Pulmonology

BAYSIDE 105, LEVEL 1

07:00 MTE22.1: A PRACTICAL APPROACH TO THE INCIDENTAL PULMONARY NODULE
David Midthun, USA

07:30 MTE22.2: A PRACTICAL APPROACH TO THE INCIDENTAL PULMONARY NODULE
David Milne, New Zealand

07:00 – 08:00 MTE23: SCREENING TOOLS FOR A HIGH RISK POPULATION - CAN WE SCREEN FOR EARLY MESOTHELIOMA?

Meet the Expert Session (ticketed): Imaging & Screening/Mesothelioma

BAYSIDE 106, LEVEL 1
Jan Van Meerbeeck, Belgium

07:00 – 08:00 MTE24: TREATMENT OF CACHEXIA OVER THE NEXT FIVE YEARS

Meet the Expert Session (ticketed): Supportive Care

BAYSIDE GALLERY A, LEVEL 1
Peter Martin, Australia

07:00 – 08:00 MTE25: LESS THAN PNEUMONECTOMY AFTER XRT (HIGH DOSE RADIOTHERAPY)

Meet the Expert Session (ticketed): Surgery

BAYSIDE GALLERY B, LEVEL 1
Kenji Suzuki, Japan

08:15 – 09:45 PL04: HOW CAN WE STOP THE EPIDEMIC OF LUNG CANCER?

Plenary Session: Prevention & Epidemiology

PLENARY HALL, GROUND LEVEL

**Chairs:** Chris Amos, USA & Caicun Zhou, China

08:15 CHAIR INTRO
08:20 PL04.1: RISK REDUCTION BY STOPPING SMOKING
Valerie Beral, UK

08:40 PL04.2: RISK FACTORS FOR LUNG CANCER IN NEVER-SMOKERS
Chien-Jen Chen, Taiwan

09:00 PL04.3: A CRITICAL REVIEW OF CT LUNG CANCER SCREENING
Elisabeth Quoix, France

09:20 PL04.4: BIOMARKER-DRIVEN PROGRAMS FOR LUNG CANCER SCREENING
Pierre Massion, USA

Session supported by Destination New South Wales
09:45 –10:30 NETWORKING BREAK

POSTER SESSION 3
- Presenters are available for questions
- Refreshments are provided
EXHIBIT HALL, HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL

10:30 – 12:00 MS16: ESTS/IASLC THYMIC SESSION

Mini Symposium: Thymoma and Other Thoracic Malignancies
BAYSIDE GALLERY A, LEVEL 1

Chairs: Peter Goldstraw, UK & Eric Lim, UK

10:30 MS16.1: PATHOLOGICAL CLASSIFICATION OF THYMIC TUMOURS IN THE MOLECULAR AGE: PROPOSALS FOR THE NEXT WHO CLASSIFICATION
William Travis, USA

10:47 MS16.2: TOWARDS A TNM-BASED PROGNOSTIC CLASSIFICATION FOR THYMIC TUMOURS
Frank Detterbeck, USA

11:04 MS16.3: SURGERY FOR THYMIC TUMOURS: OUTCOMES FROM THE ESTS DATA BASE
Enrico Ruffini, Italy

11:21 MS16.4: CHEMOTHERAPY FOR THYMIC TUMOURS
Nicolas Girard, France

11:38 MS16.5: RADIOThERAPY FOR THYMIC TUMOURS: INDUCTION, ADJUVANT AND DEFINITIVE
Ritsuko Komaki, USA

10:30 – 12:00 MS27: MECHANISMS OF ACQUIRED RESISTANCE TO TARGETED THERAPY

Mini Symposium: Medical Oncology / Biology
BAYSIDE AUDITORIUM B, LEVEL 1

Chairs: Seiji Yano, Japan & Ben Solomon, Australia

10:30 CHAIR INTRO

10:35 MS27.1: RESISTANCE TO EGFR TKIS
Seiji Yano, Japan

10:55 MS27.2: RESISTANCE TO ALK INHIBITORS
Robert Doebele, USA

11:15 MS27.3: CLINICAL DEFINITION OF TKI RESISTANCE AND HOW TO OVERCOME IT
Pasi Janne, USA

11:35 MS27.4: TRIAL DESIGN AS IT APPLIES TO RESISTANCE
Jean-Charles Soria, France

10:30 – 12:00 O28: ENDOSCOPY

Oral Abstract Session: Endoscopy/Pulmononary
PARKSIDE AUDITORIUM, LEVEL 1

Chairs: Felix Herth, Germany & Norihiko Ikeda, Japan

10:30 O28.01: EBUS-CENTERED VS. EUS-CENTERED MEDIASTINAL STAGING IN LUNG CANCER: A RANDOMIZED CONTROLLED TRIAL
Hyo Jae Kang, South Korea

10:40 O28.02: GREY SCALE TEXTURE ANALYSIS OF ENDOBRONCHIAL ULTRASOUND MINI PROBE GUIDE SHEATH IMAGES FOR PREDICTION OF BENIGN OR MALIGNANT AETIOLOGY
Phan Nguyen, Australia

10:50 O28.03: CLINICAL IMPLICATION OF EX VIVO RAMAN SPECTROSCOPY AND IN VIVO NIR SPECTROSCOPY FOR DIAGNOSIS OF PERIPHERAL LUNG CANCER
Jiri Votruba, Czech Republic

11:00 O28.04: DISCUSSANT
Luc Thiberville, France

11:15 O28.05: AN ANALYSIS OF A PROSPECTIVE STUDY FROM THE EUROPEAN LUNG CANCER WORKING PARTY (ELCWP) LOOKING AT PREDICTIVE FACTORS FOR RESPONSE TO CHEMOTHERAPY (CT): LIMITATIONS IN TRANSLATIONAL COOPERATIVE RESEARCH
Jean-Paul Sculier, Belgium

11:25 O28.06: COMPREHENSIVE MANAGEMENT OF CENTRAL TYPE EARLY LUNG CANCER
Norihiko Ikeda, Japan

11:35 O28.07: INTRA-OPERATIVE SCANNING CONFOCAL ENDOMICROSCOPY OF PLEURAL DISEASE: IN VIVO DIAGNOSIS OF MALIGNANCY
Paul Mitchell, Australia

11:45 O28.08: DISCUSSANT
Tom Sutedja, Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MO19: Lung Cancer Immunobiology</td>
<td>10:30 MO19.01: Epigenetic Targeting of CD1D Increases Anti-Tumor Inkt Activity in Non-Small Cell Lung Cancer</td>
<td>Eilis Dockry, Ireland</td>
<td>Ireland</td>
</tr>
<tr>
<td>10:35</td>
<td>MO19.02: The Tumor Immune Microenvironment in Octogenarians with Stage I Non-Small Cell Lung Cancer: Implications for Immunotherapy</td>
<td>Ming-Ching Lee, Taiwan</td>
<td>Taiwan</td>
<td></td>
</tr>
<tr>
<td>10:40</td>
<td>MO19.03: The Effects of Epidermal Growth Factor (EGFR) Receptor Inhibitors on the Immune System in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Tarek Meniawy, Australia</td>
<td>Australia</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>MO19.04: Discussant</td>
<td>David Carbone, USA</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>10:55</td>
<td>MO19.05: EGFR Signaling Effects on NK Cell-Mediated Cytotoxicity via NKG2D Ligands-NKG2D Interaction in Non-Small Cell Lung Cancer Cells</td>
<td>Riki Okita, Japan</td>
<td>Japan</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>MO19.06: The Role of Fibroblast Growth Factor-9 in the Regulation of the Tumor-Specific Immune Response in Malignant Mesothelioma</td>
<td>Sally Lansley, Australia</td>
<td>Australia</td>
<td></td>
</tr>
<tr>
<td>11:05</td>
<td>MO19.07: Lung Cancer-Initiating Cells Avoid Immune Recognition</td>
<td>Jason Steel, USA</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>11:10</td>
<td>MO19.08: Discussant</td>
<td>Elisabeth Quoix, France</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>MO19.09: Molecular Correlates of PD-L1 Status and Predictive Biomarkers in Patients with Non-Small Cell Lung Cancer (NSCLC) Treated with the Anti-PDL1 Antibody MPDL3280A</td>
<td>Scott Gettinger, USA</td>
<td>USA</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>MO19.10: Prevalence and Prognostic Association of PD-L1 Protein and Immune Gene Expression in NSCLC</td>
<td>Marcin Kowanetz, USA</td>
<td>USA</td>
<td></td>
</tr>
</tbody>
</table>
### 10:30 – 12:00 MO20: PRECLINICAL THERAPEUTIC MODELS II

**Mini Oral Abstract Session: Biology & Medical Oncology**

**BAYSIDE GALLERY B, LEVEL 1**

**Chairs: Paul Waring, Australia & Maija Kohonen-Corish, Australia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MO20.01: PROTEIN KINASE C IOTA IS REQUIRED FOR MAINTENANCE OF A TUMOR INITIATING CELL PHENOTYPE IN LUNG SQUAMOUS CELL CARCINOMA Helen Ross, USA</td>
</tr>
<tr>
<td>10:35</td>
<td>MO20.02: PROTEOMIC ANALYSIS IDENTIFIES BASELINE PI3K/AKT PATHWAY ACTIVATION AND TREATMENT-INDUCED SUPPRESSION OF MTOR SIGNALING AS DETERMINANTS OF RESPONSE TO MEK INHIBITION Kathryn Gold, USA</td>
</tr>
<tr>
<td>10:40</td>
<td>MO20.03: DEVELOPMENT AND CHARACTERIZATION OF A PANEL OF GDC-0980 RESISTANT NSCLC CELL LINES Susan Heavey, Ireland</td>
</tr>
<tr>
<td>10:45</td>
<td>MO20.04: DIVERGENT ACTIVITY OF AFATINIB (AFAT) AND CETUXIMAB (CET) IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF ACQUIRED ERLOTINIB RESISTANCE Philip Mack, USA</td>
</tr>
<tr>
<td>10:50</td>
<td>MO20.05: DISCUSSANT Carlos Gil Ferreira, Brazil</td>
</tr>
<tr>
<td>11:05</td>
<td>MO20.06: HISTONE DEACETYLASE INHIBITION DOWNREGULATES THYMIDYLATE SYNTHASE (TS) EXPRESSION AND ENHANCES PEMETREXED-INDUCED CYTOTOXICITY IN NSCLC MODELS Michele Milella, Italy</td>
</tr>
<tr>
<td>11:10</td>
<td>MO20.07: IDENTIFICATION OF NEW CHEMOTHERAPEUTIC STRATEGIES IN MESOTHELIOMA AND NON-SMALL CELL LUNG CANCER USING A DRUG-INDUCED APOPTOSIS ASSAY (MICK ASSAY) Dennis Wigle, USA</td>
</tr>
</tbody>
</table>

### 10:30 – 12:00 MO21: PROGNOSTIC AND PREDICTIVE BIOMARKERS V - EGFR

**Mini Oral Abstract Session: Biology & Medical Oncology**

**BAYSIDE AUDITORIUM A, LEVEL 1**

**Chairs: David Lam, Hong Kong & Siow Ming Lee, UK**

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MO21.01: RANDOMIZED PROTEOMIC STRATIFIED PHASE III STUDY OF SECOND LINE ERLOTINIB (E) VERSUS CHEMOTHERAPY (CT) IN PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG CANCER (PROSE): VERISTAT ANALYSIS OF LONGITUDINAL SAMPLES Silvia Novello, Italy</td>
</tr>
<tr>
<td>10:35</td>
<td>MO21.02: PRETREATMENT EVALUATION OF THE T790M MUTATION AND ITS CORRELATION WITH THE RESPONSE TO TYROSINE KINASE INHIBITORS (TKIS) OR CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH ACTIVATED EGFR MUTATIONS Francesco Grossi, Italy</td>
</tr>
<tr>
<td>10:40</td>
<td>MO21.03: VARIABILITY OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN SERUM DURING ERLOTINIB THERAPY AND ITS CLINICAL IMPLICATIONS: EXPLORATORY ANALYSIS OF A PHASE II STUDY OF ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATIONS Makoto Maemondo, Japan</td>
</tr>
<tr>
<td>10:45</td>
<td>MO21.04: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF THE AROMATASE EXPRESSION IN LUNG ADENOCARCINOMA HARBORING EGFR MUTATION Mikihiro Kohno, Japan</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>10:30</td>
<td>MO22.01:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>10:35</td>
<td>MO22.02:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**10:30 – 12:00 MO22: ADVANCED DISEASE AND OUTCOMES**

Mini Oral Abstract Session: Surgery

**PARKSIDE 110 A+B, LEVEL 1**

**Chairs:** Tokujiro Yano, Japan & Jack Roth, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>MO22.03:</td>
<td>POSTOPERATIVE REHABILITATION AND FOLLOW-UP - A RANDOMIZED STUDY</td>
<td>Erik Jakobsen, Denmark</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>MO22.04:</td>
<td>STANDARDISING THE MANAGEMENT OF PATIENTS FOLLOWING LUNG RESECTION:</td>
<td>Annabel Sharkey, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DOES IT IMPROVE OUTCOME?</td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>MO22.05:</td>
<td>SURGERY IN OCTOGENARIANS WITH EARLY STAGE NON-SMALL CELL LUNG CANCER:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SEER DATABASE ANALYSIS</td>
<td></td>
</tr>
<tr>
<td>10:55</td>
<td>MO22.06:</td>
<td>DISCUSSANT TBA</td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>MO22.07:</td>
<td>LOCAL TREATMENT OF OLIGOMETASTATIC RECURRENCE AFTER SURGERY FOR NON-SMALL CELL LUNG CANCER: SHOULD WE STILL TALK ABOUT THE FUTILE THORACOTOMY?</td>
<td>Olaf Mercier, France</td>
</tr>
<tr>
<td>11:00</td>
<td>MO22.08:</td>
<td>STANDARDISING THE MANAGEMENT OF PATIENTS FOLLOWING LUNG RESECTION:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DOES IT IMPROVE OUTCOME?</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>MO22.09:</td>
<td>SURGERY AFTER CONCURRENT CHEMORADIATION WITH 55 Gy IN 20 FRACTIONS OVER FOUR WEEKS WITH FULL DOSE PLATINUM AND VINORELBINE</td>
<td>John Littler, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>MO22.10:</td>
<td>PROSPECTIVE STUDY OF SURGERY WITH CURATIVE INTENT AND INTRAOPERATIVE PHOTODYNAMIC THERAPY TO ACHIEVE LONG-TERM PLEURAL CONTROL AND IMPROVE OVERALL SURVIVAL FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PLEURAL DISSEMINATION</td>
<td>Charles Simone, USA</td>
</tr>
</tbody>
</table>

**11:35 MO22.11: DISCUSSANT**

Brian Louie, USA
10:30 – 12:00 MO23: RADIOTHERAPY II: LUNG TOXICITY, TARGET DEFINITION AND QUALITY ASSURANCE

Mini Oral Abstract Session: Radiotherapy
BAYSIDE 204 A+B, LEVEL 2
Chairs: Mo Mo Tin, Australia & Fergus Macbeth, UK

10:30 MO23.01: FOUR-DIMENSIONAL GALLIUM-68 PERFUSION PET/CT SCANs CAN IMPROVE RADIOTHERAPY PLANNING THROUGH FUNCTIONAL AVOIDANCE OF LUNG Shankar Siva, Australia

10:35 MO23.02: QUANTIFICATION OF RADIATION-INDUCED LUNG DAMAGE WITH CT SCANS: THE POSSIBLE BENEFIT FOR RADIOGENOMICS Dirk De Ruyscher, Belgium

10:40 MO23.03: DUTCH RADIOTHERAPY LUNG AUDIT: RESULTS OF A NATIONAL PILOT Jose Belderbos, Netherlands

10:45 MO23.04: IS PRE-TRIAL QUALITY ASSURANCE (QA) EFFECTIVE? A COMPARISON OF PRE-TRIAL QA VERSUS ONGOING QA FOR THE CONVERT TRIAL Elena Wilson, UK

10:50 MO23.05: CHANGES IN LUNG RADIOTHERAPY TECHNIQUES DURING THE CONVERT TRIAL: A SURVEY OF PARTICIPATING CENTRES Elena Wilson, UK

10:55 MO23.06: DISCUSSANT Paul Van Houtte, Belgium

11:10 MO23.07: IMPACT OF A GRADIENT-BASED FDG-PET AUTO-CONTOURING METHOD ON NON-SMALL CELL LUNG CANCER DELINEATION Jose Belderbos, Netherlands

11:15 MO23.08: INTER-OBSERVER VARIABILITY IN GROSS TUMOUR VOLUME DELINEATION ON KILO-VOLTAGE CONE BEAM COMPUTED TOMOGRAPHY (CBCT) SCANS FOR LUNG CANCER RADIOTHERAPY TREATMENT VERIFICATION Sandie Watt, Australia

11:20 MO23.09: INTRA THORACIC ANATOMICAL CHANGES (ITAC) IN LUNG CANCER PATIENTS DURING THE COURSE OF RADIOTHERAPY Margriet Kwint, Netherlands

11:25 MO23.10: ADDITION OF EBUS-MAPPING OF THE MEDIASTINUM TO PET/CT BASED SELECTIVE NODAL IRRADIATION IN NSCLC DECREASES GEOGRAPHICAL MISS AND NODAL GTV VOLUME Christophe Dooms, Belgium

11:30 MO23.11: DART - BID (DOSE-DIFFERENTIATED ACCELERATED RADIATION THERAPY, 1.8 GY TWICE DAILY): A NOVEL THERAPEUTIC APPROACH FOR LOCOREGIONALLY ADVANCED, NONRESECTED NON-SMALL CELL LUNG CANCER Karl Wurstbauer, Austria

11:35 MO23.12: DISCUSSANT Anthony Brade, Canada

10:30 – 12:00 MO24: NSCLC - CHEMOTHERAPY III

Mini Oral Abstract Session: Medical Oncology
PARKSIDE BALLROOM A, LEVEL 1
Chairs: Ronald Feld, Canada & Solange Peters, Switzerland

10:30 MO24.01: TREATMENT OF ELDERLY (70 YEARS OR OLDER) WITH LUNG CANCER. A FOUR-YEAR MATERIAL IN CLINICAL PRACTICE FROM KAROLINSKA UNIVERSITY HOSPITAL - SWEDEN. Hirsh Koyi, Sweden

10:35 MO24.02: TREATMENT DECISIONS FOR ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ITALIAN CLINICAL PRACTICE: RESULTS FROM THE RIGHT-3 PROJECT BY ITALIAN ASSOCIATION OF MEDICAL ONCOLOGY Lucio Crino, Italy

10:40 MO24.03: TREATMENT OF ELDERLY PATIENTS (> 70 YEARS) WITH NON-SMALL CELL LUNG CANCER GIVEN CHEMOTHERAPY. A FOUR-YEAR MATERIAL IN CLINICAL PRACTICE FROM KAROLINSKA UNIVERSITY HOSPITAL - SWEDEN Hirsh Koyi, Sweden

10:45 MO24.04: ASSESSMENT OF HEALTH CARE PATTERNS FOR ELDERLY LUNG CANCER PATIENTS IN ONTARIO, CANADA David Dawe, Canada

10:50 MO24.05: DISCUSSANT Corey Langer, USA
10:30 – 12:00 MO25: NSCLC - COMBINED MODALITY THERAPY II

Mini Oral Abstract Session: Combined Modality / Medical Oncology

PARKSIDE BALLROOM B, LEVEL 1

Chairs: Thierry Le Chevalier, France & Ken Pittman, Australia

10:30 MO25.01: INTERIM ANALYSIS OF THE SPANISH LUNG CANCER GROUP (SLCG) RANDOMIZED PHASE II TRIAL OF THORACIC RADIOTHERAPY (RT) CONCURRENT WITH CISPLATIN (P) PLUS ORAL VINORELBINE (Ov) OR ETOPOSIDE (E) FOR UNRESECTABLE LOCALLY ADVANCED (LA) STAGE III NON-SMALL CELL LUNG CANCER (NSCLC). (GEP 10102). Dolores Isla, Spain

10:35 MO25.02: THORACIC RADIOTHERAPY WITH OR WITHOUT CONCURRENT DAILY LOW-DOSE CARBOPlatin IN ELDERLY PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: UPDATED RESULTS OF THE JCOG0301 AND POOLED ANALYSIS WITH THE JCOG9812 TRIAL Shinji Atagi, Japan

10:40 MO25.03: SAFETY DATA FROM A PHASE II STUDY OF PEMETREXED (PEM) AND CISPLATIN (CIS) WITH CONCURRENT THORACIC RADIATION AFTER PEM+CIS INDUCTION IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED (LA) NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC) Pilar Garrido, Spain

10:45 MO25.04: PHASE II STUDY COMPARING CISPLATIN/ETOPOSIDE AND WEEKLY PACLITAXEL/CARBOPlatin REGIMENS WITH CONCURRENT THORACIC RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER Jun Liang, China

10:50 MO25.05: DISCUSSANT Raymond Abratt, South Africa

11:05 MO25.06: PHASE I/II TRIAL OF RECOMBINANT HUMAN ENDOSTATIN IN COMBINATION WITH CONCURRENT CHEMORADIOThERAPY IN THE PATIENTS WITH STAGE III NON-SMALL-CELL LUNG CANCER Ming Chen, China

11:10 MO25.07: EARLY ONSET BODY WEIGHT LOSS DURING CONCURRENT CHEMORADIOThERAPY FOR NON-SMALL CELL LUNG CANCER IS NOT DUE TO DYSPHAGIA OR REDUCED CALORIE INTAKE Anne-Marie Dingemans, Netherlands
11:15 MO25.08: IMPACT OF PRETREATMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOThERAPY
Erkan Topkan, Turkey

11:20 MO25.09: A PHASE II STUDY OF 18F-FDG PET GUIDED OPTIMIZATION OF NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE NON-SMALL CELL LUNG CANCER
Jamie Chaft, USA

11:25 MO25.10: A PHASE II TRIAL OF MID-TREATMENT FDG-PET ADAPTIVE, INDIVIDUALIZED RADIATION THERAPY PLUS CONCURRENT CHEMOTHERAPY IN PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG CANCER (NSCLC)
Feng-Ming (Spring) Kong, USA

11:30 MO25.11: DISCUSSANT
Kaoru Kubota, Japan

10:30 – 12:00 MO26: ANATOMICAL PATHOLOGY II

Mini Oral Abstract Session: Pathology
BAYSIDE 105, LEVEL 1

Chairs: Elisabeth Brambilla, France & Vera Capelozzi, Brazil

10:30 MO26.01: COMPARISON OF OUTCOMES FOR PATIENTS WITH “BRONCHIOLOALVEOLAR CARCINOMA (BA)" DEFINED BY THE IASLC CLASSIFICATION VERSUS THE AJCC STAGING SYSTEM
Candice Wilshire, USA

10:35 MO26.02: PREDOMINANT HISTOLOGIC SUBTYPE BY IASLC/ATS/ERS CLASSIFICATION IS CORRELATED WITH PROGNOSIS AND EGFR MUTATION IN SURGICALLY RESECTED LUNG ADENOCARCINOMA
Naoki Yanagawa, Japan

10:40 MO26.03: IN PATIENTS WITH STAGE I LUNG ADENOCARCINOMA, TUMOR BUDDING IS A SIGNIFICANT PROGNOSTIC FACTOR FOR RECURRENCE, INDEPENDENT OF THE IASLC/ATS/ERS CLASSIFICATION, AND CORRELATES WITH A PROTUMOR IMMUNE MICROENVIRONMENT
Kyuichi Kadota, USA

10:45 MO26.04: RECLASSIFICATION OF RESECTED NON-SMALL CELL LUNG CARCINOMAS ORIGINALLY DIAGNOSED AS SQUAMOUS CELL CARCINOMA, AFTER REEVALUATION USING IMMUNOHISTOCHEMICAL ANALYSIS (P40, P63, TTF-1, AND NAPSI NA): MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERIENCE
Kyuichi Kadota, USA

10:50 MO26.05: DISCUSSANT
Yuichi Ishikawa, Japan

11:00 MO26.06: CELL BLOCK SAMPLES FROM ENDOBRONCHIAL ULTRASOUND TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) PROVIDE SUFFICIENT MATERIAL FOR ANCILLARY TESTING IN LUNG CANCER
Emily Viiret, Australia

11:05 MO26.07: USEFULNESS OF CYTOLOGICAL SAMPLES FOR THE ASSESSMENT OF ALK REARRANGEMENTS IN NSCLC PATIENTS
Maria Lozano, Spain

11:10 MO26.08: THE CONCOMITANT PRESENCE OF ECHINODERM MICROTUBE ASSOCIATED PROTEIN LIKE 4 - ANAPLASTIC LYMPHOMA KINASE (EML4-ALK) EML4-ALK FUSION GENE IN EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ERLOTINIB OR CHEMOTHERAPY IN THE EURTAC TRIAL
Niki Karachaliou, Spain

11:15 MO26.09: PROGNOSTIC IMPACT OF CD204-POSITIVE MACROPHAGES IN LUNG SQUAMOUS CELL CARCINOMA
Shunki Hirayama, Japan

11:20 MO26.10: DISCUSSANT
Kim Geisinger, USA

11:30 MO26.11: PROPOSAL ON INCORPORATING BLOOD VESSEL INVASION INTO THE T CLASSIFICATION PARTS AS A PRACTICAL STAGING SYSTEM FOR STAGE I NON-SMALL CELL LUNG CANCER
Yujin Kudo, Japan

11:35 MO26.12: PROGNOSTIC IMPACT OF MICROSCOPIC VESSEL INVASION AND VISCERAL PLEURAL INVASION IN NON-SMALL CELL LUNG CANCER
Shinya Neri, Japan

11:40 MO26.13: SIGNIFICANCE OF LEPIDIC GROWTH COMPONENT IN THE DISCRIMINATION OF MULTIPLE PRIMARY LUNG CANCERS FROM INTRAPULMONARY METASTASES
Dongmei Lin, China

11:45 MO26.14: HISTOLOGICAL PROGNOSTIC MARKERS IN SQUAMOUS CELL CARCINOMA OF THE LUNG
Andre Moreira, USA
10:30 – 12:00  MO27: PATIENT CENTRED CARE

Mini Oral Abstract Session: Supportive Care & Nurses
BAYSIDE 104, LEVEL 1

Chairs: Caitlin Broderick, Australia & John McPhelim, UK

10:30 MO27.01: OPERABLE LUNG CANCER PATIENTS EXPERIENCES OF REHABILITATION AND SUPPORTIVE NEEDS AT DIAGNOSIS. A QUALITATIVE STUDY
Malene Missel, Denmark

10:35 MO27.02: PATIENT CENTERED OUTCOMES IN THE MANAGEMENT OF MALIGNANT PLEURAL EFFUSION
Susan Walker, Canada

10:40 MO27.03: RAPPORT BETWEEN CANCER PATIENTS AND PHYSICIANS IS A CRITICAL ISSUE FOR PATIENTS’ SATISFACTION WITH TREATMENT DECISION
Junko Umihara, Japan

10:45 MO27.04: DELIVERING BETTER SUPPORTIVE CARE TO PEOPLE WITH LUNG CANCER: AN EXPLORATION OF THE USE OF A PATIENT-REPORTED OUTCOME MEASURE IN CLINICAL NURSING PRACTICE
John McPhelim, UK

10:50 MO27.05: DISCUSSANT
Janette Vardy, Australia

11:05 MO27.06: FEASIBILITY OF MEASUREMENT OF FUNCTION IN ADVANCED CANCER: COMPARISON OF THE 6-MINUTE WALK TEST, 2-MINUTE WALK TEST, ISOMETRIC ARM EXERCISES AND READING NUMBERS ALOUD
Kahren White, Australia

11:10 MO27.07: HOLISTIC NEEDS ASSESSMENT - WHAT THE PATIENT DOESN’T TELL US
Josie Roberts, UK

11:15 MO27.08: NEEDS ASSESSMENT OF ADVANCED LUNG CANCER PATIENTS - EVOLUTION OVER A DECADE?
Dianne Zawisza, Canada

11:20 MO27.09: GUIDELINE FOR TELEPHONE FOLLOW UP FOR PATIENTS UNDERGOING THORACIC SURGERY
Vanessa Beattie, UK

11:25 MO27.10: NATIONWIDE QUALITY IMPROVEMENT IN LUNG CANCER CARE: THE ROLE OF THE DANISH LUNG CANCER GROUP AND REGISTRY
Erik Jakobsen, Denmark

11:30 MO27.11: DISCUSSANT
Mary Hesdorffer, USA

12:15 – 13:45 SYMPOSIUM SUPPORTED BY BMS: PERSPECTIVES IN LUNG CANCER: IS IMMUNO-ONCOLOGY THE NEW TREATMENT PARADIGM?
PLENARY HALL, LEVEL 1

14:00 – 15:30 E10: TARGETING KRAS IN LUNG CANCER

Educational Session: Biology
PARKSIDE AUDITORIUM, LEVEL 1

Chairs: Christine Lovly, USA & Erik Thunnissen, Netherlands

14:00 CHAIR INTRO
14:05 E10.1: BIOLOGY
Tetsuya Mitsudomi, Japan

14:30 E10.2: PREDICTIVE OR PROGNOSTIC ROLE OF KRAS
Frances Shepherd, Canada

14:55 E10.3: TARGETING KRAS AND KRAS SIGNALING IN THE CLINIC
Gregory Riely, USA

14:00 – 15:30 E11: PRACTICAL ASPECTS OF TARGETED THERAPIES

Educational Session: Medical Oncology
PLENARY HALL, GROUND LEVEL

Chairs: Michael Millward, Australia & Luis Paz-Ares, Spain

14:00 CHAIR INTRO
14:05 E11.1: WHO SHOULD WE TEST FOR GENETIC ALTERATIONS, WHEN AND HOW?
Rolf Stahel, Switzerland
14:25  E11.2: MANAGEMENT OPTIONS AT FIRST PROGRESSION OF EGFR MUTANT TUMOURS
Keunchil Park, South Korea

14:45  E11.3: PANEL DISCUSSION: MDT - MANAGING TOXICITIES AND EVALUATING DRUG INTERACTIONS
Pan-Chyr Yang, Taiwan & Kenneth O’Byrne, Australia & Anne Fraser, New Zealand

14:00 – 15:30  E12: SYMPTOM CONTROL - PAIN, DYSPNOEA AND FATIGUE

Educational Session: Supportive Care
BAYSIDE 103, LEVEL 1

Chairs: Patricia Davidson, Australia & David Currow, Australia

14:00 CHAIR INTRO
14:05 E12.1: DYSPNOEA
David Currow, Australia
14:30 E12.2: PAIN
Miriam Johnson, UK
14:55 E12.3: FATIGUE AND EXERCISE
Sharon Kilbreath, Australia

14:00 – 15:30  E13: HIGH RISK PATIENTS AND LOW RISK SURGEONS

Educational Session: Surgery
PARKSIDE BALLROOM A, LEVEL 1

Chairs: Hiroshi Date, Japan & Royce Calhoun, USA

14:00 CHAIR INTRO
14:05 E13.1: SALVAGE SURGERY AFTER RADIATION: RESIDUAL TUMOUR AND COMPLICATIONS
Marinus Paul, Netherlands
14:25 E13.2: STANDARDS AND BENCHMARKING OF SURGERY
Alessandro Brunelli, Italy
14:45 E13.3: MICROMETASTASES: MAGIC OR MAINSTREAM?
Yi-Long Wu, China
15:05 E13.4: DECISION-MAKING AND THE NEW IASLC STAGING SYSTEM
Peter Goldstraw, UK

14:00 – 15:30  MS17: IMAGING DEVELOPMENTS

Mini Symposium: Imaging & Screening
BAYSIDE AUDITORIUM A, LEVEL 1

Chairs: James Jett, USA & Elisna Syahruddin, Indonesia

14:00 CHAIR INTRO
14:05 MS17.1: MOLECULAR IMAGING - WHERE ARE WE AND WHERE IS IT GOING
Tim Akhurst, Australia
14:25 MS17.2: STANDARDIZED REPORTING; GUIDELINES FOR IMAGING PROTOCOLS / INTERPRETATION
Anand Devaraj, UK
14:45 MS17.3: CORRELATION OF PET, CT AND MRI WITH PATHOLOGY AND RESPONSE
Denise Aberle, USA
15:05 MS17.4: RADIOTRACERS IN IMAGING AND THERAPY OF THORACIC ONCOLOGY
Tim Akhurst, Australia

14:00 – 15:30  MS18: OPTIMIZING CONTROL OF LOCAL AND MEDIASTATIC NSCLC WITH RADIOTHERAPY

Mini Symposium: Radiation Oncology
BAYSIDE 201 - 203, LEVEL 2

Chairs: Ritsuko Komaki, USA & Kazushige Hayakawa, Japan

14:00 CHAIR INTRO
14:05 MS18.1: WHY DID 74Gy FAIL
Walter Curran, USA
14:25 MS18.2: ALTERED FRACTIONATION
Cecile Le Pechoux, France
14:45 MS18.3: RE-IRRADIATION FOLLOWING RADICAL RADIOTHERAPY
Dirk De Ruysscher, Belgium
15:05 MS18.4: RADIATION AND RE-IRRADIATION OF CNS METASTASIS
Luhua Wang, China
### 14:00 – 15:30  MS19: NEW HEALTH TECHNOLOGY FOR LUNG CANCER; ASSESSMENT AND IMPLEMENTATION

**Mini Symposium**

**PARKSIDE BALLROOM B, LEVEL 1**

**Chairs:** Yolande Lievens, Belgium & Feng-Ming (Spring) Kong, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS19.1: ASSESSING NEW TECHNOLOGY IN LUNG CANCER RADIOTHERAPY</strong></td>
</tr>
<tr>
<td></td>
<td>Fergus Macbeth, UK</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS19.2: COST EFFECTIVENESS OF PREVENTION OF LUNG CANCER</strong></td>
</tr>
<tr>
<td></td>
<td>(DEVELOPED AND DEVELOPING WORLD)</td>
</tr>
<tr>
<td></td>
<td>Carolyn Dresler, USA</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS19.3: RESOURCE CONSTRAINTS AS A BARRIER TO LUNG CANCER MANAGEMENT</strong></td>
</tr>
<tr>
<td></td>
<td>DEVELOPING NATIONS</td>
</tr>
<tr>
<td></td>
<td>Sumitra Thongprasert, Thailand</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS19.4: RESOURCE CONSTRAINTS AS A BARRIER TO LUNG CANCER MANAGEMENT</strong></td>
</tr>
<tr>
<td></td>
<td>DEVELOPED NATIONS</td>
</tr>
<tr>
<td></td>
<td>William Evans, Canada</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30  MS20: SMALL CELL LUNG CANCER

**Mini Symposium: Medical Oncology**

**BAYSIDE 204 A+B, LEVEL 2**

**Chairs:** Nevin Murray, Canada & Egbert Smit, Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS20.1: THE CLINICAL CHALLENGE OF SMALL CELL LUNG CANCER</strong></td>
</tr>
<tr>
<td></td>
<td>Chandra Belani, USA</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS20.2: SMALL CELL CANCER BIOLOGY: RECENT INSIGHTS</strong></td>
</tr>
<tr>
<td></td>
<td>David Carbone, USA</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS20.3: OPTIMAL RADIOTHERAPY FOR SCLC</strong></td>
</tr>
<tr>
<td></td>
<td>Corinne Faivre-Finn, UK</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS20.4: NEW TREATMENTS FOR SCLC</strong></td>
</tr>
<tr>
<td></td>
<td>Alex Adjei, USA</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30  MS21: PRACTICAL PROBLEMS IN LUNG CANCER DIAGNOSIS - APPLICATION OF THE 2011 ADENOCARCINOMA CLASSIFICATION

**Mini Symposium: Pathology**

**BAYSIDE GALLERY A, LEVEL 1**

**Chairs:** Andre Moreira, USA & Prudence Russell, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS21.1: CYTOLOGICAL DIAGNOSIS</strong></td>
</tr>
<tr>
<td></td>
<td>Kim Geisinger, USA</td>
</tr>
<tr>
<td>14:22</td>
<td><strong>MS21.2: MOLECULAR DIAGNOSIS IN CYTOLOGY AND ITS PLACE</strong></td>
</tr>
<tr>
<td></td>
<td>Sandra O’Toole, Australia</td>
</tr>
<tr>
<td>14:39</td>
<td><strong>MS21.3: IMMUNOHISTOCHEMISTRY AND THE NEW CLASSIFICATION</strong></td>
</tr>
<tr>
<td></td>
<td>Giuseppe Pelosi, Italy</td>
</tr>
<tr>
<td>14:56</td>
<td><strong>MS21.4: AIS AND THE WELL DIFFERENTIATED SPECTRUM</strong></td>
</tr>
<tr>
<td></td>
<td>Yasushi Yatabe, Japan</td>
</tr>
<tr>
<td>15:13</td>
<td><strong>MS21.5: MOLECULAR ANALYSIS FOR DISTINCTION SECOND PRIMARY OF THE LUNG VS LUNG METASTASIS?</strong></td>
</tr>
<tr>
<td></td>
<td>Sanja Dacic, USA</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30  MS22: SMALL CELL LUNG CANCER 2013

**Mini Symposium: Pulmonology**

**PARKSIDE 110 A+B, LEVEL 1**

**Chairs:** Felix Herth, Germany & Chunxue Bai, China

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS22.1: THE ANATOMY OF THE MEDIASTINUM / CT IMAGING</strong></td>
</tr>
<tr>
<td></td>
<td>Noriaki Kurimoto, Japan</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS22.2: FURTHER STAGING USING IMAGING - PET, MRI AND PET/CT</strong></td>
</tr>
<tr>
<td></td>
<td>Edward Hsiao, Australia</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS22.3: MINIMALLY INVASIVE AND ENDOSCOPIC OPTIONS</strong></td>
</tr>
<tr>
<td></td>
<td>Daniela Gompelmann, Germany</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS22.4: SURGICAL TECHNIQUES FOR DEFINITIVE STAGING</strong></td>
</tr>
<tr>
<td></td>
<td>Ugo Pastorino, Italy</td>
</tr>
</tbody>
</table>
### 14:00 – 15:30 MS23: TREATMENT OF THE SMALL MALIGNANT NODULE

**Mini Symposium: Pulmonology / Radiation Oncology**

**BAYSIDE AUDITORIUM B, LEVEL 1**

**Chairs:** Thomas Sutedja, Netherlands & Soon Hin How, Malaysia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS23.1: INTRODUCTION / PRESENTATION OF CASE</strong></td>
<td>Helen Jo, Australia</td>
</tr>
<tr>
<td>14:10</td>
<td><strong>MS23.2: IS TISSUE DIAGNOSIS NECESSARY?</strong></td>
<td>Daniel Steinfort, Australia</td>
</tr>
<tr>
<td>14:27</td>
<td><strong>MS23.3: SABR FOR EARLY STAGE LUNG CANCER AND PULMONARY OLIGOMETASTASES</strong></td>
<td>Hiroshi Onishi, Japan</td>
</tr>
<tr>
<td>14:44</td>
<td><strong>MS23.4: SURGERY FOR EARLY STAGE LUNG CANCER AND OLIGOMETASTASES</strong></td>
<td>Hisao Asamura, Japan</td>
</tr>
<tr>
<td>15:01</td>
<td><strong>MS23.5: THERMAL ABLATION FOR EARLY STAGE LUNG CANCER AND OLIGOMETASTASES</strong></td>
<td>Karin Steinke, Australia</td>
</tr>
<tr>
<td>15:18</td>
<td><strong>MS23.6: PANEL DISCUSSION</strong></td>
<td></td>
</tr>
</tbody>
</table>

### 14:00 – 15:30 MS24: MESOTHELIOMA BIOLOGY AND BIOMARKERS

**Mini Symposium: Mesothelioma**

**BAYSIDE 104, LEVEL 1**

**Chairs:** Bruce Robinson, Australia & Harvey Pass, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
<td></td>
</tr>
<tr>
<td>14:04</td>
<td><strong>MS24.1: A TRACTABLE ANIMAL MODEL OF MESOTHELIOMA</strong></td>
<td>Richard Lake, Australia</td>
</tr>
<tr>
<td>14:24</td>
<td><strong>MS24.2: IN VITRO MODELS IN MESOTHELIOMA</strong></td>
<td>V. Courtney Broaddus, USA</td>
</tr>
<tr>
<td>14:47</td>
<td><strong>MS24.3: APOPTOSIS AND CHEMORESISTANCE</strong></td>
<td>Sara Busacca, UK</td>
</tr>
<tr>
<td>15:07</td>
<td><strong>MS24.4: NEW BIOMARKER RESEARCH IN MESOTHELIOMA</strong></td>
<td>Jenette Creaney, Australia</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30 MS25: TRANSLATING RESEARCH INTO PRACTICE (APPLIED STATISTICS)

**Mini Symposium: Statistics**

**BAYSIDE GALLERY B, LEVEL 1**

**Chairs:** Mary O’Brien, UK & Richard Stephens, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS25.1: DEFINING THE GOLD STANDARD: PFS VS OS</strong></td>
<td>Katsuyuki Hotta, Japan</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS25.2: STATISTICAL REQUIREMENTS FOR SCREENING TRIALS</strong></td>
<td>LucindaBillingham, UK</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS25.3: COST-EFFECTIVENESS OF MODERN THERAPIES</strong></td>
<td>Natasha Leighl, Canada</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS25.4: ASSESSING NEW TREATMENTS FOR LUNG CANCER: REGULATORY AND COST-EFFECTIVENESS IMPLICATIONS</strong></td>
<td>Suzanne Hill, Australia</td>
</tr>
</tbody>
</table>

### 14:00 – 15:30 MS26: EXPLORING THE DIVERSE IMPACT THAT THE THORACIC ONCOLOGY NURSE CAN MAKE...

**Mini Symposium: Nursing**

**BAYSIDE 105, LEVEL 1**

**Chairs:** Mary Duffy, Australia & Diana Borthwick, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>CHAIR INTRO</strong></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>MS26.1: SYMPTOM CLUSTERS</strong></td>
<td>Alex Molassiotis, Hong Kong</td>
</tr>
<tr>
<td>14:25</td>
<td><strong>MS26.2: EXPLORATION OF THE NURSE ROLE IN FOLLOW UP CARE</strong></td>
<td>Liz Darlison, UK</td>
</tr>
<tr>
<td>14:45</td>
<td><strong>MS26.3: EXERCISE AND LUNG CANCER SURVIVORSHIP</strong></td>
<td>Stacie Corcoran, USA</td>
</tr>
<tr>
<td>15:05</td>
<td><strong>MS26.4: STIGMA &amp; NIHILISM - INTERNATIONAL NURSING PERSPECTIVE</strong></td>
<td>Maria Eliana San Martin, Chile</td>
</tr>
</tbody>
</table>
15:30 – 16:15 NETWORKING BREAK

POSTER SESSION 3

- Presenters are available for questions
- Refreshments are provided

EXHIBIT HALL, HALLS 4 + 5, EXHIBITION CENTRE, GROUND LEVEL

16:15 – 17:45 PL05: GENOMICS: FROM RESEARCH TOOL TO THE LUNG CANCER CLINIC

Plenary Session

PLENARY HALL, GROUND LEVEL

Chairs: Peter Goldstraw, UK & Tony Mok, Hong Kong

16:15 CHAIR INTRO

16:20 PL05.1: IMPLICATIONS OF THE LUNG CANCER GENOME SEQUENCING
Ramaswamy Govindan, USA

16:45 PL05.2: CHALLENGES IN BIOINFORMATICS
Yu Shyr, USA

17:10 PL05.3: CHALLENGES FOR THE CLINICIAN
Chandra Belani, USA

17:35 PL05.4: CLOSING REMARKS AND INVITATION TO DENVER, 2015
Michael Boyer, Australia & Kwun Fong, Australia & Fred Hirsch, USA
Anzac Biscuit

An Anzac biscuit is a sweet biscuit popular in Australia and New Zealand made using rolled oats, flour, desiccated coconut, sugar, butter, golden syrup, baking soda and boiling water. Anzac biscuits have long been associated with the Australian and New Zealand Army Corps (ANZAC) established in World War I.

One of the food items that women in both countries sent to soldiers during the First World War was a hard, long-keeping biscuit that could survive the journey by sea, and still remain edible. These were known as Soldiers’ Biscuits, but after the Gallipoli landings in 1915, they became known as Anzac Biscuits.

Courtesy of wikipedia.org, anzac.govt.nz
What are my options?

New treatment options are needed for advanced NSCLC beyond first line

- Most patients progress after initial treatment\(^1\)
- New options would allow more flexibility in selecting treatment for these patients

Pfizer is committed to research and development of innovative new approaches for patients with the highest unmet needs in NSCLC.

POSTER DISPLAY
CHINESE ALLIANCE AGAINST LUNG CANCER SESSION

Sunday, October 27
PARKSIDE AUDITORIUM FOYER, LEVEL 1

POSTER SETUP TIME: 07:00 – 07:30
POSTER TAKE DOWN TIME: 12:00 – 12:30

Please be sure to take down your poster as you will need it again for your presentation during your assigned poster presentation day.

PRESENTING AUTHOR STAND BY TIME*:
09:25 – 09:55 (TEA BREAK)

* Time in which Poster Presenter remains at his/her Poster Board for the specified time period and is available to discuss their research personally with any interested delegate.

CALC - P01 (P1.22-001): AN NICKEL WORKERS COHORT STUDY IN CHINA (JINCHUAN COHORT)-THE LARGEST NICKEL POPULATION IN WORLD
Yana Bai, China

CALC - P02 (P1.18-001): THE PREVALENCE AND CLINICOPATHOLOGIC FEATURE OF ALK, ROS1 AND RET FUSIONS IN EAST ASIAN PATIENTS WITH LUNG ADENOCARCINOMA
Weijing Cai, China

CALC - P03 (P1.12-021): DEVELOPMENT AND VALIDATION OF A CLINICAL PREDICTION MODEL FOR N2 LYMPH NODE METASTASIS IN STAGE I NON-SMALL CELL LUNG CANCER
Kezhong Chen, China

CALC - P04 (P2.08-003): INVOLVED-FIELD RADIOTHERAPY VERSUS ELECTIVE NODAL IRRADIATION IN COMBINATION WITH CONCURRENT CHEMOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: A PROSPECTIVE RANDOMIZED STUDY
Ming Chen, China

CALC - P05 (P1.13-008): OMITTING ELECTIVE NODAL IRRADIATION AND IRRADIATING POST-INDUCTION VERSUS PRE-INDUCTION CHEMOTHERAPY TUMOR EXTENT FOR LIMITED-STAGE SMALL CELL LUNG CANCER: AN UPDATE OF A PROSPECTIVE RANDOMIZED TRIAL
Ming Chen, China

CALC - P06 (P3.08-025): LUNG TUMORS WITH BIG SIZE OR IRREGULAR SHAPE OR HIGH-MOBILITY CAN BETTER BENEFIT FROM FOUR-DIMENSIONAL RADIOTHERAPY
Ming Chen, China

CALC - P07 (P1.08-025): HOW TO DETERMINE INTERNAL MARGIN FOR CLINICAL PRACTICE? - A STUDY OF 44 LUNG CANCER CASES WITH 4D-CT IMAGING.
Ming Chen, China

CALC - P08 (P2.01-022): TREATMENT WITH EGCG IN NSCLC LEADS TO DECREASING INTERSTITIAL FLUID PRESSURE AND HYPOXIA TO IMPROVE CHEMOTHERAPY EFFICACY THROUGH REBALANCE OF ANG-1 AND ANG-2
Peng Bo Deng, China

CALC - P09 (P1.11-012): CLINICAL OBSERVATION FROM THE TREATMENT OF ICOTINIB FOR 196 CASES WITH ADVANCED NON-SMALL CELL LUNG CANCER
Qin Gu, China

CALC - P10 (P2.12-001): ERLOTINIB AS NEOADJUVANT TREATMENT IN PATIENTS WITH STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (NCT01217619, EASTERN): STUDY UPDATE
Baohui Han, China

CALC - P11 (P3.05-006): INHIBITION OF TUMOR CELL GROWTH, MIGRATION BY SIM-89, A NOVEL INHIBITOR OF C-MET TYROSINE KINASE
Baohui Han, China

CALC - P12 (P2.12-002): CLINICAL CHARACTERISTICS AND PROGNOSIS OF LUNG ADENOCARCINOMA DRIVER MUTATIONS FROM CHINESE POPULATION
Baohui Han, China

CALC - P13 (P3.22-005): XPA GENE RS1800975 SINGLE NUCLEOTIDE POLYMORPHISM AND LUNG CANCER RISK: A META-ANALYSIS
Baohui Han, China
POSTER SESSIONS

CALC - P14 (P2.11-007): RELEVANCE BETWEEN CEA LEVEL AND EGFR MUTATION, EFFICACY OF EGFR-TKI IN PATIENTS WITH LUNG ADENOCARCINOMA
Hui Han, China

CALC - P15 (P3.06-010): CLINICAL SIGNIFICANCE OF PRETREATMENT PLASMA BIOMARKERS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Xiaohong Han, China

CALC - P16 (P1.07-027): VATS LOBECTOMY FOR NON-SMALL CELL LUNG CANCER IN PATIENTS WITH SEVERE COPD
Jianxing He, China

CALC - P17 (P1.07-028): THORACOSCOPIC MINIMALLY INVASIVE SURGERY FOR NON-SMALL CELL LUNG CANCER IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Jianxing He, China

CALC - P18 (P1.07-029): NOMOGRAM FOR PREDICTING SURVIVAL IN PATIENTS WITH RESECTED NON-SMALL CELL LUNG CANCER
Jianxing He, China

CALC - P19 (P3.05-001): METFORMIN SENSITIZES EGFR-TKI-RESISTANT HUMAN LUNG CANCER CELLS IN VITRO AND IN VIVO THROUGH INHIBITION OF IL-6/STAT3 AXIS AND EMT REVERSAL
Yong He, China

CALC - P20 (P2.15-001): PREDICTORS OF LONG-TERM SURVIVALS IN PATIENTS WITH MASAOKA STAGE III THYMOMAS
ZhouGuang Hui, China

CALC - P21 (P1.15-001): POSTOPERATIVE RADIOThERAPY FOR COMPLETELY RESECTED MASAOKA STAGE III THYMOMA: A RETROSPECTIVE STUDY OF 65 CASES FROM A SINGLE INSTITUTION
ZhouGuang Hui, China

CALC - P22 (P1.15-002): RESULTS AND PROGNOSTIC FEATURES OF RECURRENT THYMOMA
ZhouGuang Hui, China

CALC - P23 (P2.15-002): PATTERNS AND PREDICTORS OF RECURRENCE AFTER RADICAL RESECTION OF THYMOMA
ZhouGuang Hui, China

CALC - P24 (P2.19-012): INTER-METHOD COMPARISON OF 18F-FDG PET METABOLIC RESPONSE ASSESSMENT IN NON-SMALL CELL LUNG CANCER
Feng-Ming (Spring) Kong, USA
on behalf of Jingbo Wang, China

CALC - P25 (P2.05-003): REGULATION OF SIRT2 FOR HUMAN NON-SMALL CELL LUNG CANCER THERAPY
Ziming Li, China

CALC - P26 (P1.10-013): NAB-PACLITAXEL (ABRAXANE) BASED CHEMOTHERAPY FOR PRETREATED ELDERLY ADVANCED NSCLC PATIENTS: AN OPEN-LABEL, SINGLE CENTER, RANDOMIZED PHASE II TRIAL
Lizhu Lin, China

CALC - P27 (P1.06-005): THE CLINICAL SIGNIFICANCE OF SERUM BAP, TRACP 5B AND ICTP AS BONE METABOLIC MARKERS FOR BONE METASTASIS SCREENING IN LUNG CANCER PATIENTS
Xiaqing Liu, China

CALC - P28 (P2.11-003): HOW TO MAKE THE CHOICE IN THE REUSE OF EGFR-TKI FOR ADVANCED NSCLC PATIENTS WHO BENEFITED FROM PRIOR GEFITINIB THERAPY: THE ORIGINAL DRUG OR SWITCHING TO A SECOND EGFR-TKI?
Xiaqing Liu, China

CALC - P29 (P3.11-043): SURVIVAL OF PATIENTS WITH ADVANCED LUNG ADENOCARCINOMA BEFORE AND AFTER APPROVED USE OF GEFITINIB IN CHINA: A COMPARATIVE CLINICAL STUDY IN A SINGLE CENTER
Yutao Liu, China

CALC - P30 (P2.06-007): META-ANALYSIS OF STAT3 AND P-STAT3 EXPRESSION AND SURVIVAL IN NON-SMALL-CELL LUNG CANCER
Shun Lu, China

CALC - P31 (P1.09-016): A SINGLE ARM, MULTI-CENTER, PHASE II STUDY OF INTERCALATED ERLOTINIB WITH GEMCITABINE/CISPLATIN AS NEOADJUVANT TREATMENT IN STAGE IIIA NON-SMALL CELL LUNG CANCER (CTONG 1101, NCT01297101): PRELIMINARY RESULT
Shun Lu, China

CALC - P32 (P3.10-044): OVERALL SURVIVAL ANALYSIS RESULTS OF TFINE STUDY (CTONG 0904): DIFFERENT DOSE DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY AND THEN MAINTENANCE THERAPY WITH SINGLE AGENT DOCETAXEL FOR ADVANCED NON-SMALL CELL LUNG CANCER
Shun Lu, China
CALC - P33 (P1.24-004): CHARACTERISTICS AND PROGNOSTIC ANALYSIS OF PULMONARY SARCOMATOMID CARCINOMA
Guowei Ma, China

CALC - P34 (P3.06-025): T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Shengxiang Ren, China

CALC - P35 (P3.11-015): AN OPEN LABEL, DOSE ESCALATION, PHASE I TRIAL TO EVALUATE THE TOLERABILITY AND ANTITUMOR ACTIVITY OF ICOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
Jianzhong Shentu, China

CALC - P36 (P1.22-005): A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH ADENOCARCINOMA HISTOLOGY (PIONEER STUDY) - CHINA SUBSET ANALYSIS
Yuankai Shi, China

CALC - P37 (P2.05-015): A NOVEL CRM1 INHIBITOR TARGETING FOR NSCLC WITH EGFR-TKI RESISTANCE MUTATION
Yuankai Shi, China

CALC - P38 (P2.11-043): ANALYSIS OF CLINICOPATHOLOGICAL FEATURES FOR CHINESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING EML4-ALK FUSION GENES
Yuankai Shi, China

CALC - P39 (P1.10-028): A PHASE II TRIAL OF ERLOTINIB VERSUS PEMETREXED AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH ADVANCED EGFR WILD-TYPE AND EGFR FISH-POSITIVE LUNG ADENOCARCINOMA
Si-Yu Wang, China

CALC - P40 (P1.06-038): SINGLE CELL GENOMIC ANALYSES OF CIRCULATING TUMOR CELLS FROM LUNG CANCER PATIENTS
Zhijie Wang, China

CALC - P41 (P2.06-034): ANALYSIS OF SENSITIVITY OF LUNG SQUAMOUS CARCINOMA WITH EGFR MUTATION TO EGFR-TKIS AND RESISTANT MECHANISM
Zhijie Wang, China

CALC - P42 (P3.11-001): CLASSIFICATION AND REGRESSION TREE ANALYSIS OF PATIENTS WITH NON-SMALL-CELL LUNG CANCER TREATED WITH GEFITINIB AFTER CHEMOTHERAPY
Zi-Ping Wang, China

CALC - P43 (P3.07-026): A NON-INTERVENTATIONAL STUDY ON EGFR MUTATION STATUS AND CLINICAL OUTCOMES OF CHINESE PATIENTS WITH COMPLETELY RESECTED LUNG ADENOCARCINOMA (ICAN STUDY)
Yi-Long Wu, China

CALC - P44 (P2.01-017): GENE EXPRESSION OF MAGE-A3 TUMOR ANTIGEN AND EGFR MUTATIONAL STATUS IN CHINESE NSCLC PATIENTS
Yi-Long Wu, China

CALC - P45 (P2.06-043): CYP1A1*2A POLYMORPHISM IS CORRELATE WITH EGFR EXON 19 MUTATION AND IS AN INDEPENDENT PROGNOSTIC INDICATOR FOR THE ADVANCED LUNG CANCER PATIENTS TREATED WITH EGFR-TKI
Yi-Long Wu, China

CALC - P46 (P3.18-001): PROGNOSTIC VALUE OF THE IASLC/ATS/ERS CLASSIFICATION IN STAGE I LUNG ADENOCARCINOMA PATIENTS
Yaping Xu, China

CALC - P47 (P3.24-017): THE IMPACT OF LOCAL RADIOTHERAPY TO THE PRIMARY SITE FOR PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER
Yaping Xu, China

CALC - P48 (P1.08-023): HOW TO MINIMIZE THE UNCERTAINTIES OF INTERNAL TARGET VOLUME IN 4DCT SCANS FOR STEREOTACTIC BODY RADIATION THERAPY OF EARLY STAGE NON-SMALL CELL LUNG CANCER
Yaping Xu, China

CALC - P49 (P2.09-014): CONCOMITANT CHEMORADIOThERAPY USING DOCETAXEL AND CISPLATIN FOR UNRESECTABLE STAGE III LUNG SQUAMOUS CELL CARCINOMA
Yaping Xu, China

CALC - P50 (P2.06-039): THE STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION, PROTEIN OVEREXPRESSION AND GENE AMPLIFICATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMAS
Yaping Xu, China
CALC - P51 (P2.11-002): A PROSPECTIVE, OPEN-LABELLED, RANDOMIZED, MULTICENTER PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ERLOTINIB VS NP CHEMOTHERAPY AS ADJUVANT THERAPY IN POST RADICAL OPERATION STAGE IIIA NSCLC PATIENTS WITH EGFR 19 OR 21 EXON MUTATION (EVAN, ML28280, NCT01683175)
Dongsheng Yue, China

CALC - P52 (P2.13-001): ADDITIVE FIRST-LINE CHEMOTHERAPIES IMPROVE PROGRESSION-FREE SURVIVAL FOR COMBINED SMALL CELL LUNG CANCER IN A PHASE II RANDOMIZED TRIAL
Jie Zhang, China

CALC - P53 (P1.06-012): A DISINTEGRIN AND METALLOPROTEINASE-9 IS HIGHLY EXPRESSED, CORRELATED WITH LYMPH NODES METASTASIS, PREDICTS WORSE PROGNOSIS AND MAY HELP IMPROVING PERSONALIZED POSTOPERATIVE TREATMENT IN RESECTED NON-SMALL CELL LUNG CANCER
Jun Zhang, China

CALC - P54 (P2.11-016): A COMPARATIVE ANALYSIS OF EGFR MUTATION STATUS IN ASSOCIATION WITH THE EFFICACY OF TKI IN COMBINATION WITH WBRT/SRS/SURGERY PLUS CHEMOTHERAPY IN BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER
Lanjun Zhang, China

CALC - P55 (P3.08-016): CLINICAL OUTCOME OF [18F] FDG-PET/CT VERSUS CONVENTIONAL CT BASED PLANNING FOR RADIOTHERAPY IN LOCALLY ADVANCED NSCLC PATIENTS: A PROPENSITY-SCORE MATCHING STUDY
Wenwen Zhang, China

CALC - P56 (P1.07-002): EFFECT OF SYNCHRONOUS SOLITARY BONE METASTASECTOMY ON RESECTABLE NON-SMALL CELL LUNG CANCER PATIENTS
Tiancheng Zhao, China

CALC - P57 (P1.11-044): PROGRESSION-FREE SURVIVAL IS A POOR SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN THE FIRST LINE EGFR-TKI TREATMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATION
Wen Zhao Zhong, China

CALC - P58 (P2.05-018): INTERFERON-β EFFICIENTLY INHIBITED ENDOTHELIAL PROGENITOR CELL-INDUCED TUMOR ANGIogenesis
Wen Yong Zhou, China
### Monday | October 28, 2013

<table>
<thead>
<tr>
<th>Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.01 CANCER BIOLOGY</td>
</tr>
<tr>
<td>P1.02 NOVEL CANCER GENES AND PATHWAYS</td>
</tr>
<tr>
<td>P1.03 TECHNOLOGY AND NOVEL DEVELOPMENT</td>
</tr>
<tr>
<td>P1.04 TUMOR IMMUNOLOGY</td>
</tr>
<tr>
<td>P1.05 PRECLINICAL MODELS OF THERAPEUTICS/IMAGING</td>
</tr>
<tr>
<td>P1.06 PROGNOSTIC AND PREDICTIVE BIOMARKERS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.07 SURGERY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Radiotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.08 RADIOThERAPY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Combined Modality</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.09 COMBINED MODALITY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.10 CHEMOTHERAPY</td>
</tr>
<tr>
<td>P1.11 NSCLC NOVEL THERAPIES</td>
</tr>
<tr>
<td>P1.12 NSCLC EARLY STAGE</td>
</tr>
<tr>
<td>P1.13 SCLC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mesothelioma</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.14 MESOTHELIOMA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Thymoma and Other Thoracic Malignancies</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.15 THYMOMA</td>
</tr>
<tr>
<td>P1.16 OTHER THORACIC MALIGNANCIES</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.17 BRONCHOSCOPY, ENDOSCOPY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.18 PATHOLOGY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Imaging and Screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.19 IMAGING</td>
</tr>
<tr>
<td>P1.20 EARLY DETECTION AND SCREENING</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prevention &amp; Epidemiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.21 DIAGNOSIS AND STAGING</td>
</tr>
<tr>
<td>P1.22 EPIDEMIOLOGY, ETIOLOGY</td>
</tr>
<tr>
<td>P1.23 TOBACCO CONTROL, PREVENTION AND CHEMOPREVENTION</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Supportive Care and Nursing</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.24 CLINICAL CARE</td>
</tr>
<tr>
<td>P1.25 NURSES</td>
</tr>
</tbody>
</table>
Monday, October 28

POSTER SETUP TIME: 08:30 – 09:30

POSTER TAKE DOWN TIME: 16:30 – 18:00

(Posters not taken down after 18:00 will be discarded by management)

PRESENTING AUTHOR STAND BY TIME*: 09:45 –10:30 AND 15:30 – 16:15 (NETWORKING BREAKS)

* Time in which Poster Presenter remains at his/her Poster Board for the specified time period and is available to discuss their research personally with any interested delegate.

BIOLOGY

P1.01 Poster Session 1 Cancer Biology

P1.01-001: VEGF IS AN AUTOCRINE SURVIVAL FACTOR IN NON-SMALL CELL LUNG CANCER, MEDIATING ITS EFFECTS VIA THE NEUROPILIN-1 RECEPTOR.
Martin Barr, Ireland

P1.01-002: CLINICOPATHOLOGICAL AND BIOLOGICAL SIGNIFICANCE OF EPIREGULIN EXPRESSION IN NON-SMALL CELL LUNG CANCER
Noriaki Sunaga, Japan

P1.01-003: TARGETING EMT IN LUNG CANCER: AN INTEGRATED ANALYSIS OF AXL AND OTHER MESENCHYMAL TARGETS IN THE CANCER GENOME ATLAS (TCGA)
Lauren Byers, USA

P1.01-004: ROLE OF THE EXTRACELLULAR MATRIX IN VARIATIONS OF INVASIVE PATHWAYS IN LUNG CANCERS
Vanessa De Sa, Brazil

P1.01-005: EGFR AND KRAS MUTATIONS IN PATIENTS HAVING LUNG ADENOCARCINOMA ASSOCIATED WITH HUMAN PAPILLOMA VIRUS INFECTION
Andres Cardona, Colombia

P1.01-006: INTRA-TUMOR PRESSURE OF LUNG CANCER MAY CORRELATE TUMOR AGGRESSIVENESS
Takeshi Mori, Japan

P1.01-007: ANTIMETASTATIC ACTIVITY OF GANETESPIB: PRECLINICAL STUDIES AND ASSESSMENT OF NEW LESION GROWTH IN THE GALAXY-1 NSCLC TRIAL
Vojislav Vukovic, USA

P1.01-008: INHIBITION OF BINDING AT EXON 4 OF OSTEOPONTIN INCREASES APOPTOSIS AND APOPTOTIC PROTEIN EXPRESSION IN NON-SMALL CELL LUNG CANCER
Jessica Donington, USA

P1.01-009: THE ROLE OF AUTOPHAGY INDUCED BY TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CARCINOMA
Yuan Yuan Li, Hong Kong

P1.01-010: HETEROGENEITY OF BIOMARKERS BETWEEN THE PRIMARY TUMOR AND THE METASTATIC LYMPH NODES IN NON-SMALL CELL LUNG CANCER
Masao Nakata, Japan

P1.01-011: TARGETING THE UROKINASE PLASMINOGEN ACTIVATOR (UPA) SYSTEM TO OVERCOME CISPLATIN RESISTANCE IN NSCLC
Anne-Marie Baird, Ireland

P1.01-012: THE KDM6 LYSINE DEMETHYLASES ARE CANDIDATE THERAPEUTIC TARGETS IN MALIGNANT PLEURAL MESOTHELIOMA
Kenneth O’Byrne, Australia

P1.01-013: DIFFERENCES IN GENE EXPRESSION PROFILES AND CARCINOGENESIS PATHWAYS IN CISPLATIN RESISTANCE OF FOUR CANCERS
Yong Yang, China

P1.01-014: EFFECTS OF COMBINED EPIGENETIC THERAPY WITH THE HISTONE METHYLTRANSFERASE EZH2 INHIBITOR AND THE HISTONE DEACETYLASE INHIBITOR ON NSCLC CELLS.
Taichi Takashina, Japan

P1.01-015: OVERABUNDANCE OF ACTIVATED STROMAL FIBROBLASTS (TAFS) IN NSCLC ON RESPONSE TO EXTRACELLULAR MATRIX (ECM) RIGIDITY
Noemi Reguart, Spain

P1.01-016: TARGETING NF-κB REGULATED PATHWAYS TO OVERCOME CISPLATIN RESISTANCE IN NON SMALL CELL LUNG CANCER
Anne-Marie Baird, Ireland

P1.01-017: THE RETAIN OF EXTRAPULMONARY ADMINISTERED COLOIDAL CARBON IN THE MEDIASTINAL LYMPHNODES OF WISTAR RAT
Martin Sobotka, Czech Republic

P1.01-018: EPIDERMAL GROWTH FACTOR UP-REGULATES CD151 PROTEIN EXPRESSION TO PROMOTE NON-SMALL CELL LUNG CANCER PROLIFERATION
Chin Yein Chin, Singapore
P1.01-019: STUDY OF ABERRANT COPY NUMBER OF GENES IN ADENOCARCINOMA OF LUNG IN NEVER-SMOKERS WITH RESPECT TO EGFR MUTATIONS BY MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA®)
Joseph Siu-kie Au, Hong Kong

P1.01-020: EXPRESSION PROFILE OF SEROTONIN 2B RECEPTOR (HTR2B) IN NON-SMALL-CELL LUNG CANCER
Hiroshi Yokouchi, Japan

P1.01-021: CLASS III BETA-TUBULIN EXPRESSION IN NON-SMALL-CELL LUNG CANCER AS A PREDICTIVE MARKER FOR PAACLITAXEL.
Takuya Ohashi, Japan

P1.01-022: CALBINDIN-D28K EXPRESSION IS CORRELATED WITH THE ORGANOTROPISM OF LUNG CANCER ADRENAL METASTASIS.
Tatsuya Yoshimasu, Japan

P1.01-023: THE EXPRESSION OF ATBF1 IS INVERSELY PROPORTION TO THE EXPRESSION OF ESTROGEN RECEPTOR IN LUNG CANCER CELLS
Masaaki Inoue, Japan

P1.01-024: EVALUATION OF VASCULAR NORMALIZATION IN HUMAN LUNG ADENOCARCINOMA INDUCED BY EGCG AND THE EFFICACY OF COMBINE CHEMOTHERAPY IN ITS NORMALIZATION TIME WINDOW
Peng Bo Deng, China

P1.01-025: APOPTOSIS-RELATED GENE TRANSCRIPTION IN HUMAN A549 LUNG CANCER CELLS VIA A3 ADENOSINE RECEPTOR
Hitomi Kamiya, Japan

P1.01-026: PRO-TUMORIGENIC ALTERATION OF SIGNALLING PATHWAYS IN NORMAL MESOTHELIUM: CONTRIBUTION OF NON-MESOTHELIAL CELLS IN MALIGNANT MESOTHELIOMA CARCINOGENESIS
Tatyana Chernova, UK

P1.01-027: LONG NON-CODING RNAs: A NEW FRONTIER IN THE STUDY OF HUMAN DISEASES
Yong Song, China

P1.02 Poster Session 1
Novel Cancer Genes and Pathways

P1.02-001: A COMMON POLYMORPHISM IN PRE-MICORNA-146A IS ASSOCIATED WITH LUNG CANCER RISK IN A KOREAN POPULATION
Mi Young Kim, South Korea

P1.02-002: ATM DEFICIENCY INCREASES RADIATION SENSITIVITY IN NSCLC CELL LINES IN VITRO AND CONFERS A POOR OUTCOME IN EARLY RESECTED NSCLC.
Gwyn Bebb, Canada

P1.02-003: SYNERGETIC STUDY OF CHEMOTHERAPEUTIC DRUGS ACCORDING TO ATM STATUS IN NSCLC CELL LINES
D. Bebb, Canada

P1.02-004: DIFFERENTIAL PATHWAY DISRUPTION IN LUNG ADENOCARCINOMAS FROM CURRENT AND NEVER-SMOKERS - A MULTI-OMICS DATA INTEGRATION ANALYSIS
Kelsie Thu, Canada

P1.02-005: PROGNOSTIC ROLE OF EXPRESSION LEVELS OF FABP3, H19, TFP12, AKR1B10 CYP3A5, SCGB3A2 GENES IN ADENOCARCINOMA STAGE I PATIENTS
Lucio Crino, Italy

P1.02-006: IDENTIFICATION OF TARGETABLE DRIVER MUTATIONS IN MOLECULARLY SELECTED NEVER-SMOKER LUNG ADENOCARCINOMAS
Lucio Crino, Italy

P1.02-007: VALIDATION AND FUNCTION OF A NOVEL MIRNA SIGNATURE IN CISPLATIN RESISTANT NON-SMALL CELL LUNG CANCER CELLS
Lauren Mac Donagh, Ireland

P1.02-008: HSSB1: AN ESSENTIAL REGULATOR OF GENOMIC INTEGRITY IN LUNG CANCER
Mark Adams, Australia

P1.02-009: KCTD11 METHYLATION IN NON-ADENOCARCINOMA LUNG CANCER
Jian Ni, China

P1.02-010: EVALUATION OF THE ONCOGENIC ABILITY OF EML4-ALK TO TRANSFORM HUMAN BRONCHIAL EPITHELIAL CELLS (HBECs) SHIGEHISA KAJIKAWA, Japan
Shigehisa Kajikawa, Japan

P1.02-011: RANK AND RANK LIGAND (RANKL) EXPRESSION IN PRIMARY HUMAN LUNG CANCER
Daniel Branstetter, USA

P1.02-012: PARACRINE RECEPTOR ACTIVATION BY MICROENVIRONMENT AS A MECHANISM OF RET INHIBITOR RESISTANCE IN CCDC6-RET LUNG CANCER CELLS
Hyun Chang, South Korea

P1.02-013: SDHB IS OVEREXPRESSED AND MAY BE A CANDIDATE TARGET FOR THERAPEUTIC INTERVENTION IN MALIGNANT PLEURAL MESOTHELIOMA
Kenneth O’Byrne, Australia

P1.02-014: THE GENE-EXPRESSION PROFILES IN ADVANCED LUNG ADENOCARCINOMA ASSOCIATED WITH WOOD SMOKE OR TOBACCO EXPOSURE ARE DIFFERENT IN BRAIN METASTASIS
Alette Gomez, Mexico

P1.02-015: DIVERSE EFFECTS OF PAI-1 PROTEINS ON LUNG AND PROSTATE CANCER CELL INVASION.
Joanna Chorostowska-Wynimko, Poland
P1.02-016: NON-SMALL CELL LUNG CANCER AND EGFR MUTATION IN POLAND - PRELIMINARY RESULTS FROM SINGLE INSTITUTION STUDY
Wlodzimierz Olszewski, Poland

P1.02-017: NLBP (NOVEL-LZAP BINDING PROTEIN) PROMOTES THE PROLIFERATION OF LUNG ADENOCARCINOMA CELLS THROUGH THE REGULATION OF P120 CATENIN
Hae-Seong Nam, South Korea

P1.02-018: THE WNT SIGNALING PATHWAY IN LUNG CARCINOID
Rosario Garcia Campelo, Spain

P1.02-019: C-MET EXPRESSION IN UNRESECTABLE OR STAGE IV CHEMONAIVE ADENOCARCINOMA OF THE LUNG AND ITS CO-EXISTENCE WITH OTHER DRIVEN MUTATIONS OR GENETIC ABNORMALITIES.
Edgardo Santos, USA

P1.02-020: EVALUATION OF GENE EXPRESSION PROFILES FOR THE DIFFERENTIAL DIAGNOSIS OF LUNG ADENOCARCINOMA AND MALIGNANT PLEURAL MESOTHELIOMA
Atila Akkoclu, Turkey

P1.02-021: OVEREXPRESSION OF B-CRYSTALLIN PREDICTS POOR PROGNOSIS IN NON-SMALL-CELL LUNG CANCER
Di Ge, China

P1.02-022: DOWNREGULATION OF PAX6 BY SIRNA INHIBITS PROLIFERATION AND CELL CYCLE PROGRESSION OF HUMAN NON-SMALL CELL LUNG CANCER CELL LINES
Wentao Yue, China

P1.03 Poster Session 1 Technology and Novel Development

P1.03-001: MULTIPLEXING TECHNOLOGY FOR IN SITU BIOMARKER PROFILING OF NON-SMALL CELL LUNG CANCER (NSCLC)
Kathleen Bove, USA

P1.03-002: MULTIPLEXED ANALYSIS OF LUNG CANCER FOR DISTINGUISHING ADENOCARCINOMA FROM SQUAMOUS CELL CARCINOMA
Kathleen Bove, USA

P1.03-003: NOVEL DETECTION METHOD FOR EGFR T790M MUTATION BY EPROBE MEDIATED PCR AND MELTING CURVE ANALYSIS
Jun Atsumi, Japan

P1.03-004: ROBUST GLOBAL MICRORNA EXPRESSION PROFILING USING NEXT-GENERATION SEQUENCING TECHNOLOGIES
Shirley Tam, Canada

P1.03-005: HIGH THROUGHPUT ARRAY AND SENSITIVE MASS SPECTROMETRY TECHNOLOGY APPLIED TO TRANSBRONCHIAL NEEDLE ASPIRATION ALLOW THE (DETECTION OF HUNDREDS MOLECULAR TARGETS) TUMOR PROFILING FOR ROUTINE CARE PERSONALIZED MEDICINE
Armine Izadifar, France

P1.03-006: THE EFFICIENCY OF DETECTION OF KRAS, EGFR AND BRAF MUTATIONS IN PRIMARY LUNG CANCER VIA PERIPHERAL BLOOD CIRCULATING TUMOUR CELLS
Eric Lim, UK

P1.04 Poster Session 1 Tumor Immunology

P1.04-001: COMBINING PRIME-BOOST ANTI-TUMOUR VACCINATION WITH DEBULKING SURGERY FOR THE TREATMENT OF MALIGNANT MESOTHELIOMA
Richard Lake, Australia

P1.05 Poster Session 1 Preclinical Models of Therapeutics/Imaging

P1.05-001: EGFR-TKI RESISTANCE DUE TO BIM POLYMORPHISM CAN BE CIRCUMVENTED IN COMBINATION WITH HDAC INHIBITION
Shinji Takeuchi, Japan

P1.05-002: REVERSAL OF RESISTANCE TO EGFR TYROSINE KINASE INHIBITOR BY EGFR T790M SPECIFIC SIRNA IN NON-SMALL CELL LUNG CANCER
Choon-Taek Lee, South Korea

P1.05-003: THE PDGFR/SRC SIGNALING PATHWAY-TARGETED THERAPY WITH NOVEL TUSC2-NANOPARTICLES AND TYROSINE KINASE INHIBITORS FOR HUMAN LUNG CANCER
Lin Ji, USA

P1.05-004: MOLECULAR MECHANISM OF RESISTANCE TO AFATINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER (NSCLC) CELL LINES AND POTENTIAL THERAPEUTIC IMPLICATIONS
Francesco Grossi, Italy

P1.05-005: VEGF SIGNALING INHIBITION BY CEDIRANIB ENHANCES THE ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF RADIATION THERAPY MORE SUBSTANTIALLY THAN CHEMOTHERAPY IN ORTHOTOPIC LUNG CANCER MODELS
Osamu Takahashi, USA
P1.05-006: TARGETED DELIVERY OF RRM1-SPECIFIC SIRNA LEADS TO TUMOUR GROWTH INHIBITION IN MALIGNANT PLEURAL MESOTHELIOMA
Glen Reid, Australia

P1.05-007: LARGE SCALE ESTABLISHMENT OF GENETICALLY DIVERSE PATIENT-DERIVED PRIMARY TUMOR XENOGRAFTS FROM RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Lucia Kim, South Korea

P1.05-008: THE HSP 90 INHIBITORS SUPPRESS CELL GROWTH BY SUPPRESSION OF ALK AND TGF-BETA1 SIGNALING IN CRIZOTINIB-RESISTANT H2228 CELLS BY EPITHELIAL TO MESENCHYMAL TRANSITION
Hyeong Ryul Kim, South Korea

P1.05-009: DEVELOPMENT OF SMALL CELL LUNG CANCER PRIMARY XENOGRAFTS USING SPECIMENS OBTAINED BY ENDOBRONCHIAL-ULTRASOUND TRANSBRONCHIAL NEEDLE ASPIRATION: A NOVEL PRE-CLINICAL MODEL
Tracy Leong, Australia

P1.05-010: PRE-CLINICAL VALIDATION OF ELECTRO-CHEMOTHERAPY (ECT) IN THE TREATMENT OF LUNG TUMOURS
Saleem Jahangeer, Ireland

P1.05-011: ANTITUMOR AGENT KNG-1-484C CAUSES CELL DEATH THROUGH INDUCING CYCLE ARREST
Ting-Fang Che, Taiwan

P1.06 Poster Session 1
Prognostic and Predictive Biomarkers

P1.06-001: HDL-CHOLESTEROL IS REDUCED IN ADVANCED STAGE LUNG CANCER PATIENTS WITH WEIGHT LOSS
Bulent Karagoz, Turkey

P1.05-018: INHIBITION OF NON-SMALL-CELL LUNG CANCER GROWTH BY PH CONTROL RELEASE NANOPARTICLE CARRYING MIR-135B ANTAGOMIR
Ching-Wen Lin, Taiwan

P1.05-019: JNU-42756493 IS A POTENT AND SELECTIVE FGFR1-4 KINASE INHIBITOR WITH PROMISE FOR CLINICAL USE IN PATIENTS WITH FGFR DRIVEN TUMORS
Timothy Perera, Belgium

P1.05-020: IDENTIFYING THERAPEUTIC TARGETS FOR MESOTHELIOMA USING SIRNA
Cleo Robinson, Australia

P1.05-021: DUAL CHECKPOINT BLOCKADE USING ANTI-PD-1 AND ANTI-CTLA4 COMBINED WITH CISPLATIN CHEMOTHERAPY IS EFFECTIVE IN A MURINE MESOTHELIOMA MODEL
Richard Lake, Australia

P1.05-022: BET BROMODOMAINS: ARE THEY A POTENTIAL THERAPEUTIC TARGETS IN MALIGNANT PLEURAL MESOTHELIOMA?
Kenneth O’Byrne, Australia

P1.05-023: THE KDM4/JMJD2 LYSINE DEMETHYLASES ARE CANDIDATE THERAPEUTIC TARGETS IN MALIGNANT PLEURAL MESOTHELIOMA
Kenneth O’Byrne, Australia

P1.05-024: PARP INHIBITION INCREASES SENSITIVITY OF NSCLC CELLS TO CISPLATIN
Martin Barr, Ireland

P1.05-025: EGFR BLOCKADE INCREASES LUNG CANCER STEM CELL-LIKE CELLS BY UPREGULATION OF NOTCH3 SIGNALING.
David Carbone, USA

P1.05-001: HDL-CHOLESTEROL IS REDUCED IN ADVANCED STAGE LUNG CANCER PATIENTS WITH WEIGHT LOSS
Bulent Karagoz, Turkey

P1.06-002: INTRATUMOR VARIATION OF BIOMARKER EXPRESSION BY IMMUNOHISTOCHEMISTRY IN RESECTABLE NON-SMALL CELL LUNG CANCER
Jens Sorensen, Denmark

P1.06-003: COMPARATIVE EFFECTIVENESS OF DDPCR FOR THE DETECTION OF EGFR MUTATIONS.
Marissa Daniels, Australia

P1.06-004: RO51 IMMUNOHISTOCHEMISTRY AMONG MAJOR GENOTYPES OF NON-SMALL CELL LUNG CARCINOMA
Fred Hirsch, USA

P1.05-012: THE HSP90 INHIBITOR, AT13387, DISPLAYS SINGLE AGENT ACTIVITY IN ERLOTINIB-SENSITIVE AND -RESISTANT MODELS OF EGFR-ACTIVATED NSCLC
Nicola Wallis, UK

P1.05-013: APOPTOSIS-TARGETED DRUG AND T-CELL DELIVERY TO LUNG CANCER
Keon Uk Park, South Korea

P1.05-014: CANCER STEM CELL-LIKE POPULATION FROM NON-SMALL CELL LUNG CANCER IS PREFERENTIALLY SUPPRESSED BY EGFR-TKIS
Qinghua Zhou, China

P1.05-015: ASSESSMENT OF THE ACTIVITY OF Pemetrexed and Dasatinib AS SINGLE AGENTS AND IN COMBINATION IN THREE MALIGNANT PLEURAL MESOTHELIOMA CELL LINES
Valentina Monica, Italy

P1.05-016: EPHB4 RECEPTOR KINASE, A NOVEL THERAPEUTIC TARGET FOR LUNG CANCER
Barbara Gitlitz, USA

P1.05-017: ASCORBIC ACID AND AHCC SUPPRESS LUNG FIBROSIS AND CANCER CAUSED BY IRRADIATION
Tadashi Hongyo, Japan
P1.06-005: THE CLINICAL SIGNIFICANCE OF SERUM BAP, TRACP 5B AND ICTP AS BONE METABOLIC MARKERS FOR BONE METASTASIS SCREENING IN LUNG CANCER PATIENTS
Xiaoqing Liu, China

P1.06-006: PROGNOSTIC VALUE OF SERIAL PERIPHERAL CIRCULATING TUMOUR CELLS (CTC) EVALUATION IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) DURING FIRST LINE TREATMENT.
Jose Luis Gonzalez Larriba, Spain

P1.06-007: RELATIONSHIP BETWEEN 5FU RELATED ENZYMES AND EGFR MUTATION STATUS IN NON-SMALL CELL LUNG CANCER TREATED WITH 5-1 ADJUVANT THERAPY
Koji Mochinaga, Japan

P1.06-008: EXPRESSION OF PTRF/CAVIN-1 IS ASSOCIATED WITH POOR PROGNOSIS OF LUNG ADENOCARCINOMA
Hidetoshi Inoue, Japan

P1.06-009: EXPRESSION OF BMP-7 IN NON-SMALL CELL LUNG CANCER AND ITS CLINICAL SIGNIFICANCE
Masaya Aoki, Japan

P1.06-010: EXPRESSION OF 1,6-FUCOSYLTRANSFERASE IS ASSOCIATED WITH PROGNOSIS AND HISTOLOGY IN NON-SMALL CELL LUNG CANCERS
Rio Honma, Japan

P1.06-011: NEXT GENERATION SEQUENCING IN LUNG CANCERS - FOCUSING ON THE KINOME
Aslaug Helland, Norway

P1.06-012: A DISINTEGRIN AND METALLOPROTEINASE-9 IS HIGHLY EXPRESSED, CORRELATED WITH LYMPH NODES METASTASIS, PREDICTS WORSE PROGNOSIS AND MAY HELP IMPROVING PERSONALIZED POSTOPERATIVE TREATMENT IN RESECTED NON-SMALL CELL LUNG CANCER
Jun Zhang, China

P1.06-013: DETECTION OF CIRCULATING TUMOUR CELLS IN ADVANCED NON-SMALL CELL LUNG CANCER
Michael Fanning, Australia

P1.06-014: A NOMOGRAM FOR PREDICTING 5-YEAR RFS IN PATIENTS WITH PULMONARY CARCINOID TUMORS INCORPORATING Ki-67 AND CLINICAL VARIABLES
Thanayan Reungwetwattana, Thailand

P1.06-015: EGFR MUTATED PATIENTS: DIFFERENT PATTERN AND OUTCOME OF METASTATIC BONE DISEASE AND BRAIN METASTASES?
Anne-Marie Dingemans, Netherlands

P1.06-016: ANAPLASTIC LYMPHOMA KINASE (ALK) ALTERATIONS BY FISH IN A COHORT OF SPANISH NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS ANALYSED IN A CERTIFIED CENTRE OF REFERENCE
Edurne Arriola, Spain

P1.06-017: TARGETED PROTEOMICS AND HT-IHC FOR LUNG CANCER BIOMARKER STUDIES.
Guy Berchem, Luxembourg

P1.06-018: CUMULATIVE BIOMARKER MODEL PREDICTS 3-YEAR RECURRENCE IN RESECTED STAGE I ADENOCARCINOMA OF THE LUNG
Jessica Donington, USA

P1.06-019: COMMON AND UNCOMMON EGFR MUTATIONS AND THEIR IMPACT ON RESPONSE TO EGFR TYROSINE-KINASE INHIBITORS AND PLATINUM-BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC): LATIN-AMERICAN CONSORTIUM FOR THE INVESTIGATION OF LUNG CANCER (CLICAP)
Oscar Arrieta, Mexico

P1.06-020: IDENTIFICATION OF PROGNOSTIC IMMUNOPHENOTYPIC FEATURES IN CANCER STROMAL CELLS OF HIGH-GRADE NEUROENDOCRINE CARCINOMAS OF THE LUNG
Akiko Takahashi, Japan

P1.06-021: VALIDATION OF DNA HYPERMETHYLATION ANALYSIS IN SPUTUM FOR THE DIAGNOSIS OF LUNG CANCER
A. Jasmijn Hubers, Netherlands

P1.06-022: INVESTIGATING THE UTILITY OF PLASMA DERIVED CIRCULATING FREE DNA FOR THE DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN EUROPEAN AND JAPANESE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): ASSESS STUDY DESIGN
Martin Reck, Germany

P1.06-023: ANAPLASTIC LYMPHOMA KINASE (ALK)-DETECTION IN NON-SMALL CELL LUNG CANCER: RESULTS OF THE FIRST EUROPEAN IHC-BASED (D5F3-OPTIVIEW) PANEL TEST WITHIN 16 INSTITUTES
Maximilian Von Laffert, Germany

P1.06-024: FAM83B, A NOVEL MOLECULAR TARGET FOR LUNG SQUAMOUS CELL CARCINOMA.
Naoyuki Okabe, Japan

P1.06-025: DETERMINATION OF THE ACTIVITY OF LYSOSOMAL ENZYMES AND PROTEASE INHIBITORS IS USEFUL IN THE DIAGNOSTICS OF LUNG CANCER.
Janusz Kowalewski, Poland

P1.06-026: VALIDATION OF A PROLIFERATION-BASED EXPRESSION SIGNATURE AS PROGNOSTIC MARKER IN EARLY STAGE LUNG ADENOCARCINOMA
Raphael Bueno, USA
<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.06-027</td>
<td>POLYMORPHISMS IN DNA REPAIR AND APOPTOSIS-RELATED GENES AND CLINICAL OUTCOMES OF PATIENTS WITH NON-_SMALL CELL LUNG CANCER TREATED WITH FIRST-LINE PACLITAXEL-CISPLATIN CHEMOTHERAPY</td>
<td>Shin Yup Lee, South Korea</td>
</tr>
<tr>
<td>P1.06-028</td>
<td>DROPLET DIGITAL PCR: A NOVEL DETECTION METHOD OF ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN PLASMA OF PATIENTS WITH ADVANCED STAGE NON-_SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Carmen Lee, Hong Kong</td>
</tr>
<tr>
<td>P1.06-029</td>
<td>SERUM NITRIC OXIDE COULD BE A PREDICTOR FOR THE RESPONSE OF BEVACIZUMAB IN PATIENTS WITH NON- SMALL CELL LUNG CANCER</td>
<td>Satoshi Muto, Japan</td>
</tr>
<tr>
<td>P1.06-030</td>
<td>KRAS MUTATIONS IN RESECTABLE NSCLC PATIENTS. PROGNOSTIC IMPLICATIONS</td>
<td>Carlos Camps, Spain</td>
</tr>
<tr>
<td>P1.06-031</td>
<td>IS THERE ANY ROLE FOR MONITORING CIRCULATING TUMOR CELLS (CTC) IN STAGE III NON- SMALL-CELL LUNG CANCER (NSCLC) PATIENTS?</td>
<td>Pilar Garrido, Spain</td>
</tr>
<tr>
<td>P1.06-032</td>
<td>THE HIGH PROTEIN EXPRESSION OF EGFR USING A SPECIFIC INTERNAL DOMAIN ANTIBODY AND LOSS OF PTEN CAN BE USED AS PREDICTIVE FACTORS FOR EGFR TKIS IN PATIENTS WITH ADVANCED SQUAMOUS CELL LUNG CANCER</td>
<td>Jisu Oh, South Korea</td>
</tr>
<tr>
<td>P1.06-033</td>
<td>THE IMPACT OF PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (VEGF R2) AND HEPATOCYTE GROWTH FACTOR (HGF) ON SURVIVAL IN LONG-TERM SURVIVORS WITH ADVANCED LUNG CANCER (ALCP)</td>
<td>Zhasmina Mihaylova, Bulgaria</td>
</tr>
<tr>
<td>P1.06-034</td>
<td>MET EXPRESSION, COPY NUMBER AND ONCOGENIC MUTATIONS IN EARLY STAGE NSCLC</td>
<td>Thomas John, Australia</td>
</tr>
<tr>
<td>P1.06-035</td>
<td>VEGF-A 165 FAMILY OF ISOFORMS AS PREDICTIVE BIOMARKERS IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH BEVACIZUMAB.</td>
<td>Manuel Domine, Spain</td>
</tr>
<tr>
<td>P1.06-036</td>
<td>RELATIONSHIP BETWEEN SERUM SODIUM LEVELS AND TUMOR CHARACTERISTICS IN NON-SMALL CELL LUNG CANCER.</td>
<td>Abhishek Kumar, USA</td>
</tr>
<tr>
<td>P1.06-037</td>
<td>ANGIOPOIETIN-2 SERUM AND MRNA LEVELS AS PROGNOSTIC FACTORS IN NON SMALL CELL LUNG CANCER</td>
<td>Ana Coelho, Portugal</td>
</tr>
<tr>
<td>P1.06-038</td>
<td>SINGLE CELL GENOMIC ANALYSES OF CIRCULATING TUMOR CELLS FROM LUNG CANCER PATIENTS</td>
<td>Zhijie Wang, China</td>
</tr>
<tr>
<td>P1.06-039</td>
<td>IMPACT OF KI-67 LABELING INDEX AS A PREDICTIVE MARKER FOR CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER</td>
<td>Yoshimitsu Hirai, Japan</td>
</tr>
<tr>
<td>P1.06-040</td>
<td>THE BIM DELETION POLYMORPHISM PROFILE AND ITS RELATIONSHIP WITH TKIS RESISTANCE IN CHINESE NSCLC POPULATION</td>
<td>Jiayu Li, China</td>
</tr>
<tr>
<td>P1.06-041</td>
<td>PROGNOSTIC IMPACT OF CYTOSKELETON REGULATORY PROTEIN HUMAN MENA (HMENA) ISOFORMS IN RESECTED, NODE-NEGATIVE, NON-SMALL-CELL LUNG CANCER: VALIDATION OF A CLINIC-MOLECULAR PROGNOSTIC MODEL.</td>
<td>Emilio Bria, Italy</td>
</tr>
<tr>
<td>P1.06-042</td>
<td>KLOTHO EXPRESSION IN PATIENTS HAVING EGFR MUTATIONS (CLICAP STUDY)</td>
<td>Andres Cardona, Colombia</td>
</tr>
<tr>
<td>P1.06-043</td>
<td>PHARMACOGENETIC STUDY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH PLATINUM BASED CHEMOTHERAPY.</td>
<td>Margarita Majem, Spain</td>
</tr>
<tr>
<td>P1.06-044</td>
<td>DIAGNOSTIC VALIDATION OF PNA-LNA PCR CLAMP ASSAY FOR DETECTION OF EGFR EXON 19 AND 21 MUTATIONS IN NON-SMALL CELL LUNG CANCER SPECIMENS.</td>
<td>Joanna Chorostowska-Wynimko, Poland</td>
</tr>
<tr>
<td>P1.06-045</td>
<td>SERUM MICRORNA AS A PREDICTIVE MARKER FOR RADIATION PNEUMONITIS IN PATIENTS WITH INOPERABLE/UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Feng-Ming (Spring) Kong, USA</td>
</tr>
<tr>
<td>P1.06-046</td>
<td>PROGNOSTIC RELEVANCE OF THE QUANTIFICATION OF CIRCULATING TUMOR CELLS BY MEAN EPITHELIAL MARKERS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS.</td>
<td>Sae Muniz-Hernandez, Mexico</td>
</tr>
<tr>
<td>P1.06-047</td>
<td>TUMOR EXPRESSION OF TTF1 IS ASSOCIATED WITH A DOUBLING OF OVERALL SURVIVAL IN PATIENTS WITH ADVANCED LUNG ADENOCARCINOMAS</td>
<td>Matthew Hellmann, USA</td>
</tr>
<tr>
<td>P1.06-048</td>
<td>AN EXTENSIVE ANALYSIS ON T1AN0 NON-SMALL CELL LUNG CANCER: FROM SURGERY TO PATHOLOGY.</td>
<td>Pietro Bertoglio, Italy</td>
</tr>
<tr>
<td>P1.06-049</td>
<td>ANALYSIS OF TN ANTIGEN AND ITS RELATIONSHIP WITH CLINIC, HISTOLOGIC AND BIOMARKERS PROFILE IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER (NSCLC).</td>
<td>Diego Touya, Uruguay</td>
</tr>
</tbody>
</table>
P1.06-050: COST-EFFECTIVENESS OF THE PERVENIO™ RISK-SCORE (RS) ASSAY IN EARLY-STAGE NON-SMALL CELL LUNG CANCER
Joshua Roth, USA

P1.06-051: DEVELOPMENT OF A SERUM BIOMARKER PANEL PREDICTING CLINICAL OUTCOME OF CHEMOTHERAPY WITH Pemetrexed IN PATIENTS WITH NSCLC
Marta Batus, USA

P1.06-052: BIOMARKERS OF PHENOTYPIC PLASTICITY ASSOCIATED WITH CLINICAL OUTCOMES IN PATIENTS WITH LOCALLY-ADVANCED NSCLC TREATED WITH CHEMORADIATION WITH AND WITHOUT SURGERY.
Marta Batus, USA

P1.06-053: CLINICAL UTILITY OF CIRCULATING SERUM AND PLASMA BIOMARKERS FOR PERSONALISED RADIOThERAPY TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
Corinne Faivre-Finn, UK

P1.06-054: TARGETING MCL1 AMPLIFICATION IN NSCLC THROUGH ANTHRACYCLINE-MEDIATED TRANSCRIPTIONAL SUPPRESSION
Sara Busacca, UK

P1.06-055: THE RON (MST1R)/MSP PATHWAY IS A POTENTIAL THERAPEUTIC TARGET IN MALIGNANT PLURAL MESOTHELIOMA
Anne-Marie Baird, Ireland

P1.06-056: ISOLATION & ENUMERATION OF CIRCULATING TUMOR CELLS IN NON-SMALL CELL LUNG CANCER, USING SCREENCELL & VITAASSAY TECHNIQUES.
Martin Barr, Ireland

P1.06-057: THE PHALCIS TRIAL (PHARMACOGENOMIC ALIMTA CISPLATIN): A CLINICAL TRIAL IN PROGRESS BY THE SPANISH LUNG CANCER GROUP
Jose-Miguel Sanchez-Torres, Spain

P1.06-058: THE PHALCIS TRIAL (PHARMACOGENOMIC ALIMTA CISPLATIN): A CLINICAL TRIAL IN PROGRESS BY THE SPANISH LUNG CANCER GROUP
Jose-Miguel Sanchez-Torres, Spain

P1.06-059: COMPARISON OF THE CHARACTERISTICS AND CLINICAL COURSE OF PATIENTS WITH METASTATIC KRAS MUTANT LUNG CANCERS
Gregory Riely, USA

P1.07 Poster Session 1

P1.07-001: THE IMPACT OF COMBINED PULMONARY FIBROSIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE ON LONG-TERM SURVIVAL AFTER LUNG CANCER SURGERY
Yasu Sekine, Japan

P1.07-002: EFFECT OF SYNCHRONOUS SOLITARY BONE METASTASECTOMY ON RESECTABLE NON-SMALL CELL LUNG CANCER PATIENTS
Tiancheng Zhao, China

P1.07-003: SURGICAL INDICATION FOR ELDERLY LUNG CANCER PATIENTS ACCORDING DEPENDING ON THE MORTALITY RATE BY DUE TO OTHER DISEASE
Masafumi Kataoka, Japan

P1.07-004: MULTIMODALITY MANAGEMENT AND SURGICAL OUTCOMES FOLLOWING POST NEO-ADJUVANT CHEMOTHERAPY, RADICAL CHEST WALL RESECTION AND RECONSTRUCTION FOR PNENT CHEST WALL
Palaniappan Ramanathan, India

P1.07-005: LENGTH OF DISEASE FREE SURVIVAL INTERVAL IS AN INDEPENDENT PREDICTIVE PROGNOSTIC FACTOR FOR POSTRECURRENT SURVIVAL IN NSCLC
Masato Kato, Japan

P1.07-006: LUNG CANCER RESECTION IN PATIENTS WITH CHRONIC RENAL FAILURE ON HEMODIALYSIS
Yasufumi Kato, Japan

P1.07-007: INTRAPLEURAL ADMINISTRATION OF A COMBINATION OF CISPLATIN AND FIBRIN GLUE FOR PLEURAL LAVAGE CYTOLOGY-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER
Hirohiko Shinohara, Japan

P1.07-008: THE APPLICATION OF SOFT COAG IN COMBINATION WITH TRIANGLE-TENSIONING FOR VATS LobECTOMY AND SEGMENTECTOMY
Tohru Sakuragi, Japan

P1.07-009: PREOPERATIVE SIMULATION AND NAVIGATION USING THE COMBINATION OF HIGH-SPEED 3D-IMAGE ANALYSIS SYSTEM AND ROBOTIC SURGERY INCREASE THE EFFICACY AND ACCURACY IN THORACIC SURGERY
Naohiro Kajiwara, Japan

P1.07-010: PREOPERATIVE FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHY SCAN WITH POSITIVE N1 DISEASE DOES NOT PREDICT WORSE SURVIVAL IN PATHOLOGIC STAGE II PATIENTS
Min Kim, USA
P1.07-011: EXAMINATION OF THE RELEVANCE OF PROLONGED PULMONARY FISTULA AFTER PULMONARY RESECTION FOR LUNG CANCER AND FACTORS ABOUT DELAYED WOUND HEALING
Koshi Nagano, Japan

P1.07-012: COLLABORATIVE MULTIMODAL PAIN MANAGEMENT STRATEGY FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER SUBMITTED TO THORACOTOMY
Juan Fibla, Spain

P1.07-013: “MINIMALLY INVASIVE SMALL INCISION, MUSCLE- AND RIB-SPARING THORACOTOMY, MINIMALLY INVASIVE LUNG CANCER RADICAL SURGERY”, CURES “AGING, CARDIOPULMONARY DYSFUNCTION PATIENTS WITH LUNG CANCER”
Jun Zhang, China

P1.07-014: EFFECT OF ADVANCED AGE ON PERI-OPERATIVE OUTCOMES AFTER ROBOTIC-ASSISTED PULMONARY LOBECTOMY: RETROSPECTIVE ANALYSIS OF 180 CONSECUTIVE CASES
Wei Wei Zhang, USA

P1.07-015: DYSPHAGIA PALLIATION IN LOCALLY ADVANCED CARCINOMA ESOPHAGUS: ROLE OF INTRALUMINAL BRACHYTHERAPY.
Manoj Behera, India

P1.07-016: DOES THE UTILIZATION OF STAPLERS FOR THE INTERLOBAR FISSURES DISSECTION REALLY AFFECT POSTOPERATIVE RESPIRATORY FUNCTION?
Masashi Yanada, Japan

P1.07-017: PROGNOSTIC IMPACT OF CYTOREDUCTIVE SURGERY FOR NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION DETECTED AT SURGERY
Yohei Taniguchi, Japan

P1.07-018: SURGICAL TREATMENT FOR SUPER-ELDERLY PATIENTS (OVER 85 YEARS OLD) WITH LUNG CANCER
Osamu Kawashima, Japan

P1.07-019: IS VATS LOBECTOMY TOO EXPENSIVE? A COST ANALYZE OF INTRODUCING VATS LOBECTOMY TO A TERTIARY CARE HOSPITAL
Daniel French, Canada

P1.07-020: THORACOSCORE AND EUROPEAN SOCIETY OBJECTIVE SCORE DO NOT PREDICT MORTALITY IN THE UK POPULATION - IS IT TIME FOR A NEW RISK MODEL?
Annabel Sharkey, UK

P1.07-021: THE RISK FACTOR OF LATE RECURRENCE IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
Yoshihisa Kobayashi, Japan

P1.07-022: RESULTS OF STUDY EVALUATING INFLAMMATORY BIOCHEMICAL PARAMETERS AND OXIDATIVE STRESS IN PATIENTS UNDERGOING VATS AND OPEN LOBECTOMY FOR EARLY STAGE NSCLC.
Ints Silins, Latvia

P1.07-023: DIRECT PROJECTION OF THREE DIMENSIONAL VOLUME ANALYZED CT IMAGES TO THE SURGICAL FIELD BY THE PORTABLE DIGITAL LIGHT PROCESSING PROJECTOR FOR ASSISTING MINIMALLY INVASIVE THORACIC SURGERY
Takashi Anayama, Japan

P1.07-024: SURGICAL OUTCOME OF ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA
Tomas Gudbjartsson, Iceland

P1.07-025: LONG-TERM SURVIVAL OF PATIENTS WITH CN2/PN2 NON-SMALL-CELL LUNG CANCER
Eunju Ye, South Korea

P1.07-026: VATS REDUCES SURGICAL RISK OF LOBECTOMY FOR HIGH RISK PATIENTS WITH EARLY NON-SMALL CELL LUNG CANCER
Gail Darling, Canada

P1.07-027: VATS LOBECTOMY FOR NON-SMALL CELL LUNG CANCER IN PATIENTS WITH SEVERE COPD
Jianxing He, China

P1.07-028: THORACOSCOPIC MINIMALLY INVASIVE SURGERY FOR NON-SMALL CELL LUNG CANCER IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Jianxing He, China

P1.07-029: NOMOGRAM FOR PREDICTING SURVIVAL IN PATIENTS WITH RESected NON-SMALL CELL LUNG CANCER
Jianxing He, China

P1.07-030: PROGNOSTIC FACTORS FOR PATIENTS IN BRAIN METASTASIS WITH NO EXTRACRANIAL METASTASIS AFTER RESECTION OF NON-SMALL CELL LUNG CANCER
Mi Kyung Bae, South Korea

P1.07-031: IS LYMPH NODE DISSECTION AT STATION 11S NECESSARY IN PRIMARY LUNG CANCER LOCATED IN THE MIDDLE LOBE?
Riken Kawachi, Japan

P1.07-032: EXPERIENCE OF SURGICAL TREATMENT OF MYASTHENIA
Anatoliy Kasatov, Russia

P1.07-033: VIDEO-ASSISTED THORACOSCOPIC SURGERY (VATS) LOBECTOMY: A CONSENSUS STATEMENT
Christopher Cao, Australia

P1.07-034: NUMBER OF METASTATIC LYMPH NODES AND METASTATIC LYMPH NODE RATIO PREDICT PATIENT SURVIVAL IN RESECTED NON-SMALL CELL LUNG CANCER
Seijiro Sato, Japan
P1.07-035: UNCERTAIN RESECTION DUE TO INCOMPLETE INTRAOPERATIVE NODAL ASSESSMENT
Taketsugu Yamamoto, Japan

P1.07-036: IS RADIOTHERAPY UNAVOIDABLE FOR N2 DISEASE IN NSCLC
George Karimundackal, India

P1.07-037: CLINICAL CHARACTERISTICS OF COMPLETELY RESECTED LUNG CANCER WITH COMBINED PULMONARY FIBROSIS AND EMPHYSEMA
Junichiro Osawa, Japan

P1.07-038: SURGICAL TREATMENT FOR T4 NON-SMALL CELL LUNG CANCER INVASING MEDIASTINAL STRUCTURES
Hae-Won Lee, South Korea

P1.07-039: PREDICTORS OF ONE YEAR SURVIVAL AFTER LUNG CANCER SURGERY
Shoni Colquist, Australia

P1.07-040: OUTCOMES OF SURGICAL TREATMENT FOR ISOLATED ADRENAL METASTASIS IN NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND POOLED ANALYSIS
Wei Liu, China

P1.07-041: CHARACTERISTICS OF A NORTH AMERICAN PATIENT POPULATION WITH THE DIAGNOSIS OF “BRONCHIOLOALVEOLAR CARCINOMA (BAC)”
Candice Wilshire, USA

P1.07-042: VIDEO-ASSISTED THORACIC SURGERY LOBECTOMY FOR UNEXPECTED PATHOLOGIC N2 NON-SMALL CELL LUNG CANCER
Wen Yong Zhou, China

P1.07-043: SURGICAL MANAGEMENT OF LEFT NON-SMALL-CELL LUNG CANCER WITH IPSILATERAL AND CONTRALATERAL MEDIASTINAL NODE METASTASIS (N2 AND N3 DISEASE) BY SYSTEMIC EXTENDED BILATERAL MEDIASTINAL DISSECTION (HATA’S METHOD)
Toshiya Yokota, Japan

P1.07-044: EFFECTS OF PREOPERATIVE REHABILITATION ON OUTCOME OF PATIENTS WITH THORACIC TUMORS AND BORDERLINE ABNORMAL SPIROMETRY RESULTS
Maciej Glogowski, Poland

P1.07-045: PROGNOSTIC IMPLICATIONS OF BLOOD TESTS PERFORMED ROUTINELY PRIOR TO SURGICAL RESECTION OF NON-SMALL CELL LUNG CANCER
Matthew Smith, UK

P1.07-046: CLINICAL AND PATHOLOGICAL PROFILE OF LUNG CARCINOID
Rosario Garcia Campelo, Spain

P1.07-047: COULD VIDEO-ASSISTED THORACOSCOPIC LOBECTOMY PLUS MEDIASTINAL LYMPH NODE DISSECTION BE PERFORMED FOR NON-SMALL CELL LUNG CANCER IN A LOW-VOLUME HOSPITAL?
Yanguang Ding, China

P1.07-048: LEARNING CURVE FOR VIDEO-ASSISTED THORACOSCOPIC SURGERY LOBECTOMY PLUS MEDIASTINAL LYMPH NODE DISSECTION FOR NON-SMALL CELL LUNG CANCER: HOW MANY CASES ARE NEEDED TO REACH COMPETENCE WITH GUIDANCE OF CONSULTANT SURGEON?
Yanguang Ding, China

P1.08 Poster Session 1

RADIOThERAPY

P1.08-001: CORRELATION OF INTRA-FRACTION DISPLACEMENT OF THE MEDIASTINAL METASTATIC LYMPH NODES WITH PRIMARY TUMOR, LUNG AND HEART BASED ON 4DCT IN NON-SMALL CELL LUNG CANCER
Shao Qian, China

P1.08-002: RELATION OF TUMOR RESPONSE TO RADIATION DOSE DISTRIBUTION IN LOCALLy ADVANCED NON-SMALL CELL LUNG CANCER UNDERGOING CONCURRENT CHEMORADIOTHERAPY
Won Sup Yoon, South Korea

P1.08-003: I LOVE A SUNBURNT COUNTRY... TRIPARTITE COLLABORATIVE APPROACHES TO BRINGING STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) LUNG TO THE PEOPLE OF REGIONAL AUSTRALIA
Fiona Hegi-Johnson, Australia

P1.08-004: AUSTRALIAN IMPLEMENTATION OF VMAT FOR STEREOTACTIC BODY RADIOTHERAPY IN EARLY LUNG CANCER: COMPARING VMAT WITH COPLANAR AND NON-COPLANAR INTENSITY MODULATED RADIOTHERAPY AND 3D-CONFORMAL RADIOTHERAPY.
Fiona Hegi-Johnson, Australia

P1.08-005: ACTIVE BREATHING COORDINATION TO MEASURE TUMOUR MOTION IN LUNG CANCER PATIENTS: A FEASIBILITY STUDY
Penny Phan, Australia

P1.08-006: INTER-OBSERVER VARIABILITY OF GTV DELINEATION BASED ON LUNG MRI: IMPACT OF RADIOLOGIST LED WORKSHOP
Shivani Kumar, Australia
P1.08-007: OUTCOMES AND PROGNOSTIC FACTORS OF STAGE I NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH STEREOTACTIC BODY RADIOTHERAPY OR 3-DIMENSIONAL CONFORMAL RADIOTHERAPY. Itaru Soda, Japan

P1.08-008: PROGNOSTIC FACTORS IN PATIENTS WITH BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER TREATED WITH WHOLE-BRAIN RADIOTHERAPY Hideyuki Harada, Japan

P1.08-009: DYNAMIC TUMOR TRACKING RADIOTHERAPY WITH REAL-TIME MONITORING USING VERO4DRT Yukinori Matsuo, Japan

P1.08-010: NSCLC AND RADIATION PNEUMONITIS POST RADIOTHERAPY Saxby Brown, Australia

P1.08-011: DOSIMETRIC PREDICTORS OF ESOPHAGEAL TOXICITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING CHEMOTHERAPY AND RADIOTHERAPY Michael Snyder, USA

P1.08-012: SIGNIFICANT ASSOCIATION BETWEEN RADIATION INDUCED OESOPHAGITIS, NEUTROPENIA AND V20 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER Sarah Everitt, Australia

P1.08-013: STEREOTACTIC ABLATIVE RADIOTHERAPY OF EARLY STAGE NON-SMALL CELL LUNG CANCER Jakub Cvek, Czech Republic

P1.08-014: PET-BASED RADIOTHERAPY PLANNING IS HIGHLY COST-EFFECTIVE COMPARED TO CT-BASED PLANNING: A MODEL-BASED EVALUATION. Dirk De Ruyscher, Belgium

P1.08-015: COMPARISON OF ONCE-DAILY VS TWICE-DAILY THORACIC RADIOTHERAPY OUTCOMES IN LIMITED DISEASE SMALL CELL LUNG CANCER TREATED CONCURRENTLY WITH CISPLATIN AND ETOPOSIDE: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS Songmi Jeong, South Korea

P1.08-016: DOES LUNG STEREOTACTIC BODY RADIATION THERAPY AFFECT LUNG MEMBRANE DIFFUSION? Francoise Mornex, France

P1.08-017: FACTORS INFLUENCING UTILIZATION OF PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED-STAGE SMALL CELL LUNG CANCER Abraham Wu, USA

P1.08-018: POSTOPERATIVE RADIOTHERAPY IN T3N0 NON-SMALL-CELL LUNG CANCER: PROGNOSTIC VALUE OF TUMOR SIZE AND COSTAL PLEURAL INVASION Yunseon Choi, South Korea

P1.08-019: LATE RADIOGRAPHIC CHANGES AFTER LUNG STEREOTACTIC BODY RADIOTHERAPY: PILOTING A RECURRENCE SCALE AND A SYNOPTIC REPORTING SCALE Meredith Giuliani, Canada

P1.08-020: STEREOTACTIC ABLATIVE RADIOTHERAPY FOR PULMONARY OLIGOMETASTASIS FROM HEPATOCELLULAR CARCINOMA Si Yeol Song, South Korea

P1.08-021: OUTCOMES OF STEREOTACTIC BODY RADIATION THERAPY FOR STAGE I NON-SMALL CELL LUNG CANCER AND PULMONARY METASTASES. Johnson Lam, Australia

P1.08-022: NUMBER OF PATHOLOGIC NODES IN REGIONS CLOSEST TO THE OESOPHAGUS IS THE STRONGEST PREDICTOR FOR ESOPHAGITIS IN SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMO-RADIATION: AN ANALYSIS OF 170 PATIENTS. Bart Reymen, Netherlands

P1.08-023: HOW TO MINIMIZE THE UNCERTAINTIES OF INTERNAL TARGET VOLUME IN 4DCT SCANS FOR STEREOTACTIC BODY RADIATION THERAPY OF EARLY STAGE NON-SMALL CELL LUNG CANCER Yaping Xu, China

P1.08-024: FUNCTIONAL IMAGING FOR NORMAL LUNG AVOIDANCE WITH PROTON RADIOTHERAPY Jing Zeng, USA

P1.08-025: HOW TO DETERMINE INTERNAL MARGIN FOR CLINICAL PRACTICE? - A STUDY OF 44 LUNG CANCER CASES WITH 4D-CT IMAGING. Ming Chen, China

P1.08-026: FUNCTIONAL DOSIMETRIC METRICS BASED ON THE VENTILATION AND PERFUSION SPECT-CT DURING THE COURSE OF RADIOTHERAPY AND ASSOCIATION WITH RADIATION-INDUCED LUNG TOXICITY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER Feng-Ming (Spring) Kong, USA

P1.08-027: IS THERE A BENEFIT OF LUNG STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) IN OUR PATIENTS WITH MULTIPLE COMORBIDITIES?: AGE-ADJUSTED CHARLSON COMORBIDITY INDEX (ACCI) AS A PREDICTOR OF SURVIVAL IN MEDICALLY INOPERABLE EARLY STAGE NON SMALL CELL LUNG CANCER PATIENTS TREATED WITH DEFINITE RADIOTHERAPY Jason Pantarotto, Canada
P1.09-001: INDUCTION THERAPY FOR PATIENTS WITH POTENTIALLY UNRESECTABLE NSCLC (ADENOCARCINOMA). PRELIMINARY RESULT. Igor Poljakov, Russia

P1.09-002: PREOPERATIVE CHEMOTHERAPY REGIMENS FOR LOCALLY ADVANCED STAGE III NON-SMALL CELL LUNG CARCINOMA: DOWSTAGING DEPENDING ON HISTOLOGY, AGE, CHEMOTHERAPY PROTOCOL. Marroan Bachoor, Syria

P1.09-003: PROGNOSTIC IMPACT OF SECONDARY PATHOLOGIC FINDINGS ON THE OUTCOME OF PATIENTS WITH RESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH INDUCTIVE CHEMOTHERAPY OR CHEMORADIATION. Diego Marquez-Medina, Spain

P1.09-004: FEASIBILITY AND EFFICACY OF INDUCTIVE CHEMO OR CHEMORADIATION FOR PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCERS AND REDUCED RESPIRATORY FUNCTION. Diego Marquez-Medina, Spain

P1.09-005: THE OPTIMAL TIMING OF SRS ADD TO EGFR-TKI TREATMENT FOR BRAIN METASTASIS FROM ACTIVATING EGFR MUTANT NSCLC. Hyun Jung Kim, South Korea

P1.09-006: CHEMORADIOTherAPY FOR LOCALLY ADVANCED NSCLC IN RESOURCE LIMITED POPULATION: IS IT ISOEFFECTIVE? Jai Prakash Agarwal, India

P1.09-007: PROGNOSTIC VALUE OF NUMBER OF CHEMOTHERAPY CYCLE IN STAGE IIIB NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CARBOPLATIN-VINORELBINE. Ozgur Ozyilkkan, Turkey

P1.09-008: OUTCOMES IN A SINGLE INSTITUTION SERIES OF PATIENTS WITH STAGE III NON-SMALL CELL LUNG CARCINOMA TREATED WITH CURATIVE-INTENT RADIONURETHAPY AND CONCURRENT CARBOPLATIN AND PACLITAXEL CHEMOTHERAPY. Hon Trinh, Australia

P1.09-009: PRELIMINARY SAFETY AND TREATMENT DELIVERY DATA DURING CONCURRENT PHASE OF CHEMORADIATION THERAPY OF THE PROCLAIM TRIAL: A PHASE 3 TRIAL OF PEMETREXED, CISPLATIN, AND RADIOTherAPY FOLLOWED BY CONSOLIDATION PEMETREXED VERSUS ETOPOSIDE, CISPLATIN, AND RADIOTherAPY FOLLOWED BY CONSOLIDATION CYTOTOXIC CHEMOTHERAPY OF CHOICE IN PATIENTS WITH STAGE III NONSQUAMOUS CELL LUNG CANCER. Everett Vokes, USA

P1.09-010: IMPACT OF THE PRESENCE OF EGFR MUTATION ON THE DEFINITIVE CHEMORADIOTherAPY IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: PATTERN OF RELAPSES AND SURVIVAL ANALYSES IN 198 PATIENTS. Hidehito Horinouchi, Japan

P1.09-011: PHASE I CLINICAL TRIAL ASSESSING THE MEK INHIBITOR SELUMETINIB (AZD6244; ARRY-142886) WITH CONCOMITANT THORACIC RADIOTHERAPY (RT) IN PATIENTS WITH STAGE III-IV NON SMALL CELL LUNG CANCER (NSCLC). Alberto Fusi, UK

P1.09-012: PEMETREXED AS FIRST-LINE TREATMENT IN COMBINATION WITH EARLY RADIONURETHAPY IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE ANALYSIS. Xuwei Cai, China

P1.09-013: THORACIC MULTIDISCIPLINARY CLINIC (TMDC) AND THE TREATMENT OF STAGE III NON-SMALL CELL LUNG CANCER. Eliot Friedman, USA

P1.09-014: PROGNOSTIC VALUE OF AGE IN PATIENTS RECEIVING CONCURRENT CHEMORADIOTherAPY WITH DIAGNOSIS OF STAGE IIB NON-SMALL CELL LUNG CANCER. Erkan Topkan, Turkey

P1.09-015: IMPACT OF PRETREATMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTherAPY. Erkan Topkan, Turkey

P1.09-016: A SINGLE ARM, MULTI-CENTER, PHASE II STUDY OF INTERCALATED ERLOTINIB WITH GEMCITABINE/CISPLATIN AS NEOADJUVANT TREATMENT IN STAGE IIIA NON-SMALL CELL LUNG CANCER (CTONG 1101, NCT01297101): PRELIMINARY RESULT. Shun Lu, China

P1.09-017: CONTINUOUS LOW DOSE TEMOZOLAMIDE IN BRAIN METASTASIS FROM LUNG CANCER. Tanweer Shahid, India

P1.09-018: PEMETREXED AND CARBOPLATIN CONCOMITANT WITH THORACIC RADIOTHERAPY IN TREATMENT OF ELDERLY PATIENTS WITH NON-SQUAMOUS NON SMALL CELL LUNG CANCER (NSCLC): INSTITUTIONAL EXPERIENCE. Sherif Abdelwahab, Egypt

P1.09-019: SURVIVAL ANALYSIS AND EGFR GENE MUTATION STUDY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER IN PATIENTS TREATED WITH CURATIVE INTENTION. Josep Jove, Spain
MEDICAL ONCOLOGY

**P1.10** Poster Session 1
Chemotherapy

**P1.10-001**: PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH NON-SQUAMOUS NON-SMALL LUNG CANCER THAT IS REFRACTORY OR RELAPSED AFTER 1-2 PREVIOUS TREATMENT (BEST STUDY)
Kazuhiro Yanagihara, Japan

**P1.10-002**: COMPARISON OF THE TOXICITY AND EFFICACY BETWEEN TOPOTECAN- AND BELOTECAN-, A NEW CAMPTOTHECIN ANALOG, MONOTHERAPY FOR SMALL CELL LUNG CANCER: A SINGLE INSTITUTIONAL EXPERIENCE
Jeong Eun Lee, South Korea

**P1.10-003**: ALTERATION OF THE E-CADHERIN/α-CATENIN COMPLEX PREDICTS POOR RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) TREATMENT
Seol Bong Yoo, South Korea

**P1.10-004**: EXPLORATORY SUBSET ANALYSIS IN AFRICAN AMERICANS FROM THE POINTBREAK STUDY (RANDOMIZED PHASE 3 PEMETREXED + CARBOPLATIN + BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED + BEVACIZUMAB VERSUS PACLITAXEL + CARBOPLATIN + BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIIB/IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER)
Craig Reynolds, USA

**P1.10-005**: BEVACIZUMAB (BV) CAN BE SAFELY ADMINISTERED IN PTS AGED > 80 YEARS OLD
Konstantinos Syrigos, Greece

**P1.10-006**: EXAMINATION OF RECURRENCE PREDICTORS IN CASES RECEIVING UFT AS POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR LUNG CANCER
Kimitoshi Nawa, Japan

**P1.10-007**: BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Noorwati Sutandyo, Indonesia
P1.10-016: TULUNG REGISTRY: ANALYSIS OF DATA FROM PS 0-1 PATIENTS WITH ADVANCED/METASTATIC NON-SQUAMOUS NSCLC (ADENOCARCINOMA, LARGE CELL CARCINOMA) TREATED IN SECOND LINE WITH Pemetrexed
Jaromir Roubec, Czech Republic

P1.10-017: CLINICAL ACTIVITY OF LURBINECTEDIN (PMS01183) IN COMBINATION WITH GEMCITABINE (GEM) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): PRELIMINARY SUBGROUP ANALYSIS OF A PHASE IB STUDY.
Luis Paz-Ares, Spain

P1.10-018: NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PERIPHERAL NEUROPATHY
Hiroshi Sakai, Japan

P1.10-019: DIFFERENTIAL EFFICACY OF EGFR-TKI ACCORDING TO VARIANTS OF EXON 19 DELETIONAL MUTATION IN NON-SMALL CELL LUNG CANCER
Toshihiko Kaneda, Japan

P1.10-020: DOSE ADJUSTMENT OF SINGLE AGENT AMRUBICIN IN LUNG CANCER PATIENTS WITH IMPAIRED HEPATIC FUNCTION
Toshiaki Takahashi, Japan

P1.10-021: PHASE II STUDY OF S-1 PLUS IRINOTECAN FOR EGFR-MUTATED NON-SMAL LUNG CANCER (NSCLC): RESULTS OF THE INAUGURAL WORKSHOP
Akira Inoue, Japan

P1.10-022: CENTRAL EUROPEAN INITIATIVE AGAINST LUNG CANCER: RESULTS OF THE INAGURAL WORKSHOP
Robert Pirker, Austria

P1.10-023: FavorABLE RESPONSE TO EGFR-TKI IS A PREDICTIVE MARKER OF TAXANE ACTIVITY, BUT NOT OF Pemetrexed IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Seung Hun Jang, South Korea

P1.10-024: CLINICAL FEATURES OF EARLY INTERRUPTION OF EGFR-TKIS IN UNSELECTED NON SMALL CELL LUNG CANCER PATIENTS
Taewon Jang, South Korea

P1.10-025: RANDOMIZED PHASE II TRIAL OF SAFETY OF BIWEEKLY DOCETAXEL/CISPLATIN VS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WHO ARE ELDERLY OR POOR PERFORMANCE STATUS
Hoon Kim, South Korea

P1.10-026: VALIDATION OF EGFR MUTATION TESTING USING CYTOLOGY SPECIMENS IN NON-SMAL CELL LUNG CARCINOMA: MULTI-INSTITUTIONAL STUDY OF 128 CASES IN KOREA
Wan Seop Kim, South Korea

P1.10-027: A PHASE II TRIAL OF GENEXOL-PM(A CREMOPHOR-FREE, POLYMERIC MICELLE FORMULATION OF PACLITAXEL) AND GEMCITABINE IN PATIENTS WITH ADVANCED NON-SMAL CELL LUNG CANCER.
Eun Kyung Cho, South Korea

P1.10-028: A PHASE II TRIAL OF ERLOTINIB VERSUS Pemetrexed AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH ADVANCED EGFR WILD-TYPE AND EGFR FISH-POSITIVE LUNG ADENOCARCINOMA
Si-Yu Wang, China

P1.10-029: AN ANALYSIS OF THE DRUG-DRUG INTERACTION BETWEEN DOCETAXEL AND GEFITINIB IN PATIENTS WITH ADvanced NON-SMAL CELL LUNG CANCER
Masanori Motonaga, Japan

P1.10-030: COMPARATIVE PHARMACOKINETICS OF TWO FORMULATIONS OF Pemetrexed IN INDIAN ADULT CHEMO-NAIVE, ADENOCARCINOMA NON-SMAL CELL LUNG CANCER PATIENTS.
Krupal Kavathiya, India

P1.10-031: PLATINUM-BASED THERAPY WITH GEMCITABINE OR DOCETAXEL IN ADVANCED NON-SMAL CELL LUNG CANCER: A RETROSPECTIVE ANALYSIS TO EVALUATE DIFFERENCES IN RESPONSE DUE TO ETHNICITY
Qamruzzaman Chowdhury, Bangladesh

P1.10-032: SENSITIVITY AND META-REGRESSION ANALYSIS EXPLORING POTENTIAL OUTCOMES PREDICTORS IN RANDOMIZED TRIALS (RCTS) EVALUATING THE BENEFIT OF 1ST-LINE TYROSINE KINASE INHIBITORS (TKIS) FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT LUNG ADENOCARCINOMA.
Emilio Bria, Italy

P1.10-033: SAFETY AND RESOURCE USE IN PRONOUNCE: A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF Pemetrexed PLUS CARBOPLATIN WITH MAINTENANCE Pemetrexed (PEMC) AND PACLITAXEL PLUS CARBOPLATIN PLUS BEVACIZUMAB WITH MAINTENANCE BEVACIZUMAB (PCB) IN PATIENTS WITH ADVANCED NON-SQUAMOUS (NS) NON-SMAL-CELL LUNG CANCER (NSCLC)
Helen Ross, USA

P1.10-034: WEIGHT GAIN AS A PROGNOSTIC FACTOR ON PATIENT OUTCOMES IN ADVANCED, NONSQUAMOUS, NON-SMALL CELL LUNG CANCER
Philip Bonomi, USA
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.10-035</td>
<td>EFFECTIVENESS OF BEVACIZUMAB IN PATIENTS WITH LUNG ADENOCARCINOMA TREATED WITH PEMETREXED / CARBOPLATIN AS FIRST-LINE CHEMOTHERAPY</td>
<td>Manuel Magallanes</td>
<td>Mexico</td>
</tr>
<tr>
<td>P1.10-036</td>
<td>PROLONGATION OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER BEFORE AND AFTER FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF ACTIVE SECOND LINE AGENTS: A META-ANALYSIS</td>
<td>Mary Jo Fidler</td>
<td>USA</td>
</tr>
<tr>
<td>P1.10-037</td>
<td>A RETROSPECTIVE COMPARISON OF ADJUVANT CHEMOTHERAPEUTIC REGIMEN FOR NON-SMALL CELL LUNG CANCER (NSCLC): PACLITAXEL PLUS PLATINUM VERSUS VINORELBINE PLUS CISPLATIN</td>
<td>Jong-Mu Sun</td>
<td>South Korea</td>
</tr>
<tr>
<td>P1.10-038</td>
<td>A PHASE II TRIAL OF THE COMBINATION OF GEMCITABINE AND CARBOPLATIN AS ADJUVANT CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER. (KENBYO 0601)</td>
<td>Masashi Muraoka</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.10-039</td>
<td>CHARACTERISTICS OF RE-BIOPSIED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS</td>
<td>Daisuke Arai</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.10-040</td>
<td>LUNG CANCER OUTCOMES IN AN ERA OF MORE OPTIONS - SURVIVAL ANALYSIS FROM AN ASIAN CANCER CENTER</td>
<td>Wan-Teck Lim</td>
<td>Singapore</td>
</tr>
<tr>
<td>P1.10-041</td>
<td>A PHASE II TRIAL OF ERLOTINIB FOR PREVIOUSLY TREATED JAPANESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS: RESULTS OF THE CENTRAL JAPAN LUNG STUDY GROUP TRIAL (CJLSG0904).</td>
<td>Tetsunari Hase</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.10-042</td>
<td>CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED WITH ADJUVANT CHEMOTHERAPY</td>
<td>Paul Wheatley-Price</td>
<td>Canada</td>
</tr>
<tr>
<td>P1.10-043</td>
<td>DOUBLET COMBINATION OF PLATINUM WITH PEMETREXED FOR ADVANCED NON-SMALL-CELL LUNG CANCER: A RETROSPECTIVE ANALYSIS OF A SINGLE INSTITUTION</td>
<td>Santiago Ponce Aix</td>
<td>Spain</td>
</tr>
<tr>
<td>P1.10-044</td>
<td>NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Vera Hirsh</td>
<td>Canada</td>
</tr>
<tr>
<td>P1.10-045</td>
<td>VALIDATION STUDY OF POSTOPERATIVE PLATINUM-BASED ADJUVANT CHEMOTHERAPY FOR JAPANESE PATIENTS WITH COMPLETELY RESECTED PATHOLOGICAL STAGE IIIA NON-SMALL CELL LUNG CANCER</td>
<td>Kazu Shiomi</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.10-046</td>
<td>HEAT SHOCK PROTEIN 70 AS A PREDICTIVE MAKER IN PATIENTS WITH PLATINUM-BASED ADJUVANT CHEMOTHERAPY IN RESECTED NON-SMALL CELL LUNG CANCER</td>
<td>Tae Sun Park</td>
<td>South Korea</td>
</tr>
<tr>
<td>P1.10-047</td>
<td>CLINICAL FACTORS ASSOCIATED WITH THE EFFICACY OF PEMETREXED AS CONTINUATION MAINTENANCE CHEMOTHERAPY IN PATIENTS WITH ADVANCED LUNG ADENOCARCINOMA</td>
<td>Chung-Yu Chen</td>
<td>Taiwan</td>
</tr>
<tr>
<td>P1.10-048</td>
<td>REAL-WORLD EVIDENCE FOR CLINICAL EFFECTIVENESS, TOXICITY, AND HOSPITALIZATION COSTS ASSOCIATED WITH SECOND-LINE CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER</td>
<td>Wendong Chen</td>
<td>Canada</td>
</tr>
<tr>
<td>P1.10-049</td>
<td>EFFICACY OF BEVACIZUMAB COMBINED WITH PACLITAXEL AND CARBOPLATIN: A SECOND LINE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL CARCINOMA (NSCLC)</td>
<td>Sherif Abdelwahab</td>
<td>Egypt</td>
</tr>
<tr>
<td>P1.10-050</td>
<td>PHASE II TRIAL OF BIWEEKLY CHEMOTHERAPY WITH DOCETAXEL AND CISPLATIN IN HIGH RISK PATIENTS WITH UNRESECTABLE NON-SMALL CELL LUNG CANCER</td>
<td>Se-il Go</td>
<td>South Korea</td>
</tr>
<tr>
<td>P1.10-051</td>
<td>PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)</td>
<td>Abdelkader Bousahba</td>
<td>Algeria</td>
</tr>
<tr>
<td>P1.10-052</td>
<td>INFLUENCE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION SUBTYPES TO THE PROGNOSIS OF THE PATIENTS WITH NON-SMALL CELL LUNG CANCER</td>
<td>Kenichiro Hirai</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.10-053</td>
<td>SODIUMSELENITE AS A TREATMENT AGAINST CANCER. A PHASE I STUDY.</td>
<td>Ola Brodin</td>
<td>Sweden</td>
</tr>
<tr>
<td>P1.10-054</td>
<td>REDUCTION LEVELS OF CARCINOEMBRYONIC ANTIGEN AS A PREDICTIVE FACTOR OF RESPONSE TO CHEMOTHERAPY IN LUNG CANCER PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER</td>
<td>Oscar Arrieta</td>
<td>Mexico</td>
</tr>
</tbody>
</table>
P1.10-055: TREATMENT RATIONALE AND STUDY DESIGN FOR AN OPEN-LABEL RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND CISPLATIN WITH OR WITHOUT BEVACIZUMAB IN EGFR WILD-TYPE NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
Ping Yu, China

P1.10-056: THE ELDERLY PATIENT INDIVIDUALIZED CHEMOTHERAPY TRIAL (EPIC): A RANDOMIZED PHASE III MULTICENTER TRIAL OF CUSTOMIZED CHEMOTHERAPY VERSUS STANDARD OF CARE FOR 1ST LINE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
Silvia Novello, Italy

P1.10-057: ADDITION OF CUSTIRSEN, A CLUSTERIN (CLU) INHIBITOR, TO DOCETAXEL IN STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC): DESIGN OF THE ENSPIRIT PHASE 3 STUDY
Joachim Von Pawel, Germany

P1.11 Poster Session 1
NSCLC Novel Therapies

P1.11-001: EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) RELATED INTERSTITIAL LUNG DISEASE IN TAIWANESE PATIENTS WITH NON-SMALL CELL LUNG CANCER
Chi-Lu Chiang, Taiwan

P1.11-002: TOXICITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS (EGFR-TKIS) IN THE TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): A META-ANALYSIS
Pei Ni Ding, Australia

P1.11-003: EXON 19 DELETIONS, SMOKING HISTORY AND GENDER AS ADDITIONAL PREDICTIVE FACTORS FOR TREATMENT BENEFIT WITH EGFR TYROSINE KINASE INHIBITORS IN PATIENTS HARBOURING ACTIVATING EGFR MUTATIONS: A META-ANALYSIS OF 1432 PATIENTS IN SIX RANDOMISED TRIALS.
Pei Ni Ding, Australia

P1.11-004: PHASE II STUDY OF CARBOPLATIN-DOCETAXEL-BEVACIZUMAB AS FRONT-LINE TREATMENT IN PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER. ANALYSIS OF THE BEVACIZUMAB (BVZ) MAINTENANCE POPULATION
Manuel Domine, Spain

P1.11-005: EVEREST STUDY: EVOLUTION OF DISEASE-RELATED SYMPTOMS OF PATIENTS (P) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND ITS CORRELATION WITH RESPONSE TO FIRST-LINE (1L) TREATMENT.
Manuel Domine, Spain

P1.11-006: TYROSINE KINASE INHIBITORS VERSUS CHEMOTHERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATION: VENEZUELAN EXPERIENCE
George Oblitas, Venezuela

P1.11-007: PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN JAPANESE PATIENTS WITH ADVANCED, ALK-REARRANGED NSCLC AND OTHER TUMORS HARBORING GENETIC ALK ALTERATIONS
Takashi Seto, Japan

P1.11-008: A PHASE II STUDY OF HSP90 INHIBITOR AUY922 AND ERLOTINIB (E) IN PATIENTS (PTS) WITH EGFR-MUTANT LUNG CANCER AND ACQUIRED RESISTANCE (AR) TO EGFR TYROSINE KINASE INHIBITORS (EGFR TKIS).
Helena Yu, USA

P1.11-009: AN OPEN LABEL, MULTICENTER, PROSPECTIVE NON-INTERVENTIONAL (NIS) POST-AUTHORIZATION STUDY TO MONITOR THE ROUTINE CLINICAL PRACTICE OF BEVACIZUMAB IN ADDITION TO PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Christian Schumann, Germany

P1.11-010: PHYSICAL TARGETING OF LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROTON THERAPY
James Cox, USA

P1.11-011: OBSERVATIONAL STUDY OF TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION POSITIVE (EGFRM+) ADVANCED OR RECURRENT NON-SMALL-CELL LUNG CANCER (NSCLC), AFTER RADIOLOGICAL PROGRESSION TO THE FIRST-LINE THERAPY WITH EGFR TYROSINE KINASE INHIBITORS (EGFR-TKI).
Hideo Kunitoh, Japan

P1.11-012: CLINICAL OBSERVATION FROM THE TREATMENT OF ICOTINIB FOR 196 CASES WITH ADVANCED NON-SMALL CELL LUNG CANCER
Qin Gu, China

P1.11-013: GEFTINIB FOR THE FIRST-LINE TREATMENT OF NSCLC PATIENTS WITH EGFR MUTATIONS IN EXONS 19 OR 21: ANALYSIS OF 74 PATIENTS FROM CZECH REPUBLIC
Jana Skrickova, Czech Republic

P1.11-014: OUTCOME OF METASTATIC NSCLC PATIENTS TREATED AT WINDSOR REGIONAL HOSPITAL CANCER PROGRAM OVER 7 YEARS
Swati Kulkarni, Canada

P1.11-015: THE PROGNOSTIC VALUE OF TOTAL NUMBER OF HARVESTED LYMPH NODES AND NODAL RATIO IN NODE POSITIVE NON-SMALL CELL LUNG CANCER
Jae-Sung Kim, South Korea
P1.11-016: A PROSPECTIVE, MULTI-CENTER PHASE II TRIAL ON THE EFFICACY AND SAFETY OF LOW-DOSE ERLOTINIB MONOTHERAPY FOR PATIENTS WITH EGFR MUTATION-POSITIVE, PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER: RESULTS OF THORACIC ONCOLOGY RESEARCH GROUP (TORG) TRIAL 0911. Kazuhiro Yamada, Japan

P1.11-017: FIRST-LINE GEFITINIB THERAPY FOR ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP 0901 Kosuke Takahashi, Japan

P1.11-018: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Giorgio Scagliotti, Italy

P1.11-019: PHASE 2 DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THREE-WEEKLY FARLETUZUMAB WITH A PLATINUM CONTAINING DOUBLET IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLATE RECEPTOR ALPHA (FRA) EXPRESSING NON-SMALL-CELL LUNG CANCER (NSCLC) Julia Maltzman, USA

P1.11-020: ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Carmen Chung, Canada

P1.11-021: FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY Yi-Long Wu, China

P1.11-022: RETROSPECTIVE LONGITUDINAL CHART REVIEW OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN THE NETHERLANDS: A QUANTIFICATION OF DISEASE BURDEN Remziye Zaim, Netherlands

P1.11-023: MOLECULAR SCREENING IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES FOR FIRST-LINE THERAPY Remziye Zaim, Netherlands

P1.11-024: A PHASE II/II RANDOMIZED TRIAL USING GM-CSF-PRODUCING AND CD40L-EXPRESSING BYSTANDER CELL LINE (GM.CD40L) VACCINE PLUS OR MINUS CCL21 IN STAGE IV LUNG ADENOCARCINOMA: UPDATED RESULTS Jhanelle Gray, USA

P1.11-025: EGFR MUTATION STATUS IN ADENOCARCINOMA LUNG: A SINGLE CENTRE EXPERIENCE FROM NORTHERN INDIA Ashok Vaid, India

P1.11-026: FINAL RESULTS OF A PHASE 2 TRIAL OF THE ONColytic VIRUS REOVIRUS SEROTyPE 3-DEARING STRAIN (REOLYsIN®) IN METASTATIC NSCLC PATIENTS WITH A RAS-ACTIVATED PATHWAY. Miguel Villalona-Calero, USA

P1.11-027: PHASE I STUDIES OF HM781-36B, AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR (TKI) IN PATIENTS WITH ADVANCED SOLID TUMOR AND THE THERAPEUTIC POTENTIAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Dong-Wan Kim, South Korea

P1.11-028: ANTITUMOR AND IMMUNE-BIOLOGICAL ACTIVITY OF A NEW METRONOMIC CHEMOTHERAPY WITH FRACTIONED CISPLATIN AND ORAL ETOPOSIDE COMBINED WITH BEVACIZUMAB (MPEBEV) FOLLOWED BY ERLOTINIB MAINTENANCE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS Pierpaolo Correale, Italy

P1.11-029: THE ADDITION OF ANTI-ANGIOGENIC TYROSINE KINASE INHIBITORS TO CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS Bob Li, Australia

P1.11-030: TRANSAMINITIS INDUCED BY EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR PREDICTS FOR FAVOURABLE OUTCOME IN EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER John Kay Hooi Ang, Singapore

P1.11-031: COST EFFECTIVENESS ANALYSIS BETWEEN GEFITINIB AND ERLOTINIB IN THE TREATMENT OF ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER IN THAILAND BY PAYER’S PERSPECTIVE: SIX YEARS DATA FOLLOW UP Sureerat Jaruhathai, Thailand

P1.11-032: RESULTS WITH DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN A PHASE II COHORT OF PATIENTS WITH HER2-MUTANT OR AMPLIFIED LUNG CANCERS Mark Kris, USA

P1.11-033: AFATINIB IN EGFR MUTANT NON-SMALL-CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR-TKIS Federico Cappuzzo, Italy
P1.11-034: AZD9291: AN IRREVERSIBLE, POTENT AND SELECTIVE TYROSINE KINASE INHIBITOR (TKI) OF ACTIVATING (EGFR M+) AND RESISTANCE (T790M) MUTATIONS IN ADVANCED NSCLC
Malcolm Ranson, UK

P1.11-035: OUTCOMES OF AFATINIB-BASED REGIMENS FOR SALVAGE TREATMENT OF ADVANCED STAGE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO HAD BEEN HEAVILY PRETREATED
Chun-Ming Tsai, Taiwan

P1.11-036: THE EFFICACY AND SAFETY OF SUNITINIB IN EGFR-TKI PRETREATED ADVANCED NON-SMALL CELL LUNG CANCER: A RETROSPECTIVE REVIEW FROM CHINESE PATIENTS AT A SINGLE INSTITUTION
Liyan Jiang, China

P1.11-037: PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH EGFR-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Edward Garon, USA

P1.11-038: THE SIGNIFICANCE OF ALK REARRANGEMENT IN SELECTED ADVANCED NON-SMALL CELL LUNG CANCER: ALK EXPRESSION PROVIDES INSIGHTS INTO ALK TARGET THERAPY
Xiaohong Han, China

P1.11-039: A RANDOMIZED PHASE II TRIAL OF CELECOXIB COMBINED WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE AND WITH ICOTINIB AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
Tianqing Chu, China

P1.11-040: TREATMENT STRATEGIES AFTER FAILURE TO REVERSIBLE TYROSINE KINASE INHIBITORS (RTKI) IN EGFR MUTANT (MUT) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A RETROSPECTIVE ANALYSIS OF 59 SPANISH PATIENTS
Jordi Remon, Spain

P1.11-041: OVERALL SURVIVAL OF ALK TRANSLOCATION - AND OF EGFR MUTATION POSITIVE NSCLC PATIENTS TREATED WITH AND WITHOUT PERSONALIZED THERAPY: A RETROSPECTIVE ANALYSIS WITHIN THE NETWORK GENOMIC MEDICINE
Marc Bos, Germany

P1.11-042: SORAVE: SORAFENIB AND EVEROLIMUS FOR PATIENTS WITH SOLID TUMORS AND WITH KRAS MUTATED NSCLC - RESULTS OF A PHASE I STUDY
Marc Bos, Germany

P1.11-043: BARIS: A PHASE I TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF COMBINED BIBF 1120 AND RAD001 IN SOLID TUMORS AND TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF THE COMBINATION
Marc Bos, Germany

P1.11-044: PROGRESSION-FREE SURVIVAL IS A POOR SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN THE FIRST LINE EGFR-TKI TREATMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATION
Wen Zhao Zhong, China

P1.11-045: COST-EFFECTIVENESS OF CARBOPLATIN AND PEMETREXED VERSUS SINGLE AGENT PEMETREXED IN PATIENTS WITH ADVANCED NSCLC AND PERFORMANCE STATUS OF 2 (PS2)
Carlos Gil Ferreira, Brazil

P1.11-046: WOMEN WITH LUNG CANCER HARBOURING EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS: PREVALENCE, CLINICAL CHARACTERISTICS AND EGFR TYROSINE KINASE (TKI) TREATMENT-RELATED OUTCOMES. RESULTS FROM THE SPANISH WORLD07 DATABASE
Enriqueta Felip, Spain

Elisabeth Quoix, France

P1.12 Poster Session 1
NSCLC Early Stage

P1.12-001: EFFICACY OF PULMONARY RESECTION AND GAMMA KNIFE SURGERY FOR NON-SMALL CELL LUNG CANCER WITH SYNCHRONOUS BRAIN METASTASIS
Reiko Mitsueda, Japan

P1.12-002: THE CLINICOPATHOLOGICAL FEATURES OF RESECTED PERIPHERAL SQUAMOUS CELL CARCINOMAS OF THE LUNG: PROGNOSTIC IMPACT OF VASCULAR AND PLEURAL INVASION
Tomonari Kinoshita, Japan

P1.12-003: PREOPERATIVE NEUTROPHIL AND LYMPHOCYTE COUNTS ARE INDEPENDENT PROGNOSTIC FACTORS IN COMPLETELY RESECTED NON-SMALL-CELL LUNG CANCER
Naohiro Kobayashi, Japan
P1.12-004: ACCURACY OF PET/CT IN THE EVALUATION OF N1 AND N2 LYMPH NODE STATIONS IN OPERABLE NSCLC
Atila Akkoçlu, Turkey

P1.12-005: SURVIVAL FOLLOWING SURGERY WITH OR WITHOUT ADJUVANT CHEMOTHERAPY FOR STAGE I-III A NON-SMALL CELL LUNG CANCER
Zhong-Zhe Lin, Taiwan

P1.12-006: PREDICTIVE RISK FACTORS FOR MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I ADENOCARCINOMA OF THE LUNG
Geun Dong Lee, South Korea

P1.12-007: THE PREDICTORS OF EARLY RECURRENT IN PATIENTS WITH COMPLETELY RESECTED P-STAGE I NON-SMALL CELL LUNG CANCER
Kazunori Hata, Japan

P1.12-008: THE EFFECTS OF DIFFERENT PREOPERATIVE BRAIN SURVEY STRATEGY ON THE PATHOLOGICAL STAGE I NON-SMALL CELL LUNG CANCER PATIENTS
Cheng-Che Tu, Taiwan

P1.12-009: ORAL VINORELBINE IN COMBINATION WITH CISPLATIN OR CARBOPLATIN IN ADJUVANT CHEMOTHERAPY OF NON-SMALL CELL LUNG CANCER: A PROSPECTIVE MULTICENTRE STUDY OF TOLERABILITY AND SURVIVAL
Vitezslav Kolek, Czech Republic

P1.12-010: LUNG CANCER CLINICIANS’ PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN NON-SMALL-CELL LUNG CANCER: WHAT MAKES IT WORTHWHILE?
Sue-Anne McLachlan, Australia

P1.12-011: PATIENTS’ PREFERENCES FOR ADJUVANT CHEMOTHERAPY (ACT) IN EARLY NON-SMALL CELL LUNG CANCER (NSCLC): WHAT MAKES IT WORTHWHILE?
Sue-Anne McLachlan, Australia

P1.12-012: A COMPARISON OF CLINICOPATHOLOGIC FEATURES AND SURVIVAL OUTCOMES BETWEEN THE LUNG CANCER PATIENTS WITH ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA: STAGE I DISEASE OF SQUAMOUS CELL CARCINOMA IS THERE?
Takayuki Fukui, Japan

P1.12-013: LIMITED RESECTION FOR SOLID NON-SMALL CELL LUNG CANCERS PROVIDES WORSE OUTCOME DESPITE OF CLINICAL EARLY STAGE.
Sook Whan Sung, South Korea

P1.12-014: MEDIASTINAL LYMPH NODE DISECTION AND MEDIASTINAL RECURRENT IN EARLY STAGE NSCLC
Laura Romero Vielva, Spain

P1.12-015: PROGNOSTIC IMPACT OF THE AMOUNT OF TOBACCO SMOKING IN PATIENTS WITH RESECTED NON-SMALL CELL LUNG CANCER
Tatsuro Okamoto, Japan

P1.13 Poster Session 1
SCLC

P1.13-001: CLINICAL ACTIVITY OF LURBINECTEDIN (PMS01183) IN COMBINATION WITH DOXORUBICIN (DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY SUBPOPULATION ANALYSIS.
M. Forster, UK

P1.13-002: PROGNOSTIC VALUE OF 18F-FLUORODEXYGLUCOSE UPTAKE IN SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCOMITANT CHEMO-RADIOThERAPY OR CHEMOTHERAPY ALONE
Krystel Tran, Australia

P1.13-003: A PHASE IB PREOPERATIVE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS IN OPERABLE NON-SMALL CELL LUNG CANCER
Taofeek Owonikoko, USA

P1.13-004: PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF NIVEKIN MUC1oxic IN PATIENTS WITH ADVANCED NSCLC TREATED WITH NIVEKIN MUC1otic AND DOXORUBICIN AS 1ST-LINE CHEMOTHERAPY
Yain Wu, Taiwan

P1.13-005: CLINICAL ACTIVITY OF LURBINECTEDIN (PMS01183) IN COMBINATION WITH DOXORUBICIN (DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY SUBPOPULATION ANALYSIS.
M. Forster, UK

P1.13-006: CLINICAL ACTIVITY OF LURBINECTEDIN (PMS01183) IN COMBINATION WITH DOXORUBICIN (DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY SUBPOPULATION ANALYSIS.
M. Forster, UK

P1.13-007: CLINICAL ACTIVITY OF LURBINECTEDIN (PMS01183) IN COMBINATION WITH DOXORUBICIN (DOX) IN SMALL CELL LUNG CANCER (SCLC) PATIENTS (PTS): PRELIMINARY RESULTS OF A PHASE IB STUDY SUBPOPULATION ANALYSIS.
M. Forster, UK
P1.13-003: IMPACT OF PRE-TREATMENT SERUM LACTATE DEHYDROGENASE ON SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER. Harminder Takhar, Australia

P1.13-004: THE HETEROGENEOUS PHENOTYPE OF LARGE-CELL NEUROENDOCRINE PULMONARY CARCINOMA (LCNEC): A CLINICO-PATHOLOGICAL SINGLE INSTITUTION SERIES. Haim Biran, Israel

P1.13-005: PACLITAXEL AND IRINOTECAN IN PLATINUM REFRACTORY OR RESISTANT SMALL CELL LUNG CANCER: A GALICIAN LUNG CANCER GROUP EXPERIENCE. Sergio Vazquez-Estevez, Spain

P1.13-006: PHASE I/IIA STUDY OF THE NOVEL COMBINATION OF BENDAMUSTINE PLUS IRINOTECAN FOLLOWED BY ETOPOSIDE PLUS CARBOPLATIN IN UNTREATED PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER. Stefan Grant, USA

P1.13-007: THE CLINICAL IMPACT OF SUM OF THE MAXIMUM STANDARDIZED UPTAKE VALUE ON PRETREATMENT 18F-FDG-PET/CT IN SMALL CELL LUNG CANCER TREATED WITH FRONT-LINE PLATINUM BASED CHEMOTHERAPY. Se-Il Go, South Korea

P1.13-008: OMITTING ELECTIVE NODAL IRRADIATION AND IRRADIATING POST-INDUCTION VERSUS PRE-INDUCTION CHEMOTHERAPY TUMOR EXTENT FOR LIMITED-STAGE SMALL CELL LUNG CANCER: AN UPDATE OF A PROSPECTIVE RANDOMIZED TRIAL. Ming Chen, China

P1.14-001: ESTIMATES OF EXPECTED YEARS OF LIFE LOST AND LIFETIME DIRECT MEDICAL COSTS FOR MALIGNANT PLEURAL MESOTHELIOMA PATIENTS: DATA FROM TAIWAN AND NEW SOUTH WALES, AUSTRALIA. Matthew Soeberg, Australia

P1.14-002: LACK OF RESPONSE TO CHEMOTHERAPY FOR PREVIOUSLY TREATED MALIGNANT PLEURAL MESOTHELIOMA (MPM). Lee Krug, USA

P1.14-003: THE EFFECT OF FRONT-LINE CHEMOTHERAPY ON OVERALL SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA. Alper Sevinc, Turkey

P1.14-004: EXTENDED SURVIVAL FOLLOWING RECURRENCE FOR PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA TREATED WITH RADICAL PLEURECTOMY, PHOTODYNAMIC THERAPY AND CHEMOTHERAPY: THE POTENTIAL ROLE OF STAT3. Joseph Friedberg, USA

P1.14-005: PRELIMINARY RESULTS - “A PHASE I TRIAL OF ONCOYTIC MEASLES VIR THERAPY IN MESOTHELIOMA” INVESTIGATING THE INTRAPLEURAL ADMINISTRATION OF THE MODIFIED VACCINE STRAIN MEASLES VIRUS (MV-NIS) TO PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA. Tobias Peikert, USA

P1.14-006: CATHETER TRACT METASTASES ASSOCIATED WITH INDWELLING PLEURAL CATHETERS FOR MALIGNANT EFFUSIONS. Rajesh Thomas, Australia

P1.14-007: INTRAPLEURAL FIBRINOLYSIS IS EFFECTIVE IN TREATING SYMPTOMATIC LOCULATION COMPLICATING INDWELLING PLEURAL CATHETER DRAINAGE. Rajesh Thomas, Australia

P1.14-008: CLINICAL FEATURES AND CURRENT MANAGEMENT OF MALIGNANT PLEURAL MESOTHELIOMA IN FRANCE. THEGFPC 0804 STUDY. Christos Chouaid, France

P1.14-009: BIOMARKER RESULTS FROM A PHASE I STUDY OF CEDIRANIB (NSC #732208) IN COMBINATION WITH CISPLATIN AND PEMETREXED IN CHEMONAIVE PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (SWOG S0905). Anne Tsao, USA

P1.14-010: ESTIMATION OF AN OPTIMAL CHEMOTHERAPY UTILISATION RATE FOR MALIGNANT PLEURAL MESOTHELIOMA: AN EVIDENCE-BASED BENCHMARK FOR PATIENT CARE. Annette Tognela, Australia

P1.14-011: CHANGES IN EXPRESSION OF CANCER DRUG RESISTANCE GENES IN MESOTHELIOMA CELLS EXPOSED TO CARBOPLATIN. Vandana Relan, Australia

P1.14-012: ACTIVATION OF MTOR SIGNAL PATHWAY IS ASSOCIATED WITH PROLONGED SURVIVAL IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS. Ayumi Kuroda, Japan

P1.14-013: THE EFFECTIVENESS AND SAFETY OF PLATINUM BASED PEMETREXED AND PLATINUM BASED GEMCITABINE TREATMENT IN THE PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA. Guntulu Ak, Turkey
P1.14-014: PATIENTS’ WILLINGNESS TO PARTICIPATE IN A RANDOMIZED CONTROLLED TRIAL FOR MALIGNANT PLEURAL MESOTHELIOMA: A NEW PARADIGM TO IMPROVE ACCRUAL TO THORACIC ONCOLOGY TRIALS
Charles Simone, USA

P1.15 Poster Session 1
Thymoma

P1.15-001: POSTOPERATIVE RADIOTHERAPY FOR COMPLETELY RESECTED MASAOKA STAGE III THYMOMA: A RETROSPECTIVE STUDY OF 65 CASES FROM A SINGLE INSTITUTION
Zhou Guang Hui, China

P1.15-002: RESULTS AND PROGNOSTIC FEATURES OF RECURRENT THYMOMA
Zhou Guang Hui, China

P1.15-003: PHASE II STUDY OF AMRUBICIN (AMR) AND CARBOPLATIN (CBDCA) FOR INVASIVE THYMOMA (IT) AND THYMIC CARCINOMA (TC): NORTH JAPAN LUNG CANCER GROUP 0803
Shoichi Kuyama, Japan

P1.15-004: RELATIONSHIP OF THERAPEUTIC RESULTS WITH IMMUNOHISTOCHEMICAL FINDINGS IN THYMIC CARCINOMA CASES
Toru Kimura, Japan

P1.15-005: MULTIMODALITY TREATMENT FOR THYMOMA AND THYMIC CARCINOMA: RESULTS OF A SINGLE CENTER EXPERIENCE.
Ozgur Ozyilkkan, Turkey

Paul Wheatley-Price, Canada

P1.15-007: CHARACTERISTICS OF THYMOMAS DIAGNOSED IN NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE IN WARSAW (POLAND)
Renata Langfort, Poland

P1.15-008: A MULTIVARIATE ANALYSIS OF FACTORS PREDICTING SURVIVAL IN 70 PATIENTS WITH THYMIC CARCINOMA: IMPLICATIONS FOR TREATMENT STRATEGY
Masahiko Harada, Japan

P1.15-009: OUTCOMES AND PREDICTORS OF RECURRENT IN PATIENTS TREATED WITH RISK-ADAPTED, POST-OPERATIVE RADIOTHERAPY (RT) FOR THYMOMA - A SINGLE INSTITUTION, 30 YEAR RETROSPECTIVE STUDY
Anthony Brade, Canada

P1.16 Poster Session 1
Other Thoracic Malignancies

P1.16-001: OUTCOMES OF SURGICAL RESECTION AND RADIOFREQUENCY ABLATION FOR LUNG METASTASIS FROM HEPATOCELLULAR CARCINOMA
Teruki Kobayashi, Japan

P1.16-002: HISTOLOGICAL IMPACT OF PRIMARY TUMOR ON INDICATION OF REPEATED PULMONARY METASTASECTOMY
Tetsuya Mizuno, Japan

P1.16-003: FEATURES OF COMPUTED TOMOGRAPHY IMAGES AND TUMOR VIABILITY: 141 LESIONS OF PULMONARY METASTASIS OF NON-SEMINOMA
Daishiro Kato, Japan

P1.16-004: PLEURAL SOLITARY FIBROUS TUMOR: A CASE SERIES
Omar Macedo, Mexico

P1.15 Poster Session 1
Thymoma

P1.17 Poster Session 1
Bronchoscopy, Endoscopy

P1.17-001: TRANSUMBILICAL VERSUS CONVENTIONAL THORACOSCOPIC LUNG WEDGE RESECTION: SAFETY AND EFFICACY IN A CANINE SURVIVAL MODEL
Yun-Hen Liu, Taiwan

P1.17-002: THE CLINICAL SIGNIFICANCE OF ENDOBRONCHIAL ULTRASOUND IN THE DETECTION OF PERIPHERAL PULMONARY LESIONS
Ioannis Gkiozos, Greece

P1.17-003: ENDOBRONCHIAL VALVE TREATMENT FOR PULMONARY AIR LEAK AFTER ANATOMICAL RESECTION FOR CANCER.
Christophe Dooms, Belgium

P1.17-004: BRONCHOSCOPY GUIDED BY FINE MAPPING BASED ON THIN SECTION CT.
Run Tong, China

P1.17-005: EVALUATION OF THE IMPLEMENTATION OF INTERVENTIONAL BRONCHOSCOPY: LOCAL DATA FROM THE AUSTIN HOSPITAL, MELBOURNE
Yet Khor, Australia

P1.17-006: EARLY BRONCHOSCOPIC INTERVENTIONAL STRATEGY IN HIGHLY AT RISK MORBID AGEING COHORT
Tom Sutedja, Netherlands
P1.17-007: A PROPOSAL FOR A NEW CLINICAL STRATEGY AND FOLLOW-UP IN PATIENTS WITH BRONCHIAL CARCINOIDs INITIALLY TREATED BRONCHOSCOPICALLY.
Hes Brokx, Netherlands

P1.17-008: RESULTS OF A CLOSE SURVEILLANCE STRATEGY FOR SUBJECTS WITH PRE-INVASIVE ENDOBRONCHIAL SQUAMOUS LESIONS
Hes Brokx, Netherlands

P1.17-009: WHAT IS THE RATE OF SURGICAL UPSTAGING FOLLOWING NEGATIVE EBUS-TBNA OF MEDIASTINAL LYMPH NODES FOR NSCLC?
Phillip Antippa, Australia

P1.17-010: DIAGNOSTIC MEDICAL THORACOSCOPY FOR PLEURAL EFFUSIONS OF UNKNOWN ETIOLOGY: INSPECTION DELAY MAY CAUSE NON-DETERMINISTIC ENDOSCOPIC DIAGNOSIS
Kenya Kanazawa, Japan

P1.18 Poster Session 1 Pathology

P1.18-001: THE PREVALENCE AND CLINICOPATHOLOGIC FEATURE OF ALK, ROS1 AND RET FUSIONS IN EAST ASIAN PATIENTS WITH LUNG ADENOCARCINOMA
Weijing Cai, China

P1.18-002: EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS IN PRIMARY AND METASTATIC ADENOCARCINOMAS FROM A TERTIARY HOSPITAL IN SAO PAULO, BRAZIL
Vanessa De Sa, Brazil

P1.18-003: IMMUNOHISTOCHEMICAL DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
Birgit Skov, Denmark

P1.18-004: THE RELATIONSHIP BETWEEN EGFR MUTATIONS AND THE CLINICOPATHOLOGIC FEATURES OF LUNG ADENOCARCINOMAS DIAGNOSED BY THE SMALL BIOPSIES
Kyong-Cheol Shin, South Korea

P1.18-005: CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC SIGNIFICANCE OF TUMOR INVASION INTO THE INTERLOBULAR SEPTAL AREA AND PERIVASCULAR AREA (ISA/PA) IN LUNG ADENOCARCINOMA
Kazunori Kamiya, Japan

P1.18-006: CLINICOPATHOLOGICAL FEATURES AND OUTCOME OF GASTRIC METASTASIS FROM PRIMARY LUNG CANCER: A CASE REPORT AND SYSTEMATIC REVIEW
Qingyuan Huang, China

P1.18-007: MULTIPLEX TESTING OF DRIVER MUTATIONS IN NON-SMALL CELL LUNG CANCER (NSCLCs) OF AFRICAN-AMERICAN (AA) PATIENTS
Shirish Gadgeel, USA

Ryoichi Kondo, Japan

P1.18-009: CLINICOPATHOLOGIC AND RADIOLOGIC CHARACTERISTICS OF LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) K-RAS MUTATION AND ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT PRESENTED AS NODULAR GROUND-GLASS OCAPITY
Jae Ho Lee, South Korea

P1.18-010: RUNNING TO KEEP UP! THE TIMELINE OF EVOLVING RESEARCH IN EGFR TESTING AND TARGETED THERAPIES IN NEW ZEALAND
Helen Winter, New Zealand

P1.18-011: IS VISCERAL PLEURAL INVASION SIGNIFICANT PROGNOSTIC FACTOR IN LUNG CANCER PATIENTS WITH GROUND GLASS OPACITY ON THIN-SECTION CT SCAN?
Aritoshi Hattori, Japan

P1.18-012: THYROID TRANSCRIPTION FACTOR (TTF-1) NEGATIVE LUNG ADENOCARCINOMAS WILL BE WILD TYPE FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS.
Mary Jo Fidler, USA

P1.18-013: EXTRACTING HIGH QUALITY RNA FROM FFPE SAMPLES FOR GENE EXPRESSION STUDIES
Jonathan Weiss, Australia

P1.18-014: AN ANALYSIS OF MRNA AND LONG NON-CODING RNA (LNCrna) EXPRESSION DURING THE PROGRESSION FROM PRE-INVASIVE LESIONS (PL) TO INVASIVE SQUAMOUS CELL CARCINOMA (SQCC) OF THE BRONCHUS.
Andre Koper, UK

P1.18-015: SCREENING FOR ALK-REARRANGED NSCLC IN SELECTED CASES USING IMMUNOHISTOCHEMISTRY FOLLOWED BY FISH AND RT-PCR TESTING OF TUMOURS WITH INCREASED ALK PROTEIN EXPRESSION IN A ROUTINE CLINICAL DIAGNOSTIC SETTING
Anne Marie Quinn, UK

P1.18-016: THE ASSOCIATION BETWEEN SIZE AND HISTOLOGY IN DISCARDED INTRAPULMONARY LYMPH NODES (LN) FROM NON-SMALL CELL LUNG CANCER (NSCLC) RESECTION SPECIMENS: CAN WE SELECT NODES FOR EXAMINATION BY THEIR SIZE?
Raymond Osarogiagbon, USA
P1.18-017: THE PREVALENCE OF MICROMETASTASIS (MM) IN DISCARDED INTRAPULMONARY LYMPH NODES (LN) IN RESECTED NON-SMALL CELL LUNG CANCER (NSCLC).
Raymond Osarogiagbon, USA

P1.18-018: DIAGNOSIS OF LUNG CANCER: PERFORMANCE OF PRE-OPERATIVE PROCEDURES IN CLINICAL PRACTICE CORRELATED WITH CHARACTERISTICS OF THE TUMOR.
Maria Teresa Almodovar, Portugal

P1.18-019: MICROPAPILLAR HISTORY IS ASSOCIATED WITH OCCULT LYMPH NODE METASTASIS (PN2) IN PATIENTS WITH CLINICALLY N2-NEGATIVE (CN0/N1) LUNG ADENOCARCINOMA.
Yi-Chen Yeh, Taiwan

P1.18-020: MOLECULAR ALTERATIONS IN ADVANCED LUNG CANCER: GENOMIC SEQUENCING IN A COMMUNITY PROFILING PROGRAM OF THE SARAH CANNON RESEARCH INSTITUTE (SCRI).
David Spigel, USA

P1.18-021: RETROSPECTIVE ANALYSIS OF THE PREVALENCE OF NSCLC DRIVER MUTATIONS IN UNSELECTED SAMPLES.
Normand Blais, Canada

P1.18-022: THE NATURAL HISTORY OF BRONCHIAL PRE-INVASIVE DISEASE.
Jim Brown, UK

---

P1.19 Poster Session 1 Imaging

P1.19-001: INHALED CISPLATIN DISPLAYED WITH THE CYTOVIVA TECHNIQUE IN STAGE II NON-SMALL CELL LUNG CANCER PATIENTS.
Konstantinos Zarogoulidis, Greece

P1.19-002: AN OPEN-LABEL, SINGLE ARM TRIAL TO EVALUATE THE PREDICTIVE VALUE OF PERFUSION CT AND EARLY RADILOGIC RESPONSE TO CISPLATIN (C) GEMCITABINE (G) AND BEVACIZUMAB (B) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC).
Noemi Reguart, Spain

P1.19-003: TEST PERFORMANCE OF PET-CT FOR MEDIASTINAL LYMPH NODE STAGING OF PULMONARY CARCINOID TUMOURS.
Eric Lim, on Behalf of The UK Thoracic Surgery Collaborative, UK

P1.19-004: EVALUATION OF A CLOUD-BASED SOLUTION FOR LOCAL IMAGING EVALUATIONS IN CLINICAL TRIALS FOR LUNG CANCER.
Naoko Aragane, Japan

P1.19-005: COMPUTER-AIDED LUNG NODULE ANALYSIS FOCUSED ON GROUND GLASS OPACITY AND CONSOLIDATION ON THIN-SECTION COMPUTED TOMOGRAPHY.
Eiji Yamada, Japan

P1.19-006: PREDICTORS OF NODULE MALIGNANCY IN THE DANISH LUNG CANCER SCREENING TRIAL (DLCST).
Zaigham Saghir, Denmark

P1.19-007: PREDICTION OF PLEURAL ADHESION DURING VIDEO-ASSISTED THORACIC SURGERY IN LUNG CANCER PATIENTS.
Kwang Nam Jin, South Korea

P1.19-008: CLINICORADIOLOGICAL EVALUATION OF SURGICALLY RESECTED PULMONARY PLEOMORPHIC CARCINOMA.
Akiyoshi Ishida, Japan

P1.19-009: DIFFERENCES IN Proliferation of TUMOR CELLS IN GROUND-GLASS OPACITY LESIONS ON COMPUTED TOMOGRAPHY FOR PRIMARY NON-SMALL CELL LUNG CANCER.
Go Nishii, Japan

P1.19-010: PROGNOSTIC VALUE OF FDG-PET-BASED METABOLIC TUMOR VOLUME IN CONJUNCTION WITH MATHEMATICAL CLASSIFIERS IN NON-SMALl CELL LUNG CANCER PATIENTS.
Yulei Jiang, USA

P1.19-011: CORRELATION BETWEEN THE TUMOR SIZE MEASURED BY USING CHEST RADIOGRAPH AND CT CHEST COMPARISON TO THE PATHOLOGIC SIZE.
Yutthaphan Wannasopha, Thailand

P1.19-012: THE QUALITY OF CONSOLIDATION IN PART SOLID NODULE COULD BE A PREDICTOR OF SURVIVAL.
Tomohiro Ichikawa, Japan

P1.19-013: FDG-PET/CT DIFFER BRONCHIAL NETS FROM HAMARTOMAS.
Oscar Grundberg, Sweden

P1.19-014: STAGE SURVIVAL FOR LUNG CANCER STAGED BY PET/CT, EUS FNA AND/OR EBUS TBNA.
Mark Krasnik, Denmark

P1.19-015: CLINICAL APPLICATION OF THIN SECTION CHEST CT WITH COMPUTER-AIDED DETECTION SYSTEM FOR THE DETECTION OF SMALL METASTATIC NODULES IN PULMONARY METASTASECTOMY.
Chang Hyun Kang, South Korea
### P1.20 Poster Session 1
**Early Detection and Screening**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.20-001</td>
<td>EARLY LUNG CANCER DETECTION PROGRAMME - ITS IMPACT ON ACTIVITY OF THE LOCAL THORACIC SURGERY DEPARTMENT</td>
<td>Tomasz Grodzki, Poland</td>
</tr>
<tr>
<td>P1.20-002</td>
<td>ELEVATED INFLAMMATORY MARKERS COULD BE USEFUL IN EARLY DIAGNOSING AND MONITORING LUNG CANCER</td>
<td>Idris Yucel, Turkey</td>
</tr>
<tr>
<td>P1.20-003</td>
<td>LUNG CANCERS DETECTED USING LOW-DOSE CT SCREENING: RESULTS OF AN EIGHT-YEAR OBSERVATIONAL STUDY</td>
<td>Ryutaro Kakinuma, Japan</td>
</tr>
<tr>
<td>P1.20-004</td>
<td>UK LUNG CANCER SCREENING TRIAL (UKLS): BASE LINE DATA</td>
<td>John Field, UK</td>
</tr>
<tr>
<td>P1.20-005</td>
<td>COMPARISON BETWEEN CHEST RADIOGRAPHY, CHEST TOMOSYNTHESIS AND COMPUTED TOMOGRAPHY TO DETECT PULMONARY NODULES: A PHANTOM STUDY AND CLINICAL EXPERIENCE.</td>
<td>Juntima Euathrongchit, Thailand</td>
</tr>
<tr>
<td>P1.20-006</td>
<td>NON-INVASIVE DETECTION OF LUNG CANCER FROM CELLS IN SPUTUM USING CELL-CT™</td>
<td>Alan Nelson, USA</td>
</tr>
<tr>
<td>P1.20-007</td>
<td>LOW-DOSE COMPUTED TOMOGRAPHIC SCREENING IN HEALTHY ADULTS AT LOW RISK FOR LUNG CANCER</td>
<td>Chin A Yi, South Korea</td>
</tr>
<tr>
<td>P1.20-008</td>
<td>HEALTH CARE COSTS IN THE RANDOMIZED CONTROLLED DANISH LUNG CANCER CT SCREENING TRIAL</td>
<td>Jesper Pedersen, Denmark</td>
</tr>
<tr>
<td>P1.20-009</td>
<td>NEW POTENTIAL MARKER FOR THE DIAGNOSIS OF LUNG CANCER: HYALURONAN.</td>
<td>Maristela Rangel, Brazil</td>
</tr>
<tr>
<td>P1.20-010</td>
<td>A PROSPECTIVE STUDY OF ANNUAL CT SCREENING FOR LUNG CANCER IN HIV SMOKERS</td>
<td>Alicia Hulbert, USA</td>
</tr>
<tr>
<td>P1.20-011</td>
<td>RETROSPECTIVE STUDY OF LUNG CANCER SCREENING.</td>
<td>Yuki Morishige, Japan</td>
</tr>
</tbody>
</table>

### P1.21 Poster Session 1
**Diagnosis and Staging**

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.21-001</td>
<td>CANCER DIAGNOSIS IN THE ACUTE SETTING (CADIAS): A STUDY ON BEHALF OF THE LONDON CANCER ALLIANCE</td>
<td>Tom Newsom-Davis, UK</td>
</tr>
<tr>
<td>P1.21-002</td>
<td>A SURVEY OF EGFR MUTATION FREQUENCY AND TESTING PRACTICES IN ASIA PACIFIC</td>
<td>Yasushi Yatabe, Japan</td>
</tr>
<tr>
<td>P1.21-003</td>
<td>IMPACT ON STAGE MIGRATION IN LUNG CANCER FROM 6TH TO 7TH EDITION OF TNM A STUDY CONDUCTED AT TWO HOSPITALS IN NEPAL.</td>
<td>Sandhya Acharya, Nepal</td>
</tr>
<tr>
<td>P1.21-004</td>
<td>PROFILING THE CLINICAL AND DIAGNOSTIC PATHWAY OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) IN IRELAND</td>
<td>Kenneth O’Byrne, Australia</td>
</tr>
<tr>
<td>P1.21-005</td>
<td>MULTIPLE PRIMARY MALIGNANCIES IN PATIENTS WITH LUNG CANCER: CLINICAL FEATURES AND PROGNOSIS</td>
<td>SeoWoo Kim, South Korea</td>
</tr>
<tr>
<td>P1.21-006</td>
<td>DIAGNOSTIC VALUE OF CT FLUOROSCOPY-GUIDED TRANSPBRONCHIAL BIOPSY IN ENDOBRONCHIALLY INVISIBLE AND TRANSTHORACICALLY INACCESSIBLE NODULE/MASS OF THE LUNG</td>
<td>Erkan Yilmaz, Turkey</td>
</tr>
<tr>
<td>P1.21-007</td>
<td>USEFULNESS OF COMPUTED TOMOGRAPHY GUIDED PERCUTANEOUS TRANSTHORACIC BIOPSIES IN DIAGNOSING THORACIC MALIGNANCIES - EXPERIENCE FROM A STATE HOSPITAL IN MALAYSIA</td>
<td>Choo Khoon Ong, Malaysia</td>
</tr>
<tr>
<td>P1.21-008</td>
<td>ACCURACY OF NODAL STAGING IN EARLY STAGE NSCLC IN THE MODERN ERA OF PET-CT, EBUS-TBNA AND MULTIDISCIPLINARY TEAM APPROACH</td>
<td>Tajalli Saghie, Australia</td>
</tr>
<tr>
<td>P1.21-009</td>
<td>RELIABILITY OF TRANSTHORACIC FINE NEEDLE ASPIRATION AND CORE NEEDLE BIOPSY FOR THE DIAGNOSIS OF PULMONARY MUCINOUS ADENOCARCINOMA</td>
<td>Hee Young Lee, South Korea</td>
</tr>
</tbody>
</table>
P1.22 Poster Session 1  Epidemiology, Etiology

P1.22-001: AN NICKEL WORKERS COHORT STUDY IN CHINA (JINCHUAN COHORT)-THE LARGEST NICKEL POPULATION IN WORLD
Yana Bai, China

P1.22-002: NON-SMALL CELL LUNG CANCER IN YOUNG PATIENTS: CLINICOPATHOLOGICAL FEATURES
Ugur Coskun, Turkey

P1.22-003: LUNG CANCER SURVIVAL IN SOUTHERN TASMANIA
Katharine See, Australia

P1.22-004: PATHOLOGIC SUBGROUP ANALYSIS IN PATIENTS WHO WERE DIAGNOSED AS NON-SMALL CELL LUNG CARCINOMA AND ANALYSIS OF ITS EFFECT TOGETHER WITH BASIC DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS ON SURVIVAL PARAMETERS.
Ozgur Ozylikan, Turkey

P1.22-005: A PROSPECTIVE, MOLECULAR EPIDEMIOLOGICAL STUDY OF EGFR MUTATIONS IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CARCINOMA HISTOLOGY (PIioneer STUDY) - CHINA SUBSET ANALYSIS
Yuankai Shi, China

P1.22-006: THE IMPACT OF SEX HORMONE-BINDING GLOBULIN LEVELS ON THROMBOEMBOLIC EVENTS AT CANCER PATIENTS WITH ADENOCARCINOMA
Mustafa Bozkurt, Turkey

P1.22-007: THE PREVALENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION IN NON-SMALL NON-SQUAMOUS LUNG CANCER IN UAE (A SINGLE INSTITUTE EXPERIENCE IN THE MIDDLE EAST)
Hassan Jaafar, United Arab Emirates

P1.23 Poster Session 1  Tobacco Control, Prevention and Chemoprevention

P1.23-001: THE REAL ROLE OF HEALTH CARE PROFESSIONALS IN PROVIDING SMOKING CESSION COUNSELLING AMONG LUNG CANCER PATIENTS: PRELIMINARY DATA
Silvia Novello, Italy

P1.23-002: A RANDOMIZED CONTROLLED TRIAL OF BRIEF COUNSELLING INTERVENTION AND AUDIO MATERIALS FOR SMOKING CESSATION IN A LOW-DOSE CT SCREENING STUDY
Henry Marshall, Australia

P1.23-003: HEALTH CARE COSTS OF PATIENTS WITH NON SMALL CELL LUNG CANCER RELATED TO SMOKING IN THE NATIONAL CANCER INSTITUTE OF MEXICO
Oscar Arrieta, Mexico

P1.24 Poster Session 1  Clinical Care

P1.24-001: VALIDATION OF A NOVEL SUPERIOR VENA CAVA SYNDROME IDENTIFICATION, CLASSIFICATION, AND MANAGEMENT ALGORITHM
Pierre Theodore, USA

P1.24-002: EFFICACY AND SAFETY OF ORAL PALONOSETRON COMPARED WITH IV PALONOSETRON ADMINISTERED WITH DEXAMETHASONE FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS WITH SOLID TUMORS RECEIVING CISPLATIN-BASED HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)
Meinholf Karthaus, Germany

P1.24-003: A COMPARISON OF THE LUNG CANCER JOURNEY - METROPOLITAN AND NON-METROPOLITAN
Barbara Page, Australia

P1.24-004: CHARACTERISTICS AND PROGNOSTIC ANALYSIS OF PULMONARY SARCOMATOID CARCINOMA
Guowei Ma, China
P1.24-005: IMPRESSIVE RETINAL RESPONSE TO CRIZOTINIB IN A PATIENT WITH NSCLC AND ALK TRANSLOCATION
Alessandra Bearz, Italy

P1.24-006: DISCUSSION AND ANALYSIS OF LUNG CANCER AMONG YOUNG PEOPLE AT OUR HOSPITAL
Keisuke Imasaka, Japan

P1.24-007: LONG-TERM MAINTENANCE THERAPY WITH BEVACIZUMAB FOR CHINESE ADVANCED NON-SMALL CELL LUNG CANCER: A CASE REPORT
Zhe Liu, China

P1.24-008: ARE PATIENTS' NEEDS BEING MET AFTER-HOURS? AN EVALUATION OF PHONE CALLS MADE AFTER HOURS FOR PATIENTS WITH THORACIC MALIGNANCIES.
Manali Patel, USA

P1.24-009: PRIMARY GIANT AND DESTRUCTIVE HYDATID DISEASE MIMICKING MALIGNANT TUMOR OF THE CHEST WALL: CASE REPORT AND LITERATURE REVIEW
Abdullah Erdogan, Turkey

P1.24-010: SUCCESSFUL RECHALLENGE OF ERLOTINIB IN PATIENT WITH NON-SMALL CELL LUNG CANCER - REGAIN OF TYROSINE KINASE SENSITIVITY. CASE REPORT
Ewa Chmielowska, Poland

P1.24-011: HOW TO BUILD A BETTER LUNG CANCER SUPPORT GROUP: BEST PRACTICES FROM AUSTRALIA, THE UNITED KINGDOM AND THE UNITED STATES
Maureen Rigney, USA

P1.24-012: MONITORING OF PATIENTS UNDER TREATMENT WITH SINGLE FRACTION OF SBRT IN LUNG LESIONS.
Felipe Cardenal, Spain

P1.24-013: PROPHYLAXIS AGAINST PULMONARY THROMBOEMBOLISM WITH UNFRACTIONATED HEPARIN FOR THE PATIENTS UNDERGOING PULMONARY RESECTION FOR LUNG CANCER
Toshiki Takemoto, Japan

P1.24-014: METASTATIC ANGIOSARCOMA PRESENTING AS HAEMOPTYSIS AND SEVERE PAIN ON THE BACK
Medhiha Ortakoylu, Turkey

P1.24-015: CHEMORADIOTHERAPY-ASSOCIATED MYELOSUPPRESSION: ANALYSIS OF RISK FACTORS FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER
Ufuk Yilmaz, Turkey

P1.24-016: SINGLE AGENT ORAL ETOPOSIDE FOR ELDERLY AND INFIRM ADVANCED NON-SMALL CELL LUNG CANCER: A REASONABLE THERAPEUTIC OPTION
Krishnakumar Rathnam, India

P1.24-017: THERAPEUTIC AND PREVENTIVE EFFECTS OF APREPITANT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN JAPANESE PATIENTS WITH THORACIC MALIGNANCIES
Sumiyo Ito, Japan

P1.24-018: PRIMARY GIANT AND DESTRUCTIVE HYDATID DISEASE MIMICKING MALIGNANT TUMOR OF THE CHEST WALL: CASE REPORT AND LITERATURE REVIEW
Abdullah Erdogan, Turkey

P1.24-019: HOW TO BUILD A BETTER LUNG CANCER SUPPORT GROUP: BEST PRACTICES FROM AUSTRALIA, THE UNITED KINGDOM AND THE UNITED STATES
Maureen Rigney, USA

P1.24-020: CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN JAPANESE PATIENTS WITH THORACIC MALIGNANCIES
Sumiyo Ito, Japan

P1.24-021: BRONCHOPLASTY AND BRONCHOANGIOPLASTY FOR PRIMARY NON-SMALL CELL LUNG CANCER
Naoya Yamasaki, Japan

P1.24-022: MHEALTH TOOL FOR LUNG CANCER - DEVELOPMENT AND DEMONSTRATION
Janine Cataldo, USA

P1.24-023: ENVYO SERVICE, A FORM OF DIGNITY THERAPY, DESIGNED TO ASSIST COMMUNICATION AND PALLIATIVE CARE DECISION FOR PATIENTS WITH ADVANCED CANCER: A PRELIMINARY REPORT.
Sang Won Shin, South Korea

P1.24-024: ACUTE EXACERBATION OF IDIOPATHIC INTERSTITIAL PNEUMONIA AFTER RESECTION OF LUNG CANCER: INVESTIGATION OF PRE OPERATIVE CT PREDICTOR
Mi Young Kim, South Korea

P1.24-025: PALLIATION OF MALIGNANT PLEURAL EFFUSION BY PLEURODESI A COMPARATIVE STUDY
Rabab Gaafar, Egypt

P1.24-026: LUNG CANCER - YOU CAN AVOID IT, GET IT, SURVIVE IT; AN EVALUATION OF THE IRISH CANCER SOCIETY'S ANNUAL LUNG CANCER AWARENESS CAMPAIGN FROM 2011 - 2013.
Aoife Mc Namara, Ireland

P1.24-027: INTRAPULMONARY RECURRENCE AFTER COMPUTED TOMOGRAPHY-GUIDED PERCUTANEOUS NEEDLE BIOPSY OF STAGE I LUNG CANCER
Yeo Kon Kye, South Korea

P1.24-028: CHEMICAL PLEURODESI USING MISTLETOE EXTRACTION (ABNOVAVISCUM® INJECTION) FOR MALIGNANT PLEURAL EFFUSION
Jeong Su Cho, South Korea
P1.24-029: METASTASTECTOMY FOR LUNG CANCER AND LUNG RESECTION FOR METASTASES - OUR EXPERIENCE
Swamyvelu Krishnamurthy, India

P1.24-030: A RARE CASE OF SYNCHRONOUS AND METACHRONOUS LUNG CANCERS
Chuong Bui, Australia

P1.24-031: CONFIRMATION OF SURGICAL MARGIN OF RESECTED PULMONARY ADENOCARCINOMA WITH LEPIDIC GROWTH WITH THIN SLICE CT OF THE RESECTED SPECIMEN DURING SURGERY
Yasuhiro Hida, Japan

P1.24-032: IS TUBERCULOSIS A CHALLENGE FOR THE MANAGEMENT OF LUNG CANCER?
Ayse Ozcan, Turkey

P1.24-033: A RARE CASE: LUNG CANCER AND MULTIPLE MYELOMA
Ayse Bahadir, Turkey

P1.24-034: CYSTIC AND CAVITARY APPEARANCE: AN USUAL FORM OF PULMONARY METASTASIS OF PRIMER LUNG ADENOCARCINOMA
Ayse Bahadir, Turkey

P1.24-035: TIMES TO PRESENTATION AND TREATMENT: A PROSPECTIVE COMPARISION OF RURAL AND URBAN LUNG CANCER PATIENTS IN NORTH QUEENSLAND
Abhishek Joshi, Australia

P1.24-036: COMBINED MODALITY TREATMENT FOR INOPERABLE NON-SMALL CELL LUNG CANCER - A RETROSPECTIVE STUDY FROM A NEW ZEALAND REGIONAL CANCER CENTRE.
Wen-Hsun Tsai, New Zealand

P1.24-037: ADDITION OF BEVACIZUMAB TO STANDARD PALLIATIVE CHEMOTHERAPY IN ADVANCED NON SQUAMOUS CELL LUNG CARCINOMA: TATA MEMORIAL HOSPITAL EXPERIENCE.
Amit Joshi, India

P1.24-038: BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY RECEIVING CHEMOTHERAPY FOR LUNG CANCER: AN EXPLORATORY STUDY
Xavier Quantin, France

P1.24-039: OUTCOME OF A SERIES OF 25 CONSECUTIVE PATIENTS AGED 84 AND MORE WITH STAGE IV NSCLC: AN INVITATION TO SYSTEMIC TREATMENT
Elisabeth Quoix, France

P1.24-040: MANAGEMENT OF SOLID LUNG MALIGNANCY BY CT-GUIDED PERCUTANEOUS CATHETER ABLATION - DOES ADJUVANT CHEMOTHERAPY HELP?
Peter Andrew, Canada

P1.24-041: FOLLOW UP OF PATIENTS WITH LUNG CANCER: THE ROLE OF PRIMARY CARE
David Weller, UK

P1.24-042: VIDEO-ASSISTED THORACIC SURGERY LOBECTOMY FOR PATIENT RECEIVING INDUCTION CHEMORADIOThERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
Takashi Miura, Japan

P1.24-043: RESULTS OF A MULTIDISCIPLINARY TEAM IN THE MANAGEMENT OF NON-SMALL CELL LUNG CANCER IN A DEVELOPING COUNTRY
Luis Corrales-Rodriguez, Costa Rica

P1.24-044: FAVORABLE SURVIVAL OF WOMEN WITH NON-SMALL CELL LUNG CANCER (NSCLC) AFTER RESECTION OF BRAIN METASTASES (BM) AND WHOLE BRAIN RADIOTHERAPY (WBRT)
Martin Fruh, Switzerland

P1.24-045: A CASE WITH LONG TERM SURVIVAL FOLLOWING RECEIVED PACLITAXEL AS FOURTH LINE CHEMOTHERAPY IN REFRACTORY-RELAPSED SMALL-CELL LUNG CARCINOMA. (ON BEHALF OF NT-TOG GROUP)
Busymas Chawaskulyong, Thailand

P1.24-046: HOW ARE TREATED FRENCH PATIENTS WITH METASTATIC LUNG ADENOCARCINOMA WITH “UNCOMMON” EGFR MUTATIONS? HOW COULD WE DO BETTER?
Jean-Francois Morere, France

P1.24-047: A PULMONARY NEUROGENIC TUMOR: PRIMARY PULMONARY CELLULAR SCHWANNOMA
Turgut Isitmangil, Turkey

P1.24-048: STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
Heather Wakelee, USA

P1.24-049: COMPARISON OF INFORMATION PROVIDED BY THE LUNG CANCER PTS THROUGH THE SURVEY WITH THE PHYSICIAN’S EVALUATION.
Norma Pilnik, Argentina

P1.24-050: PILOT OF A WEEKLY DIETETIC TELEPHONE CLINIC FOR THORACIC ONCOLOGY OUTPATIENTS: A UK CANCER CENTRE EXPERIENCE.
Georgina Howell, UK

P1.24-051: VIDEO-ASSISTED THORACOSCOPIC SURGERY (VATS) FOR DIAGNOSIS AND THERAPY IN PRIMARY AND SECONDARY PLEURO-PULMONARY ANGIOSARCOMA
Johannes Bodner, Germany

P1.24-052: SYMPTOMS AND EARLY DIAGNOSIS OF LUNG CANCER.
Marianne Nicolson, UK

P1.24-053: REPEATED PULMONARY RESECTIONS AT PULMONARY METASTASES SURGERY
Ivan Capov, Czech Republic
P1.25 Poster Session 1
Nurses

P1.25-001: THE NATIONAL LUNG CANCER FORUM FOR NURSES (NLCFN)
Diana Borthwick, UK

P1.25-002: TESTING THE FEASIBILITY OF A LUNG CANCER NURSE COORDINATION MODEL DURING EARLY TREATMENT: PHASE II STUDY (CLINICAL TRIAL IN PROGRESS)
Andrea Serena, Switzerland

P1.25-003: CHARACTERISTICS AND OUTCOME OF UNPLANNED ADMISSIONS IN PATIENTS WITH LUNG CANCER: A LONGITUDINAL TERTIARY CENTER STUDY.
Christel Oyen, Belgium

P1.25-004: DEEP VENOUS THROMBOSIS PREVENTION EFFECT OF ELECTRICAL STIMULATION OF ACUPUPOINT COMBINATIONS IN ELDERLY BEDRIDDEN PATIENTS AFTER MAJOR SURGERY
Lili Hou, China

P1.25-005: PATIENT SAFETY FRAMEWORK ROLE OF ONCOLOGY NURSES IN THE ERA OF ORAL CANCER TREATMENTS IN PATIENTS WITH NSCLC: ARE WE READY?
Massey Nematollahi, Canada

P1.25-006: LUNG CANCER AND COMORBIDITIES: A REGIONAL POPULATION COMPARED WITH AN URBAN POPULATION
Renae Grundy, Australia
Vegemite

Vegemite is a dark brown Australian food paste made from leftover brewers’ yeast extract, a by-product of beer manufacture, and various vegetable and spice additives. It is a popular spread for sandwiches, toast, crumpets and cracker biscuits as well as a filling for pastries. It is similar to British, New Zealand and South African Marmite, Australian Promite, Swiss Cenovis and German Hefeextrakt.

Vegemite is salty, slightly bitter and malty, and rich in umami – similar to beef bouillon. The texture is smooth and the product is a paste. It is not as intensely flavoured as British Marmite and it is less sweet than the New Zealand version of Marmite.

Courtesy of wikipedia.org
Pursue life without lung cancer

The Pervenio™ Lung RS test:
More informed decisions for high-risk, early-stage non-squamous, NSCLC patients

Visit lifelabdx.com for more information
## Biology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.01</td>
<td>CANCER BIOLOGY</td>
<td>P2.01-001 – P2.01-026</td>
</tr>
<tr>
<td>P2.02</td>
<td>NOVEL CANCER GENES AND PATHWAYS</td>
<td>P2.02-001 – P2.02-021</td>
</tr>
<tr>
<td>P2.03</td>
<td>TECHNOLOGY AND NOVEL DEVELOPMENT</td>
<td>P2.03-001 – P2.03-007</td>
</tr>
<tr>
<td>P2.04</td>
<td>TUMOR IMMUNOLOGY</td>
<td>P2.04-001 – P2.04-003</td>
</tr>
<tr>
<td>P2.05</td>
<td>PRECLINICAL MODELS OF THERAPEUTICS/IMAGING</td>
<td>P2.05-001 – P2.05-026</td>
</tr>
<tr>
<td>P2.06</td>
<td>PROGNOSTIC AND PREDICTIVE BIOMARKERS</td>
<td>P2.06-001 – P2.16-050</td>
</tr>
</tbody>
</table>

## Surgery

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.07</td>
<td>SURGERY</td>
<td>P2.07-001 – P2.07-050</td>
</tr>
</tbody>
</table>

## Radiotherapy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.08</td>
<td>RADIOThERAPy</td>
<td>P2.08-001 – P2.08-027</td>
</tr>
</tbody>
</table>

## Combined Modality

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.09</td>
<td>COMBINED MODALITY</td>
<td>P2.09-001 – P2.09-018</td>
</tr>
</tbody>
</table>

## Medical Oncology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.10</td>
<td>CHEMOTHERAPY</td>
<td>P2.10-001 – P2.10-051</td>
</tr>
<tr>
<td>P2.11</td>
<td>NSCLC NOVEL THERAPIES</td>
<td>P2.11-001 – P2.11-048</td>
</tr>
<tr>
<td>P2.12</td>
<td>NSCLC EARLY STAGE</td>
<td>P2.12-001 – P2.12-023</td>
</tr>
<tr>
<td>P2.13</td>
<td>SCLC</td>
<td>P2.13-001 – P2.13-007</td>
</tr>
</tbody>
</table>

## Mesothelioma

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.14</td>
<td>MESOTHELIOMA</td>
<td>P2.14-001 – P2.14-015</td>
</tr>
</tbody>
</table>

## Thymoma and Other Thoracic Malignancies

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.15</td>
<td>THYMOMA</td>
<td>P2.15-001 – P2.15-008</td>
</tr>
<tr>
<td>P2.16</td>
<td>OTHER THORACIC MALIGNANCIES</td>
<td>P2.16-001 – P2.16-004</td>
</tr>
</tbody>
</table>

## Endoscopy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.17</td>
<td>BRONCHOSCOPY, ENDOSCOPY</td>
<td>P2.17-001 – P2.17-009</td>
</tr>
</tbody>
</table>

## Pathology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.18</td>
<td>PATHOLOGY</td>
<td>P2.18-001 – P2.18-022</td>
</tr>
</tbody>
</table>

## Imaging and Screening

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.19</td>
<td>IMAGING</td>
<td>P2.19-001 – P2.19-014</td>
</tr>
<tr>
<td>P2.20</td>
<td>EARLY DETECTION AND SCREENING</td>
<td>P2.20-001 – P2.20-011</td>
</tr>
</tbody>
</table>

## Prevention & Epidemiology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.21</td>
<td>DIAGNOSIS AND STAGING</td>
<td>P2.21-001 – P2.21-010</td>
</tr>
<tr>
<td>P2.22</td>
<td>EPIDEMIOLOGY, ETIOLOGY</td>
<td>P2.22-001 – P2.22-013</td>
</tr>
<tr>
<td>P2.23</td>
<td>TOBACCO CONTROL, PREVENTION AND CHEMOPREVENTION</td>
<td>P2.23-001 – P2.23-002</td>
</tr>
</tbody>
</table>

## Supportive Care and Nursing

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Poster IDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.24</td>
<td>CLINICAL CARE</td>
<td>P2.24-001 – P2.24-060</td>
</tr>
<tr>
<td>P2.25</td>
<td>NURSES</td>
<td>P2.25-001 – P2.25-002</td>
</tr>
</tbody>
</table>
Tuesday, October 29

POSTER SETUP TIME: 08:30 – 09:30

POSTER TAKE DOWN TIME: 16:30 – 18:00

(Posters not taken down after 18:00 will be discarded by management)

PRESENTING AUTHOR STAND BY TIME*:
09:45 – 10:30 AND 15:30 – 16:15
(NETWORKING BREAKS)

* Time in which Poster Presenter remains at his/her Poster Board for the specified time period and is available to discuss their research personally with any interested delegate.

**BIOLOGY**

**P2.01** Poster Session 2
Cancer Biology

P2.01-001: Deregulated Interleukin-6 Signaling Suppresses Lung Tumorigenesis in Mice Induced by Nicotine-Derived Nitrosamine Ketone
Saleela Ruwanpura, Australia

P2.01-002: Targeting Chaperone Activity and Chaperone Expression in Human Lung Cancer Cells Sensitizes Them to Chemotherapy and Radiotherapy
Alexander Kabakov, Russia

P2.01-003: Modulation of cisplatin activity in NSCLC by KRAS mutants: role of specific mutations at codon 12
Marina Garassino, Italy

P2.01-004: Type of P53 Mutation Influences Oncogenic Potential and Spectrum of Associated K-RAS Mutations in Lung Specific Transgenic Mice.
Wenrui Duan, USA

P2.01-005: Diagnostic Application of 9p21 Homozygous and Heterozygous Deletion Detected by Fluorescence in Situ Hybridization (FISH) and P16 Real-Time PCR in Malignant Mesothelioma
Makoto Hamasaki, Japan

P2.01-006: Novel Small Compounds Targeting Cancer Stem Cells of Non-Small Cell Lung Cancer
Pei-Jung Lu, Taiwan

P2.01-007: Distinct Characteristics of Small Cell Lung Cancer (SCLC) Correlate with Central or Peripheral Origin - Microarray Analysis of Snap Frozen Tissue Samples.
Eisaku Miyauchi, Japan

P2.01-008: Significance of Cancer-Associated Fibroblasts in the Regulation of Gene Expression in the Leading Cells of Invasive Lung Cancer
Jian An, China

P2.01-009: Altered Expression of AKT/Transformer and AKT/2 Correlates with Invasion and Metastasis in Lung Adenocarcinoma
Naoko Imamura, Japan

P2.01-010: A Model of Chronic Inflammation Affects the Invasive Capacity and Induces Several Hallmarks of Cancer in a Normal Bronchial Epithelial Cell Line
Anne-Marie Baird, Ireland

P2.01-011: The Il-23 Family May Be a Novel Therapeutic Target in Non Small Cell Lung Cancer
Anne-Marie Baird, Ireland

P2.01-012: Pequi Fruit (Caricar Brasiliense Camb) Protects Against Oxidative Stress Induced by Urethane in a Experimental Model of Lung Cancer.
Vera Capelozzi, Brazil

P2.01-013: MicroRNA Expression of Non-Terminal Respiratory Unit Type Lung Adenocarcinoma
Mi-Hyun Kim, South Korea

P2.01-014: Fundamental Examination in the Plasticity of Cancer Stem-Like Cell (CSC) / Cancer-Initiating Cell (CIC) in Lung Cancer
Saijo Hiroshi, Japan

P2.01-015: Gene Expression of MAGE-A3 and PRAME Tumor Antigens and EGFR Mutational Status in Lung Adenocarcinoma in a German Center
Karen Langfeld, Belgium

P2.01-016: Targeting the PI3K-Mtor-Nfkb Pathway to Overcome Cisplatin Resistance in NSCLC.
Susan Heavey, Ireland

P2.01-017: Gene Expression of MAGE-A3 Tumor Antigen and EGFR Mutational Status in Chinese NSCLC Patients
Yi-Long Wu, China

P2.01-018: Defective DNA Damage Response in Lungs of Asthmatics: A Possible Link to Lung Cancer?
Rakhshinda Rehman, India
P2.01-019: HETEROGENEITY OF EGFR MUTATION DETECTED IN A PATIENT TREATED WITH GEFITINIB AS NEO-ADJUVANT CHEMOTHERAPY
Kosuke Mizoguchi, Japan

P2.01-020: DOWN-REGULATION OF SOMATOSTATIN RECEPTOR 2 DECREASES CELL PROLIFERATION IN LUNG CANCER
Pierre Massion, USA

P2.01-021: AMP CONVERTED FROM INTRACELLULARLY TRANSPORTED ADENOSINE UPREGULATES P33 EXPRESSION TO INDUCE MALIGNANT PLEURAL MESOTHELIOMA CELL APOPTOSIS
Yoshitaka Nogi, Japan

P2.01-022: TREATMENT WITH EGCG IN NSCLC LEADS TO DECREASING INTERSTITIAL FLUID PRESSURE AND HYPOXIA TO IMPROVE CHEMOTHERAPY EFFICACY THROUGH REBALANCE OF ANG-1 AND ANG-2
Peng Bo Deng, China

P2.01-023: ER HOMEOSTASIS AND MOTILITY OF NSCLC CELL LINES CAN BE THERAPEUTICALLY TARGETED WITH COMBINED HSP90 AND HDAC INHIBITORS.
Maya Gottfried, Israel

P2.01-024: QUANTITATIVE DETERMINATION OF EGFR GENE ABERRANT METHYLATION IN NON SMALL CELL LUNG CANCER (NSCLC): A COMPARATIVE ANALYSIS IN TUMOR TISSUE, NORMAL LUNG TISSUE, PERIPHERAL BLOOD, SPUMUS AND BRONCHIAL ASPIRATE. CORRELATION WITH CLINICAL VARIABLES.
Manuel Cobo Dols, Spain

P2.01-025: DIFFERENTIAL MIRNA EXPRESSION IN NEUROENDOCRINE TUMOURS OF THE LUNG Annette Fisseler-Eckhoff, Germany

P2.01-026: “EGFR” GENE MUTATION IN ADVANCED NON SMALL CELL LUNG CANCER-A CASE SERIES
Azhar Rashid, Pakistan

P2.01-019: HETEROGENEITY OF EGFR MUTATION DETECTED IN A PATIENT TREATED WITH GEFITINIB AS NEO-ADJUVANT CHEMOTHERAPY
Kosuke Mizoguchi, Japan

P2.02 Poster Session 2
Novel Cancer Genes and Pathways

P2.02-001: MED12, A COMPONENT OF THE TRANSCRIPTIONAL MEDIATOR COMPLEX, AND STAT3 INFLUENCE OUTCOME TO PLATINUM-BASED CHEMOTHERAPY IN PATIENTS (P) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Daniela Morales-Espinosa, Mexico

P2.02-002: STRATIFIN EXPRESSED IN EARLY INVASIVE LUNG ADENOCARCINOMA FUNCTIONALLY ENHANCES TUMOR PROGRESSION AND DOWN-REGULATES SCFFBW7 UBQUITIN LIGASE ACTIVITY
Aya Shiba, Japan

P2.02-003: DNA METHYLATION AND EXPRESSION PATTERNS IN ADENOCARCINOMAS OF THE LUNG OF NEVER-SMOKERS WITH DISCORDANT METHYLATION AND EXPRESSION PATTERNS OF HOMEBOX RELATED GENES
Aaron Mansfield, USA

P2.02-004: ERK/MAP-KINASE SIGNALING PATHWAY AND NEUROENDOCRINE DIFFERENTIATION OF NON-SMALL CELL LUNG CANCER
Yuhchyau Chen, USA

P2.02-005: EXPRESSION OF FIBROBLAST GROWTH FACTOR-9 IS ASSOCIATED WITH POOR PROGNOSIS OF RESECTED NON-SMALL CELL LUNG CANCER PATIENTS
Keiko Ohgino, Japan

P2.02-006: THE SELECTIVE REGULATION OF EGFR MUTANTS BY C-TERMINUS OF HSC70-INTERACTING-PROTEIN(ChIP) IN LUNG ADENOCARCINOMA
Chaeuk Chung, South Korea

P2.02-007: HDGF, ADAM9 INVOLVED IN A NOVEL PATHWAY OF CELL GROWTH AND INVASION OF NON-SMALL CELL LUNG CANCER CELLS, MAY BECOME NOVEL MOLECULAR STAGING BIOMARKERS, PROGNOSTIC AND PREDICTIVE BIOMARKERS OF NSCLC
Jun Zhang, China

P2.02-008: ELEVATED MICROSATELLITE ALTERATIONS AT SELECTED TETRA-NUCLIEOTIDE (EMAST) IN NON-SMALL CELL LUNG CANCERS - A POTENTIAL DETERMINANT OF SUSCEPTIBILITY TO MULTIPLE MALIGNANCIES
Hiromasa Arai, Japan

P2.02-009: EXPRESSION OF A SPlicing VARIANT OF THE CADM1 SPECIFIC TO SMALL CELL LUNG CANCER
Shinji Kikuchi, Japan

P2.02-010: FREQUENCY OF ALK GENE REARRANGEMENT IN SAUDI LUNG CANCER Fouad Al-Dayel, Saudia Arabia

P2.02-011: IMPACT OF FAMILY HISTORY OF CANCER ON THE INCIDENCE OF MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR GENE IN NON-SMALL CELL LUNG CANCER PATIENTS
Jiayu Li, China

P2.02-012: LONG NON-CODING RNA BC070487 REPRODUCES THE NOVEL TUMOR SUPPRESSOR GENE ZNFX1 DURING TOBACCO-INDUCED HUMAN PULMONARY CARCINOGENESIS
David Schrump, USA
P2.02-013: THE IMPORTANCE OF IMMUNOREGULATORY GENES IN NON SMALL CELL LUNG CANCER
Eva Garcia, Spain

P2.02-014: DISCOVERY OF CIRCULATING PROTEIN BIOMARKERS OF LUNG DYSPLASIA
Rachel Ostroff, USA

P2.02-015: PROTEOMIC INSIGHTS WITH LUNG CANCER TUMORS BASED ON HISTOPATHOLOGIC SUBTYPES AND GENOTYPES
Rachel Ostroff, USA

P2.02-016: PRMT5, A NOVEL EPGENETIC TARGET IN LUNG CANCERS
Gregory Otterson, USA

P2.02-017: ANALYSIS OF P53, RB, C-MET, C-KIT AND PDGF / IN LUNG CARCINOID
Rosario Garcia Campelo, Spain

P2.02-018: THE NOTCH/HER1/ASCL1 SIGNALING PATHWAY IN LUNG CARCINOID
Rosario Garcia Campelo, Spain

P2.02-019: ANALYSIS OF P53, RB, C-MET, C-KIT AND PDGF / IN LUNG CARCINOIDS.
Rosario Garcia Campelo, Spain

P2.02-020: MICRORNA DEREGULATION ASSOCIATED WITH NODE POSITIVE LUNG ADENOCARCINOMA
Katey Enfield, Canada

P2.03-001: GENE EXPRESSION PROFILE OF A549 CELLS FROM TISSUE OF 4D MODEL PREDICTS POOR PROGNOSIS IN LUNG CANCER PATIENTS
Min Kim, USA

P2.03-002: IMPPLICATIONS OF CXCR4 AND ESTROGEN/PROGESTERONE RECEPTOR (ER/PR) PATHWAY ACTIVITY IN NON SMALL CELL LUNG CANCER (NSCLC)
Shannon Otsuka, Canada

P2.03-003: TWO GROUPS OF LUNG ADENOCARCINOMA CELL LINES THAT SHOW DISTINCT MORPHOLOGY AND CANCER-STROMAL INTERACTION IN 3 DIMENSIONAL CULTURE AND MOUSE XENOGRAFT
Toshiro Niki, Japan

P2.02-010: MICRORNA DEREGULATION ASSOCIATED WITH NODE POSITIVE LUNG ADENOCARCINOMA
Katy Enfield, Canada

P2.03-004: CLINICAL APPLICATION OF TARGETED DEEP SEQUENCING AS A MOLECULAR SCREENING FOR EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) THERAPY IN NEVER-SMOKING LUNG ADENOCARCINOMA
Ji-Youn Han, South Korea

P2.02-011: PROTEOMIC INSIGHTS WITH LUNG CANCER TUMORS BASED ON HISTOPATHOLOGIC SUBTYPES AND GENOTYPES
Rachel Ostroff, USA

P2.03-005: ROTARY DISSECTOR: FRICTIONAL FORCE ACHIEVED BY USING THE POROUS POLYPROPYLENE ROTARY DISSECTOR IN CLINICAL SETTINGS
Junichi Shimada, Japan

P2.02-012: DISCOVERY OF CIRCULATING PROTEIN BIOMARKERS OF LUNG DYSPLASIA
Rachel Ostroff, USA

P2.03-006: DETERMINING READ ORIGIN OF NEXT-GENERATION SEQUENCING DATASETS FROM LUNG CANCER XENOGRAFTS
Kieren Marini, Australia

P2.02-013: THE IMPORTANCE OF IMMUNOREGULATORY GENES IN NON SMALL CELL LUNG CANCER
Eva Garcia, Spain

P2.03-007: CHANGES IN PULMONARY IMMUNE CELL RECRUITMENT AND FUNCTION DURING CIGARETTE SMOKE-INDUCED LUNG CARCINOGENSES IN MICE
Robert Keith, USA

P2.03-008: CLINICAL APPLICATION OF TARGETED DEEP SEQUENCING AS A MOLECULAR SCREENING FOR EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (EGFR-TKI) THERAPY IN NEVER-SMOKING LUNG ADENOCARCINOMA
Ji-Youn Han, South Korea

P2.03-009: ROTARY DISSECTOR: FRICTIONAL FORCE ACHIEVED BY USING THE POROUS POLYPROPYLENE ROTARY DISSECTOR IN CLINICAL SETTINGS
Junichi Shimada, Japan

P2.03-010: DETERMINING READ ORIGIN OF NEXT-GENERATION SEQUENCING DATASETS FROM LUNG CANCER XENOGRAFTS
Kieren Marini, Australia

P2.03-011: CHANGES IN PULMONARY IMMUNE CELL RECRUITMENT AND FUNCTION DURING CIGARETTE SMOKE-INDUCED LUNG CARCINOGENSES IN MICE
Robert Keith, USA

P2.04-001: MYELOID DERIVED SUPPRESSOR CELLS (MDSC) ARE INCREASED IN PATIENTS WITH ADVANCED NON-SQUAMOUS LUNG CANCER (ANSQ) COMPARED TO HEALTHY CONTROLS AND EARLY STAGE NON-SQUAMOUS LUNG CANCER (NSQ) AND ARE RELATED TO THE WHO PERFORMANCE STATUS. SUBANALYSIS OF THE NVALT12 STUDY
Joachim Aerts, Netherlands

P2.04-002: DIFFERENTIAL EXPRESSION OF PD-L1, PD1 AND CTLA4 RECEPTOR ACCORDING TO HISTOLOGY AND TUMOUR VS. SURROUNDING NON-MALIGNANT LUNG TISSUE IN NON-SMALL CELL LUNG CANCER: RNA SEQUENCING DATA
Dirk De Ruyscher, Belgium

P2.04-003: NOVIEL MECHANISM OF IMMUNE-TOLERANCE DUE TO ABERRANT EXPRESSION OF NATURAL KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS (KIRS) AND ENHANCED PLATELET INTERACTIONS
Daniel Chan, USA
P2.05-001: RECOMBINANT HUMAN APO2L/TRAIL (DULANERMIN) IN COMBINATION WITH CARBOPLATIN/PEMETREXED IN MALIGNANT PLEURAL MESOTHELIOMA (MPM): ANTICANCER EFFECTS IN VITRO AND IN VIVO.
Adolfo Favaretto, Italy

P2.05-002: RESISTANCE TO BH3 MIMETIC S1 IN SCLC CELLS THAT UP-REGULATE AND PHOSPHORYLATE BCL-2 THROUGH ERK1/2.
Yubo Liu, China

P2.05-003: REGULATION OF SIRT2 FOR HUMAN NON-SMALL CELL LUNG CANCER THERAPY.
Ziming Li, China

P2.05-004: SYNERGISTIC ANTITUMOR ACTIVITY OF BEVACIZUMAB AND ERLOTINIB IN EGF-R-MUTATED NON-SMALL CELL LUNG CANCER XENOGRaFT MODELS.
Yoichiro Moriya, Japan

P2.05-005: ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN EGFR-TKI RESISTANT NON-SMALL CELL LUNG CANCER XENOGRaFT MODELS.
Kaname Yamamoto, Japan

P2.05-006: ANTITUMOR ACTIVITY OF BEVACIZUMAB IN COMBINATION WITH PEMETREXED AS MAINTENANCE THERAPY FOR NON-SMALL CELL LUNG CANCER IN A XENOGRaFT MODEL: COMPARISON WITH PEMETREXED MONOTHERAPY AND ANALYSIS OF THE COMBINATION MECHANISM.
Nobuyuki Ishikura, Japan

P2.05-007: SIGNIFICANCE OF THE RECOMMENDED DOSE ERLOTINIB FOR AVOIDING ACQUIRED RESISTANCE IN NSCLC CELLS WITH EXON19 DELETION AND L858R MUTATION OF EGFR.
Koh Furugaki, Japan

P2.05-008: STEM CELL TRANSCRIPTION FACTORS OCT4 AND NANOG INVOLVED IN CHEMoresistance AND EGFR-TKI RESISTANCE OF NSCLC.
Jiayu Li, China

P2.05-009: PORPhySOME-ENHANCED BRONCHOSCOPY FLUORESCENCE DETECTION AND PHOTOThERMAL ABLATION OF PERIPHERAL LUNG CANCER: PRELIMINARY IN VIVO STUDIES.
Takashi Anayama, Canada

P2.05-010: SEVERAL RECEPTOR TYROSINE KINASE IS ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA CELLS WITH EGFR MUTATION.
Kenichi Suda, Japan

P2.05-011: CHARACTERISATION OF CHEMO-RESISTANT SYNGENEIC ORTHOTOPIC RAT PRE-ClinICAL MODELS OF MESOTHELIOMA.
Amanda Hudson, Australia

P2.05-012: AN INDUCIBLE TRANSITION CELL MODEL REFLECTING EPITHELIOID VERSUS SARCOMATOID DIFFERENTIATION OF MALIGNANT PLEURAL MESOTHELIOMA.
Karim Schelch, Austria

P2.05-013: SILENCING THE TUBB3 GENE IN Vivo SENSITISES NON-SMALL CELL LUNG CANCER TO CISPLATIN.
Maria Kavallaris, Australia

P2.05-014: SCHEDULE-DEPENDENT INTERACTIONS BETWEEN PEMETREXED AND VINORELBINE IN HUMAN LUNG CANCER CELLS.
Rudolf Huber, Germany

P2.05-015: A NOVEL CRM1 INHIBITOR TARGETING FOR NSCLC WITH EGFR-TKI RESISTANCE MUTATION.
Yuankai Shi, China

P2.05-016: THORACOSCOPIC COLOR AND FLUORESCENCE IMAGING SYSTEM FOR SENTINEL LYMPH NODE MAPPING IN PORCINE LUNG USING INDOCYANINE GREEN-NEOMANNOSYL HUMAN SERUM ALBUMIN.
Hyun Koo Kim, South Korea

P2.05-017: EVALUATION OF THE SELECTIVE AURORA B KINASE INHIBITOR AZD1152 IN SCLC LINES WITH AND WITHOUT MYC FAMILY AMPLIFICATION.
Barbara Helfrich, USA

P2.05-018: INTERFERON- EfficientLY INHIBITED ENDothelial PROGENITOR CELL-INDUCED TUMOR ANGIoGENESIS.
Wen Yong Zhou, China

P2.05-019: THERAPEUTIC EFFICACY OF DNA VACCINE BY TARGETING THE MUTANT KRAS IN KRASG12D-INDUCED LUNG CANCER MODEL.
Tzu-Yang Weng, Taiwan

P2.05-020: COMBINED GEMCITABINE AND ANTI-CTLA4 THERAPY TO TARGET RESIDUAL TUMOUR FOLLOWING PARTIAL DEBULKING SURGERY IN A MOUSE MESOTHELIOMA MODEL.
Bruce Robinson, Australia

P2.05-021: MOLECULAR ANALYSIS OF ASPeSTOS-INDUCED MESOTHELIOMAS FROM SV40 TAG TRANSGENIC MICE SHOWS THAT THEY ARE HIGHLY CONCORDANT WITH HUMAN MESOTHELIOMA.
Cleo Robinson, Australia

P2.05-022: THERAPEUTIC POTENTIAL OF THE FGFR TYROSINE KINASE INHIBITOR, AZD4547 IN SQUAMOUS NON-SMALL CELL LUNG CANCER.
Paul Smith, UK
P2.05-023: IN VIVO MICRO-IMAGING OF APOPTOSIS IN A MURINE XENOGRAFT MODEL OF HUMAN LUNG ADENOCARCINOMA
Luc Thiberville, France

P2.05-024: PREDICTION OF DRUG SENSITIVITY IN SECOND LINE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
Josine Quispel-Janssen, Netherlands

P2.05-025: PEPTIDE-MEDIATED LIPOSOMAL DOXORUBICIN ENHANCES DRUG DELIVERY EFFICIENCY AND THERAPEUTIC EFFICACY IN LUNG CANCER ANIMAL MODELS
Han-Chung Wu, Taiwan

P2.05-026: A DEVELOPMENT DRUG CANDIDATE TARGETING EGFR KINASE FOR LUNG CANCER: DBPR112
Hsing-Pang Hsieh, Taiwan

P2.06 Poster Session 2 Prognostic and Predictive Biomarkers

P2.06-001: INTRODUCING A NOVEL RT-PCR ASSAY FOR THE DETECTION OF ROS1 FUSION GENES IN NSCLC
Martin Maus, Germany

P2.06-002: PROTEIN TYROSINE KINASE SUBSTRATES PROFILING TO DETECT SHORT-TERM SURVIVORS IN EARLY STAGE LUNG ADENOCARCINOMA
Sven Hillinger, Switzerland

P2.06-003: CLINICAL SIGNIFICANCE OF DETECTION OF EGFR AND KRAS MUTATIONS IN PLASMA/PLEURAL EFFUSION IN PATIENTS WITH ADVANCED NSCLC
Zhengtang Chen, China

P2.06-004: SERUM LEVELS OF MUC1 GLYCOPROTEIN (IHC025) IN PRIMARY LUNG CANCER PATIENTS
Oleg Pikin, Russia

P2.06-005: THE HIGH INCIDENCE OF OVERLAP BETWEEN ACTIONABLE BIOMARKERS IN NSCLC: POTENTIAL IMPACT ON FUTURE CLINICAL TRIAL DESIGN
David Shames, USA

P2.06-006: CLINICAL AND PROGNOSTIC IMPORTANCE OF XIAP AND USP8 IN ADVANCED STAGES OF NON-SMALL CELL LUNG CANCER
Suleyman Buyukberber, Turkey

P2.06-007: META-ANALYSIS OF STAT3 AND P-STAT3 EXPRESSION AND SURVIVAL IN NON-SMALL-CELL LUNG CANCER
Shun Lu, China

P2.06-008: POLYMORPHISMS IN THE EXON 20 OF EGFR GENE IN METASTATIC LUNG ADENOCARCINOMA: PROGNOSTIC RELEVANCE AND SENSITIVITY TO ERLOTINIB.
Gilberto Castro Jr., Brazil

P2.06-009: SIMULTANEOUS PROFILING OF MULTIGENE MUTATIONS FOR THE EFFECTIVE AND EFFICIENT DIAGNOSIS OF NON-SMALL CELL LUNG CARCINOMA
Bing Yu, Australia

P2.06-010: ANALYTICAL PERFORMANCE OF THE COBAS EGFR MUTATION ASSAY FOR JAPANESE NON-SMALL CELL LUNG CANCER
Tatsuo Ohira, Japan

P2.06-011: PHOSPHORYLATED-AKT EXPRESSION IS A PROGNOSTIC MARKER IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
Po Yee Yip, Australia

P2.06-012: IMPACT OF EGFR T790M MUTATIONS AND BIM MRNA EXPRESSION ON PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) TREATED WITH ERLOTINIB OR CHEMOTHERAPY IN THE RANDOMIZED PHASE III EURTAC TRIAL
Rafael Rosell, Spain

P2.06-013:GENETIC PROFILING OF LUNG CANCER IN YOUNG ADULTS PATIENTS: EARLY DATA ASSESSMENT USING NEXT-GENERATION SEQUENCING.
Silvia Novello, Italy

P2.06-014: QUANTITATIVE TEST OF MUTANT EGFR AND ITS EFFECT ON EFFICACY OF EGFR TKI IN ADVANCED NSCLC
Jiayu Li, China

P2.06-015: NOVEL PLASMA PROTEINS ASSOCIATED WITH PROGNOSIS IN MALIGNANT PLEURAL MESOTHELIOMA
Steven Kao, Australia

P2.06-016: EXPRESSION AND CLINICAL SIGNIFICANCE OF THE MONOCARBOXYLATE TRANSPORTER MCT1 AS A NOVEL THERAPEUTIC TARGET IN SMALL-CELL-LUNG-CANCER (SCLC)
Alberto Fusi, UK

P2.06-017: LONG NON CODING RNAs (lncRNAs) ARE DYSREGULATED IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Casey Wright, Australia

P2.06-018: CORRELATION OF TS MRNA EXPRESSION LEVEL AND TS PROTEIN LEVEL DETECTED BY IMMUNOSTAINING FOR USE IN POST-OPERATIVE PRIMARY LUNG CANCER THERAPY
Noriyuki Matsutani, Japan
P2.06-019: EGFR MUTATION DETECTION IN CTDNA ISOLATED FROM NSCLC PATIENT PLASMA: A CROSS-PLATFORM COMPARISON OF LEADING TECHNOLOGIES
Kenneth Thress, USA

P2.06-020: PRETREATMENT THYMIDYLATED SYNTHASE PROTEIN EXPRESSION LEVELS REMAINS STABLE DURING PACLITAXEL AND CARBOPLATIN TREATMENT IN NON-SMALL CELL LUNG CANCER
Jens Sorensen, Denmark

P2.06-021: IS RRMI A PREDICTIVE MARKER FOR VINORELBINE EFFICACY - THE RESULTS FROM A COHORT OF MALIGNANT PLEURAL MESOTHELIOMAS TREATED WITH CISPLATIN AND VINORELBINE.
Jens Sorensen, Denmark

P2.06-022: USE OF THE REAL-TIME PCR AND MULTIPLEX LIGATION-DEPENDANT PROBE AMPLIFICATION (MLPA) ASSAY IN THE MOLECULAR DIAGNOSIS FOR NSCLC BIOMARKER DETECTION.
Mariusz Kowalewski, Poland

P2.06-023: GENE EXPRESSION SIGNATURE AND IMMUNOHISTOCHEMICAL ASSESSMENT OF NRF2 PATHWAY ACTIVATION FOR ADJUVANT CHEMOTHERAPY BENEFIT IN LUNG SQUAMOUS CELL CARCINOMA (SQCC)
Shingo Sakashita, Canada

P2.06-024: PROGNOSTIC VALUE OF RALA AND RALB OVEREXPRESSION IN KRAS MUTANT LUNG CANCER
Eun Young Kim, South Korea

P2.06-025: PROGNOSTIC IMPACT OF CXCL16 AND CXCR6 IN TWO NON-SMALL CELL LUNG CANCER COHORTS: COMBINED HIGH STROMAL AND TUMOR CELL CXCL16 EXPRESSION YIELDS AN IMPROVED SURVIVAL
Roy Bremnes, Norway

P2.06-026: ASSOCIATION OF NEW YORK-ESOPHAGEAL ANTIGEN-1 (NY-ESO-1) PROMOTER METHYLATION AND SURVIVAL IN STAGE III NON-SMALL CELL LUNG CANCER
Mun Sem Liew, Australia

P2.06-027: LOW FREQUENCY KRAS MUTATIONS IN COLORECTAL CANCER PATIENTS AND THE PRESENCE OF MULTIPLE MUTATIONS IN ONCOGENIC DRIVERS IN NON-SMALL CELL LUNG CANCER PATIENTS
Liyan Jiang, China

P2.06-028: ERCC1 MRNA EXPRESSION AND KRAS MUTATION STATUS IN EGFR WILD TYPE (WT) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Lucio Crino, Italy

P2.06-029: ALTERATIONS DETECTED IN GLYCERO PHOSPHOLIPID PROFILE OF LUNG CANCER TISSUE SAMPLES BY MASS SPECTROMETRY
Tanel Laisaar, Estonia

P2.06-030: RADIATION-INDUCED LUNG DAMAGE QUANTIFICATION WITH CT SCANS: CORRELATION WITH SINGLE NUCLEOTIDE POLYMORPHISMS
Dirk De Ruyscher, Belgium

P2.06-031: MUTATIONAL PROFILING OF SYNCHRONOUS BONE METASTASES FROM LUNG ADENOCARCINOMA: FEASIBILITY AND RESULTS IN A PROSPECTIVE COHORT OF 46 PATIENTS (POUMOS STUDY)
Nicolas Girard, France

P2.06-032: SMO MUTATIONS OCCUR IN NON-SMALL CELL LUNG CANCER (NSCLC) AND MAY RESPOND TO HEDGEHOG INHIBITORS
Anne Tsao, USA

P2.06-033: IDENTIFICATION OF IGF-1R ACTIVATION AS A CANDIDATE MOLECULAR TARGET IN KRAS-MUTATED LUNG CANCER
Hiroshi Mizuuchi, Japan

P2.06-034: ANALYSIS OF SENSITIVITY OF LUNG SQUAMOUS CARCINOMA WITH EGFR MUTATION TO EGFR-TKIS AND RESISTANT MECHANISM
Zhijie Wang, China

P2.06-035: ACQUIRED RESISTANCE IN NSCLC WITH EGFR MUTATION TREATED WITH TKI’S: SINGLE CENTER EXPERIENCE AND TREATMENT OUTCOME
Frank Griesinger, Germany

P2.06-036: DNA DAMAGE RESPONSE DURING CURATIVE RADIOThERAPy OF NON-SMALL CELL LUNG CANCER: IN-VIVO BIODOSIMETRY WITH PERIPHERAL BLOOD LYMPHOCYTES AND SYSTEMIC EFFECTS MEASURED IN HAIR FOLLICLES
Shankar Siva, Australia

P2.06-037: TRANSFORMING GROWTH FACTOR-1 GENETIC POLYMORPHISMS RELATE TO ERLOTINIB INDUCED DIARRHEA TRANSFORMING GROWTH FACTOR-1 GENETIC POLYMORPHISMS RELATE TO ERLOTINIB INDUCED DIARRHEA TRANSFORMING GROWTH FACTOR-1 GENETIC POLYMORPHISMS RELATE TO ERLOTINIB INDUCED DIARRHEA
Tatsuo Kimura, Japan

P2.06-038: COMPARISON OF EXPRESSION PROFILING OF CIRCULATING AND TISSUE MIRNAS LOOKING FOR POSSIBLE NON-INVASIVE BIOMARKERS FOR THE TREATMENT OF METASTATIC NSCLC PATIENTS: PRELIMINARY RESULTS.
Domenico Galetta, Italy

P2.06-039: THE STATUS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION, PROTEIN OVEREXPRESSION AND GENE AMPLIFICATION IN ESOPHAGEAL SQUAMOUS CELL CARCINOMAS
Yaping Xu, China
P2.06-040: CIRCULATING CYTOKINES AND ANGIOGENIC FACTORS (CAFs) AS MARKERS OF CLINICAL RESPONSE IN A RANDOMIZED PHASE II STUDY OF TRAMETINIB VS DOCETAXEL FOR PATIENTS WITH KRAS-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) (MEK114653, NCT01362296)
Hai Tran, USA

P2.06-041: PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR 165 (VEGF 165) IN ADVANCED NON-SMALL CELL LUNG CANCER
Mohamed Belal, Egypt

P2.06-042: THYMIDYLATED SYNTHASE EXPRESSION AS PREDICTIVE BIOMARKER OF Pemetrexed SENSITIVITY IN ADVANCED THORACIC CANCER PATIENTS.
Manuel Domine, Spain

P2.06-043: CYP1A1*2A POLYMORPHISM IS CORRELATE WITH EGFR EXON 19 MUTATION AND IS AN INDEPENDENT PROGNOSTIC INDICATOR FOR THE ADVANCED LUNG CANCER PATIENTS TREATED WITH EGFR-TKI
Yi-Long Wu, China

P2.06-044: THE INFLUENCE OF TP53 MUTATION ON THE PROGNOSIS OF PATIENTS WITH EARLY STAGE NON-SMALL CELL LUNG CANCER MAY DEPEND ON THE INTRATUMOR HETEROGENEITY OF THE MUTATION
Shin Yup Lee, South Korea

P2.06-045: C-MET EXPRESSION IN MALIGNANT MESOTHELIOMAS
Peter Illei, USA

P2.06-046: EML4-ALK MONITORING OF CRIZOTINIB RESPONSE IN BLOOD PLATELETS AND PLASMA OF NSCLC PATIENTS
Egbert Smit, Netherlands

P2.06-047: BLOCKER SEQUENCING - AN IMPROVEMENT IN SANGER SEQUENCING WHICH SUPERCHARGES LOW LEVEL MUTATION DETECTION
Benjamin Legendre, Jr., USA

P2.06-048: MALIGNANT MESOTHELIOMA LACKING MERLIN SHOWS ENHANCED SENSITIVITY TO THE FAK INHIBITOR VS-6063: EVALUATION OF MERLIN/NF2 STATUS IN CLINICAL SAMPLES
Mitchell Keegan, USA

P2.06-049: TTF1 NEGATIVE STATUS IS A NEGATIVE PREDICTOR OF BENEFIT TO ERLOTINIB (E) IN METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
Haris Charalambous, Cyprus

P2.06-050: VALIDATION AND UTILIZATION OF A CLINICAL NEXT GENERATION SEQUENCING ASSAY TO IDENTIFY MUTATIONS AND GENOMIC COPY NUMBER CHANGES IN LUNG CANCER
Charuhas Deshpande, USA

P2.07 Poster Session 2

P2.07-001: LONG-TERM LUNG CANCER SURVIVORS HAVE PERMANENTLY DECREASED QUALITY OF LIFE FOLLOWING SURGERY
Ilkka Ionen, Finland

P2.07-002: SENTINEL NODE BIOPSY REDUCES THE NEED FOR SYSTEMATIC MEDIASTINAL LYMPHADENECTOMY IN STAGE IA NSCLC
Nenad Ilic, Croatia

P2.07-003: SAMPLING VS. SYSTEMATIC FULL LYMPHATIC DISSECTION IN SURGICAL TREATMENT OF NON-SMALL CELL LUNG CANCER
Konstantinos Syrigos, Greece

P2.07-004: WEDGE RESECTION AND SEGMENTECTOMY IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER
Konstantinos Syrigos, Greece

P2.07-005: A COMPARATIVE STUDY OF DIAGNOSING AND STAGING BY MEDIASTINOSCOPY OR EBUS ON LUNG CANCER
Yang Shen-Tu, China

P2.07-006: PREDICTING FACTORS FOR EARLY AND LONG TERM MORTALITY AND COMPLICATIONS AFTER THORACOTOMY IN PATIENTS WITH PRIMARY LUNG CANCER
Cynthia Arkel, Netherlands

P2.07-007: SURGICAL TREATMENT OF ELDERLY PATIENTS WITH RESECTABLE LUNG CANCER
Yo Kawaguchi, Japan

P2.07-008: RADIOLOGICAL-PATHOLOGICAL CORRELATION FOR RESECTED SMALL LUNG NODULES WITH PURE GROUND GLASS OPACITY DETECTED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY
Masafumi Yamaguchi, Japan

P2.07-009: WHAT IS AN APPROPRIATE TREATMENT STRATEGY FOR SUPERIOR SULCUS TUMORS?
Takuma Tsukioka, Japan

P2.07-010: SURGICAL TREATMENT AND OUTCOME OF MULTIPLE PRIMARY LUNG CANCERS
Shizu Saito, Japan

P2.07-011: A PILOT STUDY ON THE EFFECTS OF PERIOPERARTIvE ADMINISTRATION OF THE NEUTROPHIL ELASTASE INHIBITOR, SIVELESTAT, TO NON-SMALL CELL LUNG CANCER PATIENTS WITH PREOPERATIVE RISK FACTORS OF ACUTE RESPIRATORY DISTRESS SYNDROME AFTER PULMONARY RESECTION
Takuro Kometani, Japan
P2.07-012: LONG-TERM RESULTS OF LIMITED RESECTION FOR SMALL ADENOCARCINOMA SHOWING GROUND-GLASS OPACITY
Takehiro Watanabe, Japan

P2.07-013: RISK FACTORS FOR LOCOREGIONAL FAILURE IN COMPLETELY RESECTED N1 NON-SMALL CELL LUNG CANCER WITHOUT POSTOPERATIVE RADIOTHERAPY
Eunjue Yi, South Korea

P2.07-014: INTRAPLEURAL PERFUSION HYPERTHERMIC CHEMOTHERAPY IN MALIGNANT PLEURAL EFFUSION AND PLEURAL SEEDING
Eunjue Yi, South Korea

P2.07-015: CLINICAL OUTCOME OF 16 EXTREMELY ELDER PATIENTS (85-YEAR-OLD OR OVER) WITH SURGICALLY RESECTED NON-SMALL CELL LUNG CANCER
Takahiro Yoshioka, Japan

P2.07-016: PERIOPERATIVE NUTRITION OF INDUCTION CHEMORADIOThERAPY FOLLOWED BY SURGERY IN LOCALLy ADVANCED NON-SMALL LUNG CANCER PATIENTS
Junichi Soh, Japan

P2.07-017: PULMONARY RESECTION FOR LUNG CANCER PATIENTS WITH CEREBROVASCULAR AND CARDIOVASCULAR COMORBIDITIES
Nobuhiro Izumi, Japan

P2.07-018: CURATIVE SURGERY IN LUNG CANCER: CASES PRESENTED AT MULTIDISCIPLINARY MEETINGS COMPARED WITH A CONTEMPORANEOUS CONTROL GROUP.
Philippa Bowers, Australia

P2.07-019: POSTOPERATIVE OUTCOME OF PATIENTS WITH PULMONARY LARGE-CELL NEUROENDOCRINE CARCINOMA
Tomohiro Koike, Japan

P2.07-020: CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS WITH UNEXPECTED PATHOLOGICAL N1 AND N2 LUNG CANCER
Tomohiro Haruki, Japan

P2.07-021: RESULTS OF SURGICAL TREATMENT FOR LUNG CANCER IN PATIENTS AGED 80 YEARS OR OVER - SINGLE INSTITUTION OVER 20 YEAR EXPERIENCE
Takuro Miyazaki, Japan

P2.07-022: PROGNOSTIC IMPLICATION OF CYTODIAGNOSIS OF MINUTE PLEURAL EFFUSION FOUND AT THORACOTOMY IN NSCLC PATIENTS
Mitsutoshi Shiba, Japan

P2.07-023: EXTENDED SLEEVE LOBECTOMY AFTER INDUCTION CHEMORADIOThERAPY FOR LOCALLy ADVANCED NON-SMALL CELL LUNG CANCER
Hiromasa Yamamoto, Japan

P2.07-024: PREDICTIVE FACTORS FOR POSTOPERATIVE MORBIDITY IN PATIENTS UNDERGOING ESOPHAGEAL CANCER:
Swamyvelu Krishnamurthy, India

P2.07-025: NEW PATHOLOGICAL CLASSIFICATION OF LUNG ADENOCARCINOMA IS USEFUL FOR SELECTING LIMITED CASES UNDERGOING SUBLOBAR RESECTION AS A CURATIVE SURGERY.
Akira Shimamoto, Japan

P2.07-026: DOES SURGEON GRADE INFLUENCE EARLY POSTOPERATIVE OUTCOMES IN MAJOR RESECTION FOR LUNG TUMORS?
C.S. Pramesh, India

P2.07-027: RETROSPECTIVE ANALYSIS OF 236 CONSECUTIVE ROBOTIC-ASSISTED PULMONARY LOBECTOMIES AT A SINGLE INSTITUTION: A BI-PHASIC LEARNING CURVE
Kathryn Rodriguez, USA

P2.07-028: PROVENCARE®: EVIDENCE BASED CARE TO OPTIMIZE LUNG CANCER RESECTION OUTCOMES
Nikhilesh Korgaonkar, USA

P2.07-029: CLINICAL FEATURES AND OUTCOME OF SURGICALLY RESECTED SECONDARY PRIMARY NON-SMALL CELL LUNG CANCER
Masatoshi Kikihana, Japan

P2.07-030: THE ROLE OF MEDIASTINAL LYMPh NODE DISSECTION DURING PULMONARY METASTASECTOMY IN PATIENTS WITH NO EVIDENCE OF MEDIASTINAL LYMPh NODE METASTASIS BASED ON PREOPERATIVE COMPUTED TOMOGRAPHY AND POSITRON EMISSION TOMOGRAPHY
Joo Yeon Kim, South Korea

P2.07-031: LOCALLy ADVANCED LUNG CANCER WITH LOW NODAL INVOLVEMENT AND CONCOMITANT TUBERCULOSIS IN A TERTIARY CARE CANCER CENTRE OF INDIA
Palaniappan Ramanathan, India

P2.07-032: VIDEO-ASSISTED THORACIC SURGERY VERSUS OPEN THORACOTOMY FOR NON-SMALL CELL LUNG CANCER - A META-ANALYSIS OF PROPENSITY SCORE MATCHED PATIENTS
Christopher Cao, Australia

P2.07-033: A COMPARATIVE STUDY OF COMPLETE VIDEO-ASSISTED THORACOSCOPIC LOBECTOMY AND VIDEO-ASSISTED MINI-THORACOTOMY IN TREATMENT OF LUNG CANCER
Yi Zhang, China

P2.07-034: AUDIT OF MEDIASTINAL LYMPh NODE (MLN) EXAMINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) RESECTIONS USING A SPECIMEN COLLECTION KIT AND CHECKLIST INTERVENTION.
Raymond Osarogiagbon, USA
P2.07-035: COMPARISON OF CANCER-SPECIFIC OUTCOMES BETWEEN OPEN AND MINIMALLY INVASIVE SURGERY (MIS) LOBECTOMY FOR EARLY STAGE NON-SMALL-CELL LUNG CANCER (NSCLC)
Candice Wilshire, USA

P2.07-036: LOWER-THAN-EXPECTED FEV1 AFTER UPPER LOBE RESECTION FOR LUNG CANCER IN THE EARLY POSTOPERATIVE PERIOD
Yuji Hirami, Japan

P2.07-037: MINIMALLY INVASIVE ANATOMIC SEGMENTECTOMY AS PRIMARY TREATMENT FOR LUNG LESIONS
Eserval Junior, Brazil

P2.07-038: ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER ARE OFTEN NOT OPERATED ON - RESULTS FROM A POPULATION-BASED STUDY
Tomas Gudbjartsson, Iceland

P2.07-039: SURVIVAL OUTCOME OF PATIENTS UNDERGOING SURGICAL RESECTION OF NSCLC IN BRUNEI DARUSSALAM
Chee Fui Chong, Brunei

P2.07-040: IS POSTOPERATIVE FEV1 (POFEV1) MORE ACCURATELY ESTIMATED BY FUNCTIONAL RESPIRATORY IMAGING (FRI) THAN BY CONVENTIONAL METHODS?
Jan Van Meerbeeck, Belgium

P2.07-041: TALC PLEURODESIS OR IPC FOR MALIGNANT PLEURAL EFFUSION. IS IT TIME TO CHANGE?
Annabel Sharkey, UK

P2.07-042: IS PLASMA FIBRINOGEN A NOVEL INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS UNDERGOING SURGERY FOR NON-SMALL CELL LUNG CANCER?
Matthew Smith, UK

P2.07-043: EFFECT OF FEMALE GENDER ON PERI-OPERATIVE OUTCOMES AFTER ROBOTIC-ASSISTED PULMONARY LOBECTOMY: RETROSPECTIVE ANALYSIS OF 180 CONSECUTIVE CASES
Frank Velez-Cubian, USA

P2.07-044: RISK FACTORS FOR RECURRENCE AFTER PATHOLOGICAL STAGE IA NON-SMALL CELL LUNG CANCER RESECTION
Yoshimi Otani, Japan

P2.07-045: POST LUNG SURGERY REHABILITATION
Pernille Mikkelsen, Denmark

P2.07-046: EFFECT OF AIRWAY STENTING ON QUALITY OF LIFE (QOL) IN PATIENTS WITH MALIGNANT AIRWAY OBSTRUCTION: A SINGLE INSTITUTIONAL EXPERIENCE AT MAYO CLINIC ARIZONA (MCA)
Harshita Paripati, USA

P2.07-047: A NEW MINIMALLY INVASIVE SURGICAL TECHNIQUE TO ACCESS A FUSED PLEURAL SPACE FOR BIOPSY, GENE THERAPY OR OTHER NOVEL INTRAPELURAL THERAPEUTICS - A REPORT OF 34 PATIENTS
Joseph Friedberg, USA

P2.07-048: CAUSES, PREDICTORS AND CONSEQUENCES OF CONVERSIONS IN VATS LOBECTOMY FOR NSCLC
Johannes Bodner, Germany

P2.07-049: QUANTIFICATION OF RADIATION DOSE ALONG THE ESOPHAGUS AND PROXIMAL STOMACH IN ESOPHAGEAL CANCER PATIENTS TREATED WITH NEO-ADJUVANT CHEMORADIOThERAPY AND RISk OF ANASTAMOTIC COMPLICATION
Jason Pantarotto, Canada

P2.07-050: SHORT TERM PREOPERATIVE EFFICACY OF TIOTROPIUM FOR PATIENTS WITH RESECTABLE LUNG CANCER AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: PRELIMINARY RESULTS OF ONE ARM PROSPECTIVE STUDY
Takeshi Matsunaga, Japan

P2.08 Poster Session 2 Radiotherapy

P2.08-001: START OF PHASE TRANSITION “NORM---EARLY LUNG CANCER” SIGNIFICANTLY DEPENDED ON BLOOD IMMUNE CELL CIRCUIT
Oleg Kshivets, Russia

P2.08-002: MODERN POST-OPERATIVE RADIOThERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER MAY IMPROVE LOCAL CONTROL AND SURvIvAL: A PUBLICATION-BASED META-ANALySIS
Dirk De Ruyscher, Belgium

P2.08-003: INVOLVED-FIELD RADIOThERAPY VERSUS ELECTIVE NODAL IRRADIATION IN COMBINATION WITH CONCURRENT CHEMOTHERAPY FOR LOCALLy ADVANCED NON-SMALL CELL LUNG CANCER: A PROSPECTIVE RANDOMIZED STUDY
Ming Chen, China

P2.08-004: IMPACT OF MEDICAL CO-MORBIDITIES ON SURvIvAL IN PATIENTS TREATED WITH STEREOTACTIC BODY RADIOThERAPY FOR EARLY STAGE NON-SMALL CELL LUNG CANCER
Mei Ling Yap, Canada
P2.08-005: 4D-PET/CT-BASED ADAPTIVE DOSE ESCALATED RADIOThERAPY (RT) IN LOCALLy ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) Mei Ling Yap, Canada

P2.08-006: EFFICACY OF SINGLE DOSE 8-GY PALLIATIvE CHEST IRRADIATION IN PAIN PALLIATION OF PATIENTS WITH LOCCOREGIONALLY RECURRENT STAGE IV NON-SMALL CELL LUNG CANCER Erkan Topkan, Turkey

P2.08-007: IMPACT SURGICAL RESECTION AND RADIOSURGERY DIRECTED TO BRAIN METASTASIS ON SURVIVAL OUTCOMES IN NON-SMALL CELL LUNG CANCER PATIENTS WITH SYMPTOMATIC SINGLE BRAIN METASTASIS Erkan Topkan, Turkey

P2.08-008: A PROSPECTIVE STUDY TO DETERMINE INTER-OBSERVER VARIABILITY OF GROSS TUMOR VOLUME WITH FDG-PET/CT COMPARED TO CT ALONE IN STAGE III NON-SMALL CELL LUNG CANCER USING THREE-DIMENSIONAL ANALYSIS. Naseer Ahmed, Canada

P2.08-009: STEREOTACTIC ABLATIvE BODY RADIOThERAPY (SABR) OUTCOMES FOR PRIMARY AND METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PULMONARY TUMORS Isabelle Thibault, Canada

P2.08-010: OUTCOME OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATED (EGFRM) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P) WITH BRAIN METASTASES (BM) IN A SINGLE INSTITUTION: VALUE OF THE LUNG-GPA CLASSIFICATION Felipe Cardenal, Spain

P2.08-011: UTILITy OF MRI IN LUNG CANCER RADIOThERAPY: A LITERATURE REVIEW Shivani Kumar, Australia

P2.08-012: TREATMENT OF MULTIPLE PRIMARY LUNG CANCERS (MPLC) WITH STEREOTACTIC ABLATIVE RADIOThERAPY (SABR) Gwendolyn Griffioen, Netherlands

P2.08-013: PROTON RADIOThERAPY FOR LOCALLy-ADvANCED NON-SMALL CELL LUNG CANCER, A COST-EFFECTIVE ALTERNATIVE TO PHOTON RADIOThERAPY IN BELGIUM? Yolande Lievens, Belgium

P2.08-014: THE INFLUENCE OF AGE ON THE OUTCOME OF CONCURRENT CHEMO-RADIOThERAPY IN LOCALLy ADVANCED NSCLC Olfred Hansen, Denmark

P2.08-015: STEREOTACTIC BODY RADIOThERAPY WITH HELICAL TOMOTHERAPY FOR LUNG TUMOR: TREATMENT OUTCOME AND FEASIBILITY Sung Hwan Kim, South Korea

P2.08-016: USE OF PALLIATIvE RADIOThERAPY IN LUNG CANCER DURING THE LAST WEEKS OF THE LIFE. Amela Tursunovic, Denmark

P2.08-017: INCREASING EXPECTED LOCAL CONTROL FOR LOCALLy ADVANCED NSCLC PATIENTS WITH INHOMOGENEOUS DOSE-ESCALATION Tine Nielsen, Denmark

P2.08-018: INTEROBSERVER VARIABILITY IN TARGET VOLUME DELINEATIONS IN POSTOPERATIVE RADIOThERAPY FOR NSCLC. Tine Schytte, Denmark

P2.08-019: PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT OR PEMETREXED CONTINUATION MAINTENANCE TREATMENT IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A REPORT OF PATIENT SAFETY IN THE PARAMOUNT TRIAL Nadia Chouaki, France

P2.08-020: PROGNOSITC PARAMETERS FOR LOCAL AND REGIONAL CONTROL IN LOCALLy ADVANCED NSCLC PATIENTS TREATED WITH CONCURRENT CHEMO-RADIOThERAPY Chun Chen, Netherlands

P2.08-021: COMPARISON OF TWO RADIOThERAPY PLANNING TECHNIQUES FOR STAGE IIIA AND IIIB NSCLC: VOLUMETRIC MODULATED ARC THERAPY (VMAT) VS 3D CONFORMAL RADIOThERAPY (3DCRT) Katherine Small, Australia

P2.08-022: NON-SMALL CELL LUNG CANCER (NSCLC): CHANGES IN VOLUME DURING RADIOThERAPY AND POTENTIAL ADAPTIvE RADIOThERAPY PLANNING Ge Kai Ho, Australia

P2.08-023: INTENSITY-MODULATED RADIATION THERAPY FOR INOPERABLE NON-SMALL CELL LUNG CANCER: EXPERIENCE AT SAMSUNG MEDICAL CENTER Yong Chan Ahn, South Korea

P2.08-024: A NEW DOSE CONSTRAINT REDUCE THE INCIDENCE AND SEVERITY OF RADIATION-INDUCED PNEUMONITIS IN LOCALLy ADVANCED NSCLC TREATED WITH INTENSITY-MODULATED RADIOThERAPY Azza Khalil, Denmark

P2.08-025: A STUDY OF RESPIRATORy-INDUCED TUMOUR MOTION BASED ON ANATOMICAL LUNG LOCATION USING 4DCT IN LUNG CANCER PATIENTS Shankar Siva, Australia

P2.08-026: PROSPECTIvE STUDY OF STAGE I NON-SMALL-CELL LUNG CANCER TREATED WITH HYPOFRACTIONATED SIB IMRT Baosheng Li, China
P2.08-027: ATLAS SEGMENTATION FOR LUNG STEREOTACTIC ABLATIVE RADIOTHERAPY
Fiona Hegi-Johnson, Australia

COMBINED MODALITY

P2.09 Poster Session 2
Combined Modality

P2.09-001: PHASE II STUDY OF CONCURRENT CHEMO-RA DIOTHERAPY (CRT) WITH WEEKLY CISPLATIN PLUS ORAL VINORELBINE IN FIT ELDERLY PATIENTS WITH NONRESECTABLE LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) ASSESSED BY STANDARDIZED GERIATRIC ASSESSMENT (RACCOSA, GFPC 08-06 STUDY): INTERIM ANALYSIS.
Chrystele Locher, France

P2.09-002: PROGNOSTIC IMPACT OF CONVENTIONAL AND MODIFIED MEASUREMENT OF MEDIASTINAL LYMPH NODE INVOLVEMENT IN THE OUTCOME OF PATIENTS WITH RESECTED LOCALLY ADVANCED NON-SMALL CELL LUNG CANCERS PREVIOUSLY TREATED WITH INDUCTIVE CHEMO OR CHEMORADIATION
Diego Marquez-Medina, Spain

P2.09-003: CONCURRENT CHEMORADIATION (CCHRT) FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II STUDY FROM THE GALICIAN LUNG CANCER GROUP.
Joaquin Casal, Spain

P2.09-004: PHASE II STUDY OF SEQUENTIAL VERSUS CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY IN POOR RISK PATIENTS WITH INOPERABLE STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): FINAL RESULTS OF THE SPANISH LUNG CANCER GROUP 00-05 STUDY
Felipe Cardenal, Spain

P2.09-005: CISPLATIN, S-1 AND CONCURRENT THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER: A PHASE II STUDY OF OKAYAMA LUNG CANCER STUDY GROUP 0501
Hiroshi Ueoka, Japan

P2.09-006: LONG-TERM RESULTS OF A PHASE II TRIAL OF S-1 AND CISPLATIN WITH CONCURRENT THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
Tateaki Naito, Japan

P2.09-007: COMPARISON OF TOXICITY AND OUTCOMES OF CONCURRENT RADIOTHERAPY WITH CARBOPLATIN/PACLITAXEL AND CISPLATIN/ETOPOSIDE IN STAGE III NON-SMALL CELL LUNG CANCER
Mun Sem Liew, Australia

P2.09-008: CONCURRENT CHEMORADIOThERAPY (CCTRT) FOR LOCALLY ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) FOLLOWED BY CONSOLIDATION PEmETREXED: A PHASE II STUDY
Corinne Faivre-Finn, UK

P2.09-009: IMPACT OF CHANGE IN HEMOGLOBIN LEVELS DURING TREATMENT ON PROGNOSIS IN NON-ANEMIC LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY
Erkan Topkan, Turkey

P2.09-010: VARIATION IN THE UPTAKE OF THE COMBINED MODALITY PRACTICE GUIDELINE FOR SURGICALLY UNRESECTABLE STAGE III NSCLC IN ONTARIO
William Evans, Canada

P2.09-011: TUMOR ARISING FROM LOWER LOBES IS A POOR PROGNOSTIC FACTOR IN NON-SMALL CELL LUNG CANCER PATIENTS WITH N2 DISEASE TREATED WITH INDUCTION CHEMORADIOTHERAPY
Ken Suzawa, Japan

P2.09-012: PROGNOSTIC VALUE OF TUMOR SURVIVIN EXPRESSION IN STAGE III NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH PLATINUM-BASED CHEMORADIATION THERAPY FOLLOWED BY SURGERY
Hyeong Ryul Kim, South Korea

P2.09-013: TREATMENT OUTCOME IN 136 PATIENTS (PTS) WITH INOPERABLE OR IRRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC), STAGED WITH PET-SCAN, TREATED WITH CONCURRENT (CC) LOW-DOSE DAILY CISPLATIN AND HIGH-DOSE RADIOTHERAPY
Willemin Kolff, Netherlands

P2.09-014: CONCOMITANT CHEMORADIOTHERAPY USING DOCETAXEL AND CISPLATIN FOR UNRESECTABLE STAGE III LUNG SQUAMOUS CELL CARCINOMA
Yaping Xu, China

P2.09-015: ROLE OF POSTOPERATIVE RADIOTHERAPY AFTER CURATIVE RESECTION AND ADJUVANT CHEMOTHERAPY FOR PATIENTS WITH PATHOLOGICAL STAGE N2 NON-SMALL CELL LUNG CANCER: A PROPENSITY SCORE MATCHING ANALYSIS
Hak Jae Kim, South Korea

P2.09-016: A FEASIBILITY STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISPLATIN, PEMETREXED AND BEVACIZUMAB FOLLOWED BY SURGERY FOR NONSQUAMOUS NON-SMALL-CELL LUNG CANCER
Kazuya Takamochi, Japan
P2.09-017: PHASE III STUDY OF CONCURRENT CISPLATIN WITH PEMTREXED VERSUS VINORELBINE AND LCAhRT FOR UNRESECTABLE STAGE III NSCLC
Baosheng Li, China

P2.09-018: INCORPORATING ERLOTINIB INTO INDUCTION CHEMOTHERAPY FOLLOWED BY CONCURRENT CHEMORADIATION OF UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER ACCORDING TO EGFR MUTATION STATUS: PRELIMINARY RESULT OF A RANDOMIZED PHASE II STUDY
Jin Soo Lee, South Korea

P2.10 Poster Session 2
Chemotherapy

P2.10-001: MODELLING OF COST EFFECTIVENESS IN ADVANCE NSCLC OF A FOUR ARM TREATMENT SEQUENCE WITH BIOMARKERS. USING A FILEMAKER APP
John Davidson, Australia

P2.10-002: PHASE I DOSE ESCALATION STUDY OF PEMTREXED AND CARBOPLATIN IN CHEMOTHERAPY-NAIVE ELDERLY PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.
Hiroaki Takeoka, Japan

P2.10-003: A MULTICENTER, PROOF-OF-CONCEPT STUDY OF SHORT-TERM SUPPLEMENTATION OF FOLIC ACID AND VITAMIN B12 PRIOR TO CISPLATIN-PEMETREXED THERAPY FOR NON-SMALL CELL LUNG CANCER.
Yusuke Takagi, Japan

P2.10-004: ADDITION OF BEVACUZIMAB (BEV) TO PEMTREXED (PEM) PLUS CISPLATIN (CIS) INDUCTION AND PEM MAINTENANCE THERAPY IN 1ST LINE SETTING FOR TREATMENT OF ADVANCED NONSQUAMOUS NON SMALL CELL LUNG CANCER (NS-NSCLC) - FINAL RESULTS AND SAFETY UPDATE FROM A PHASE 2 STUDY
Gunnar Hillerdal, Sweden

P2.10-005: ERLOTINIB (E) CAN BE SAFELY ADMINISTERED IN PTS > 80 YEARS OLD
Ioannis Gkiozos, Greece

P2.10-006: PROGNOSTIC VALUE OF THE RATIO OF POSITRON EMISSION UPTAKE TO PRIMARY TUMOR SIZE IN ADVANCED NON-SMALL CELL LUNG CANCER
Yong Song, China

P2.10-007: PHASE II TRIAL OF PEMETREXED AND CARBOPLATIN FOLLOWED BY PEMETREXED CONTINUATION-MAINTENANCE THERAPY IN PREVIOUSLY UNTREATED ADVANCED NON-SMALL CELL LUNG CANCER
Kazumi Nishino, Japan

P2.10-008: ESTABLISHING THE OPTIMAL NEBULIZATION SYSTEM FOR PACITAXEL, DOCETAXEL, CISPLATIN, CARBOPLATIN AND GEMCITABINE; BACK TO DRAWING THE RESIDUAL CUP.
Konstantinos Zarogoulidis, Greece

P2.10-009: INTRINSIC AND ACQUIRED RESISTANCE PATTERNS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
David Stewart, Canada

P2.10-010: FULL ORAL VINORELBINE (NVBO) ON D1 AND D8 WITH CARBOPLATIN (CBDCA) AS FIRST LINE TREATMENT IN ADVANCED NON-SMALL LUNG CANCER (NSCLC) PATIENTS: RESULTS OF A PROSPECTIVE STUDY IN NONRANDOMIZED AND UNSELECTED POPULATION OF 396 PATIENT
Jana Skrickova, Czech Republic

P2.10-011: PEMETREXED IN COMBINATION WITH CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SQUAMOUS NSCLC: CZECH EXPERIENCE WITH 233 PATIENTS
Jana Skrickova, Czech Republic

P2.10-012: EVALUATION OF AMRUBICIN AS A THIRD OR LATER LINE OF CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
Satoshi Igawa, Japan

P2.10-013: RANDOMIZED NON COMPARATIVE MULTICENTER PHASE II STUDY OF SEQUENTIAL ERLOTINIB WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH NON SMALL CELL LUNG CANCER (NSCLC) AFTER FAILURE OF FIRST LINE CHEMOTHERAPY (TARSEQ): A GFPC 10.02 STUDY.
Alain Vergnenegre, France

P2.10-014: A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACITAXEL IN PATIENTS WITH NON-SQUAMOUS (NON-SQ) NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING MUTATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE AFTER FAILING FIRST-LINE EGFR-TYROSINE KINASE INHIBITORS (TKIS) HANSHIN ONCOLOGY GROUP 0109
Yoshinobu Namba, Japan

P2.10-015: LESS TOXIC CHEMOTHERAPY IMPROVES UPTAKE OF ALL LINES OF CHEMOTHERAPY IN ADVANCED NON SMALL CELL LUNG CANCER, PARTICULARLY IN THE ELDERLY: A TEN YEAR RETROSPECTIVE POPULATION-BASED REVIEW
Nevin Murray, Canada
P2.10-016: PHASE II STUDY OF GEFITINIB AND INSERTED CISPLATIN PLUS DOCETAXEL AS A FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION
Shintaro Kanda, Japan

P2.10-017: EFFICACY OF PEMETREXED IN ADVANCED NON-SMALL CELL LUNG CANCER WITH ASYMPTOMATIC BRAIN METASTASES
Hidenori Kitai, Japan

P2.10-018: DRUG SELECTION IN NON-SMALL CELL LUNG CANCER PATIENTS: PERSPECTIVE OF KOREAN PHYSICIAN
Choonhee Son, South Korea

P2.10-019: A PROSPECTIVE COHORT STUDY OF NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH BEVACIZUMAB
Katsuhiro Naoki, Japan

P2.10-020: DOSE ESCALATION AND PHARMACOKINETIC STUDY OF CARBOPLATIN AND PEMETREXED FOR ELDERLY PATIENTS WITH ADVANCED NON-SQUAMOUS, NON-SMALL-CELL LUNG CANCER: KUMAMOTO THORACIC ONCOLOGY STUDY GROUP TRIAL 1002
Sho Saeki, Japan

P2.10-021: THE EFFECT OF GEFITINIB IN PATIENTS WITH POSTOPERATIVE RECURRENT NON-SMALL CELL LUNG CANCER HARBOURING MUTATIONS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR.
Ryo Ko, Japan

P2.10-022: PROSPECTIVE OBSERVATIONAL COHORT STUDY OF SECOND-LINE CHEMOTHERAPY ADMINISTRATION AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NSCLC IN JAPAN (SAPPHIRE STUDY)
Yasushi Goto, Japan

P2.10-023: FEASIBILITY STUDY OF PEMETREXED (PEM) PLUS BEVACIZUMAB (BV) AS THE FIRST-LINE TREATMENT FOR ELDERLY ADVANCED OR RECURRENT NON-SQUAMOUS (NON-SQ) NON-SMALL CELL LUNG CANCER (NSCLC): TORG1015.
Toshiyuki Kozuki, Japan

P2.10-024: USEFULNESS OF CREATININE/CYSTATIN C RATIO AS A PREDICTIVE MARKER FOR ADVERSE EFFECTS OF CHEMOTHERAPY.
Kensuke Suzuki, Japan

P2.10-025: WEEKLY PACLITAXEL (WPCT) FOR PRE-TREATED PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A SINGLE INSTITUTION EXPERIENCE IN THE DAILY CLINICAL PRACTICE.
Orazio Caffo, Italy

P2.10-026: FINAL RESULTS OF EGFR MUTATION REANALYSIS AND KRAS MUTATION SCREENING BY SCORPION ARMS METHOD: PHASE II STUDY OF ERLOTINIB FOR EGFR WILD TYPE NON-SMALL CELL LUNG CANCER PATIENTS. CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0903 TRIAL.
Eiichi Maruyama, Japan

P2.10-027: MUTATION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE AND EFFICACY OF GEFITINIB IN SQUAMOUS CELL CARCINOMA OF LUNG
Toshiro Miwa, Japan

P2.10-028: EFFICACY AND SAFETY OF ERLOTINIB IN ELDERLY VERSUS NON-ELDERLY PATIENTS: ANALYSIS OF THE POLARSTAR STUDY OF 9,909 JAPANESE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ERLOTINIB.
Taro Koba, Japan

P2.10-029: EDUCATING COMMUNITY HEALTH PROFESSIONALS ABOUT LUNG CANCER: A PILOT EVALUATION OF A WEB-BASED EDUCATIONAL TOOL
P. Ellis, Canada

P2.10-030: EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) SCORE: AGREEMENT BETWEEN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS AND THEIR ONCOLOGISTS AND CLINICAL IMPLICATIONS
Marie Malalasekera, Australia

P2.10-031: CHINESE RANDOMIZED PHASE II TRIAL OF CUSTOMIZED CHEMOTHERAPY BASED ON BRCA1-RAP80 MRNA EXPRESSION IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) (CHICTR-TRC-12001860/BREC-CHINA)
Lifeng Wang, China

P2.10-032: PALLIATIVE CHEMOTHERAPY OF LUNG CANCER IN ELDERLY: SINGLE CENTER EXPERIENCES
Jaemin Jo, South Korea

P2.10-033: PHASE II STUDY OF WEEKLY AMRUBICIN IN PATIENTS WITH REFRACTORY OR RELAPSED NON-SMALL CELL LUNG CANCER
Masahiro Iwasaku, Japan

P2.10-034: IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)
Faysal Dane, Turkey

P2.10-035: EGFR MUTATION (M) STATUS IN SERUM ONLY TO TREAT NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P)
Enric Carcereny, Spain
P2.10-036: OVERALL SURVIVAL AND HOSPITALIZATION RATES IN MEDICARE PATIENTS DIAGNOSED WITH ADVANCED NSCLC TREATED WITH BEVACIZUMAB-PACLITAXEL-CARBOPLATIN VS PACLITAXEL-CARBOPLATIN: A RETROSPECTIVE COHORT STUDY
Corey Langer, USA

P2.10-037: EFFICACY AND SAFETY OF MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NONSQAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) AFTER COMPLETING AT LEAST 4 CYCLES OF PEMETREXED PLUS CISPLATIN INDUCTION TREATMENT: A CROSS-TRIAL ANALYSIS OF TWO PHASE III TRIALS
Giorgio Scagliotti, Italy

P2.10-038: NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PREDICTIVE FACTORS
Vera Hirsh, Canada

P2.10-039: OUTCOMES OF FIRST LINE BEVACIZUMAB-BASED CHEMOTHERAPY FOR NSCLC RELATIVE TO THE MEDICATIONS USED TO CONTROL HYPERTENSION (HTN).
Haythem Ali, USA

P2.10-040: PROGNOSTIC SIGNIFICANCE, ACCURACY AND USEFULNESS OF ONCOLOGISTS’ ESTIMATES OF SURVIVAL TIME FOR PATIENTS STARTING FIRST-LINE CHEMOTHERAPY FOR ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Belinda Kiely, Australia

P2.10-041: OPTIMISING REGULATORY T CELL (TREG) DEPLETION IN COMBINATION WITH CHEMOTHERAPY FOR ENHANCED ANTI-TUMOUR IMMUNITY
Anna Nowak, Australia

P2.10-042: LUNG CANCER AMONG SWEDISH AND IMMIGRANTS. INCIDENS, HISTOPATHOLOGY, TREATMENT AND SURVIVAL.
Hirsh Koyi, Sweden

P2.10-043: PHASE II STUDY OF BIWEEKLY IRINOTECAN PLUS BEVACIZUMAB IN HEAVILY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Andres Cardona, Colombia

P2.10-044: IMPACT OF COMORBIDITIES ON SURVIVAL IN ELDERLY PATIENTS WITH NON SMALL CELL LUNG CANCER.
Ozden Altundag, Turkey

P2.10-045: PHASE II STUDY OF PEMETREXED (PEM) + CARBOPLATIN (CB) + BEVACIZUMAB (BEV) AS FIRST LINE THERAPY FOR NON-SQAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WITHOUT EGFR MUTATION. CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0909 TRIAL.
Yasuhiro Goto, Japan

P2.10-046: A PHASE I/II STUDY OF BEXAROTENE WITH WEEKLY PACLITAXEL AND CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
Konstantin Dragnev, USA

P2.10-047: THE THREE-DRUGS REGIMEN CPBEV (CIS-PLATINUM, PEMETREXED AND BEVACIZUMAB) IS VERY ACTIVE WHEN USED AS FIRST-LINE THERAPY FOR LOCALLY ADVANCED OR METASTATIC ADENOCARCINOMA OF THE LUNG: FINAL RESULTS OF A PHASE III TRIAL.
Hector Soto-Parrar, Italy

P2.10-048: THERAPEUTIC EFFICACY OF GEFITINIB FOR POSTOPERATIVE RECURRENT CANCER IN PATIENT WITH EGFR MUTATION
Takefumi Oikawa, Japan

P2.10-049: LUNG AND BONE METASTASIS ARE ASSOCIATED WITH DIFFERENT RESPONSE AND DISEASE CONTROL RATE OF FIRST-LINE THERAPY IN PATIENTS WITH ADENOCARCINOMA OF LUNG.
Yung-Hung Luo, Taiwan

P2.10-050: EFFICACY OF DENOSUMAB IN PATIENTS WITH METASTATIC LUNG CANCER WITH EGFR MUTATIONS
Yoshihiro Suido, Japan

P2.10-051: THE FINAL ANALYSIS OF PROSPECTIVE, FEASIBILITY STUDY OF S-1 AND CARBOPLATIN COMBINATION CHEMOTHERAPY FOR THE PATIENTS WITH INTERSTITIAL PNEUMONIA (IP) AND ADVANCED NON SMALL CELL LUNG CANCER (NSCLC).
Terufumi Kato, Japan

P2.11 Poster Session 2
NSCLC Novel Therapies

P2.11-001: ALK GENOTYPING VIA LIQUID BASED THINPREP SLIDES PREPARED FROM FINE NEEDLE ASPIRATES IN NSCLC
Raymond Tubbs, USA

P2.11-002: A PROSPECTIVE, OPEN-LABELED, RANDOMIZED, MULTICENTER PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ERLOTINIB VS NP CHEMOTHERAPY AS ADJUVANT THERAPY IN POST RADICAL OPERATION STAGE IIIA NSCLC PATIENTS WITH EGFR 19 OR 21 EXON MUTATION (EVA32001, NCT015263175)
Dongsheng Yue, China

P2.11-003: HOW TO MAKE THE CHOICE IN THE REUSE OF EGFR-TKI FOR ADVANCED NSCLC PATIENTS WHO BENEFITED FROM PRIOR GEFITINIB THERAPY: THE ORIGINAL DRUG OR SWITCHING TO A SECOND EGFR-TKI?
Xiaoqing Liu, China
P2.11-004: A PHASE IB, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOLOGY OF PI3-KINASE (PI3K) INHIBITOR GDC 0941 IN COMBINATION WITH EITHER PACLITAXEL (PAC) AND CARBOPLATIN (CARBO) WITH OR WITHOUT BEVACIZUMAB (BEV), OR PEMETREXED (PEM), CISPLATIN (CIS), AND BEV IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).
Grace Dy, USA

P2.11-005: RANDOMIZED PHASE II STUDY OF PEMETREXED V. PEMETREXED/BEVACIZUMAB V. CARBOPLATIN/PEMETREXED/BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER AND POOR PERFORMANCE STATUS
David Spigel, USA

P2.11-006: REVIEW OF 10 YEARS OF ASCO ABSTRACTS FOR NON-SMALL CELL LUNG CANCER (NSCLC) AND THE IMPACT OF MOLECULAR BIOMARKERS (MB) IN CLINICAL TRIAL SELECTION CRITERIA
Ryan Gentzler, USA

P2.11-007: RELEVANCE BETWEEN CEA LEVEL AND EGFR MUTATION, EFFICACY OF EGFR-TKI IN PATIENTS WITH LUNG ADENOCARCINOMA
Hui Han, China

P2.11-008: HIGH PROPORTION OF UNUSUAL EGFR MUTATIONS IN AN AUSTRALIAN POPULATION OF NON-SQUAMOUS NSCLC
Henry Ainge-Allen, Australia

P2.11-009: ERLOTINIB IN METASTATIC PULMONARY ADENOCARCINOMAS HARBOURING EGFR ACTIVATING MUTATIONS, IN SAO PAULO - BRAZIL.
Rafael Caires-Lima, Brazil

P2.11-010: PHASE I STUDY OF HM61713, A NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT SELECTIVE INHIBITOR, IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS HAVING AN ACTIVATING EGFR MUTATION BUT FAILED TO PRIOR EGFR TYROSINE KINASE INHIBITOR (TKI) THERAPY.
Dong-Wan Kim, South Korea

P2.11-011: A PHASE IB STUDY OF HIGH-DOSE INTERRMITTENT (HDI) AFATINIB IN EGFR T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR TKIS
D. Ross Camidge, USA

P2.11-012: PHASE IA/IB STUDY OF THE ANTI-MET ANTIBODY ONARTUZUMAB (METMAB) IN PATIENTS WITH SOLID TUMORS OR MET-POSITIVE LUNG CANCER
Hidehito Horinouchi, Japan

P2.11-013: A RANDOMISED PHASE II TRIAL OF OLAPARIB MAINTENANCE VERSUS PLACEBO MONOTHERAPY IN PATIENTS WITH CHEMOSENSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Dean Fennell, UK

P2.11-014: BIOMARKERS REDUCE CLINICAL TRIAL RISK AND THE COST OF DRUG DEVELOPMENT IN NON-SMALL CELL LUNG CANCER (NSCLC)
Gilberto Lopes, USA

P2.11-015: COMPARATIVE EFFECTIVENESS OF Gefitinib, Erlotinib, Afatinib AND CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
Gilberto Lopes, USA

P2.11-016: A COMPARATIVE ANALYSIS OF EGFR MUTATION STATUS IN ASSOCIATION WITH THE EFFICACY OF TKI IN COMBINATION WITH WBRT/SRS/SURGERY PLUS CHEMOTHERAPY IN BRAIN METASTASIS FROM NON-SMALL CELL LUNG CANCER
Lanjun Zhang, China

P2.11-017: ICOTINIB IN ADVANCED LUNG ADENOCARCINOMA PATIENTS PRETREATED WITH PEMETREXED
Nong Xu, China

P2.11-018: EGFR MUTATIONS IN NSCLC PATIENTS IN CENTRAL EUROPE: THE INSIGHT OBSERVATIONAL STUDY
Robert Pirker, Austria

P2.11-019: TREATMENT STRATEGIES IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NSCLC IN CENTRAL EUROPE: FINDINGS FROM THE INSIGHT OBSERVATIONAL STUDY
Peter Berzinec, Slovakia

P2.11-020: SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
Atsushi Horiike, Japan

P2.11-021: INTERIM OUTCOME ANALYSIS OF PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN IN UNRESECTABLE, LOCALLY ADVANCED LUNG ADENOCARCINOMA
Si-yu Wang, China

P2.11-022: PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFTINIB IN CAUCASIAN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): POST-HOC EXPLORATORY ANALYSES OF EGFR MUTATIONS IN PLASMA-DERIVED CFDNA SAMPLES
Jean-Yves Douillard, France
P2.11-023: BE-POSITIVE: GEFRITINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS HARBORING ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS. A COMBINED RETROSPECTIVE AND PROSPECTIVE ANALYSIS FROM ITALIAN PATIENTS.
Silvia Novello, Italy

P2.11-024: EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
Silvia Novello, Italy

P2.11-025: ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
Abraham Wu, USA

P2.11-026: RET FUSION-POSITIVE ADVANCED LUNG CANCERS: RESPONSE TO FIRST-LINE CHEMOTHERAPY AND SURVIVAL IN COMPARISON TO ROS1 AND ALK FUSION-POSITIVE AND EGFR- AND KRAS-MUTANT LUNG CANCERS
Alexander Drilon, USA

P2.11-027: THE RESPONSE OF NON-ADENOCARCINOMA NON-SMALL-CELL LUNG CANCER PATIENTS WITH EGFR MUTATIONS TO EGFR-TKI: A RETROSPECTIVE MULTICENTER STUDY (LOGIK 1104)
Kenji Sugio, Japan

P2.11-028: ERLOTINIB SALVAGE THERAPY IN PULMONARY ADENOCARCINOMA PATIENTS WHO HAD DISEASE PROGRESSED AFTER PREVIOUS EGFR-TKI TREATMENT AND PLATINUM-BASED CHEMOTHERAPIES
Wen-Shuo Wu, Taiwan

P2.11-029: EGFR-MUTATIONS AND RESULTING TREATMENT IN A NSCLC POPULATION-BASED COHORT IN CENTRAL SWEDEN
Martin Sandelin, Sweden

P2.11-030: IS THERE ANY PREDICTOR FOR CLINICAL OUTCOME IN EGFR MUTANT NSCLC PATIENTS TREATED WITH EGFR TKIS?
Jong-Mu Sun, South Korea

P2.11-031: RADIOFREQUENCY ABLATION OF LIVER METASTASES MAY PROLONG THE SURVIVAL OF PULMONARY ADENOCARCINOMA PATIENTS WITH LIVER METASTASIS
Shih-En Tseng, Taiwan

P2.11-032: PATIENT REPORT OF DACOMITINIB (PF-00299804)-ASSOCIATED SYMPTOM AND HRQOL BENEFIT IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Karen Reckamp, USA

P2.11-033: ALK-EML4-TESTING IN NON-SMALL CELL LUNG CANCER: EXPERIENCES FROM KAROLINSKA UNIVERSITY HOSPITAL IN SWEDEN
Stephanie Mindus, Sweden

P2.11-034: INDIRECT COMPARISONS OF HARM/ BENEFIT PROFILE OF EGFR TYROSINE KINASE INHIBITORS AS FIRST LINE TREATMENT IN EGFR MUTATED NSCLC PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Marina Garassino, Italy

P2.11-035: ASSOCIATION OF TUMOR PD-L1 EXPRESSION AND IMMUNE BIOMARKERS WITH CLINICAL ACTIVITY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538)
Scott Antonia, USA

P2.11-036: ASSOCIATION BETWEEN TUMOR EGFR MUTATION AND PRIMARY TUMOR LOCATION IN PATIENTS WITH ADENOCARCINOMA OF THE LUNGS
Yung-Hung Luo, Taiwan

P2.11-037: EGFR ACTIVATING MUTATION AND BONE METASTASIS HAVE ASSOCIATION WITH CNS METASTASIS AT DIAGNOSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Ki Hwan Kim, South Korea

P2.11-038: EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL
Scott Gettinger, USA

P2.11-039: RESULTS FROM PHASE III TRIAL OF DENDRITIC CELL BASED VACCINE IMMUNOTHERAPY IN PATIENTS WITH -IIIA STAGE NON-SMALL-CELL LUNG CANCER
Natalia Khranovska, Ukraine

P2.11-040: PHASE 1 STUDY OF IPILIMUMAB IN COMBINATION WITH PACLITAXEL/ CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Hihoshi Nokihara, Japan

P2.11-041: EFFECT OF TREATMENT DURATION ON INCIDENCE OF ADVERSE EVENTS (AES) IN A PHASE III STUDY OF CRIZOTINIB VERSUS CHEMOTHERAPY IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Benjamin Solomon, Australia

P2.11-042: ACID SUPPRESSION THERAPY IMPAIRS ERLOTINIB EFFICACY IN NON-SMALL CELL LUNG CANCER
Michael Chu, Canada

P2.11-043: ANALYSIS OF CLINICOPATHOLOGICAL FEATURES FOR CHINESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING EML4-ALK FUSION GENES
Yuankai Shi, China
P2.11-044: PHASE IB STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF OLAPARIB (AZD2281) PLUS GEFTINIB IN PATIENTS (P) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P). (NCT=151374/GECP-GOAL)
Rosario Garcia Campelo, Spain

P2.11-045: TRY: A PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF COMBINED TRASTUZUMAB AND AUY922 IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH HER2 OVEREXPRESSION OR AMPLIFICATION OR MUTATION.
Marc Bos, Germany

P2.11-046: A NOVEL APPROACH TO INCREASE THE EFFICIENCY OF SURVIVAL-ENDPOINT PHASE II TRIALS.
George Simon, USA

P2.11-047: SEQUENTIAL TREATMENT WITH ERLOTINIB AND PEMETREXED IN PRETREATED PATIENTS WITH LUNG ADENOCARCINOMA.
Ondrej Fiala, Czech Republic

P2.12 Poster Session 2
NSCLC Early Stage

P2.12-001: ERLOTINIB AS NEOADJUVANT TREATMENT IN PATIENTS WITH STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (NCT01217619, EASTERN): STUDY UPDATE
Baohui Han, China

P2.12-002: CLINICAL CHARACTERISTICS AND PROGNOSIS OF LUNG ADENOCARCINOMA DRIVER MUTATIONS FROM CHINESE POPULATION.
Baohui Han, China

P2.12-003: POSTOPERATIVE RECURRENT AND THE PERSONALIZED POSTOPERATIVE SURVEILLANCE FOR RESECTED LUNG CANCER PATIENTS
Satoshi Shiono, Japan

P2.12-004: PERCUTANEOUS CRYOABLATION FOR THE TREATMENT OF INOPERABLE STAGE I NON-SMALL CELL LUNG CANCER: MID-TERM OUTCOME.
Yoshikane Yamauchi, Japan

P2.12-005: RESULTS OF RADICAL TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS WITH A SINGLE SYNCHRONOUS METASTASIS
Margriet Kwint, Netherlands

P2.12-006: FACTORS IMPACTING THE MANAGEMENT OF SOLID LUNG TUMORS BY PERCUTANEOUS RADIOFREQUENCY ABLATION IN NON-SURGICAL PATIENTS
Peter Andrew, Canada

P2.12-007: PET/CT FINDINGS OF ADENOCARCINOMA PATIENTS
Atila Akkoçlu, Turkey

P2.12-008: DO PET/CT FINDINGS PREDICT CLINICAL STAGING IN NSCLC?
Atila Akkoçlu, Turkey

P2.12-009: ADJUVANT CHEMOTHERAPY WITH ORAL VINORELBINE USED IN DOUBLET WITH CARBOPLATIN IN NON-SMALL CELL LUNG CANCER AFTER RADICAL RESECTION TOLERABILITY AND SHORT TERM SURVIVAL.
Vitezslav Kolek, Czech Republic

P2.12-010: DOES PRESENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INFLUENCE CLINICAL BEHAVIOR IN PATIENTS WITH EARLY STAGE NON-SMALL CELL LUNG CANCER (ES-NSCLC)?
Satomi Yamamoto, Japan

P2.12-011: PRE-RADIOThERAPy PET SUv MAXIMUM PREDICTS FOR OVERALL SURvIvAL IN PATIENTS WITH EARLY-STAGE NSCLC TREATED WITH STEREOTACTIC BODY RADIATION THERAPY
Roy Decker, USA

P2.12-012: PROGNOSTIC IMPACT OF VISCERAL PLEURAL INVASION IN RESECTED TUMORS OF NON-SMALL CELL LUNG CANCER
Kenji Sugio, Japan

P2.12-013: PATTERNS OF RECURRENT FOLLOWING SURGICAL RESECTION OF STAGE I-III NON-SMALL CELL LUNG CANCER (NSCLC)
Hui-li Wong, Australia

P2.12-014: BRAIN METASTASES FOLLOWING SURGICAL RESECTION OF STAGE I-III NON-SMALL CELL LUNG CANCER (NSCLC)
Betty Zhang, Australia

P2.12-015: INVESTIGATION OF THE FDG PET- DERIVED TOTAL GLYCOLYTIC ACTIVITY (TGA) AS PROGNOSTIC TOOL IN PATIENTS WITH EARLY STAGE RESECTED NON-SMALL CELL LUNG CANCER
Maria Werner-Wasik, USA

P2.12-016: PREDICT FACTORS OF LYMPHATICS METASTASIS OR EARLY DISTANT AND REGIONAL FAILURE AFTER COMPLETE RESECTION IN CT1 LUNG ADENOCARCINOMA
Xue-Ning Yang, China
P2.12-017: CLINICAL IMPACT OF DYNAMIC
CONTRAST-ENHANCED CT IN STAGE IA
NON-SMALL CELL LUNG CANCER: NET
ENHANCEMENT IS AN INDEPENDENT
PREDICTOR OF RECURRENCE.
Eun Young Kim, South Korea

P2.12-018: BRAIN METASTASES AS A FIRST SITE
OF RECURRENCE IN SURGICALLY RESECTED
NON-SMALL-CELL LUNG CANCER
Jong-Mu Sun, South Korea

P2.12-019: COMPLIANCE, TOXICITY AND
SUCCESSFUL GOALS IN ADJUVANT SETTING.
RESULTS FROM TWO REFERRAL CENTERS IN
SOUTH AMERICA.
Edgar Olguin, Argentina

P2.12-020: THE IMPACT OF ADJUVANT THERAPY
IN RESECTED PATIENTS WITH EARLY STAGE
NON-SMALL CELL LUNG CARCINOMA:
THE ERCC1 AND EGFR EXPRESSIONS ARE
ASSOCIATED WITH SURVIVAL.
Akif Turna, Turkey

P2.12-021: SELECTIVE MEDIASTINAL LYMPH
NODE DISSECTION FOR CN0 NON-SMALL CELL
LUNG CANCER
Taichiro Ishizumi, Japan

P2.12-022: A FEASIBILITY STUDY OF
POSTOPERATIVE ADJUVANT CHEMOTHERAPY
WITH FLUOROPYRIMIDINE S-1 IN PATIENTS WITH
STAGE II-IIIA NON-SMALL CELL LUNG CANCER
Mitsuhiro Tsuboi, Japan

P2.12-023: PRE-TREATMENT 18FDG-PET SUVMAX
AS A PREDICTOR OF DISTANT METASTASIS IN
EARLY STAGE NSCLC TREATED WITH DEFINITIVE
RADIOThERAPY
Vimoj Nair, Canada

P2.13 Poster Session 2

P2.13-001: ADDITIVE FIRST-LINE
CHEMOTHERAPIES IMPROVE PROGRESSION-
FREE SURVIVAL FOR COMBINED SMALL CELL
LUNG CANCER IN A PHASE II RANDOMIZED
TRIAL.
Jie Zhang, China

P2.13-002: RANDOMIZED PHASE II STUDY OF
SINGLE AGENT OSI-906, AN ORAL, SMALL
MOLECULE, TYROSINE KINASE INHIBITOR
(TKI) OF THE INSULIN GROWTH FACTOR-1
RECEPTOR (IGF-1R) VERSUS TOPOTECAN FOR
THE TREATMENT OF PATIENTS WITH RELAPSED
SMALL CELL LUNG CANCER (SCLC)
Alberto Chiappori, USA

P2.13-003: PROGNOSTIC FACTORS FOR
EXTENSIVE STAGE SMALL CELL LUNG CANCER.
Choonhee Son, South Korea

P2.13-004: LITHIUM AS A NEUROPROTECTIVE
AGENT IN PATIENTS UNDERGOING
PROPHYLACTIC CRANIAL IRRADIATION (PCI)
FOR SMALL CELL LUNG CANCER (SCLC): THE
TULIP STUDY
Violet Mukaro, Australia

P2.13-005: PALONOSTRON (ALOXI®)
EFFECTIVELY PREVENTS NAUSEA AND EMESIS
IN SCLC PATIENTS RECEIVING PLATINUM-BASED
THREE DAYS REGIMEN.
Ioannis Gkiozos, Greece

P2.13-006: A PHASE IIA STUDY OF HA-IRINOTECAN, A
CD44-TARGETED FORMULATION OF HYALURONIC
ACID AND IRINOTECAN, IN THE TREATMENT OF
EXTENSIVE STAGE SMALL CELL LUNG CANCER
AND ITS EFFECT ON CANCER STEM-LIKE CELLS.
Muhammad Alamgeer, Australia

P2.13-007: IMPACT OF AGE ON TREATMENT
AND SURVIVAL IN PATIENTS WITH SMALL CELL
LUNG CANCER.
Harminder Takhar, Australia

MESOTHELIOMA

P2.14 Poster Session 2

P2.14-001: TRIMODALITY TREATMENT OF
MALIGNANT PLEURAL MESOTHELIOMA (MPM).
A REVIEW OF 53 CONSECUTIVE PATIENTS WITH
MALIGNANT PLEURAL MESOTHELIOMA, PERIOD
10-YEARS JANUARY 2002- DECEMBER 2012.
Fadil Gradica, Albania

P2.14-002: VALIDATION OF THE CALGB
AND EORTC PROGNOSTIC MODELS FOR
MESOTHELIOMA BASED ON MULTIPLE CALGB
TRIALS (ALLIANCE)
Herbert Pang, USA

P2.14-003: PHASE I AND PHARMACOKINETIC
STUDY OF AMATUXIMAB, A NOVEL CHIMERIC
ANTIBODY TO MESOTHELIN, IN PATIENTS WITH
ADVANCED SOLID TUMORS
Takayasu Kurata, Japan

P2.14-004: EORTC AND CALGB PROGNOSTIC
MODELS, BUT NOT NEUTROPHIL-TO-
LYMPHOCYTE RATIO, ARE PROGNOSTIC
IN UNSELECTED PATIENTS WITH NEWLY
DIAGNOSED MALIGNANT MESOTHELIOMA
Tarek Meniawy, Australia

P2.14-005: ASSESSMENT OF POSTOPERATIVE
COMPICATIONS AFTER THE FIRST ALL
JAPAN MULTI-INSTITUTIONAL TRIAL OF
INDUCTION CHEMOTHERAPY FOLLOWED
BY EXTRAPLEURAL PNEUMONECTOMY FOR
MALIGNANT PLEURAL MESOTHELIOMA
Noriyasu Usami, Japan
P2.14-006: IS PLEURECTOMY-DECORTICATION A Viable MANAGEMENT OPTION IN THE TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA?
Henrietta Wilson, UK

Matthew Soeberg, Australia

P2.14-008: EFFECT OF AQUAPORIN 1 MODULATION IN MALIGNANT PLEURAL MESOTHELIOMA: INHIBITION OF CELL PROLIFERATION AND COLONY FORMATION IN VITRO AND TUMOUR GROWTH IN VIVO USING A HETEROTOPIC MOUSE MODEL
Jack Driml, Australia

P2.14-009: NOVEL CLINICAL ASSESSMENT OF MALIGNANT PLEURAL MESOTHELIOMA
Ritu Gill, USA

P2.14-010: INTRAPLEURAL PERFUSION HYPERThERMO-CHEMOTHERAPY WITH CISPLATIN IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA.
Hirozo Sakaguchi, Japan

P2.14-011: MESOBANk: A UK BASED BIORESOURCE FOR MALIGNANT PLEURAL MESOTHELIOMA
Robert Rintoul, UK

P2.14-012: ONCOLYTIC HERPES VIRUS THERAPY FOR MESOTHELIOMA- A PHASE I STUDY OF INTRAPLEURAL ONCOLYTIC VIRUS HSV1716 (NCT01721018)
John Edwards, UK

P2.14-013: A RANDOMISED PHASE II TRIAL OF ORAL VINORELBINE AS SECOND-LINE THERAPY FOR PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) EXPRESSING BRAC1 - VIM TRIAL
Dean Fennell, UK

P2.14-014: A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF V5-6063 AS MAINTENANCE THERAPY IN SUBJECTS WITH MALIGNANT PLEURAL MESOTHELIOMA WHICH HAS NOT PROGRESSED ON AT LEAST 4 CYCLES OF PEMETREXED/PLATINUM THERAPY
Anna Nowak, Australia

P2.14-015: A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING TREMELIMUMAB TO PLACEBO IN SECOND AND THIRD LINE TREATMENT OF SUBJECTS WITH UNRESECTABLE PLEURAL OR PERITONEAL MESOTHELIOMA
Hedy Lee Kindler, USA

P2.15 Poster Session 2
Thymoma

P2.15-001: PREDICTORS OF LONG-TERM SURVIVALS IN PATIENTS WITH MASAOKA STAGE III THYMOMAS
Zhou Guang Hui, China

P2.15-002: PATTERNS AND PREDICTORS OF RECURRENT AFTER RADICAL RESECTION OF THYMOMA
Zhou Guang Hui, China

P2.15-003: GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
Jonathan Riess, USA

P2.15-004: MANAGEMENT OF PRIMARY TUMOURS OF THE THYMUS AND USEFULNESS OF 18F-FLUORODEOXYGlcose POSITRON EMISSION TOMOGRAPHY (FDG-PET)
Ioannis Gkiozos, Greece

P2.15-005: LONG-TERM SURVIVAL AFTER THE MULTIMODAL TREATMENT OF THYMIC CARCINOMAS: A SINGLE CENTER EXPERIENCES IN 90 CASES.
Geun Dong Lee, South Korea

P2.15-006: RETROSPECTIVE STUDY ON THE EFFICACY OF MULTIDISCIPLINARY THERAPY FOR THYMIC CANCERS
Masayuki Hashimoto, Japan

P2.15-007: DIGITAL MICROSCOPY REPRODUCIBILITY STUDY OF THYMIC EPITHELIAL NEOPLASMS
Andre Moreira, USA

P2.15-008: COMPARISON OF OUTCOMES AFTER EXTENDED THYMECTOMY FOR MYASTHENIA GRAVIS BY PRESENCE OF THYMOMA
Shoko Kadoma, Japan

P2.16 Poster Session 2
Other Thoracic Malignancies

P2.16-001: DIAGNOSIS AND SURGICAL RESECTION OF SOLITARY PULMONARY NODULES IN PATIENTS WITH BREAST CANCER
Kimihiro Shimizu, Japan

P2.16-002: LONG-TERM TREATMENT RESULTS IN SOFT TISSUE SARCOMAS OF THE THORACIC WALL TREATED BY PRE-OR-POSTOPERATIVE RADIOThERAPY IN A MULTIDISCIPLINARY APPROACH- RESULTS OF THE CTF SARCOMA GROUP
H. Fazilet Dincbas, Turkey
P.2.16-003: THE EFFICACY OF VATS VERSUS OPEN THORACOTOMY: A SYSTEMATIC REVIEW
Mun Yoong Cheang, Australia

P.2.16-004: MEDICAL MANAGEMENT OF PULMONARY CARCINOID TUMORS
Curtis Chong, USA

**ENDOSCOPY**

P.2.17 Poster Session 2 Bronchoscopy, Endoscopy

P.2.17-001: A COMBINATION USE OF MULTI-GUIDED DEVICES IN THE BASIS OF THE OBTAINED DATA FROM VIRTUAL BRONCHOSCOPIC NAVIGATION LUNGPOINT SYSTEM USING THIN VIDEO-BRONCHOSCOPE FOR DIAGNOSING SMALL (≤30 MM) PERIPHERAL PULMONARY LESIONS SUSPECTED LUNG CANCER
Masafumi Misawa, Japan

P.2.17-002: RETROSPECTIVE STUDY OF 5-YEAR EXPERIENCE WITH ENDOBRONCHIAL CRYOBIOPSY IN REPUBLIC OF ESTONIA
Tonu Vanakesa, Estonia

P.2.17-003: EARLY EXPERIENCE OF ENDOBRONCHIAL ULTRASOUND-MINIPROBE (EBUS-MP) FOR INVESTIGATION OF PERIPHERAL PULMONARY MASS LESIONS
Kristopher Skwarski, UK

P.2.17-004: ENDOBRONCHIAL ULTRASOUND GUIDED TRANSPBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA) INVESTIGATION OF MEDIASTINAL LYMPHADENOPATHY OF UNKNOWN AETIOLOGY
Kristopher Skwarski, UK

P.2.17-005: CONVENTIONAL VS ULTRATHIN BRONCHOSCOPY IN THE DIAGNOSIS OF SOLITARY PULMONARY NODULES (SPN)
Antoni Rosell Gratacos, Spain

P.2.17-006: LONG TERM OUTCOME OF INITIAL BRONCHOSCOPIC TREATMENT STRATEGY IN PATIENTS WITH BRONCHIAL CARCINOID
Hes Brokx, Netherlands

P.2.17-007: MISCLASSIFICATION OF MEDIASTINAL LYMPH NODES BY ENDOBRONCHIAL ULTRASOUND (EBUS)
Cho Leem, South Korea

P.2.17-008: A NEW PROCEDURE FOR SAMPLING FINE NEEDLE ASPIRATIONS ENABLES ISOLATION OF HIGH QUALITY MRNA
Peter Meldgaard, Denmark

P.2.17-009: HOW TO PERFORM EBUS TBNA AND WHEN IS IT SUFFICIENT?
Mark Krasnik, Denmark

**PATHEOLOGY**

P.2.18 Poster Session 2 Pathology

P.2.18-001: RETROSPECTIVE ANALYSIS OF THE CLINICO-PATHOLOGICAL PROFILE OFALK POSITIVE PATIENTS IN THE SOUTH OF SPAIN (ANDALUSIAN AREA)
Jesus Corral, Spain

P.2.18-002: A COMPREHENSIVE COMPARATIVE ANALYSIS OF THE HISTOMORPHOLOGICAL FEATURES OF ALK-REARRANGED LUNG ADENOCARCINOMA BASED ON DRIVER ONCOGENE MUTATIONS: FREQUENT EXPRESSION OF EPITHELIAL-MESENCHYMAL TRANSITION MARKERS THAN OTHER GENOTYPE
Hyojin Kim, South Korea

P.2.18-003: SPREAD THROUGH ALVEOLAR SPACES (STAS): A NEWLY RECOGNIZED PATTERN OF INVASION IN LUNG ADENOCARCINOMA ASSOCIATED WITH INCREASED RECURRENCE IN PATIENTS UNDERGOING LIMITED RESECTION FOR ≤2CM TUMORS
Junichi Nitadori, Japan

P.2.18-004: CLINICAL APPLICATION OF IMMUNOCYTOCHEMICAL DETECTION OF ALK REARRANGEMENT ON CYTOLOGY SLIDES FOR DETECTION OR SCREENING OF LUNG ADENOCARCINOMA
Hisashi Tanaka, Japan

P.2.18-005: MORPHOLOGICAL AND GENETIC CLASSIFICATION OF LUNG CANCER: VARIATION IN PRACTICE AND IMPLICATIONS FOR TAILORED TREATMENT
John Gosney, UK

P.2.18-006: HER2 AND BRAF MUTATIONS IN NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P)
Enric Carcereny, Spain

P.2.18-007: CORRELATING HISTOLOGIC AND MOLECULAR FEATURES IN THE LUNG ADENOCARCINOMA TCGA PROJECT
William Travis, USA

P.2.18-008: TRANSFORMATION TO SARCOMATOID CARCINOMA IN ALK-REARRANGED ADENOCARCINOMA WHICH DEVELOPED ACQUIRED RESISTANCE TO CRIZOTINIB AND RECEIVED SUBSEQUENT CHEMOTHERAPIES
Yoshihisa Kobayashi, Japan

P.2.18-009: MUTATION TESTING IN NON-SMALL CELL LUNG CANCER - SUITABILITY OF SMALL BIOPSY AND CYTOLOGY SPECIMENS
Wendy Cooper, Australia
P2.18-010: COPY NUMBER CHANGES IN CHROMOSOME 2P ARE UNIQUE EVENTS AMONG ALK FUSION POSITIVE LUNG ADENOCARCINOMAS
Hironori Ninomiya, Japan

P2.18-011: BRONCHOPULMONARY CARCINOID TUMOR (BPC) - IS IT TIME TO CHANGE MICROSCOPIC CRITERIA OF DIAGNOSIS?
Renata Langfort, Poland

P2.18-012: BRONCHIAL WASHING/BRUSHING SAMPLES ARE COMPARABLE TO BIOPSY SAMPLES FOR EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER
Yoo-Duk Choi, South Korea

P2.18-013: INCIDENCE OF EGFR, KRAS, BRAF, ALK, AND P53 ALTERATIONS IN A COHORT OF 159 CONSECUTIVELY TESTED PATIENTS FROM A CERTIFIED LUNG CANCER CENTER, CORRELATION WITH CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME.
Frank Griesinger, Germany

P2.18-014: IMPACT OF NON SMALL CELL LUNG CANCER (NSCLC) IMMUNOPHENOTYPING IN CHEMOTHERAPY RESPONSE.
Silvia Novello, Italy

P2.18-015: EGFR AND KRAS MUTATIONAL ANALYSIS USING SMALL AMOUNTS OF DNA FROM FNA AND SMALL CNB IS FEASIBLE AND REPRODUCIBLE USING A COMMERCIAL REAL TIME PCR METHOD, VALIDATION OF THIS PCR METHOD IN CYTOLOGICAL SAMPLES.
Maria Lozano, Spain

P2.18-016: HIGH THROUGHPUT SOMATIC MUTATION PROFILING IN PARAFFIN EMBEDDED NON-SMALL CELL LUNG CANCER BIOPSIES USING THE LUNGCARTA™ PANEL IN CLINICAL ROUTINE PRACTICE.
Jean-Francois Morere, France

P2.18-017: MULTIPLEXED-BASED MUTATION PROFILING OF NON SMALL CELL LUNG CANCER SMALL BIOPSY SAMPLES USING THE SEQUENOM LUNGCARTA™ PANEL AND MASSARRAY® SYSTEM.
Anne Marie Quinn, UK

P2.18-018: OUTCOMES OF LUNG ADENOCARCINOMA PATIENTS WITH SIGNET RING CELL TUMORS: A THREE-WAY EVALUATION.
Ping Yang, USA

P2.18-019: CLINICOPATHOLOGICAL FEATURES IN NON-SMALL CELL LUNG CANCER PATIENTS WITH EGFR AND KRAS MUTATIONS.
Tepppei Nishii, Japan

P2.18-020: APPROPRIATENESS EVALUATION OF HANDLING METHOD FOR THE SMALL LUNG ADENOCARCINOMA IN THE FROZEN SECTION DIAGNOSIS BY RADIOLOGICAL-PATHOLOGICAL CORRELATION.
Tetsuya Isaka, Japan

P2.18-021: HOW ACCURATE ARE WE IN DIAGNOSING SQUAMOUS CELL CARCINOMA OF THE LUNG IN CYTOLOGY SPECIMENS AND RELEVANCE TO MOLECULAR TESTING? AN INSTITUTIONAL EXPERIENCE.
Charuhas Deshpande, USA

P2.18-022: DO EGFR- AND KRAS-MUTATIONS OCCUR IN SQUAMOUS CELL LUNG CARCINOMAS?
Julien Vincenten, Netherlands

P2.19 Poster Session 2

IMAGING AND SCREENING

P2.19-001: THE IMAGING CHARACTERISTICS OF F-18 FDG PET-CT ON EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS IN NON-SMALL CELL LUNG CANCER.
Atilla Akkoclu, Turkey

P2.19-002: PULMONARY TULAREMIA: A RARE DISEASE WHICH CAN BE MISTAKEN FOR LUNG CANCER.
Gunnar Hillerdal, Sweden

P2.19-003: A TEXTURE ANALYSIS APPROACH TO ASSESS THE SEVERITY OF ACUTE NORMAL TISSUE CHANGES IN THORACIC CT SCANS FOLLOWING RADIATION THERAPY FOR LUNG CANCER.
Alexandra Cunliffe, USA

P2.19-004: CHARACTERIZATION OF SOLITARY PULMONARY LESIONS COMBINING VISUAL PERFUSION AND QUANTITATIVE DIFFUSION MR IMAGING.
Johan Coolen, Belgium

P2.19-005: TUMOR GROWTH RATE OF GROUND-GLASS NODULES AFTER LONG-TERM FOLLOW-UP: THE USEFULNESS OF A COMBINATION OF INITIAL COMPUTED TOMOGRAPHY ATTENUATION AND TUMOR SIZE AS A PREDICTOR FOR TUMOR GROWTH.
Takashi Eguchi, Japan

P2.19-006: NOVEL COMPUTED TOMOGRAPHY WINDOWS FOR PREDICTING PATHOLOGICAL INVASION AREA IN PULMONARY SUBSOLID TUMORS.
Takashi Eguchi, Japan

P2.19-007: PULMONARY NODULE DETECTION BY JUNIOR MEDICAL STAFF IS IMPROVED BY DIGITAL TOMOSYNTHESIS COMPARED TO CHEST X-RAY.
Xiang-Wen Lee, Australia
P2.19-008: THE PROGNOSTIC VALUE OF TUMOR METABOLIC VOLUME IN PET-CT STUDY FOR UNRESECTABLE NON-SMALL-CELL LUNG CANCER TREATED WITH DEFINITE RADIOTHERAPY
Maciej Pelak, Poland

P2.19-009: A PREDICTION MODEL TO ESTIMATE THE PROBABILITY OF MALIGNANCY OF SOLITARY PULMONARY NODULES INTERGRATING PET-CT AND CLINICAL DATA.
Xue-Ning Yang, China

P2.19-010: THE ASSOCIATION BETWEEN BASELINE CLINICAL-RADIOLOGICAL CHARACTERISTICS AND GROWTH OF PULMONARY NODULES WITH GROUND-GLASS OPAcity
Yoshihisa Kobayashi, Japan

P2.19-011: COMPENSATION OF VITAL CAPACITY OF RESIDUAL LOBES AFTER LUNG RESECTION IN PATIENTS WITH LUNG CANCER
Masako Matsutani, Japan

P2.19-012: INTER-METHOD COMPARISON OF 18F-FDG PET METABOLIC RESPONSE ASSESSMENT IN NON-SMALL CELL LUNG CANCER
Feng-Ming (Spring) Kong, USA

P2.19-013: PILOT STUDY OF LOW DOSE COMPUTED TOMOGRAPHY SCREENING IN FIRST RELATIVE OF LUNG CANCER PATIENT (PRELIMINARY REPORT)
Somcharoen Saeteng, Thailand

P2.19-014: WHOLE-BODY DIFFUSION-WEIGHTED MRI FOR STAGING NON-SMALL CELL LUNG CANCER PATIENTS
Jefferson Gross, Brazil

P2.20: POSTER SESSIONS

P2.20-001: EFFECT OF REPEATED ANNUAL SPUTUM CYTOLOGY SCREENING ON HIGH RISK POPULATION: CHANGE OF INCIDENCE OF SQUAMOUS CELL CARCINOMA
Akira Sakurada, Japan

P2.20-002: INVESTIGATING SUSPECTED LUNG CANCER: FAST TRACK IN STOCKHOLM
Gunnar Hillerdal, Sweden

P2.20-003: DIAGNOSTIC WORK-UP AND SURGERY IN PARTICIPANTS OF GDANSK LUNG CANCER SCREENING PROGRAM - THE EXTENT OF FUTILE PROCEDURES IN NON-MALIGNANT CONDITION
Witold Rzyman, Poland

P2.20-004: DNA COPY NUMBER ABERRATIONS IN ENDOBRONCHIAL LESIONS: A VALIDATED PREDICTOR FOR CANCER
Robert A.A. Van Boerdonk, Netherlands

P2.20-005: VOLUME DOUBLING TIMES OF SUBSOLID NODULES DETECTED USING LOW-DOSE CT LUNG CANCER SCREENING BASED ON AN EIGHT-YEAR PROSPECTIVE OBSERVATION
Ryutaro Kakinuma, Japan

P2.20-006: AUTOANTIBODIES TO A PANEL OF LUNG CANCER-ASSOCIATED ANTIGENS CAN PROVIDE SIGNIFICANT DISCRIMINATION BETWEEN MALIGNANT AND NON-MALIGNANT LUNG NODULES
Pierre Massion, USA

P2.20-007: COMPUTED TOMOGRAPHY (CT) SCREENING FOR LUNG CANCER: DOES THE MORTALITY ENDPOINT PROVIDE DEFINITIVE EVIDENCE FOR CT SUPERIORITY IN THE NATIONAL LUNG SCREENING TRIAL (NLST)?
Gary Strauss, USA

P2.20-008: INVESTIGATING SYMPTOMS OF LUNG CANCER: AN EVIDENCE-BASED GUIDE FOR GENERAL PRACTITIONERS
Elizabeth King, Australia

P2.20-009: EARLY DETECTION OF MEDIASTINAL TUMORS USING LOW-DOSE SPIRAL COMPUTED TOMOGRAPHY.
Ikuma Kasuga, Japan

P2.20-010: RAMAN SPECTROSCOPY BASED BREATH ANALYSIS WITH POTENTIAL FOR LUNG CANCER DETECTION
Haishan Zeng, Canada

P2.20-011: A PROSPECTIVE CLINICAL STUDY EVALUATING STAGE DEPENDENT SPUTUM MICRO-RNA EXPRESSION PROFILES FOR THE DETECTION OF NON-SMALL CELL LUNG CANCER
Rene Razzak, Canada

P2.20 Poster Session 2
Early Detection and Screening

P2.20-001: EFFECT OF REPEATED ANNUAL SPUTUM CYTOLOGY SCREENING ON HIGH RISK POPULATION: CHANGE OF INCIDENCE OF SQUAMOUS CELL CARCINOMA
Akira Sakurada, Japan

P2.20-002: INVESTIGATING SUSPECTED LUNG CANCER: FAST TRACK IN STOCKHOLM
Gunnar Hillerdal, Sweden

P2.20-003: DIAGNOSTIC WORK-UP AND SURGERY IN PARTICIPANTS OF GDANSK LUNG CANCER SCREENING PROGRAM - THE EXTENT OF FUTILE PROCEDURES IN NON-MALIGNANT CONDITION
Witold Rzyman, Poland

P2.20-004: DNA COPY NUMBER ABERRATIONS IN ENDOBRONCHIAL LESIONS: A VALIDATED PREDICTOR FOR CANCER
Robert A.A. Van Boerdonk, Netherlands

P2.21: PREVENTION & EPIDEMIOLOGY

P2.21-001: SOLITARY PULMONARY SQUAMOUS CELL CARCINOMA IN PATIENTS WITH A HISTORY OF SQUAMOUS CELL CARCINOMA: METASTASIS OR SECOND PRIMARY TUMOUR?
Tomohiro Murakawa, Japan

P2.21-002: IDENTIFICATION OF MALIGNANT PLEURAL EFFUSIONS (MPES) SECONDARY TO LUNG CANCER BY TUMOUR MARKERS: A NATIONAL MULTI-CENTRE TRIAL
Salvatore Griffo, Italy

P2.21-003: THE RELATIONSHIP BETWEEN THE TYPE OF BONE METASTASIS AND EGFR GENE MUTATION IN NON-SMALL CELL LUNG CANCER
Kumi Akanabe, Japan
<table>
<thead>
<tr>
<th>Poster Session 2</th>
<th>Epidemiology, Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P2.22-001</strong>: JAPANESE NATION WIDE LUNG CANCER REGISTRIES CONDUCTED BY THE JAPANESE JOINT COMMITTEE OF LUNG CANCER REGISTRY (JJCLCR)</td>
<td>Noriyoshi Sawabata, Japan</td>
</tr>
<tr>
<td><strong>P2.22-002</strong>: STUDY OF SOME FACTORS RELATED TO EPIDEMIOLOGY IN MALIGNANT PLEURAL MESOTHELIOMA</td>
<td>Nguyen Lam, Vietnam</td>
</tr>
<tr>
<td><strong>P2.22-003</strong>: BIM (BCL2L11) DELETION POLYMORPHISM IS ONE OF MAJOR RISK FACTORS OF LUNG CANCER IN KOREAN POPULATION.</td>
<td>Eun Na Cho, South Korea</td>
</tr>
<tr>
<td><strong>P2.22-004</strong>: SURVIVAL IMPROVEMENT IN PRIMARY LUNG CANCER PATIENTS IN A 10-YEAR PERIOD: RESULTS OF THE FRENCH KBP-2000-CPHG AND KBP-2010-CPHG COHORTS</td>
<td>Chrystele Locher, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster Session 2</th>
<th>Tobacco Control, Prevention and Chemoprevention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P2.23-001</strong>: DOES DISSATISFACTION WITH BODY IMAGE IN ADOLESCENTS A DETERMINANT OF SMOKING BEHAVIOR?</td>
<td>Henrique Queiroga, Portugal</td>
</tr>
<tr>
<td><strong>P2.23-002</strong>: PROTECTING FROM SECOND HAND SMOKE: AN ASSESSMENT OF SHS EXPOSURE IN PUBLIC PLACES IN TWO STATES OF INDIA</td>
<td>Urvashi Kaushik, India</td>
</tr>
</tbody>
</table>
P2.24-001: LUNG CANCER IN RURAL AND REMOTE ABORIGINAL AND TORRES STRAIT ISLANDER COMMUNITIES IN QUEENSLAND
Barbara Page, Australia

P2.24-002: TOLERABILITY AND BARRIERS TO DELIVERY OF ADJUVANT CISPLATIN/ VINORELBINE CHEMOTHERAPY IN NON SMALL CELL LUNG CANCER
Abbey Jebb, New Zealand

P2.24-003: THIRD-LINE THERAPY AND BEYOND FOR PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Jesus Corral, Spain

P2.24-004: CHEST WALL TOXICITY FOLLOWING SABR FOR EARLY LUNG CANCER: A DOSIMETRIC ANALYSIS.
John Littler, UK

P2.24-005: ORAL EGFR TKIS AS FIRST LINE TREATMENT FOR NSCLC: EXPERIENCE FROM A TERTIARY CARE CENTRE IN NORTH INDIA
Digambar Behera, India

P2.24-006: BRONCHIAL ASSOCIATED LYMPHOID TISSUE (BALT) LYMPHOMA - IS RITUXIMAB ALONE A VIABLE OPTION INSTEAD OF AGGRESSIVE LOCAL THERAPY AND HIGH DOSE CHEMOTHERAPY EVEN IN THE RELAPSED SETTING FOR THIS RATHER RARE ENTITY?
Rajitha Sunkara, USA

P2.24-007: FIRST-LINE PEMETREXED PLUS CISPLATIN FOLLOWED BY MAINTENANCE PEMETREXED VS CARBOPLATIN-PACLITAXEL PLUS BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB (ERACLE) IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER: A QUALITY OF LIFE-ORIENTED, MULTICENTER RANDOMIZED PHASE III TRIAL OF THE GOIM (GRUPPO ONCOLOGICO ITALIA MERIDIONALE).
Domenico Galetta, Italy

P2.24-008: EVIQ - A WEB BASED, POINT OF CARE TREATMENT RESOURCE - ITS ROLE IN LUNG Cancer
Lisa King, Australia

P2.24-009: ATYPICAL CT FINDINGS IN A PATIENT WITH A BRAF V600E MUTATED PULMONARY LANGERHANS CELL HISTIOCYTOSIS (PLCH)
Ella Willenbacher, Austria

P2.24-010: ADVANCED NON SMALL LUNG CANCER LONG TERM SURVIVORS - CLINICAL DATA ANALYSIS. SINGLE CENTER EXPERIENCE
Ewa Chmielowska, Poland

P2.24-011: LEFT VENTRICULAR THROMBOSIS DUE TO CHEMOTHERAPY USING BEVACIZUMAB FOR LUNG CANCER.
Hidekazu Tachi, Japan

P2.24-012: PUBLIC ATTITUDES ABOUT LUNG CANCER: STIGMA, SUPPORT, AND PREDICTORS OF SUPPORT
Jared Weiss, USA

P2.24-013: EFFICACY AND SAFETY OF ERLOTINIB IN CROATIAN PATIENTS
Marko Jakopovic, Croatia

P2.24-014: PRIMARY LUNG CANCER COEXISTING WITH LUNG METASTASES FROM OTHER MALIGNANCIES
Noritoshi Nishiyma, Japan

P2.24-015: THE ROLE OF WALCE (WOMEN AGAINST LUNG CANCER IN EUROPE) IN HELPING PATIENTS AND THEIR CAREGIVERS TO COPE WITH CANCER.
Silvia Novello, Italy

P2.24-016: WHY DO WE TREAT LUNG CANCER PATIENTS WITH CHEMOTHERAPY UNTIL THE END OF LIFE?
Fabio Lopes, Portugal

P2.24-017: 5 CASES OF LONG-TERM SURVIVAL IN POSTERIOR SPINAL FIXATION SURGERY AGAINST VERTEBRAL METASTASIS OF LUNG CANCER
Tomoyuki Igarashi, Japan

P2.24-018: PRIMARY MEDIASTINAL CASTLEMAN’ DISEASE: SURGICALLY CURABLE ANEMIA : A CASE REPORT
Si Young Choi, South Korea

P2.24-019: PLEURODESIS WITH BLEOMYCIN IN ADVANCED NON SMALL CELL LUNG CANCER: A SINGLE CENTRE EXPERIENCE FROM SOUTHERN INDIA
Krishnakumar Rathnam, India

P2.24-020: UK LUNG CANCER SURVIVAL: WHERE ARE WE GOING WRONG?
Henrietta Wilson, UK

P2.24-021: ADJUVANT OR INDUCTION CHEMOTHERAPY FOR NON SMALL CELL LUNG CANCER TREATED WITH CHEMORADIOThERAPY: AN INvIDUAL DATA METAANALySIS OF PhASE II TRIALS
Paul Van Houtte, Belgium

P2.24-022: IMPLEMENTING DySPNEA MANAGEMENT: A QUALITy IMPROvEMENT PROJECT FOR PATIENTS WITH LUNG CANCER IN ONTARIO, CANADA
Yee Ung, Canada

P2.24-023: A DESCRIPTIVE PILOT STUDY TO EVALUATE THE CURRENT PRACTICES OF DETERMINING “DO NOT RESUSCITATE STATUS” IN PATIENTS WITH INCURABLE LUNG CANCER AT CANCER CARE MANITOBA, CANADA.
Naseer Ahmed, Canada
P2.24-024: METABOLIC ACTIVITY ON [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography and glucose transporter-1 expression may predict clinical outcomes in patients with limited disease of small cell lung cancer receiving concurrent chemoradiation
Jin Hyoung Kang, South Korea

P2.24-025: APPLYING THE RESULTS OF THE FRAGMATIC TRIAL TO REAL LIFE: LONGITUDINAL QUALITATIVE STUDY EXPLORING THE EXPERIENCES OF PATIENTS PARTICIPATING IN A RANDOMISED PHASE III CLINICAL TRIAL INVESTIGATING THE EFFECT OF FRAGMIN ADDED TO STANDARD THERAPY IN LUNG CANCER
Simon Noble, UK

P2.24-026: LUNG CANCER PATHWAY AT THE ROYAL ADELAIDE HOSPITAL: IMPACT OF TREATMENT INTENT AND PATIENT LOCATION.
Justin Ng, Australia

P2.24-027: CISPLATIN PLUS PEMETREXED AND CONCURRENT RADIATION WITH CONSECUTIVE SURGERY IN LOCALLY ADVANCED ADENOCARCINOMA OF THE RIGHT LUNG - CASE REPORT
Milada Zemanova, Czech Republic

P2.24-028: PHOTODYNAMIC THERAPY FOR AIRWAY MALIGNANCIES: A 15-YEAR SINGLE INSTITUTION EXPERIENCE
Patrick Ross, USA

P2.24-029: PATTERNS OF PALLIATIVE CARE INVOLVEMENT IN METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS: LIMITATIONS OF EARLY PALLIATIVE CARE IN A RURAL AUSTRALIAN CENTRE
Amy Prawira, Australia

P2.24-030: INCREASING THERAPEUTIC EFFICACY AND SAFETY OF DOCETAXEL IN LUNG CANCER
Gouri Shankar Bhattacharyya, India

P2.24-031: PRE-TREATMENT SYMPTOM PROFILES PREDICT SURVIVAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Mei-Ling Chen, Taiwan

P2.24-032: BRONCHOSCOPY IN THE CZECH REPUBLIC, 2012
Miloslav Marel, Czech Republic

P2.24-033: THE VALUE OF ASSESSING MUSCLE DEPLETION IN LUNG CANCER (SARCOPENIA) RATHER THAN BODY SURFACE AREA, IN THE WORK-UP TO CHEMOTHERAPY. REFLECTIONS FROM A SYSTEMATIC REVIEW.
Jemima Collins, UK

P2.24-034: TREATMENT BEYOND PROGRESSION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBOURING EGFR MUTATIONS - THE MANCHESTER LUNG CANCER GROUP EXPERIENCE
Emma Halkyard, UK

P2.24-035: DESCRIPTION OF LUNG CANCER PATIENTS WITH ECOG 2 AT DIAGNOSIS. EXPERIENCE OF OUR HOSPITAL
Angel Artal, Spain

P2.24-036: ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY.
Angel Artal, Spain

P2.24-037: FEASIBILITY OF CREATIVE ART THERAPY AS A SUPPORTIVE CARE MODALITY FOR PATIENTS WITH METASTATIC LUNG CANCER TREATED WITH CHEMOTHERAPY
Nicolas Girard, France

P2.24-038: LUNG CANCER AND COMBINED PULMONARY FIBROSIS AND EMPHYSEMA SYNDROME IN WESTERN PATIENTS: A SERIES OF 47 PATIENTS
Nicolas Girard, France

P2.24-039: RENAL FAILURE IS THE FIRST CAUSE OF DOUBLE MAINTENANCE (BEVACIZUMAB + PEMETREXED) DISCONTINUATION FOR TOXICITY IN REAL WORLD SETTING
Radj Gervais, France

P2.24-040: ANALYSIS OF WHY CERTAIN RESPIRATORY CANCER PATIENTS DIAGNOSED AND/OR RECEIVING CANCER DIRECTED TREATMENT HAVE REPEAT PRESENTATIONS AT MULTIDISCIPLINARY TEAM MEETINGS.
Stephen Dunn, Australia

P2.24-041: A PILOT STUDY OF A STEROID SULPHATASE INHIBITOR (BN83495) IN PATIENTS WITH RASH DUE TO TREATMENT WITH AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)
Linda Mileskin, Australia

P2.24-042: ROLE OF COMORBIDITY ON SURVIVAL AFTER RADIO- AND CHEMOTHERAPY FOR NON-SURGICALLY TREATED LUNG CANCER
Anders Mellemgaard, Denmark

P2.24-043: DEVELOPING AN OPTIMAL BEST PRACTICE MODEL OF CARE FOR THE MANAGEMENT OF LUNG CANCER IN AUSTRALIA: A NATIONAL APPROACH
Sue Sinclair, Australia

P2.24-044: USE AND COMPARISON OF ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED ANAEMIA (CIA) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
Santiago Ponce Aix, Spain
P2.24-045: ENHANCING PSYCHOLOGICAL SERVICES FOR PEOPLE WITH LUNG CANCER
Maria Tfanou, Australia

P2.24-046: QUALITY OF LIFE IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION UNDERGOING PLEURODESIS
Ricardo Terra, Brazil

P2.24-047: PALLIATIVE CARE UNITS IN THE MANAGEMENT OF PATIENTS WITH ADVANCED LUNG CANCER - THE EXPERIENCE OF THE MEDICAL UNIVERSITY OF VIENNA
Sophie Schur, Austria

P2.24-048: PREVALENCE OF PULMONARY EMBOLISM IN PATIENTS WITH ONCOGENE ADDICTED ADVANCED LUNG ADENOCARCINOMA
Lucio Crino, Italy

P2.24-049: THE SIGNIFICANCE OF FEVER AFTER THE FIRST ADMINISTRATION OF ZOLEDRONATE AS A PROGNOSTIC FACTOR IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER.
Hiroki Izumi, Japan

P2.24-050: TREATMENT PATHWAYS OF PATIENTS DIAGNOSED WITH NON-SMALL CELL LUNG CANCER - AN AUDIT OF PRACTICE AT A REGIONAL TEACHING HOSPITAL.
Cameron Hunter, Australia

P2.24-051: CICATRICIAL FIBROMATOSIS WITH HIGH SUV WERE SUSPECTED BY A LOCAL RECURRENTENCE OF BRONCHIAL STUMP IN PATIENT WITH LUNG CANCER
Yoo Sang Yoon, South Korea

P2.24-052: A SINGLE CENTRE REVIEW OF ENDOTHELIAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING: A REGIONAL AUSTRALIAN EXPERIENCE.
Scott Twaddell, Australia

P2.24-053: 11-YEAR SURVIVAL OF A PATIENT WITH UNTREATED, EGFR POSITIVE, PULMONARY ADENOCARCINOMA
Nicolas Kahn, Germany

P2.24-054: RELATIONSHIP BETWEEN DISTRESS LEVEL AND SURVIVAL RATE AMONG NEWLY DIAGNOSED STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC): PILOT STUDY
Marco Buso, Brazil

P2.24-055: REALCARE: RECOVERY AFTER LUNG RESECTION. STUDY DESIGN AND PRELIMINARY RESULTS.
Josien Timmerman, Netherlands

P2.24-056: VATS LOBECTOMY USING SUBCOSTAL INCISION IN NSCLC
Jinwook Hwang, South Korea

P2.24-057: STEREOTACTIC BODY RADIATION THERAPY (SBRT) - THE SUCCESS OF A NEW TECHNIQUE IN A COMPLEX CLINICAL CASE
Ana Figueredo, Portugal

P2.24-058: THORACIC MULTIDISCIPLINARY MEETING DISCUSSION OUTCOMES AT AUCKLAND CITY HOSPITAL: CONCORDANCE WITH ACTUAL PATIENT MANAGEMENT FOR LUNG MALIGNANCIES
Christopher Lewis, New Zealand

P2.24-059: RESULTS OF TREATING ADVANCED STAGE NON SMALL CELL LUNG CANCER BY ERLOTINIB AT THE PULMONARY DEPARTMENT, CHO RAY HOSPITAL: FIRST VIETNAMESE CASE REPORT
Le Thuong Vu, Vietnam

P2.24-060: VATS LOBECTOMY USING SUBCOSTAL INCISION IN NSCLC
Jinwook Hwang, South Korea

P2.25 Poster Session 2 Nurses

P2.25-001: WORKFLOW IMPROVEMENT AND RESULTS OF STANDARDIZATION OF THORACIC SURGERY PROCEDURES AMONG SIX HOSPITALS
Yasushi Iwasaki, Japan

P2.25-002: HOW DO PATIENTS WITH LUNG CANCER EXPERIENCE RADIATION INDUCED OESOPHAGITIS?
Mary Duffy, Australia
Kangaroo

Kangaroos belong to the animal family Macropus, literally “big foot.” Thanks to their large feet, kangaroos can leap some 30 feet in a single bound, and travel more than 30 mph (48 kmh). Kangaroos use their strong tails for balance while jumping.

Kangaroos are highly social. They often live in groups known as mobs, troops or courts, which can range in size from 10 to more than 100 kangaroos. Males box with each other to establish dominance.

On the Australian coat of arms the Emu and the Kangaroo were selected as symbols of Australia to represent the country progress because they are always moving forward and never move backwards.

Courtesy of nationalgeographic.com, livescience.com, koalaexpress.com.au
Bristol-Myers Squibb is leading the way in Immuno-Oncology

Join us at World Conference on Lung Cancer 2013
October 27 - October 30 at Booth 1210
to learn more about Immuno-Oncology research in multiple tumor types.

www.immuno oncology.com
## Wednesday | October 30, 2013

### Biology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.01</td>
<td>CANCER BIOLOGY</td>
</tr>
<tr>
<td>P3.02</td>
<td>NOVEL CANCER GENES AND PATHWAYS</td>
</tr>
<tr>
<td>P3.03</td>
<td>TECHNOLOGY AND NOVEL DEVELOPMENT</td>
</tr>
<tr>
<td>P3.04</td>
<td>TUMOR IMMUNOLOGY</td>
</tr>
<tr>
<td>P3.05</td>
<td>PRECLINICAL MODELS OF THERAPEUTICS/IMAGING</td>
</tr>
<tr>
<td>P3.06</td>
<td>PROGNOSTIC AND PREDICTIVE BIOMARKERS</td>
</tr>
</tbody>
</table>

### Surgery

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.07</td>
<td>SURGERY</td>
</tr>
</tbody>
</table>

### Radiotherapy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.08</td>
<td>RADIOThERAPy</td>
</tr>
</tbody>
</table>

### Combined Modality

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.09</td>
<td>COMBINED MODALITY</td>
</tr>
</tbody>
</table>

### Medical Oncology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.10</td>
<td>CHEMOTHERAPY</td>
</tr>
<tr>
<td>P3.11</td>
<td>NSCLC NOVEL THERAPIES</td>
</tr>
<tr>
<td>P3.12</td>
<td>NSCLC EARLY STAGE</td>
</tr>
<tr>
<td>P3.13</td>
<td>SCLC</td>
</tr>
</tbody>
</table>

### Mesothelioma

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.14</td>
<td>MESOTHELIOMA</td>
</tr>
</tbody>
</table>

### Thymoma and Other Thoracic Malignancies

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.15</td>
<td>THYMOMA</td>
</tr>
<tr>
<td>P3.16</td>
<td>OTHER THORACIC MALIGNANCIES</td>
</tr>
</tbody>
</table>

### Endoscopy

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.17</td>
<td>BRONCHOSCOPY, ENDOSCOPY</td>
</tr>
</tbody>
</table>

### Pathology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.18</td>
<td>PATHOLOGY</td>
</tr>
</tbody>
</table>

### Imaging and Screening

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.19</td>
<td>IMAGING</td>
</tr>
<tr>
<td>P3.20</td>
<td>EARLY DETECTION AND SCREENING</td>
</tr>
</tbody>
</table>

### Prevention & Epidemiology

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.21</td>
<td>DIAGNOSIS AND STAGING</td>
</tr>
<tr>
<td>P3.22</td>
<td>EPIDEMIOLOGY, ETIOLOGY</td>
</tr>
<tr>
<td>P3.23</td>
<td>TOBACCO CONTROL, PREVENTION AND CHEMOPREVENTION</td>
</tr>
</tbody>
</table>

### Supportive Care and Nursing

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.24</td>
<td>CLINICAL CARE</td>
</tr>
<tr>
<td>P3.25</td>
<td>NURSES</td>
</tr>
</tbody>
</table>
**Wednesday, October 30**

**POSTER SETUP TIME: 08:30 – 09:30**

**POSTER TAKE DOWN TIME: 16:30 – 18:00**

(Posts not taken down after 18:00 will be discarded by management)

**PRESENTING AUTHOR STAND BY TIME*:**

09:45 – 10:30 AND 15:30 – 16:15

(NETWORKING BREAKS)

* Time in which Poster Presenter remains at his/her Poster Board for the specified time period and is available to discuss their research personally with any interested delegate.

### **BIOLOGY**

<table>
<thead>
<tr>
<th>P3.01</th>
<th>Poster Session 3 Cancer Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.01-001: DOWNREGULATION OF THYMIDYLATE SYNTHASE WITH ARSENIC TRIOXIDE IN NON-SMALL CELL LUNG CANCER: IN VITRO AND IN VIVO</td>
<td>Sze Kwan Lam, Hong Kong</td>
</tr>
<tr>
<td>P3.01-002: DENDRITIC CELLS PROMOTED THE SDF-1-EXpressING PREMETASTATIC NICHE FORMATION IN MEDIASTINAL LYMPH NODE METASTASIS FOR LUNG CANCER VIA COX-2-DERIVED PGE2-EP3 SIGNALING.</td>
<td>Fumihiro Ogawa, Japan</td>
</tr>
<tr>
<td>P3.01-003: IDENTIFICATION AND TUMORIGENIC ROLE OF MESENCHYMAL STEM CELLS FROM HUMAN LUNG CANCER</td>
<td>Luca Ampollini, Italy</td>
</tr>
<tr>
<td>P3.01-004: PRE-ClinICAL EVALUATION OF DEATH RECEPTOR-5 ACTIVATION AS A FEASIBLE OPTION FOR K-RAS MUTANT NSCLC THERAPY</td>
<td>Cinthya Sternberg, Brazil</td>
</tr>
<tr>
<td>P3.01-005: EFFICACY OF ARSENIC TRIOXIDE IN THE TREATMENT OF MALIGNANT PLEURAL EFFUSION CAUSED BY PLEURAL METASTASIS OF LUNG CANCER</td>
<td>Yuan-Sheng Zang, China</td>
</tr>
<tr>
<td>P3.01-006: DISCOVERY OF NEW MEMBRANE-ASSOCIATED PROTEINS PREFERENTIALLY EXPRESSED IN SMALL-CELL LUNG CANCER</td>
<td>Sebahat Ocak, Belgium</td>
</tr>
<tr>
<td>P3.01-007: ENERGY METABOLISM IN LUNG ADENOCARCINOMA</td>
<td>Chuong Hoang, USA</td>
</tr>
<tr>
<td>P3.01-008: THE IMPORTANCE OF THE SECRETED FRIZZLED-RELATED PROTEIN (SFRP) TUMOUR SUPPRESSOR GENE FAMILY AND THE EFFECT OF LONG-TERM ASBESTOS EXPOSURE ON SFRP EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)</td>
<td>Yuen Yee Cheng, Australia</td>
</tr>
<tr>
<td>P3.01-009: FGFR-2 INDUCES CHEMORESISTANCE IN MODEL AND LUNG CANCER CELLS THROUGH S6K2/HNRPA1-MEDIATED ENHANCED TRANSLATION OF ANTI-APOPTOTIC PROTEINS</td>
<td>Michael Seckl, UK</td>
</tr>
<tr>
<td>P3.01-010: TUMOR-DERIVED MICROVESICLES MEDIATE THE TRANSFER OF GEFITINIB RESISTANCE IN LUNG CANCER CELLS HARBORING T790M EGFR MUTATION</td>
<td>Kye Young Lee, South Korea</td>
</tr>
<tr>
<td>P3.01-011: HETEROGENEITY IN TUMOUR CONTENT AND NECROSIS IN PRIMARY LUNG CANCERS: IMPLICATIONS FOR MOLECULAR ANALYSIS</td>
<td>Felicia Goh, Australia</td>
</tr>
<tr>
<td>P3.01-012: CO-TARGETING THE PI3K AND MEK PATHWAYS IN NSCLC: AN IN VITRO EVALUATION AND MUTATION PREVALENCE IN AN IRISH PATIENT COHORT.</td>
<td>Susan Heavey, Ireland</td>
</tr>
<tr>
<td>P3.01-013: KATS MAY BE A CANDIDATE THERAPEUTIC TARGET IN MALIGNANT PLEURAL MESOTHELIOMA</td>
<td>Kenneth O’Byrne, Australia</td>
</tr>
<tr>
<td>P3.01-014: EXPRESSION AND POST-TRANSLATIONAL MODIFICATIONS OF AKT ISOFORMS IN MALIGNANT PLEURAL MESOTHELIOMA CELLS</td>
<td>Kenneth O’Byrne, Australia</td>
</tr>
<tr>
<td>P3.01-015: OUTCOME IN PEMETREXED/CISPLATIN-TREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS ACCORDING TO MRNA EXPRESSION LEVELS OF BRCA1, TS, AEG1 AND REV3</td>
<td>Bartomeu Massuti, Spain</td>
</tr>
<tr>
<td>P3.01-016: GENETIC ALTERATIONS AND CELLULAR PROPERTIES OF ACQUIRED ARSENIC RESISTANCE IN SMALL CELL LUNG CANCER</td>
<td>Chun Yan Zheng, Hong Kong</td>
</tr>
<tr>
<td>P3.01-017: NITRIC OXIDE ADAPTED LUNG TUMOR CELLS EXPRESS TUMOR STEM CELL-LIKE MARKERS</td>
<td>Arkadiusz Dudek, USA</td>
</tr>
<tr>
<td>P3.01-018: SUPPORTING EVIDENCE FOR A NEW TUMOR STEM CELL PLASTICITY MODEL BASED ON ADAPTATION TO NITRIC OXIDE</td>
<td>James Radosevich, USA</td>
</tr>
<tr>
<td>P3.01-019: ANALYSIS OF INTEGRINS IN MALIGNANT MESOTHELIOMA (MM).</td>
<td>Ngan Ching Cheng, Australia</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

P3.02 Poster Session 3
Novel Cancer Genes and Pathways

P3.02-001: KIF5B/RET FUSION GENE IN SURGICALLY-TREATED JAPANESE ADENOCARCINOMA OF THE LUNG
Hidefumi Sasaki, Japan

P3.02-002: IDENTIFICATION OF CPG ISLAND METHYLATOR PHENOTYPE PREDICTS THE PROGNOSIS OF SMALL CELL LUNG CANCER
Yuichi Saito, Japan

P3.02-003: ATP7A IS A NOVEL DETERMINANT OF TOXICITY AND RESPONSE IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING PACITAXEL AND CARBOPLATIN
Benjamin Harris, Australia

P3.02-004: DYSREGULATION OF HIPPO TUMOR-SUPPRESSIVE PATHWAY IN MALIGNANT MESOTHELIOMA
Yoshitake Sekido, Japan

P3.02-005: GENOME-WIDE IDENTIFICATION OF GENES WITH AMPLIFICATION AND/OR FUSION IN SMALL CELL LUNG CANCER
Jun Yokota, Japan

P3.02-006: DOWNREGULATION OF THE CANDIDATE TUMOR SUPPRESSOR GENE SIRPA INDUCES SENESCENCE MEDIATED BY RB AND P27 AND IS ASSOCIATED WITH MUTATION OF EGFR
Larissa Pikor, Canada

P3.02-007: PREFERENTIAL EXPRESSION OF MET IN LUNG ADENOCARCINOMA VS LUNG SQUAMOUS-CELL CARCINOMA
Hartmut Koeppen, USA

P3.02-008: TRIMS14 IS A NOVEL TUMOR SUPPRESSOR GENE IN NON-SMALL-CELL LUNG CANCER
Josephine Hai, Canada

P3.02-009: ROR1 AS A NOVEL THERAPEUTIC TARGET FOR EGFR-MUTANT NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS WITH THE EGFR T790M MUTATION
Niki Karachaliou, Spain

P3.02-010: A PCR-BASED TEST DETECTING ECTOPTIC EXPRESSIONS OF PLACENTA/GERMLINE GENES CAN PREDICT AGGRESSIVE LUNG TUMOURS
Christian Brambilla, France

P3.02-011: QUANTITATIVE DETERMINATION OF METHYLATION PATTERNS IN FHit AND APC GENES IN NON SMALL CELL LUNG CANCER (NSCLC): A COMPARATIVE ANALYSIS IN TUMOR TISSUE, NORMAL LUNG TISSUE, PERIPHERAL BLOOD, SPUTUM AND BRONCHIAL ASPIRATE. CORRELATION WITH CLINICAL VARIABLES.
Manuel Cobo Dols, Spain

P3.02-012: CYSTEINE DIOXYGENASE 1 (CDO1): A NOVEL TUMOR SUPPRESSOR GENE REGULATED BY HYPERMETHYLATION.
Hae-Won Lee, South Korea

P3.02-013: ATF2 CONTRIBUTES TO PLATINUM RESISTANCE IN NON SMALL CELL LUNG CANCER AND CJUN/ATF2 CELASTROL MEDIATED MODULATION RESTORES PLATINUM SENSITIZATION.
Valentina Monica, Italy

P3.02-014: INTERACTION BETWEEN ENVIRONMENTAL EXPOSURE AND HPV INFECTION ON DEVELOPING LUNG CANCER AMONG TAIWANESE NONSMokers
Ya-Wen Cheng, Taiwan

P3.02-015: GENOMIC ALTERATION IN SPUTUM SAMPLES AND DNAFC OF LUNG CANCER HIGH RISK CHILEAN POPULATION.
Marta Adonis, Chile

P3.02-016: PROTEINASE INHIBITION REGULATES THE ANTI-TUMOR ACTIVITY OF PAI-1 TOWARDS LUNG AND PROSTATE CANCER CELLS
Joanna Chorostowska-Wynimko, Poland

P3.02-017: ALPHA-CATULIN/ILk SIGNALING AXIS COULD BE POTENTIAL THERAPEUTIC TARGET FOR TREATING NSCLC METASTASIS
Yuh-Ling Chen, Taiwan

P3.02-018: EGFR MUTATION AND ITS SUBTYPES IN INDIAN POPULATION: A STUDY FROM SINGLE ACADEMIC CENTRE- TATA MEMORIAL CENTRE
Anuradha Choughule, India

P3.02-019: FGFR1 AMPLIFICATION IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH EARLY-STAGE SQUAMOUS CELL CARCINOMAS OF THE LUNG (SQCLC)
Matthew Hellmann, USA

P3.02-020: NSCLC MOLECULAR PORTRAIT OF THE SAMPLE OF CZECH POPULATION AND INDICATIONS OF TARGETED THERAPY
Milos Pesek, Czech Republic

P3.02-021: INTERDEPENDENT ROLE OF MUC16/TSPY5 IN LUNG CANCER CELL PROLIFERATION
Apar Kishor Ganti, USA

P3.02-022: DEEP-SEQUENCING MUTATIONAL ANALYSIS OF ATM IN NSCLC CELL LINES
D. Bebb, Canada
P3.03: Poster Session 3
Technology and Novel Development

P3.03-001: THE OVERXPRESSION OF TS PROTEIN INDUCED BY NPE6-PDT
Sachio Maehara, Japan

P3.03-002: HETEROGENEITY OF ADENO CARCINOMA OF LUNG - CHANGE IN IMMUNOHISTOCHEMISTRY AND HISTOPATHOLOGY CHACTER IN PATIENTS TREATED WITH CHEMOTHERAPY OR EGFR-TKIS
Gouri Shankar Bhattacharyya, India

P3.03-003: THE RELATIONSHIP BETWEEN FRESH MACROSCOPIC APPEARANCE OF TISSUE SPECIMEN BY CT GUIDED BIOPSY AND ITS CLINICOPATHOLOGICAL FEATURE IN 58 PATIENTS WITH NSCLC.
Toshiyuki Nakai, Japan

P3.04 Poster Session 3
Tumor Immunology

P3.04-001: COMBINED ADJUVANT CHEMOIMMUNOTHERAPY WITH CBDCA+GEM AND AUTOLOGOUS TUMOR LYSATE-TRANSDUCED DENDRITIC CELL VACCINATIONS IN PATIENTS WITH OPERABLE NSCLC
Kosei Yasumoto, Japan

P3.04-002: A PHASE II TRIAL TO ASSESS THE SAFETY AND IMMUNOLOGICAL ACTIVITY OF TROVAX PLUS PEMETREXED/CISPLATIN IN PATIENTS WITH MALIGNANT PLEURAL MESTOYELIOMA - SKOPOS TRIAL
Jason Lester, UK

P3.04-003: HIGH LEVELS OF CIRCULATING IMMUNOSUPPRESSIVE CELLS PREDICT WORST CLINICAL OUTCOME IN NON-SMALL LUNG CANCER (NSCLC) PATIENTS
Athanasios Kotsakis, Greece

P3.04-004: INTERLEUKIN-15: A POTENTIAL FACTOR IN ESTABLISHMENT AND PROGRESSION OF LUNG CANCER
Jason Steel, USA

P3.05 Poster Session 3
Preclinical Models of Therapeutics/Imaging

P3.05-001: METFORMIN SENSITIZES EGFR-TKI-RESISTANT HUMAN LUNG CANCER CELLS IN VITRO AND IN VIVO THROUGH INHIBITION OF IL-6/STAT3 AXIS AND EMT REVERSAL
Yong He, China

P3.05-002: RESISTANCE TO BH3 MIMETIC S1 IN NON-SMALL CELL LUNG CANCER CELLS THAT PHOSPHORYLATE BIM THROUGH ERK1/2 AND LEAD TO ITS PROTEASOMAL DEGRADATION
Yubo Liu, China

P3.05-003: ROLE OF ATM IN RESPONSE OF NON-SMALL CELL LUNG CANCER CELL LINES TO THERAPEUTIC AGENTS
D. Bebb, Canada

P3.05-004: TARGETING GLUCOSYLCERAMIDE SYNTHASE INDUCTION OF CELL SURFACE GLOBOTRIAOSYLCERAMIDE (GB3) CO-EXPRESSED WITH MULTIDRUG RESISTANCE 1 (MDR1) PROTEIN AS NEW TREATMENT APPROACH IN ACQUIRED CISPLATIN-RESISTANCE OF MALIGNANT PLEURAL MESTOYELIOMA AND NON-SMALL CELL LUNG CANCERCISPLATIN-RESISTANCE IN A MALIGNANT MESTOYELIOMA CELL LINE
Parviz Behnam Motlagh, Sweden

P3.05-005: DEREGLATION OF BCL-2 FAMILY PROTEIN EXPRESSION AND PRESERVED POST-TARGET APOPTOSIS RESISTANCE TO THE BH3-MIMETIC GX15-070 ON ACQUISITION OF C1SPLATIN-RESISTANCE IN A MALIGNANT MESTOYELIOMA CELL LINE
Andreas Tyler, Sweden

P3.05-006: INHIBITION OF TUMOR CELL GROWTH, MIGRATION BY SIM-89, A NOVEL INHIBITOR OF C-MET TYROSINE KINASE
Baohui Han, China

P3.05-007: EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED GOLD NANOPARTICLES FOR THE RADIATION TREATMENT OF NON-SMALL CELL LUNG CANCER
Rene Razzak, Canada

P3.05-008: NOVEL ANTI-CANCER PROPERTIES OF A MARCKS ED DOMAIN PEPTIDE OCCUR THROUGH UNIQUE ALTERATIONS OF PI3K/AKT SIGNALING
Ching-Hsien Chen, USA

P3.05-009: METABOLIC REPROGRAMMING OVERCOMES RESISTANCE TO ABT-737-INDUCED APOPTOSIS IN PRE-CLINICAL MODELS OF MALIGNANT PLEURAL MESTOYELIOMA
Marion Macfarlane, UK

P3.05-010: GENERATION AND BIOLOGICAL CHARACTER ANALYSIS OF EGFR-TKI RESISTANT CELL LINE
Yuankai Shi, China

P3.05-011: TARGETING EPITHELIAL TO MESENCHYMAL TRANSITION WITH MET INHIBITORS REVERTS CHEMORESISTANCE IN SMALL CELL LUNG CANCER
Edurne Arriola, Spain
P3.05-012: POTENTIAL BIOMARKERS OF GROWTH INHIBITION OF AFATINIB (BIBW-2992) IN COMBINATION WITH DASATINIB (BMS-354825) IN GEFITINIB RESISTANT NON SMALL CELL LUNG CANCER CELLS (NSCLC)
Alex Chang, Singapore

P3.05-013: EFFECT OF PSA DERIVATIVES ON DNA METHYLTRANSFERASE (DNMT) INHIBITION AND RADIATION SENSITIZATION IN A549 LUNG CANCER CELL LINE
Hak Jae Kim, South Korea

P3.05-014: Eribulin, A Tubulin Targeted Chemotherapeutic Agent, Inhibits the In Vitro Growth of Small Cell Lung Cancer Cell Lines.
Barbara Helfrich, USA

P3.05-015: POSITRON-EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY WITH THE GLUCOSE ANALOGUE [18F] FLUORODEOXYGLUCOSE IN ORTHOTOPIC IMPLANTATION SCID MOUSE MODEL OF LUNG CANCER
Hiromitsu Takizawa, Japan

P3.05-016: EFFECTIVE COMBINATION THERAPIES WITH MEK INHIBITORS FOR THE TREATMENT OF MUTANT-BRAF LUNG CANCERS.
Aparna Rao, Australia

P3.05-017: LKB1 LOSS INDUCES CHARACTERISTIC PATHWAY ACTIVATION IN HUMAN TUMORS AND CONJURES SENSITIVITY TO MEK INHIBITION DUE TO ATTENUATED PI3K-AKT-FOXO3 SIGNALING.
David Carbone, USA

P3.05-018: DOES ELONGATION OF TREATMENT TIME IN RESPIRATORY GATED RADIOTHERAPY ALTER CELL SURVIVALS?
Sanghyuk Song, South Korea

P3.05-019: BIM EXPRESSION IN EGFR-MUTANT LUNG CANCER 3D SPHEROIDS PREDICTS RESPONSIVENESS TO TYROSINE KINASE INHIBITORS
Hyun-Kyung Lee, South Korea

P3.05-020: STRATEGIES FOR THE PREVENTION OF MESOTHELIOMA IN MEXTAG MICE
Cleo Robinson, Australia

P3.05-021: TARGETING HDACs TO OVERCOME CISPLATIN RESISTANCE IN MALIGNANT PLURAL MESOTHELIOMA
Anne-Marie Baird, Ireland

P3.05-022: BMS-777607 AS A CANDIDATE THERAPEUTIC AGENT IN MALIGNANT PLEURAL MESOTHELIOMA
Kenneth O'Byrne, Australia

P3.05-023: TREATMENT WITH THE MTOR KINASE INHIBITOR CC-223 OVERCOMES RESISTANCE TO THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR ERLOTINIB IN NON-SMALL CELL LUNG CANCER CELLS
Simon Ekman, USA

P3.06 Poster Session 3
Prognostic and Predictive Biomarkers

P3.06-001: SERUM NESFATIN-1 LEVEL AS A BIOMARKER IN NON-SMALL CELL LUNG CANCER
Bulent Karagoz, Turkey

P3.06-002: RLIP76 EXPRESSION IS PROGNOSTIC AND PREDICTIVE OF CHEMOTHERAPY BENEFIT IN RESECTED NSCLC
Damien Urban, Australia

P3.06-003: CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Sukhmani Padda, USA

P3.06-004: T790M MUTATION IN PATIENTS WITH ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS: IS IT ASSOCIATED WITH CLINICALLY DISTINCT FEATURES?
Jun Ho Ji, South Korea

P3.06-005: A PROSPECTIVE PROTOCOL FOR SIMULTANEOUS GENOMIC TESTING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Fernando Lopez-Rios, Spain

P3.06-006: INTEGRATED GENOMIC ANALYSIS OF EGFR-MUTANT NON-SMALL CELL LUNG CANCER IMMEDIATELY FOLLOWING ERLOTINIB INITIATION IN PATIENTS
Petros Gianikopoulos, USA

P3.06-007: CLINICAL FEASIBILITY STUDY OF A NOVEL SORTING SYSTEM FOR DETECTING EGFR MUTATIONS FROM CAPTURED CIRCULATING TUMOR CELLS IN PATIENTS WITH LUNG CANCER
Takeshi Sawada, Japan

P3.06-008: PROGNOSTIC AND PREDICTIVE VALUE OF KRAS MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER
Deok Won Hong, South Korea

P3.06-009: PARADOXICAL INCREASE IN KI67 WITH NEOADJUVANT CHEMOTHERAPY IN NSCLC
Glen Weiss, USA

P3.06-010: CLINICAL SIGNIFICANCE OF PRETREATMENT PLASMA BIOMARKERS IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
Xiaohong Han, China

P3.06-011: THE IMPACT OF E-CADHERIN TRANSCRIPTIONAL FACTORS ON THE SURVIVAL OF PULMONARY PLEOMORPHIC CARCINOMA
So Miyahara, Japan
P3.06-012: PHARMACOGENETIC STUDY OF JAPANESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMAL Lung Cancer TREATED WITH PEMETREXED PLUS CISPLATIN
Hisao Imai, Japan

P3.06-013: ICE COLD-PCR COMBINED WITH NEXT-GENERATION SEQUENCING: INCREASED SENSITIVITY FOR HIGH THROUGHPUT DETECTION OF MUTATIONS.
Benjamin Legendre, Jr., USA

P3.06-014: POSITIVE PROGNOSTIC IMPACT OF MIR-210 IN NON-SMAL Lung Cancer
Roy Bremnes, Norway

P3.06-015: INTEGRATED PROGNOSIS IN EARLY STAGE RESECTABLE Lung ADENOCARCINOMA
Edward Kim, USA

P3.06-016: ALDEHYDE DEHYDROGENASE 1 EXPRESSION IN CANCER CELLS COULD HAVE PROGNOSTIC VALUE FOR PATIENTS WITH NON-SMAL Lung CANCER WHO ARE TREATED WITH NEOADJUVANT THERAPY: IDENTIFICATION OF PROGNOSTIC MICRONVIRONMENTAL FACTORS AFTER CHEMORADIATION
Yoshitaka Zenke, Japan

P3.06-017: DISTINCTIVE INSULIN-LIKE GROWTH FACTOR 1 GENE COPY NUMBER AND PROTEIN EXPRESSION IN NON-SMALL CELL Lung CANCER
Thang Tran, Australia

P3.06-018: ECT2 OVEREXPRESSION AND GENE ALTERATION ARE ASSOCIATED WITH THE OUTCOME OF EARLY-STAGE Lung ADENOCARCINOMA
Yuko Minami, Japan

P3.06-019: MDM2 309T>G POLYMORPHISM AND RISK OF Lung CANCER IN A JAPANESE POPULATION
Seiichi Kakegawa, Japan

P3.06-020: PROGNOSTIC MARKERS FOR MESOTHELIOMA PATIENTS TREATED WITH INDUCTION CHEMOTHERAPY FOLLOWED BY EXTRAPLEURAL PNEUMONECTOMY
Isabelle Opitz, Switzerland

P3.06-021: CHANGES IN EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION DURING CHEMOTHERAPY IN NON-SMAL Lung CANCER
Jens Sorensen, Denmark

P3.06-022: POPULATION BASED STUDY OF THE PREVALENCE OF EGFR MUTATIONS IN NON-SMAL Lung CANCER (NSCLC)
Birgit Skov, Denmark

P3.06-023: USEFULNESS OF PLEURAL EFFUSION FOR THE DETECTION OF EGFR MUTATION BY USING DIRECT SEQUENCING AND PNA CLAMPING
Seung Joon Kim, South Korea

P3.06-024: RETROSPECTIVE ANALYSIS OF REBIOPIES IN A COHORT OF EGFR-MUTATED NSCLC-PATIENTS WITH TKI-RESISTANCE; INCIDENCE OF THE T790M MUTATION.
Justine Kuiper, Netherlands

P3.06-025: T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Shengxiang Ren, China

P3.06-026: THYMIDYLATED SYNTHASE (TS) MRNA AND PROTEIN EXPRESSION IN ADVANCED NON-SMAL Lung CANCER (NSCLC) PATIENTS TREATED WITH PEMETREXED-BASED THERAPY.
Valentina Monica, Italy

P3.06-027: A COMPARISON OF FISH AND IMMUNOHISTOCHEMISTRY IN THE DETECTION OF ALK REARRANGEMENT IN Lung ADENOCARCINOMA
John Le Quesne, UK

P3.06-028: APPROACH TO BIOMARKER TESTING: PERSPECTIVES FROM VARIOUS SPECIALTIES
Natasha Leighl, Canada

P3.06-029: PREDICTIVE ROLE OF SERUM TUMOR MARKERS IN NSCLC PATIENTS TREATED WITH ERLOTINIB
Ondrej Fiala, Czech Republic

P3.06-030: CIRCULATING TUMOR CELLS AS A NOVEL PREDICTIVE MARKER IN PATIENTS WITH ADVANCED ADENOCARCINOMA OF THE LUNG TREATED WITH PLATINUM AND PEMETREXED
Francesco Grossi, Italy

P3.06-031: MRNA AND SPLICE VARIANT ANALYSIS IN ENDORBONCHIAL LINING FLUID COLLECTED BY BRONCHOSCOPIC MICROSAMPLING IN PROXIMITY OF PULMONARY NODULES
Nicolas Kahn, Germany

P3.06-032: EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENTS USING ALK/EM4 TRICHECK FLUORESCENCE IN SITU HYBRIDISATION (FISH) IN NON-SMAL Lung CANCERS (NSCLC) AND ITS UTILITY FOR EQUIVOCAL CASES.
Christina Selinger, Australia

P3.06-033: SUBCELLULAR LOCALIZATION OF NRF2 PROMOTES TUMOR AGGRESSIVENESS, POOR OUTCOME, AND UNFAVORABLE RESPONSE TO CHEMOTHERAPY VIA INCREASED IKKβ STABILITY IN NSCLC
Huei Lee, Taiwan

P3.06-034: DUAL-FUNCTION PROTEIN APE1 IS A NOVEL BIOMARKER TO PREDICT TUMOR RESPONSE IN CHINESE PATIENTS WITH STAGES IIIB TO IV NON-SMAL Lung CANCER.
Dong Wang, China
P3.06-035: STUDY OF THE CORRELATIONS BETWEEN SNPS IN ANGIgenic GENES AND TREATMENT RESPONSE/OuTCOME IN PATIENTS WITH Advanced NSCLC (NON-SQUAMOUS HISTOLOGY) TREATED IN FIRST LINE WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB (CPB): THE ANGIOMET STUDY. Bartomeu Massuti, Spain

P3.06-036: PROSPECTIVE CORRELATIVE STUDY OF FDG-PET SUV AND PROTEOMIC PROFILE (VERISTRAT) OF NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ERLOTINIB. Hector J. Soto Parra, Italy

P3.06-037: EXPRESSION OF STEMNESS FACTORS OCT4 AND NANOG IN RESECTABLE NON-SMALL CELL LUNG CANCER. Carlos Camps, Spain

P3.06-038: NEW SCORING SYSTEM ASSESSING THE PROBABILITY OF MALIGNANCY AS THE CAUSE OF LARGE PERICARDIAL EFFUSION IS ABLE TO IMPROVE THE DIAGNOSTIC ALGORITHM OF NEOPLASTIC PERICARDITIS. Monika Szturmowicz, Poland

P3.06-039: EXPRESSION OF MUCIN 1 IN NON-SMALL CELL LUNG CANCER: RELATIONSHIP BETWEEN IMMUNOHISToCHEMISTRY, TUMOUR CHARACTERISTICS AND SURVIVAL. Paul Mitchell, Australia

P3.06-040: CHARACTERIZATION OF PD-L1 EXPRESSION AND ASSESSMENT OF ASSOCIATION WITH TUMOR HISTOLOGY AND GENE EXPRESSION STATUS IN PRETREATMENT NON-SMALL CELL LUNG CANCER (NSCLC) TUMOR SPECIMENS. Christopher Harbison, USA

P3.06-041: SERUM MIrna SIGNATURE PREDICTS SURVIVAL IN PATIENTS WITH UNRESECtABLE/INOPERABLE NON-SMALL CELL LUNG CANCER TREATED WITH DEFINITIVE RADIATION THERAPY. Feng-Ming (Spring) Kong, USA

P3.06-042: PLEURAL FLUID ADA IS ASSOCIATED WITH SURVIVAL OF PATIENTS WITH MALIGNANT PLEURAL EFFUSION. Ricardo Terra, Brazil

P3.06-043: MODULATION OF THE CYCLOOXYGENASE PATHWAY IS ASSOCIATED WITH EFFICACY IN A RANDOMIZED PHASE II TRIAL OF ERLOTINIB AND CELECOXIB OR PLACEBO IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Karen Reckamp, USA

P3.06-044: KRAS, EGFR MUTATIONS AND EGFR GENE COPY STATUS AS PREDICTIVE MARKERS OF RESPONSE AND TIME TO PROGRESSION IN EGFR WILD-TYPE STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH EGFR TYROSINE-KINASE INHIBITORS. Manuel Domine, Spain

P3.06-045: E-CADHERIN AND VIMENTIN AS BIOMARKERS OF CLINICAL OUTCOMES AMONG EGFR+ LUNG ADENOCARCINOMA (LA) PATIENTS TREATED WITH ERLOTINIB (CLICAP). Claudiao Martin, Argentina

P3.06-046: THE TUMOR SUPPRESSOR INTEGRIN-ALPHA 7 IS FREQUENTLY DOWNREGULATED IN MALIGNANT PLEURAL MESOTHELIOMA: BIOLOGICAL AND PROGNOSTIC CONSEQUENCES. Mir Hoda, Austria

P3.06-047: PROGNOSTIC VALUE OF NEUTROPHIL LYMPHOCYTE RATIO IN SECOND LINE ADVANCED MALIGNANT PLEURAL MESOTHELIOMA. Rabab Gaafar, Egypt

P3.06-048: PROGRESS WITH CANDIDATE PREDICTIVE GENE EXPRESSION SIGNATURES FOR MEK INHIBITORS IN NON-SMALL CELL LUNG CANCER (NSCLC). Paul Smith, UK

P3.06-049: DETECTION OF EGFR MUTATION IN BRONCHIAL LAVAGE FLUID AFTER TRANSBRONCHIAL BIOPSY USING A NOVEL HIGH-SPEED REAL-TIME PCR SYSTEM. Tomohiro Sakamoto, Japan

P3.06-050: CHARACTERISTIC IMMUNOPHENOTYPE OF SOLID SUBTYPE COMPONENT IN LUNG ADENOCARCINOMA. Teruhiisa Takuwa, Japan

P3.06-051: CIRCULATING BIOMARKERS MAY HELP GUIDE SELECTION OF ERLOTINIB VERSUS CHEMOTHERAPY IN PRETREATED ADVANCED NSCLC PATIENTS. Marta Batus, USA

P3.06-052: A NOVEL TECHNIQUE THAT DISTINGUISHES LOW-LEVEL SOMATIC DNA VARIANTS FROM FFPE-INDUCED ARTIFACTS IN LUNG AND OTHER SOLID TUMORS BY NEXT-GENERATION SEQUENCING (NGS). Nitin Udar, USA

P3.06-053: A DIAGNOSTIC STUDY TO DETERMINE THE PREVALENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN ASIAN AND RUSSIAN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) OF ADENOCARCINOMA AND NON-ADENOCARCINOMA HISTOLOGY: IGNITE STUDY DESIGN. Baohui Han, China
P3.07-001: LONG-TERM OUTCOME AND CURRENT PROBLEMS OF VATS VERSUS OPEN LOBECTOMY FOR CLINICAL STAGE IA NON-SMALL CELL LUNG CANCER
Mitsunori Higuchi, Japan

P3.07-002: PLEURAL LYMPH FLOWS EXCEEDING THE LUNG SEGMENT
Yui Watanabe, Japan

P3.07-003: FUNCTIONAL OUTCOMES IN RECONSTRUCTION OF MASSIVE CHEST WALL DEFECTS: A 17-YEAR EXPERIENCE
Mark Clemens, USA

P3.07-004: A NOVEL SOFT-COAGULATION SYSTEM FOR LUNG CANCER SURGERY: MINIMIZATION OF SURGEONS’ RISK
Akihiko Uchiyama, Japan

P3.07-005: RECURRENCE-FREE AND POST-RECURRENCE SURVIVAL AND THE INCIDENCE OF METACHRONOUS PRIMARY LUNG CANCER AFTER COMPLETE RESECTION OF NON-SMALL CELL LUNG CANCER
Chiaki Endo, Japan

P3.07-006: ROBOTIC ASSISTED LOBECTOMY: A PLATFORM FOR INCREASING MINIMALLY INVASIVE PULMONARY RESECTIONS
Patrick Ross, USA

P3.07-007: INDUCTION TREATMENT FOR LOCALLY ADVANCED LUNG CANCER DETERIORATES PULMONARY FUNCTION
Hiroshi Niwa, Japan

P3.07-008: SURGERY OF NON-SMALL CELL LUNG CANCER IN THE ELDERLY, COMPARISON BETWEEN 75-79 YEARS OLD CASES AND 80 YEARS OR OLDER CASES
Osamu Kawamata, Japan

P3.07-009: COMBINED USE OF VIRTUAL PUNCTURE BY SIMULATOR WITH METHYLENE BLUE STAIN LOCALIZATION OF THE PULMONARY PERIPHERAL NODULES
Yang Shen-Tu, China

P3.07-010: THORACOSCOPIC PNEUMONECTOMY - AN 11 YEAR EXPERIENCE
Todd Demmy, USA

P3.07-011: PROGNOSTIC AND PREDICTIVE FACTORS FOR RECURRENCE-FREE SURVIVAL IN PATIENTS WITH COMPLETELY RESECTED PN2 NON-SMALL CELL LUNG CANCER
Hirofumi Uehara, Japan

P3.07-012: PULMONARY RESECTION FOR STAGE I NON-SMALL CELL LUNG CANCER IN ELDERLY PATIENTS
Byungjoon Park, South Korea

P3.07-013: CHYLOTHORAX COMPLICATING VIDEO-ASSISTED THORACOSCOPIC PULMONARY RESECTION IN NON-SMALL CELL LUNG CANCER
Chao-Yu Liu, Taiwan

P3.07-014: POST-RECURRENCE SURVIVAL OF SURGICALLY RESECTED NON-SMALL CELL LUNG CANCER PATIENTS IN THE ERA OF EGFR-TKI
Yuki Matsumura, Japan

P3.07-015: ROBOTIC-ASSISTED PULMONARY RESECTION FOR NON-SMALL CELL LUNG CANCER IN HIGH RISK VETERAN POPULATION: A SINGLE INSTITUTION EXPERIENCE
Amir Abolhoda, USA

P3.07-016: CLINICAL IMPACT OF POSTOPERATIVE CARDIO-PULMONARY COMPLICATIONS ON LONG-TERM OUTCOME IN LUNG CANCER PATIENTS
Takashi Nojiri, Japan

P3.07-017: EXAMINATION OF THE SURGICAL PROCEDURES FOR METASTATIC PULMONARY TUMORS (CONFIRMATION OF THE TUMOR LOCAL EXISTENCE BY THE PALPATION)
Shozo Fujino, Japan

P3.07-018: ASSESSING SURVIVAL AND GRADING THE SEVERITY OF COMPLICATIONS IN OCTOGENARIANS UNDERGOING PULMONARY LOBECTOMY
Brian Louie, USA

P3.07-019: SEX-BASED DIFFERENCES IN MORBIDITY AND MORTALITY ASSOCIATED WITH NON-SMALL CELL LUNG CANCER RESECTIONS
Jessica Donington, USA

P3.07-020: NONINTUBATED THORACOSCOPIC LOBECTOMY FOR LUNG CANCER: EXPERIENCE OF TWO MEDICAL CENTERS FROM TAIWAN AND CHINA
Jianxing He, China

P3.07-021: PULMONARY METASTASIS, PARTICULARLY OF SARCOMAS, AMENABLE TO AGGRESSIVE SURGICAL MANAGEMENT
Michael Mann, USA

P3.07-022: PREOPERATIVE LIPIODOL MARKING FOR SMALL-SIZED LUNG TUMORS
Junichi Shimada, Japan

P3.07-023: CHANGES IN SYMPTOM OCCURRENCE RATES AND SEVERITY RATINGS BEFORE AND FOLLOWING LUNG CANCER SURGERY
Trine Oksholm, Norway

P3.07-024: THE ENDO-FINGER TECHNIQUE FOR THE LOCALIZATION OF SMALL PULMONARY GROUND GLASS NODULES UNDER THORACOSCOPIC SURGERY
Kazuhiro Sakamoto, Japan
POSTER SESSIONS

P3.07-025: PREOPERATIVE PHYSIOLOGIC ASSESSMENT OF LUNG CANCER SURGERY USING THE MODIFIED ACCP GUIDELINES
Tatsuo Nakagawa, Japan

P3.07-026: A NON-INTERVENTIONAL STUDY ON EGFR MUTATION STATUS AND CLINICAL OUTCOMES OF CHINESE PATIENTS WITH COMPLETELY RESECTED LUNG ADENOCARCINOMA (ICAN STUDY)
Yi-Long Wu, China

P3.07-027: RISK FACTORS AND OUTCOME OF PNEUMONECTOMY IN LUNG CANCER PATIENTS
Laura Romero Vielva, Spain

P3.07-028: LONG-TERM RESULT OF ROBOT-ASSISTED ESOPHAGECTOMY FOR ESOPHAGEAL CANCER: TECHNICAL FEASIBILITY AND ONCOLOGICAL RELIABILITY.
Chang-Hyun Kang, South Korea

P3.07-029: CLINICOPATHOLOGICAL FEATURES OF RESECTED SUBCENTIMETER LUNG CANCER
Hiroyuki Sakurai, Japan

P3.07-030: SURGICAL TREATMENT OF BRONCHOPULMONARY CARCINOID TUMORS - A SINGLE INSTITUTION EXPERIENCE
Piotr Rudzinski, Poland

P3.07-031: SURGICAL OUTCOME OF RESECTED LUNG CANCER PATIENTS COMPPLICATED WITH COMBINED PULMONARY FIBROSIS AND EMPHYSEMA
Mariko Fukui, Japan

P3.07-032: SYSTEMIC EXTENDED BILATERAL MEDIASTINAL LYMPH NODE DISSECTION THROUGH A MEDIAN STERNOTOMY WITH NON-SMALL CELL CARCINOMA OF THE RIGHT UPPER LOBE.
Toshiya Yokota, Japan

P3.07-033: SURGICAL TREATMENTS FOR NSCLC OF FEMALE PATIENTS UNDER 50 YEARS OLD
Ryosuke Kaku, Japan

P3.07-034: THERAPEUTIC OUTCOMES IN 24 CASES OF POSTOPERATIVE BRONCHOPLEURAL FISTULA IN LUNG CANCER SURGERY
Kentaro Imai, Japan

P3.07-035: BENEFIT OF PREOPERATIVE LOCALIZATION USING FRAGMENTED PLATINUM MICROCOIL FOR FLUOROSCOPY-AIDED THORACOSCOPIC RESECTION OF SOLITARY PULMONARY NODULES
Deog Gon Cho, South Korea

P3.07-036: POSTRECURRENCE SURVIVAL OF SURGICALLY RESECTED PULMONARY ADENOCARCINOMA PATIENTS ACCORDING TO EGFR AND KRAS MUTATION STATUS
Yoichi Ohtaki, Japan

P3.07-037: A SYSTEMATIC REVIEW AND META-ANALYSIS ON PULMONARY RESECTIONS BY ROBOTIC VIDEO-ASSISTED THORACIC SURGERY
Christopher Cao, Australia

P3.07-038: LONG-TERM OUTCOME AFTER RESECTION OF NON-SMALL CELL LUNG CANCER INVADING THE THORACIC INLET
Marc De Perrot, Canada

P3.07-039: VIDEO-ASSISTED MEDIASTINOSCOPY LYMPHadenectomy IS ASSOCIATED WITH BETTER SURVIVAL THAN MEDIASTINOSCOPY IN PATIENTS WITH OPERABLE AND INOPERABLE NON-SMALL CELL LUNG CANCER PATIENTS.
Akif Turna, Turkey

P3.07-040: TEMPORAL TRENDS IN SURGICAL OUTCOMES FOR EARLY STAGE NON-SMALL CELL LUNG CANCER
Benjamin Robinson, Australia

P3.07-041: STUDY ON SURGICAL CASES FOR SIMULTANEOUS MULTIPLE GGNS IN BILATERAL LUNG
Hironori Ishida, Japan

P3.07-042: PROPHYLACTIC LANDIOLOL ADMINISTRATION CAN PREVENT ATRIAL FIBRILLATION AFTER LOBECTOMY?
Koichiro Kajiura, Japan

P3.07-043: PNEUMONECTOMY, BRONCHOPLASTY, PULMONARY ARTERIOPLASTY, AND COMBINED RESECTIONS OF THE SUPERIOR VENA CAVA ARE FEASIBLE EVEN IN SALVAGE SURGERY AFTER TREATED LUNG CANCER
Yukio Tsushima, Japan

P3.07-044: SYSTEMATIC NODAL DISSECTION DURING PULMONARY METASTASECTOMY: RESULTS OF A CLINICAL STUDY
Vaclav Jedlicka, Czech Republic

P3.07-045: THIN-SECTION COMPUTED TOMOGRAPHY FINDINGS OF LUNG ADENOCARCINOMA INHERENT WITH METASTATIC POTENTIAL
Keiju Aokage, Japan

P3.07-046: A NOVEL TECHNIQUE FOR PALLIATING RECURRENT PLEURAL EFFUSIONS WITH A PORT-ACCESSSED TUNNELED CATHETER
Joseph Friedberg, USA

P3.07-047: DEVELOPING THORACIC SURGERY QUALITY ACROSS A BROAD REGION OF WESTERN UNITED STATES: THORACIC SURGERY INITIATIVE (TSI)
John Handy, USA

P3.07-048: VATS LOBECTOMY FOR NSCLC IN GERMANY - RESULTS OF A NATIONWIDE SURVEY
Johannes Bodner, Germany
P3.08-001: FEASIBILITY OF STEREOTACTIC BODY RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY FOR PATIENTS OVER 75 YEARS OLD WITH STAGE I NON-SMALL-CELL LUNG CANCER.
Masaki Kokubo, Japan

P3.08-002: AN EVIDENCE-BASED ESTIMATION OF SURVIVAL AND LOCAL CONTROL BENEFIT OF RADIOTHERAPY FOR LUNG CANCER
Jesmin Shafiq, Australia

P3.08-003: FDG-PET PARAMETERS AS PREDICTORS FOR OUTCOME IN NON SMALL CELL LUNG CANCER NSCLC TREATED WITH STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) AT THE ST JAMES’S INSTITUTE OF ONCOLOGY
Katy Clarke, UK

P3.08-004: SIGNIFICANCE OF LOW DOSE DISTRIBUTION IN DEVELOPING RADIATION PNEUMONITIS AFTER HELICAL TOMOTHERAPY BASED HYPOFRACTIONATED RADIOTHERAPY FOR PULMONARY METASTASES
Chul Seung Kay, South Korea

P3.08-005: IAEA RCA 6065: IMPROVING ACCESS TO STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) FOR LUNG CANCER PATIENTS IN ASIA.
Fiona Hegi-Johnson, Australia

P3.08-006: RESPIRATORY FUNCTION CHANGES AFTER STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) IN STAGE I NON-SURGICAL NSCLC: PRELIMINARY RESULTS FROM A SINGLE INSTITUTION PROSPECTIVE STUDY.
Silvia Novello, Italy

P3.08-007: STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) OF CENTRALLY LOCATED EARLY STAGE LUNG CANCER ACCRUED TO RTG 0813: NOVEL SCORING SYSTEM TO COMPARE PLAN QUALITY OF VOLUMETRIC MODULATED ARC THERAPY (VMAT) VERSUS ROBOTIC RADIOSURGERY
Vimoj Nair, Canada

P3.08-008: COMPARISON OF AUTO-SEGMENTED PET VOLUMES IN DISCRETE LUNG TUMORS WITH CT BASED MANUAL CONTOURS: IMPLICATIONS IN RADIOTHERAPY PLANNING.
Madhava Kanakamedala, USA

P3.08-009: RADIOTHERAPY FOR POSTOPERATIVE THORACIC LYMPH NODE RECURRENT IN PATIENTS WITH NON-_SMALL CELL LUNG CANCER WITHOUT DISTANT METASTASIS
Jiro Okami, Japan

P3.08-010: THE POTENTIAL USE OF MRI TO DELINEATE LUNG CANCER VOLUMES FOR RADIOTHERAPY
Shivani Kumar, Australia

P3.08-011: STEREOTACTIC ABLATIVE RADIOTHERAPY: A POTENTIALLY CURABLE APPROACH TO MULTIPLE PRIMARY LUNG CANCER
Joe Chang, USA

P3.08-012: I-START TRIAL: A UK PHASE I/II TRIAL OF ISOXIC ACCELERATED RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
Jason Lester, UK

P3.08-013: HIGH LOCAL CONTROL RATES WITH POST-OPERATIVE RADIOTHERAPY THERAPY IN INCOMPLETELY RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Shaun Din, USA

P3.08-014: VERY HIGH RADIATION DOSE ESCALATION IN NSCLC DOES NOT LEAD TO UNEXPECTED TOXICITY: A PLANNED TOXICITY ANALYSIS OF THE PET-BOOST STUDY (NCT01024829)
Jose Belderbos, Netherlands

P3.08-015: DOSIMETRIC FACTORS ASSOCIATED WITH WEIGHT LOSS DURING RADIOTHERAPY TREATMENT FOR NON-SMALL CELL LUNG CANCER
Nicole Kiss, Australia

P3.08-016: CLINICAL OUTCOME OF [18F] FDG-PET/CT VERSUS CONVENTIONAL CT BASED PLANNING FOR RADIOTHERAPY IN LOCALLY ADVANCED NSCLC PATIENTS: A PROPENSITY-SCORE MATCHING STUDY
Wenwen Zhang, China

P3.08-017: HIGH-DOSE, CONVENTIONALLY FRACTIONATED THORACIC REIRRADIATION FOR SECOND PRIMARY LUNG TUMORS OR RECURRENT DISEASE
Gwendolyn Griffioen, Netherlands

P3.08-018: STEREOTACTIC BODY RADIOTHERAPY FOR OLIGOMETASTATIC DISEASE TO THE LUNG
Jonathan Ashman, USA

P3.08-019: VISUAL ASSESSMENT OF THE PRESENCE OF CENTRAL PHOTOPENIA ON FDG-PET IMAGING IN NON-SMALL CELL LUNG CANCER (NSCLC) AND ITS PROGNOSTIC INFLUENCE ON SURVIVAL IN PATIENTS TREATED WITH RADIOTHERAPY. A SUBSET ANALYSIS OF TROG 99.05.
Richard Cox, Australia

P3.08-020: COMPARISON OF TWO RADIOTHERAPY PLANNING TECHNIQUES FOR STAGE IIIA AND IIIB NSCLC: HYBRID VOLUMETRIC MODULATED ARC THERAPY (VMAT) VS 3D CONFORMAL RADIOTHERAPY (3D CRT)
Kylie Unicomb, Australia
P3.08-021: PATIENT SPECIFIC QUALITY ASSURANCE FOR LUNG CANCER STEREOTACTIC ABLATIVE BODY RADIOTHERAPY Shankar Siva, Australia

P3.08-022: SURVIVAL ANALYSIS OF HYPO-FRACTIONATED RADICAL RADIOTHERAPY FOR THE TREATMENT OF NON-SMALL-CELL LUNG CANCER USING 55GY IN 20 FRACTIONS: THE NORTH WALES CANCER CENTRE EXPERIENCE Niladri Ghosal, UK

P3.08-023: ACUTE ESOPHAGITIS AND CONCOMITANT CHEMORADIOThERAPY WITH NAveLBINe. RESULTS FROM NARLAL, A PHASE II RANDOMIZED TRIAL. Tine Schytte, Denmark

P3.08-024: PRELIMINARY EXPERIENCE IN BRONCHOSCOPIC PLACEMENT AND IN-TREATMENT IMAGING OF TWO DIFFERENT FIDUCIAL MARKERS FOR GUIDANCE OF LUNG CANCER RADIATION. Daniel Steinfurt, Australia

P3.08-025: LUNG TUMORS WITH BIG SIZE OR IRREGULAR SHAPE OR HIGH-MOBILITY CAN BETTER BENEFIT FROM FOUR-DIMENSIONAL RADIOTHERAPY Ming Chen, China

P3.08-026: FACTORS INFLUENCING ONE YEAR SURVIVAL IN RADICAL RADIOTHERAPY TREATED LUNG CANCER PATIENTS DECEMBER 2010-NOVEMBER 2011, BEATSON WEST SCOTLAND CANCER CENTRE Stephen Harrow, UK

P3.09-001: NSCLC IN ELDERLY PATIENTS WITH BRAIN METS: ROLE OF COMBINED ERLOTINIB AND TEMOZOLOMIDE WITH RADIATION THERAPY. Manoj Behera, India

P3.09-002: I WANT IT ALL! THE BETTER OUTCOME OF PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING CHEMORADIATION FOLLOWED BY SURGERY OVER ANY OTHER COMBINATION OF INDUCTIVE CHEMOTHERAPY, RADIATION OR SURGERY Diego Marquez-Medina, Spain

P3.09-003: PHASE II STUDY OF NIMOTUZUMAB IN COMBINATION WITH CONCURRENT CHEMORADIOThERAPY (CRT) IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). Kazushige Hayakawa, Japan

P3.08-027: RADIATION PNEUMONITIS IN IMRT vS. 3D CONFORMAL RADIATION THERAPY Ramesh Rengan, USA
P3.09-013: OUTCOMES AND PREDICTORS FOR RECURRENCE AND SURVIVAL AFTER NEOADJUVANT CONCURRENT CHEMORADIATION FOLLOWED BY OPERATION IN PATIENTS WITH CLINICAL STAGE III-N2 NON-SMALL-CELL LUNG CANCER
Hyun-ju Lim, South Korea

P3.09-014: CONCURRENT CHEMORADIOThERAPY FOR PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CARCINOMA; A REAL-LIFE EXPERIENCE
Ufuk Yilmaz, Turkey

P3.09-015: THE ROLE OF ADJUVANT TREATMENT IN N2 POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMORADIATION FOLLOWED BY SURGERY: A RETROSPECTIVE SINGLE CENTER EXPERIENCE.
Jin Seok Ahn, South Korea

P3.09-016: A PHASE II STUDY OF CISPLATIN AND ORAL VINORELBINE CONCOMITANTLY WITH RADIOThERAPY IN LOCALLy ADVANCED NON-SMALL-CELL LUNG CANCER TREATMENT: EFICACY AND SAFETY RESULTS.
Sergio Vazquez, Spain

P3.09-017: CONCURRENT CHEMORADIOThERAPY (CONCRT) USING CISPLATIN-VINORELBINE IN LOCALLy ADVANCED (LA) NON-SMALL CELL LUNG CANCER (NSCLC)
Haris Charalambous, Cyprus

P3.09-018: IFCT-0803 TRIAL: A PHASE II STUDY OF CETUXIMAB, PEMETREXED, CISPLATIN AND CONCURRENT RADIOThERAPY IN PATIENTS WITH LOCALLy ADVANCED, UNRESECTABLE, STAGE III, NON SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY SAFETY ANALYSIS
Jean Tredaniel, France

P3.10-001: TRANSGLUTAMINASE 2 CAN BE PREDICTIVE OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR EFFICACY AND CYTOTOXIC CHEMOTHERAPY SUCCESS IN NON-SMALL CELL LUNG CANCER
Jae-Heon Jeong, South Korea

P3.10-002: RESOURCE UTILIZATION OF NSCLC PATIENTS RECEIVING PLATINUM-BASED THERAPIES ACROSS EUROPE: RESULTS FROM THE FRAME OBSERVATIONAL STUDY
Denis Moro-Sibilot, France

P3.10-003: A RANDOMIZED PHASE 2 TRIAL OF PEMETREXED (P) AND GEFITINIB (G) VERSUS G AS FIRST-LINE TREATMENT FOR PATIENTS WITH STAGE IV NON-SQUAMOUS (NS) NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
Tarun Puri, India

P3.10-004: JAW OSTEOONECROSIS IN LUNG CANCER PATIENTS: A RETROSPECTIVE ANALYSIS
Konstantinos Syrigos, Greece

P3.10-005: A PHASE II STUDY OF AMRUBICIN AND CARBOPLATIN FOR PREVIOUSLY UNTREATED PATIENTS WITH EXTENSIVE-DISEASE SMALL CELL LUNG CANCER
Hirokazu Taniguchi, Japan

P3.10-006: POST-PROGRESSION SURVIVAL AFTER TREATMENT WITH EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
Yoshihito Kogure, Japan

P3.10-007: AVASTIN® FOR ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A NESTED CASE CONTROL STUDY EXPLORING RISK FACTORS FOR HEMOPTYSIS IN JAPAN
Koichi Goto, Japan

P3.10-008: A PHASE I STUDY EVALUATING THE CONTINUATION OF GEFITINIB BEYOND PROGRESSIVE DISEASE FOLLOWED BY THE ADDITION OF DOCETAXEL
Satoshi Watanabe, Japan

P3.10-009: PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL AS FIRST-LINE CHEMOTHERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION
Akihiro Tamiya, Japan

P3.10-010: A STUDY OF PEMETREXED MONOTHERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH IMPAIRED RENAL FUNCTION
Norihiko Funaguchi, Japan

Noriyuki Ebi, Japan

P3.10-012: FEASIBILITY STUDY OF DOCETAXEL AND BEVACIZUMAB IN ELDERLY PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER: THORACIC ONCOLOGY RESEARCH GROUP (TORG) 1014.
Makiko Yomota, Japan
P3.10-013: OPEN-LABEL, RANDOMIZED MULTICENTRE, PHASE II TRIAL OF ORAL VINORELBINE (NVBO) OR INTRAVENOUS VINORELBINE (NVBIV) WITH CISPLATIN (CDDP) IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A CHINESE EXPERIENCE (CA225 STUDY)
Li Zhang, China

P3.10-014: EFFICACY AND SAFETY OF DOCETAXEL PLUS OXALIPLATIN AS A FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
Young-Chul Kim, South Korea

P3.10-015: FINAL ANALYSIS OF DOSE ESCALATION STUDY OF CARBOPLATIN PLUS PEMETREXED FOLLOWED BY MAINTENANCE PEMETREXED FOR ELDERLY PATIENTS (≥75 YEARS OLD) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Motohiro Tamiya, Japan

P3.10-016: A PHASE I/II STUDY OF COMBINATION CHEMOTHERAPY WITH ERLOTINIB AND S-1 IN PRETREATED NON-SMALL-CELL LUNG CANCER (NSCLC): THORACIC ONCOLOGY RESEARCH GROUP (TORG) 0808/0913
Naoyuki Nogami, Japan

P3.10-017: THE ROLE OF CYTOKERATIN FRAGMENT ANTIGEN 21-1 (CYFRA21-1) AS A PREDICTIVE MARKER FOR THE PATIENTS WITH NON-SMALL-CELL LUNG CANCER TREATED WITH PEMETREXED
Hiroyuki Minemura, Japan

P3.10-018: AN ADMINISTRATION TIMING AND DOSAGE OF THE gefitinib IN THE ADVANCED NON-SMALL-CELL LUNG CANCER PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
Sakae Fujimoto, Japan

P3.10-019: ORAL S-1 AND CARBOPLATIN FOLLOWED BY MAINTENANCE S-1 FOR CHEMO-NAIVE PATIENTS WITH ADVANCED SQUAMOUS CELL LUNG CANCER (OSAKA-LCSG 1102)
Takayuki Shiroyama, Japan

P3.10-020: PHASE I AND PHARMACOKINETIC STUDY OF ERLOTINIB ADMINISTERED IN COMBINATION WITH AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED NON-SMALL CELL LUNG CANCER
Sakiko Otani, Japan

P3.10-021: PHASE II MULTICENTER TRIAL OF ERLOTINIB FOR ADVANCED NON-SMALL-CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
Kazutoshi Isobe, Japan

P3.10-022: EFFICACY AND SAFETY OF BEVACIZUMAB-BASED THERAPY IN ADVANCED NON-SQUAMOUS NON SMALL CELL LUNG CANCER: A RETROSPECTIVE STUDY
Kentaro Ito, Japan

P3.10-023: PHASE II STUDY OF PEMETREXED + CARBOPLATIN AS FIRST LINE THERAPY FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT EGFR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0906 TRIAL
Tomoki Kimura, Japan

P3.10-024: PHASE II STUDY OF PEMETREXED + CARBOPLATIN + BEVACIZUMAB AS FIRST LINE THERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0910 TRIAL
Tomoki Kimura, Japan

P3.10-025: TAXANE-PLATINUM INDUCTION CHEMOTHERAPY IN LOCOREGIONALLY ADVANCED NON-SMALL-CELL LUNG CANCER: OUTCOMES AND PROGNOSTIC FACTORS
Jin Hyoung Kang, South Korea

P3.10-026: OUTCOMES OF PATIENTS UNDERGOING ADJUVANT PLATINUM-VINORELBINE CHEMOTHERAPY FOR RESECTED NON-SMALL CELL LUNG CANCER (NSCLC)
Jim Coward, Australia

P3.10-027: SELECTION OF PATIENTS WITH ADENOCARCINOMA OF THE LUNG FOR GEFINITIB BY FDG PET METABOLIC RESPONSE
Jungmin Jo, South Korea

P3.10-028: PATHOLOGIC COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY AND INTERCALATED ERLOTINIB IN EGFR-MUTATED ADENOCARCINOMA STAGE IIIA: CASE REPORT
Frank Griesinger, Germany

P3.10-029: SECOND LINE CHEMOTHERAPY EXPOSURE IN A GERMAN CANCER SOCIETY CERTIFIED LUNG CANCER CENTER: SINGLE CENTER EXPERIENCE OF 3 YEARS AND RELEVANCE FOR MAINTENANCE THERAPY
Frank Griesinger, Germany

Takashi Kasai, Japan

P3.10-031: COMPARATIVE STUDY BETWEEN BELOTECAN/CISPLATIN AND ETOPOSIDE/CISPLATIN (COMBAT) IN PATIENTS WITH PREVIOUSLY UNTREATED, EXTENSIVE STAGE SMALL CELL LUNG CANCER
In-Jae Oh, South Korea

P3.10-032: EFFICIENCY AND SAFETY OF ERLOTINIB IN THE SECOND AND THE FURTHER LINES OF TREATMENT FOR PATIENTS (CAUCASIAN ETNIC) WITH ADVANCED, NON-SMALL-CELL LUNG CANCER IN EASTERN SLOVAKIA
Igor Andrasina, Slovakia
P3.10-033: PROGNOSTIC FACTORS IN STAGE III NON-SMALL CELL LUNG CANCER PATIENTS WITH POSTOPERATIVE BRAIN METASTASES
Yoshinori Sakata, Japan

P3.10-034: IS LOSS OF MGMT A THERAPEUTIC TARGET IN LUNG CANCER?
Hongdo Do, Australia

P3.10-035: USEFULNESS OF IHC FOR DETECTION OF THE ALK-FUSION GENE IN NON-SMALL CELL LUNG CANCER
Eri Sugiyama, Japan

P3.10-036: AFATINIB IN PLATINUM- AND GEFITINIB OR ERLOTINIB-PRETREATED PATIENTS WITH NSCLC. A SINGLE INSTITUTION EXPERIENCE IN A COMPASSIONATE-USE-PROGRAM
David Heigener, Germany

P3.10-037: DRUG THERAPY FOR PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER.
David Naskhletashvili, Russia

P3.10-038: THE EFFICACY AND SAFETY OF Pemetrexed AFTER THE FAILURE OF GEFITINIB IN PATIENTS WITH ADENOCARCINOMA WITH EGFR MUTATION.
Kyu-Sik Kim, South Korea

P3.10-039: IMPACT OF XANTHINE OXIDOREDUCTASE AND BRCA1 ON PROGNOSIS OF ADVANCED NON-SMALL CELL LUNG CANCER
Ozden Altundag, Turkey

P3.10-040: OPTIMAL DURATION OF CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER. A PROSPECTIVE POPULATION-BASED AUDIT.
Noelle O’Rourke, UK

P3.10-041: IMPACT OF A COMPREHENSIVE GERIATRIC ASSESSMENT ON MANAGEMENT STRATEGIES IN ELDERLY PATIENTS WITH ADVANCED NO SMALL CELL LUNG CANCER (NSCLC): A POLED ANALYSIS OF TWO PHASE 2 PROSPECTIVE STUDY OF THE GFPC GROUP.
Christos Chouaid, France

P3.10-042: CISPLATIN VS. CARBOPLATIN-BASED CHEMORADIOThERAPY IN ELDERLY PATIENTS WITH UNRESECTED STAGE III NON-SMALL CELL LUNG CANCER
Juan Wisnivesky, USA

P3.10-043: NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): AN ECONOMIC ANALYSIS
David Spigel, USA

P3.10-044: OVERALL SURVIVAL ANALYSIS RESULTS OF TFINE STUDY (CTONG 0904): DIFFERENT DOSE DOCETAXEL PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY AND THEN MAINTENANCE THERAPY WITH SINGLE AGENT DOCETAXEL FOR ADVANCED NON-SMALL CELL LUNG CANCER
Shun Lu, China

P3.10-045: COMBINATION CHEMOTHERAPY WITH BEVACIZUMAB, DOCETAXEL AND CARBOPLATIN FOR CHEMOTHERAPY-NAIVE PATIENTS WITH NON-SQUAMOUS CELL LUNG CARCINOMA: PHASE II STUDY.
Masaru Matsumoto, Japan

P3.10-046: PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER(NSCLC) RECEIVED MULTI-LINE TREATMENTS HAD BETTER EFFICACY
Xiaochen Zhang, China

P3.10-047: WEIGHT GAIN DURING FIRST-LINE CHEMOTHERAPY FOR LOCALLY ADVANCED AND METASTATIC NON-SMALL-CELL LUNG CANCER IS ASSOCIATED WITH IMPROVED SURVIVAL
Mary Jo Fidler, USA

P3.10-048: REFERRAL PATTERNS IN ADVANCED NON SMALL LUNG CANCER: IMPACT ON DELIVERY OF TREATMENT AND SURVIVAL IN BRITISH COLUMBIA
Krista Noonan, Canada

P3.10-049: COMBINATION CHEMOTHERAPY AND AUTOPHAGY INHIBITION WITH HYDROXYCHLOROQUINE FOR ADVANCED NON-SMALL CELL LUNG CANCER
Joseph Aisner, USA

P3.10-050: CHANGES OF PULMONARY FUNCTION AFTER PLATINUM BASED CHEMOTHERAPY IN SMALL CELL LUNG CARCINOMA
Wooho Ban, South Korea

P3.10-051: CHANGE IN PULMONARY FUNCTION AFTER CHEMOTHERAPY IS DIFFERENT BETWEEN SQUAMOUS CELL CARCINOMA AND ADENOCARCINOMA OF THE LUNG
Wooho Ban, South Korea

P3.10-052: TAXANE MONOTHERAPY IN ADVANCED EGFR MUTATION POSITIVE LUNG CANCER: A SINGLE INSTITUTION EXPERIENCE
Christina Baik, USA

P3.10-053: PHASE II STUDY OF A NOVEL TAXANE (CABAZITAXEL-XRP 6258) IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: TOXICITY REPORT
Rodolfo Bordoni, USA

P3.10-054: METASTATIC NSCLC OUTCOMES AT A SINGLE CANADIAN INSTITUTION OVER A DECADE
Shannon Otsuka, Canada
P3.10-055: LONG PROGRESSIVE FREE SURVIVAL TO PACLITAXEL AND CISPLATIN IN FIRST LINE IS ASSOCIATED WITH BETTER RESPONSE AND PROGRESSION FREE SURVIVAL TO DOCETAXEL IN SECOND LINE IN ADVANCED NON-SMALL CELL LUNG CANCER
Eleazar Macedo, Mexico

P3.11 Poster Session 3
NSCLC Novel Therapies

P3.11-001: CLASSIFICATION AND REGRESSION TREE ANALYSIS OF PATIENTS WITH NON-SMALL-CELL LUNG CANCER TREATED WITH GEFTINIB AFTER CHEMOTHERAPY
Zi-Ping Wang, China

P3.11-002: NEW TOXICITY PROFILE AS RADILOGICAL RESPONSE MARKER IN THE CONTEXT OF MTOR THERAPY IN ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
Jesus Corral, Spain

P3.11-003: THE USE OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN TREATMENT OF ADVANCED EGFR WILD-TYPE NON-CELL LUNG CANCER: A META-ANALYSIS STUDY
Kit Man Wong, Canada

P3.11-004: A PROSPECTIVE STUDY OF THE USE OF CIRCULATING MARKERS AS PREDICTORS FOR EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR TREATMENT IN PULMONARY ADENOCARCINOMA
Yuh-Min Chen, Taiwan

P3.11-005: RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF GEFTINIB DOSE-ESCALATION (500MG/D VERSUS 250MG/D) IN ADVANCED NSCLC PATIENT ACHIEVED STABLE DISEASE (SD) AFTER ONE-MONTH GEFTINIB TREATMENT
Li Zhang, China

P3.11-006: ERLOTINIB (E) AND DOVITINIB (TkI258) (D) IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
Millie Das, USA

P3.11-007: PRELIMINARY SAFETY RESULTS OF MONET-A: A PROSPECTIVE, ASIAN PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF THE INVESTIGATIONAL AGENT MOTESANIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN FOR ASIAN PATIENTS OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Hiroshige Yoshioka, Japan

P3.11-008: PHASE II STUDY OF METRONOMIC CHEMOTHERAPY (MC) WITH BEVACIZUMAB (B) IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NS-NSCLC)
Francisco Robert, USA

P3.11-009: TULUNG REGISTRY: DATA ANALYSIS OF PATIENTS WITH NON-SQUAMOUS NSCLC (ADENOCARCINOMA, LARGE CELL CARCINOMA) AND PS 0-1 TREATED WITH ERLOTINIB IN SECOND LINE SETTING
Jaromir Roubec, Czech Republic

P3.11-010: PATTERNS OF RELAPSE AND PROGNOSIS AFTER CRIZOTINIB THERAPY FAILURE IN ALK+ NON-SMALL CELL LUNG CANCER
Noriko Yanagitani, Japan

P3.11-011: PRELIMINARY SAFETY RESULTS OF MONET-A: A PROSPECTIVE, ASIAN PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL OF THE INVESTIGATIONAL AGENT MOTESANIB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN FOR ASIAN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Wu-Chou Su, Taiwan

P3.11-012: EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN ADVANCED SQUAMOUS CELL CARCINOMA OF THE LUNG.
Malaka Ameratunga, Australia

P3.11-013: TREATMENT WITH HIGH-DOSE, WEEKLY ERLOTINIB IN EGFR-MUTATED NSCLC-PATIENTS WITH EXTRA-CRANIAL PROGRESSIVE DISEASE
Justine Kuiper, Netherlands

P3.11-014: SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE ANTI-NAPI2B ANTIBODY-DRUG CONJUGATE DNIB0600A: A PHASE I STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND PLATINUM-RESISTANT OVARIAN CANCER
David Gerber, USA

P3.11-015: AN OPEN LABEL, DOSE ESCALATION, PHASE I TRIAL TO EVALUATE THE TOLERABILITY AND ANTITUMOR ACTIVITY OF ICOTINIB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER
Jianzhong Shentu, China

P3.11-016: USING STATISTICAL MODELS TO IMPROVE PHASE II STUDY DESIGNS
Helen Barraclough, Australia

P3.11-017: OBSERVATIONAL POST-AUTHORIZATION PROSPECTIVE STUDY TO CHARACTERIZE THE INCIDENCE OF EGFR POSITIVE MUTATION (M+) IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (P) AND THEIR CLINICAL MANAGEMENT IN GALICIA (NCT01717105): A GALICIAN LUNG CANCER GROUP STUDY (GGCP 048-10)
Sergio Vazquez, Spain
P3.11-018: CLINICAL RESPONSE OF LUNG CANCER PATIENTS TO AUTOLOGOUS DENDRITIC CELL VACCINATION: A COMPILEDATION OF CASES FROM THE LUNG CENTER OF THE PHILIPPINES
Maria Teresa Barzaga, Philippines

P3.11-019: GEFTINIB EFFICACY IN EGFR MUTATED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS BASED ON TYPE OF MUTATION: A STUDY FROM THE GALICIAN LUNG CANCER GROUP.
Martin Lazaro, Spain

P3.11-020: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFTINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
Jean-yves Douillard, France

P3.11-021: BEVACIZUMAB (B) (10 MG/KG) IN COMBINATION WITH CISPLATIN (C) AND DOCETAXEL (D) ADMINISTERED EVERY 2 WEEKS IN PATIENTS (P) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): GGCOP047/10 STUDY.
Martin Lazaro, Spain

P3.11-022: DEEP VEIN TROMBOSIS AMONG LUNG CANCER PATIENTS USING WELLS’ SCORE: A SINGLE INSTITUTION EXPERIENCE
Elisa Syahruruddin, Indonesia

P3.11-023: COMPARATIVE SAFETY PROFILE OF AFATINIB IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MUTATION-POSITIVE (EGFR M+) NON-SMALL CELL LUNG CANCER (NSCLC)
Kenneth O’Byrne, Australia

P3.11-024: QUARTZ QUALITY OF LIFE AFTER TREATMENT FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER: AN UPDATE ON THE UK MEDICAL RESEARCH COUNCIL QUARTZ TRIAL.
Richard Stephens, UK

P3.11-025: PROGNOSTIC AND PREDICTIVE ROLE OF KRAS MUTATIONS IN PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER TREATED WITH DOCETAXEL OR ERLOTINIB AS SECOND LINE TREATMENT IN THE TAILOR TRIAL
Marina Garassino, Italy

P3.11-026: RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.
Jeffrey Crawford, USA

Peter Ellis, Canada

P3.11-028: EXPLORATION OF THE RELATIONSHIP BETWEEN NEUTROPHIL COUNT AND CLINICAL CONSEQUENCES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SELUMETINIB PLUS DOCETAXEL: PREDICTED EFFECT OF PRIMARY PROPHYLACTIC GCSF
Pasi Janne, USA

P3.11-029: THE SELECT-1 STUDY DESIGN: SELUMETINIB IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF KRAS MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER.
Pasi Janne, USA

P3.11-030: A PHASE I/II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
Bente Holm, Denmark

P3.11-031: THE CLINICAL IMPORTANCE OF EGFR-TESTING IN NON-SMALL CELL LUNG CANCER: THREE YEAR EXPERIENCE FROM KAROLINSKA UNIVERSITY HOSPITAL IN SWEDEN
Stephanie Mindus, Sweden

P3.11-032: A PILOT SINGLE INSTITUTION STUDY OF AUTOLOGOUS TUMOR AUTOPHAGOSOME (DRIBBLE) VACCINATION WITH DOCETAXEL IN PATIENTS (PTS) WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC)
Rachel Sanborn, USA

P3.11-033: BRAIN METASTASIS FEATURES AND ASSOCIATION WITH TUMOR EGFR MUTATION IN PATIENTS WITH ADENOCARCINOMA OF THE LUNGS
Yung-Hung Luo, Taiwan

P3.11-034: ONE YEAR FOLLOW-UP OF A PHASE I/II STUDY OF A HIGHLY SELECTIVE ALK INHIBITOR CH5424802/RO5424802 IN ALK-REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Akira Inoue, Japan

P3.11-035: AN OPEN LABEL COMPASSIONATE USE PROGRAMME OF BIBW 2992/AFATINIB IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS PRE-TREATED WITH ERLOTINIB OR GEFTINIB IN KOREA
Jong-Mu Sun, South Korea
P3.11-036: COMPARISON OF CLINICAL OUTCOME BETWEEN GEFITINIB AND ERLOTINIB TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 OR EXON 21 MUTATIONS
Jong-Mu Sun, South Korea

P3.11-037: A PHASE II STUDY OF SORAFENIB AND METFORMIN IN PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER (NSCLC) WITH A KRAS MUTATION
Wouter Mellema, Netherlands

P3.11-038: EGFR MUTATIONS IN SQUAMOUS NSCLC - PREVALENCE AND TREATMENT RESULTS WITH EGFR TYROSINE KINASE INHIBITORS IN SLOVAK REPUBLIC
Peter Berzinec, Slovakia

P3.11-039: EXPLORATION OF PATIENT HEALTH STATUS AS MEASURED BY THE GENERIC PREFERENCE-BASED QUESTIONNAIRE EQ-5D ALONGSIDE THE START TRIAL OF TECMOTIDE (L-BLP25) IN NON-SMALL CELL LUNG CANCER
Mark Socinski, USA

P3.11-040: ANALYSIS OF PATIENT-REPORTED OUTCOMES FROM THE LUME-LUNG 1 TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY IN SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Silvia Novello, Italy

P3.11-041: TREATMENT WITH CRIZOTINIB IN PATIENTS WITH IV STAGE NON-SMALL CELL LUNG CANCER (NSCLC) WITH ALK TRANSLOCATION: A SINGLE INSTITUTION EXPERIENCE
Silvia Novello, Italy

P3.11-042: MOLECULAR INEQUALITY IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) AND IMPLICATIONS FOR CLINICAL TRIALS
Kenneth O’Byrne, Australia

P3.11-043: SURVIVAL OF PATIENTS WITH ADVANCED LUNG ADENOCARCINOMA BEFORE AND AFTER APPROVED USE OF GEFITINIB IN CHINA: A COMPARATIVE CLINICAL STUDY IN A SINGLE CENTER
Yutao Liu, China

P3.11-044: CLINICAL IMPACT OF EGFR MUTATION FRACTION AND TUMOUR CELLULARITY IN EGFR MUTATION POSITIVE NSCLC
Natasha Leighl, Canada

P3.11-045: EGFR-TKI AFTER DISEASE PROGRESSION WITH CENTRAL NERVOUS SYSTEM METASTASIS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS
Kazuo Kasahara, Japan

P3.11-046: ROS1 OVEREXPRESSION BY IMMUNOHISTOCHEMISTRY IN NON-SMALL CELL LUNG CANCER: CLINICAL CHARACTERISTICS, NATURAL HISTORY AND POTENTIAL NEW THERAPEUTIC TARGET BASED ON TWO AUSTRALIAN CASES
Bob Li, Australia

P3.11-047: FACTORS ASSOCIATED WITH BRAIN METASTASIS IN METASTATIC NON-SMALL CELL LUNG CANCER
Ana Oton, USA

P3.11-048: COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK+ NON-SMALL CELL LUNG CANCER (NSCLC)
Gilberto Lopes, Singapore

P3.11-049: AFATINIB IN ADVANCED PRETREATED NSCLC - A CANADIAN EXPERIENCE
Barbara Melosky, Canada

P3.12 Poster Session 3
NSCLC Early Stage

P3.12-001: LUNG KRUEPPEL-LIKE FACTOR KLF2 IMPROVE POST-OPERATIVE PROGNOSIS OF LUNG ADENOCARCINOMA CORRELATION WITH CHEMOKINE RECEPTOR CCR7 AND GENETICAL MUTATIONS OF P53
Meiji Itakura, Japan

P3.12-002: PROGNOSTIC SIGNIFICANCE OF THE LYMPH NODE INVOLVEMENT IN STAGE II-N1 NON-SMALL CELL LUNG CANCER
Shun Lu, China

P3.12-003: PREOPERATIVE MANAGEMENT OF NSCLC PATIENTS WITH PET/CT N2 POSITIVE MEDIASTINAL LYMPH NODES
Atila Akkoclu, Turkey

P3.12-004: A PRACTICE-BASED ANALYSIS TO GAUGE THE FEASIBILITY OF GENOTYPE-DIRECTED INDUCTION THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)
Geoffrey Oxnard, USA
P3.12-005: CLINICAL SIGNIFICANCE OF PREOPERATIVE ARTERIAL BLOOD GAS IN PATIENTS WITH STAGE I NON-SMALL CELL LUNG CANCER
Shinjiro Mizuguchi, Japan

P3.12-006: CLINICAL SIGNIFICANCE OF KI67 EXPRESSION IN CURATIVELY RESECTED NON-SMALL CELL LUNG CANCER
Hee Kyung Ahn, South Korea

P3.12-007: A CLINICAL RELEVANCE OF INTRAOPERATIVE PLEURAL LAVAGE CYTOLOGY IN NON-SMALL LUNG CANCER
Masao Saito, Japan

P3.12-008: VARIATIONS IN THE UPTAKE OF PRACTICE GUIDELINE RECOMMENDATIONS ON ADJUVANT CHEMOTHERAPY USE FOLLOWING SURGICAL RESECTION IN ONTARIO
William Evans, Canada

P3.12-009: PATTERNS OF CARE IN PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY FOR RESECTED NON-SMALL CELL LUNG CANCER (NSCLC) IN SOUTH WESTERN SYDNEY LOCAL HEALTH DISTRICT (SWSLHD)
Annette Tognela, Australia

P3.12-010: IMPACT OF PARIETAL PLEURAL INVASION AT ADHESION SITES OF LUNG CANCERS AND IMPLICATIONS FOR PROGNOSIS IN THE 7TH TNM CLASSIFICATION
Masashi Mikubo, Japan

P3.12-011: SURVIVAL IN RESECTABLE T1 AND T2 STAGE NON-SMALL CELL LUNG CANCER
Laura Romero Vielva, Spain

P3.12-012: CLINICAL AND PROGNOSTIC IMPLICATION OF ALK AND ROS1 REARRANGEMENT IN NEVER SMOKER WITH SURGICALLY RESECTED LUNG ADENOCARCINOMA
Hye Ryun Kim, South Korea

P3.12-013: RADICAL TREATMENT OF SYNCHRONOUS OLIGOMETASTATIC NON-SMALL CELL LUNG CARCINOMA (NSCLC): PATIENT OUTCOMES AND PROGNOSTIC FACTORS.
Gwendolyn Griffioen, Netherlands

P3.12-014: PROGNOSTIC IMPACT OF LYMPHOVASCULAR INVASION ACCORDING TO THE TUMOR SIZE IN PATIENTS WITH PN0 NON-SMALL CELL LUNG CANCER
Hiroyuki Tao, Japan

P3.12-015: SURGERY FOR EARLY NON-SMALL CELL LUNG CANCER WITH PREOPERATIVE ERLOTINIB (SELECT): A CORRELATIVE BIOMARKER STUDY
Adrian Sacher, Canada

P3.12-016: FREQUENCY IN EGFR, K-RAS, BRAF AND ALK MUTATIONS IN A COHORT OF CANCERS: ALK TRANSLOCATIONS ARE MORE FREQUENTLY SEEN IN ADVANCED DISEASE
Eric Lim, UK

P3.12-017: THE LACK OF IMPACT OF PREOPERATIVE PET ON THE RISK, AND PACE, OF SUBSEQUENT FAILURE FOLLOWING SURGERY FOR EARLY STAGE NON-SMALL CELL LUNG CANCER?
Lawrence Marks, USA

Katsuo Kojima, Japan

P3.12-019: FEASIBILITY AND EFFICACY OF RADICAL LOCAL THERAPY FOR OLIGO-RECURRENCE OF NSCLC
Ryu Nakajima, Japan

P3.12-020: DERAILED ANALYSIS OF LUNG CANCER WITH SCATTERED CONSOLIDATION
Ryosuke Tachi, Japan

P3.12-021: THE ROLE OF PENTRAxin 3, AN ACUTE PHASE PROTEIN, AND OF SMOLDERING INFLAMMATION AT THE TUMOR SITE IN LUNG CANCER PROGRESSION AND PROGNOSIS. A CLINICOPATHOLOGIC STUDY
Maurizio Infante, Italy

P3.12-022: PATTERNS OF DISEASE RECURRENCE AND MODALITY OF DETECTION FOLLOWING SURGERY FOR EARLY STAGE LUNG CANCER
Jim Brown, UK

P3.12-023: INTERNATIONAL TAILORED CHEMOTHERAPY ADJUVANT TRIAL: ITACA TRIAL
Silvia Novello, Italy

P3.12-024: A MULTI-CENTER PHASE II RANDOMIZED STUDY OF CUSTOMIZED NEOADJUVANT THERAPY VS. STANDARD CHEMOTHERAPY (CT) IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH RESECTABLE STAGE IIIA (N2) DISEASE (CONTEST TRIAL)
Francesco Grossi, Italy

P3.12-025: SURVIVAL IN OCTOGENARIANS WITH PATHOLOGICAL STAGE I NON-SMALL CELL LUNG CANCER PATIENTS UNDERWENT COMPLETE RESECTION
Yu-Chao Yu, Taiwan

P3.13-001: COULD PRETREATMENT PET-CT STANDART UPTAKE VALUES HAVE A ROLE IN THE RESPONSE TO TREATMENT AND THE SURVIVAL IN PATIENTS WITH SMALL CELL LUNG CANCER?
Mahmut Gumus, Turkey
P3.13-002: STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES AFTER PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED DISEASE SMALL-CELL LUNG CANCER
Kuniko Sunami, Japan

P3.13-003: SURVIVAL OF PATIENTS WITH SMALL CELL LUNG CARCINOMA IN TAIWAN
Zhong-Zhe Lin, Taiwan

P3.13-004: A MULTICENTER PHASE II STUDY OF BELOTECAN, A NEW CAMPTOTHECIN ANALOGUE, IN ELDERLY PATIENTS WITH PREVIOUSLY UNTREATED, EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Chang Dong Yeo, South Korea

P3.13-005: CONVERT - THE CHALLENGES OF OPENING CENTRES AND RECRUITING PATIENTS TO AN INTERNATIONAL MULTI-CENTRE CHEMO-RADIOTHERAPY TRIAL IN LIMITED-STAGE SMALL CELL LUNG CANCER
Corinne Faiivre-Finn, UK

P3.13-006: DOCETAXEL-CARBOPlatin (DC) AS SECOND LINE TREATMENT IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC): A PHASE II STUDY.
Ad Schreurs, Netherlands

P3.13-007: PILOT TRIAL OF AN ADJUVANT PENTAVALENT VACCINE FOR PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
Lee Krug, USA

P3.13-008: LONG-TERM SURVIVAL OF 187 PATIENTS WITH SMALL CELL LUNG CANCER BASED ON THE AJCC 6TH AND 7TH TNM EDITION
Yon Mi Sung, South Korea

P3.14-001: ASSESSING THE ROLE OF CHEMOTHERAPY FOR SOLITARY FIBROUS TUMORS OF THE PLEURA IN A ROUTINE PRACTICE SETTING
Nicolas Girard, France

P3.14-002: SECOND LINE CHEMOTHERAPY TREATMENT OPTIONS, IN MALIGNANT MESOTHELIOMA TUMORS, RESISTANT TO Pemetrexed.
Konstantinos Syrigos, Greece

P3.14-003: VOLATILE ORGANIC COMPOUNDS AS DIAGNOSTIC TOOL FOR MALIGNANT PLEURAL MESOTHELIOMA.
Jan Van Meerbeeck, Belgium

P3.14-004: ADJUVANT HEMITHORACIC RADIOTHERAPY AFTER EXTRAPLEURAL PNEUMONECTOMY FOR MALIGNANT PLEURAL MESOTHELIOMA: EXPERIENCE AT THE SYDNEY CANCER CENTRE
Andrej Bece, Australia

P3.14-005: INTEGRATING A WELL LIVING PROGRAMME INTO A SUPPORT GROUP FOR EPP SURVIVORS AND CARERS
Jocelyn McLean, Australia

P3.14-006: RADIOThERAPY FOR THE TREATMENT OF PAIN IN MALIGNANT PLEURAL MESOTHELIOMA: A SYSTEMATIC REVIEW
Noelle O’Rourke, UK

P3.14-007: CHIMERIC ANTIBODY RECEPTOR (CAR) AUGMENTED ADOPTIVE T CELL THERAPY (ACT) FOR PATIENTS WITH PROGRESSIVE MALIGNANT PLEURAL MESOTHELIOMA (MPM)
Edmund Moon, USA

P3.14-008: RESECTION AND HEATED PLEURAL CHEMOPERFUSION FOR EPITHELIOID MALIGNANT PLEURAL MESOTHELIOMA; A SINGLE CENTER EXPERIENCE
Ronny Ben Avi, Israel

Pier Luigi Filosso, Italy

P3.14-010: EVALUATION OF MESOTHELIOMA TUMOR THICKNESS MEASUREMENT VARIABILITY
Anna Nowak, Australia

P3.14-011: GENOMIC PROFILING OF EPITHELIAL MALIGNANT PLEURAL MESOTHELIOMA (MPM) USING MASSIVELY PARALLEL SEQUENCING.
Tanguy Seiwert, USA

P3.14-012: PATHOLOGICAL COMPLETE RESPONSE AFTER PLATINUM-BASED CHEMOTHERAPY IN MALIGNANT PLEURAL MESOTHELIOMA
Sanjeev Kumar, Australia

P3.14-013: LONGITUDINAL OBSERVATION OF HEALTH RELATED QUALITY OF LIFE FOLLOWING EXTRAPLEURAL PNEUMONECTOMY FOR MALIGNANT PLEURAL MESOTHELIOMA
Jason Fowler, Australia

P3.14-014: CHEMOTHERAPY FOR MESOTHELIOMA: PATIENT, CAREGIVER AND HEALTH PROFESSIONALS’ PERCEPTIONS OF TREATMENT AND WHAT INFLUENCES ACCESS.
Haryana Dhillon, Australia
**Thymoma and Other Thoracic Malignancies**

**P3.15 Poster Session 3**

**Thymoma**

P3.15-001: PRIMARY MEDIASTINAL TUMORS: EPIDEMIOLOGICAL ANALYSIS OF 12-YEARS OBSERVATIONS.
Renata Langfort, Poland

P3.15-002: CAN D2-40 ANTIBODY HELP IN IDENTIFYING B2 THYMOMAS? PRELIMINARY OBSERVATIONS.
Renata Langfort, Poland

P3.15-003: STAGE AND PRESENCE OF MYASTHENIA DETERMINE THE RECURRENCE FREE SURVIVAL IN THYMOMA: SINGLE INSTITUTE EXPERIENCE
Patricia Sebastian, India

**P3.16 Poster Session 3**

**Other Thoracic Malignancies**

P3.16-001: LATE-DEVELOPING TONGUE ADENOID CYSTIC CARCINOMA AFTER PULMONARY METASTASECTOMY
Young Jo Sa, South Korea

P3.16-002: OUTCOME AND PROGNOSTIC FACTORS OF BRONCHOPULMONARY NEUROENDOCRINE TUMORS (BNETS): A SINGLE INSTITUTIONAL SERIES
Birgitta Hiddinga, Belgium

P3.16-003: OVERALL SURVIVAL AND SURGICAL OUTCOMES FOR MEDIASTINAL GERM-CELL TUMORS: THE NATIONAL CANCER INSTITUTE OF MEXICO EXPERIENCE.
Omar Macedo, Mexico

**Endoscopy**

**P3.17 Poster Session 3**

**Bronchoscopy, Endoscopy**

P3.17-001: ASSESSMENT OF PULMONARY HEMORRHAGE BY BRONCHOSCOPY AND CT FINDINGS IN PATIENTS TREATED WITH BEVACIZUMAB
Naoki Furuya, Japan

P3.17-002: VIRTUAL BRONCHOSCOPY AND VIRTUAL BRONCHOSCOPIC LUNG BIOPSY USING OSIRIX
Atsushi Sano, Japan

P3.17-003: IMPLEMENTATION OF RAPID ON-SITE EVALUATION FOR LINEAR EBUS: LOCAL EXPERIENCE FROM THE AUSTIN HOSPITAL, MELBOURNE
Raymond Wong, Australia

P3.17-004: BREATH-HOLD LOW DOSE CT IMMEDIATELY FOLLOWING PET/CT ENABLES GOOD QUALITY VIRTUAL BRONCHOSCOPY PRIOR TO EBUS GUIDE SHEATH BIOPSY
David Fielding, Australia

P3.17-005: DIAGNOSTIC YIELD OF FLEXIBLE BRONCHOSCOPY IN EVALUATING PERIPHERAL LUNG LESIONS WITHOUT ENDOBRONCHIAL LESIONS
Sang Haak Lee, South Korea

P3.17-006: ENDOBRONCHIAL ULTRASOUND ELASTOGRAPHY IN MEDIASTINAL LYMPH NODES: INITIAL EXPERIENCES
Takeo Inoue, Japan

P3.17-007: RAPID ON-SITE CYTOLOGIC EVALUATION (ROSE) OF BRONCHIAL BRUSHINGS DURING BRONCHOSCOPIC INVESTIGATION OF PERIPHERAL PULMONARY LESIONS: DIAGNOSTIC ACCURACY AND IMPACT ON PROCEDURE TIME
Daniel Steinfort, Australia

P3.17-008: ELECTROMAGNETIC NAVIGATION BRONCHOSCOPY INCREASES DIAGNOSTIC YIELD AFTER NON-DIAGNOSTIC ENDOBRONCHIAL ULTRASOUND GUIDE SHEATH FOR PERIPHERAL PULMONARY LESIONS
Steven Leong, Australia

P3.17-009: A PROSPECTIVE CLINICAL STUDY OF MICRORNA EXPRESSION PROFILING OF BRONCHOALVEOLAR LAVAGE FLUIDS AND SPUTUM AS A MEANS TO DISTINGUISH EARLY STAGE NON-SMALL CELL LUNG CANCER CASES FROM CANCER-FREE CONTROLS
Julian Kim, Canada

**Pathology**

**P3.18 Poster Session 3**

**Pathology**

P3.18-001: PROGNOSTIC VALUE OF THE IASLC/ATS/ERS CLASSIFICATION IN STAGE I LUNG ADENOCARCINOMA PATIENTS
Yaping Xu, China

P3.18-002: PREDICTING STRATIFICATION FOR RECURRENCE OF EARLY LUNG ADENOCARCINOMA BASED ON 7TH TNM CLASSIFICATION AND IASLC/ATS/ERS CLASSIFICATION
Masaoki Ito, Japan
P3.18-003: ROS1 GENE REARRANGEMENTS IN NON-SMALL CELL LUNG CARCINOMA - A NEW GENETIC TARGET THAT CAN BE IDENTIFIED BY IMMUNOHISTOCHEMISTRY AND FISH
Wendy Cooper, Australia

P3.18-004: PULMONARY OSSIFICATIONS: TO BE CONSIDERED IN THE DIFFERENTIAL DIAGNOSIS OF SOLITARY PULMONARY NODULES.
Paul Van Schil, Belgium

P3.18-005: EGFR MUTATION TESTING METHODS IN CLINICAL PRACTICE IN CENTRAL EUROPE: FINDINGS FROM THE INSIGHT OBSERVATIONAL STUDY
Wlodzimierz Olszewski, Poland

P3.18-006: NON-TERMINAL RESPIRATORY UNIT LUNG ADENOCARCINOMA: CAN HAVE 3 SUBTYPES AND IS ASSOCIATED WITH POOR PROGNOSIS
Akihiko Yoshizawa, Japan

P3.18-008: EGFR MUTATION TESTING IN SAUDI ARABIAN LUNG ADENOCARCINOMA
Fouad Al-Dayel, Saudia Arabia

P3.18-009: CLINICOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LUNG MUCINOUS ADENOCARCINOMA IN SURGICALLY RESECTED CASES
Hideomi Ichinokawa, Japan

P3.18-010: 5 DRIVER GENES IN CHINESE FEMALE LUNG ADENOCARCINOMA
Baohui Han, China

P3.18-016: THE USEFULNESS OF FROZEN SECTION DIAGNOSIS AS FOR THE DECISION MAKING MILESTONE DURING THE SURGERY FOR PULMONARY GROUND GLASS NODULES: EMBEDDING MEDIUM INFLATION TECHNIQUE
Jaehyun Jeon, South Korea

P3.19 Poster session 3 Imaging

P3.19-001: CORRELATION BETWEEN WHOLE TUMOR SIZE AND SOLID COMPONENT SIZE ON HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN THE PREDICTION OF THE DEGREE OF PATHOLOGIC MALIGNANCY AND THE PROGNOSTIC OUTCOME IN PRIMARY LUNG ADENOCARCINOMA
Hisashi Saji, Japan

P3.19-002: FIBROTIC CHANGES ON LOW-DOSE CHEST CT AS A RISK FACTOR OF LUNG CANCER DEVELOPMENT IN SUBJECTS WITH ASBESTOS EXPOSURE
Kenichi Gemba, Japan

P3.19-003: THE CORRELATION BETWEEN COMPUTED TOMOGRAPHY FINDINGS AND THE CLINICOPATHOLOGICAL FACTORS IN SMALL-SIZED ADENOCARCINOMAS OF THE LUNG (10 MM OR LESS IN DIAMETER)
Fumi Karino, Japan

P3.19-004: COMPARISON OF OBJECTIVE CRITERIA AND EXPERT VISUAL INTERPRETATION TO CLASSIFY BENIGN AND MALIGNANT HILAR AND MEDIASTINAL NODES ON 18-F FDG PET/CT.
Phan Nguyen, Australia
P3.19-005: QUANTITATIVE CT PREDICTS HISTOLOGICAL TUMOR INVASIVENESS: ANALYSIS ON 211 LESIONS OF CT1N0M0 LUNG ADENOCARCINOMA
Kei Shikuma, Japan

P3.19-006: PSEUDOPATHOLOGIC VERTEBRAL BODY ENHANCEMENT IN THE PRESENCE OF SUPERIOR VENA CAVA OBSTRUCTION ON COMPUTED TOMOGRAPHY
Yon Mi Sung, South Korea

P3.19-007: RELIABILITY ANALYSIS OF VISUAL RANKING OF CORONARY ARTERY CALCIFICATION ON LOW-DOSE CT OF THE THORAX FOR LUNG CANCER SCREENING: COMPARISON WITH ECG-GATED CALCIUM SCORING CT
Yon Mi Sung, South Korea

P3.19-008: POSITRON EMISSION TOMOGRAPHY SCAN IN LUNG CANCER: NEW INSIGHTS IN TUMOR BIOLOGY?
Maria Teresa Almodovar, Portugal

P3.19-009: NEWLY DEVELOPED EARLY LUNG CANCER DURING FOLLOW-UP OF IDIOPATHIC INTERSTITIAL PNEUMONIA: SERIAL HRCT OBSERVATIONS
Mi Young Kim, South Korea

P3.19-010: THE STATUS OF EGFR MUTATIONS IN MIXED GROUND-GLASS OPACITY (PART-SOLID GGO) ON THIN-SECTION CT
Haruhiro Saito, Japan

P3.19-011: THE ROLE OF 18F-FDG PET/CT AND 68GA-DOTANOC PET/CT IN DIFFERENTIATING TYPICAL AND ATYPICAL PULMONARY CARCINOID
Filippo Lococo, Italy

P3.19-012: COMPARISON OF THREE MODELS TO ESTIMATE THE PROBABILITY OF MALIGNANCY IN CHINESE PATIENTS WITH SOLITARY PULMONARY NODULES
Xue-Ning Yang, China

P3.19-013: THE RELATIONSHIP BETWEEN IODINE-RELATED ATTENUATION OF DUAL-ENERGY CT AND STANDARDIZED UPTAKE VALUE OF 18FDG PET-CT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Eun Young Kim, South Korea

P3.19-014: CT MORPHOLOGIC PATTERNS, PATHOLOGIC SUBTYPES, AND GENETIC PHENOTYPES: A CORRELATION STUDY IN 600 NODULAR LUNG ADENOCARCINOMAS
Hyun-Ju Lee, South Korea

P3.19-015: SHOULD CORE BIOPSY WITH LARGER NEEDLE REPLACE FNAB IN ASSESSING LUNG MASSES?
Silvia Novello, Italy

P3.19-016: FAST FOURIER TRANSFORM ANALYSIS FOR THE CONTOUR OF PULMONARY NODULES
Mitsumasa Kawago, Japan

P3.19-017: 18F-FDG-PET-CT IMAGING IN MALIGNANT MESOTHELIOMA
Nil Mandel, Turkey

P3.19-018: INCIDENTAL DETECTION ON COMPUTED TOMOGRAPHY IS AN INDEPENDANT PROGNOSTIC FACTOR OF SURVIVAL IN PATIENTS OPERATED FOR NON-SMALL CELL LUNG CARCINOMA
Tomas Gudbjartsson, Iceland

P3.19-019: EVALUATION OF ERLOTINIB TREATMENT RESPONSE IN NON-SMALL CELL LUNG CANCER USING EORTC METABOLIC CRITERIA, PERCIST AND ANATOMIC CRITERIA RECIST
Hector J. Soto Parra, Italy

P3.20 Poster session 3
Early Detection and Screening

P3.20-001: DNA METHYLATION PROFILING IN NSCLC IDENTIFIES PUTATIVE DIAGNOSTIC MARKERS FOR SCREENING AND EARLY DETECTION OF LUNG CANCER
Arifumi Iwamaru, Japan

P3.20-002: FIRST LOW DOSE CHEST CT LUNG CANCER SCREENING PROGRAMS IN POLAND - OVERALL RESULTS
Tomasz Grodzki, Poland

P3.20-003: A PRACTICE GUIDELINE FOR LOW DOSE CT SCREENING FOR LUNG CANCER: EVIDENCE BASED RECOMMENDATIONS BEFORE IMPLEMENTATION.
Yee Ung, Canada

P3.20-004: ANALYSIS OF EXHALED BREATH FOR SCREENING OF LUNG CANCER PATIENTS
Jangchul Park, Japan

P3.20-005: CARDIAC CT AND PULMONARY NODULES; INCIDENTAL FINDINGS AND INCIDENCE OF MALIGNANCY IN AN AUSTRALIAN POPULATION
James Robertson, Australia

P3.20-006: PROTEOMIC ANALYSIS OF THE BRONCHIAL EPITHELIUM TO DEVELOP A MOLECULAR SIGNATURE OF RISK FOR LUNG CANCER
Pierre Massion, USA

P3.20-007: CHEST X-RAY (CXR) SCREENING FOR LUNG CANCER: OVERDIAGNOSIS, ENDPOINTS, AND RANDOMIZED POPULATION TRIALS (RPTS)
Gary Strauss, USA

P3.20-008: PROMPTING EARLIER DIAGNOSIS OF LUNG CANCER: EVALUATION OF A PUBLIC EDUCATION CAMPAIGN IN NSW TO RAISE AWARENESS OF LUNG CANCER SYMPTOMS
Mayanne Lafontaine, Australia
P3.20-009: DIAGNOSTIC PERFORMANCE OF A FILTER-BASED ANTIBODY-INDEPENDENT PERIPHERAL BLOOD CIRCULATING TUMOUR CELL CAPTURE PAIRED WITH CYTOMORPHOLOGIC CRITERIA FOR THE DIAGNOSIS OF LUNG CANCER
Eric Lim, UK

P3.20-010: LOW DOSE COMPUTERIZED TOMOGRAPHY (LDCT) AS A LUNG CANCER SCREENING TOOL IN AN ENDEMIC AREA OF TUBERCULOSIS: A PRELIMINARY REPORT
Natthaya Triphuridet, Thailand

P3.20-011: LUNG DENSITY VERSUS EMPHYSEMA AS PREDICTOR OF MALIGNANCY RISK OF PULMONARY NODULES DETECTED ON FIRST SCREENING CT
Keishi Ohtani, Canada

P3.21-001: METASTATIC LOCATIONS IN NON-SMALL CELL LUNG CANCER AND THEIR PROGNOSTIC SIGNIFICANCE
Razvan Diaconescu, Canada

P3.21-002: LUNG-EPICLIN: ANALYSIS OF EGFR MUTATIONS AND ASSOCIATED CLINICO-PATHOLOGICAL PARAMETERS IN PATIENTS WITH NSCLC IN RUSSIAN FEDERATION
Sergei Tjulandin, Russia

P3.21-003: THE LUNGPATh STUDY: VARIATION IN LUNG CANCER DIAGNOSTICS IN ENGLAND. DOES THE AVAILABILITY OF PET SCANNING AND EBUS AFFECT PATIENT CARE?
Paul Cane, UK

P3.21-004: THERAPEUTIC DELAY DUE TO MOLECULAR TESTING IN PATIENTS WITH STAGE IV NSCLC NEWLY DIAGNOSED.
Juan Lacava, Argentina

P3.21-005: CLINICAL CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS IN NEVER SMOKERS
Young Sik Park, South Korea

P3.21-006: THE N-CLASSIFICATION BASED ON THE NUMBER OF METASTATIC LYMPH NODE IS SUPERIOR TO REGIONAL N-CLASSIFICATION IN PREDICTING OUTCOMES AFTER SURGICAL RESECTION FOR NON-SMALL CELL LUNG CANCER.
Sang Yoon Yeom, South Korea

P3.21-007: EGFR MUTATION ANALYSIS IN SPUTUM OF LUNG CANCER PATIENTS: A MULTICENTER MULTITECHNIQUE STUDY
A. Jasmijn Hubers, Netherlands

P3.21-008: EFFECTIVE DIAGNOSIS OF POSTOPERATIVE MEDIASTINAL RECURRENCE OF LUNG CANCER BY ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION
Takayoshi Yamamoto, Japan

P3.21-009: DIFFERENTIAL DIAGNOSIS OF INTRATHORACIC LYMPHADENOPATHY AND/OR INFLITRATES IN PATIENTS WITH MALIGNANT TUMOURS
Radka Bittenglova, Czech Republic

P3.21-010: A RETROSPECTIVE COMPABILITY ASSESSMENT OF ALK TRANSLOCATION DIAGNOSIS IN NSCLC
Takashi Yokoi, Japan

P3.21-011: PROPOSAL OF AN ALTERNATIVE PROGNOSIS PREDICTION METHOD - HAZARD RATIO SCORING SYSTEM BASED ON WELL-SUITED NOMOGRAM.
Hae-Won Lee, South Korea

P3.21-012: INSTITUTIONAL EXPERIENCE IN OBTAINED BIOPSY IN PATIENTS WITH NSCLC IN ONE CENTER IN ARGENTINA
Eduardo Richardet, Argentina

P3.22-001: INCIDENCE OF LUNG CANCER AND PULMONARY EMPHYSEMA, A STUDY OF 708 AUTOPSY CASES FROM UNIVERSITY HOSPITAL MOTOL, PRAGUE
Miloslav Marel, Czech Republic

P3.22-002: LUNG CANCER: HISTOLOGY, GENDER AND AGE CHANGES OVER THE PAST 25 YEARS IN BRAZIL
Maria Teresa Ruiz-Tsukazan, Brazil

P3.22-003: EGFR GENOTYPING AND EPIDEMIOLOGY, CLINICAL AND PATHOLOGICAL FEATURES IN 191 PATIENTS WITH METASTATIC PULMONARY ADENOCARCINOMA IN SAO PAULO - BRAZIL.
Gilberto Castro Jr., Brazil

P3.22-004: CANCER AND TUBERCULOSIS, EXPERIENCE IN A CHEST HOSPITAL
Claudio Martin, Argentina

P3.22-005: XPA GENE RS1800975 SINGLE NUCLEOTIDE POLYMORPHISM AND LUNG CANCER RISK: A META-ANALYSIS
Baohui Han, China

P3.22-006: INCIDENCE AND 5-YEAR SURVIVAL OF LUNG CANCER IN QUEENSLAND, AUSTRALIA: AN EPIDEMIOLOGICAL STUDY.
Elizabeth Ahern, Australia
P3.22-007: DETERMINING COMPLETENESS OF CASE ASCERTAINMENT TO A LUNG CANCER REGISTRY: A SINGLE INSTITUTIONAL STUDY. Robert Stirling, Australia


P3.22-009: LUNG CANCER IN WOMEN: CLINICAL AND PATHOLOGIC FEATURES. Meltem Tor, Turkey

P3.22-010: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC-AD) IN PATIENTS UNDER 50 - A NEW REALITY. Ana Figueredo, Portugal

P3.23 Poster Session 3 Tobacco Control, Prevention and Chemoprevention

P3.23-001: THE CLINICAL SIGNIFICANCE OF SMOKING CESSATION IN PATIENTS WITH CANCER. Ioannis Gkiozos, Greece

P3.23-002: ASSESSMENT OF SMOKING AMONG HIGH SCHOOL STUDENTS FROM NORTHERN PORTUGAL. Henrique Queiroga, Portugal

P3.23-003: IMPLEMENTATION OF A TOBACCO TREATMENT PROGRAM WITHIN A MULTIDISCIPLINARY THORACIC ONCOLOGY SURGERY CLINIC. Matthew Steliga, USA

P3.23-004: THORACIC ONCOLOGY PROVIDERS AND ADDRESSING TOBACCO USE IN CANCER PATIENTS: A REPORT FROM AN IASLC SURVEY. Carolyn Dresler, USA

P3.24 Poster Session 3 Supportive Care

P3.24-001: ONLINE SUPPORT: CONTENT ANALYSIS OF A “SAFE” ONLINE HAVEN FOR INDIVIDUALS AFFECTED BY LUNG CANCER. Maureen Rigney, USA

P3.24-002: INCIDENCE OF LUNG ENTRAPMENT IN MALIGNANT PLEURAL EFFUSION. Imran Bin Mohamed Noor, Singapore

P3.24-003: COMPLIANCE WITH CANCER TREATMENT INDICATORS - RESULTS OF A 3 MONTH AUDIT OF PATIENTS WITH LUNG CANCER TREATED WITH CURATIVE INTENT. Greg Frazer, New Zealand

P3.24-004: LUNG ADENOCARCINOMA WITH EML4-ALK RELLOCATION AND OVARIAN TERATOMA IN A 20-YEAR-OLD WOMAN. A CASE REPORT. Gianpiero Romano, Italy

P3.24-005: THE ROLE OF LESSER RESECTION FOR TREATMENT OF EARLY STAGE NON-SMALL CELL LUNG CANCER IN MEDICALLY COMPROMISED PATIENTS. Marzi Mehta, Australia

P3.24-006: THE CONTRIBUTION OF HISTOPATHOLOGICAL EVALUATION OF SMALL SAMPLES OBTAINED BY EBUS PUNCTURE FOR DIAGNOSIS OF PATHOLOGICAL MASSES IN MEDIASTINUM. Martina Vasakova, Czech Republic

P3.24-007: DO PATIENTS DISCUSSED AT LUNG CANCER MULTIDISCIPLINARY TEAM MEETINGS RECEIVE GUIDELINE-RECOMMENDED TREATMENT? Shalini Vinod, Australia

P3.24-008: EPITHELIAL-MYOEPITHELIAL CARCINOMA OF THE TRACHEA: ALTERNATIVE MANAGEMENT OF INOPERABLE DISEASE. Henrietta Wilson, UK

P3.24-009: HISTOLOGIC AND GENOTYPIC EVOLUTION IN LUNG CANCER HARBORING MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR): A CLINICAL CASE. Silvia Novello, Italy

P3.24-010: THE EFFICACY OF A MINDFULNESS BASED INTERVENTION BODY AND AFFECTIVE INTERVENTION(MB-BAI) WITH CANCER PATIENTS AND THEIR RELATIVES. Silvia Novello, Italy

P3.24-011: MULTIPLE PRIMARY TUMORS IN 65-YEAR OLD HEAVY SMOKER. Emilia Swietlik, Poland

P3.24-012: USEFULNESS OF THORACOSCOPY IN THORACIC TUMORS: DIAGNOSIS, STAGING AND THERAPEUTIC. Pena Emmanuel, Mexico

P3.24-013: IMPROVING ACCESS TO TREATMENT FOR LUNG CANCER PATIENTS (ACCESS TLC): RESULTS OF A PILOT USING PATIENT INTERVIEWS TO DETERMINE TIME TO TREATMENT. Regina Vidaver, USA

P3.24-014: MULTICENTER STUDY OF ZOLEDRONIC ACID IN LUNG CANCER PATIENTS WITH BONE METASTASIS. THORACIC ONCOLOGY RESEARCH GROUP (TORG) 1017. Yukio Hosomi, Japan
P3.24-015: PULMONARY ADENOCARCINOMA IN A PATIENT WITH HERMANSKY-PUDLAK SYNDROME
Ayse Ozcan, Turkey

P3.24-016: A CASE OF PRIMARY MYOEPITHELIAL CARCINOMA OF THE LUNG
Tsunehiro Ii, Japan

P3.24-017: THE IMPACT OF LOCAL RADIOTHERAPY TO THE PRIMARY SITE FOR PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER
Yaping Xu, China

P3.24-018: CHEST WALL DESMOID TUMOR WITH RAPID GROWTH AFTER THE RESECTION OF LUNG CANCER
Motohiro Nishimura, Japan

P3.24-019: LOCAL MANAGEMENT OF NSCLC WITH OPERABLE PRIMARY LESION AND SYNCHRONOUS SOLITARY BRAIN METASTASIS
Kyuwang Chung, Chung, Korea

P3.24-020: CASE STUDIES OF MULTIDISCIPLINARY TREATMENT FOR LARGE CELL NEUROENDOCRINE LUNG CARCINOMA
Masao Naruke, Japan

P3.24-021: ADVANCING LUNG CANCER EARLY DETECTION: THE ROLE OF THE PATIENT ADVOCACY CHARITY IN OUTREACH AND EDUCATION IN SUPPORT OF RESPONSIBLE SCREENING
Amy Copeland, USA

P3.24-022: A NOVEL WEB-BASED, MOBILE-DEVICE ENABLED CLINICAL COLLABORATION PLATFORM IN LUNG CANCER - MULTIDISCIPLINARY PATIENT EVALUATIONS VIA NETWORKING TECHNOLOGY
Pierre Theodore, USA

P3.24-023: A HUGE LUNG CARCINOMA PRESENTING WITH MAJOR RESPIRATORY DISTRESS IS NOT NECESSARILY A CONTRAINDICATION FOR SURGICAL TREATMENT, EVEN WHEN EXTENDED PNEUMONECTOMY IS REQUIRED.
Georges Decker, Luxembourg

P3.24-024: LYMPHANGIOMA OF THE DIAPHRAGM
Kaori Ichise, Japan

P3.24-025: LUNG CANCER - A SCOTTISH EXPERIENCE
Diana Borthwick, UK

P3.24-026: SOLITARY FIBROUS TUMOR OF THE PLEURA: PRESENTATION AND MANAGEMENT
Patsy Skabla, USA

P3.24-027: THE EFFECTIVENESS OF AN OUTPATIENT INTERDISCIPLINARY TEAM IN REDUCING DISTRESS IN PATIENTS WITH LUNG CANCER & MESOTHELIOMA
Kellie Blyth, Australia

P3.24-028: IMMUNO-HISTOCHEMISTRY (IHC) TYPING OF MOLECULAR MARKERS, ITS CORRELATION WITH CLINICAL PARAMETERS AND RESPONSE TO CHEMOTHERAPY IN NON SMALL CELL LUNG CANCER (NSCLC) - A PILOT STUDY.
Bapsy Poonamalle, India

P3.24-029: PROGRESSION OF RADIATION INDUCED ESOPHAGEAL STENOSIS IN A NON-SMALL CELL LUNG CANCER (NSCLC) PATIENT TREATED WITH SORAFENIB
Anne-Marie Dingemans, Netherlands

P3.24-030: ACTIVITY AND TOLERABILITY OF CARBOPLATIN AND GEMCITABINE IN FIRST-LINE TREATMENT OF ELDERLY THAI PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC).
Chaiyut Charoentum, Thailand

P3.24-031: ANAMORELIN HCL FOR THE TREATMENT OF ANOREXIA-CACHExIA IN NSCLC: BASELINE CHARACTERISTICS OF PATIENTS IN THE PHASE III CLINICAL TRIAL ROMANA 2 (HT-ANAM-302)
David Currow, Australia

P3.24-032: SECOND OPINION FOR THORACIC CANCER AND ITS IMPACT ON DIAGNOSIS AND TREATMENT STRATEGY: A SINGLE INSTITUTIONAL SERIES
Thomas Malfait, Belgium

P3.24-033: A CASE OF LUNG ADENOCARCINOMA HARBORING BOTH A KRAS MUTATION AND AN EML4-ALK FUSION GENE WITH RESPONSE TO CRIZOTINIB.
Michael Menefee, USA

P3.24-034: PRIMARY PULMONARY LYMPHOMA MIMIKING LUNG ABSCESS
Seung Pyung Lim, South Korea

P3.24-035: EVALUATING HEALTH RELATED QUALITY OF LIFE AND SYMPTOMS BY USING THE ELECTRONIC (EPRO) VERSION OF THE LCSS (ELCSS-QL) IN A 622 PATIENT PROSPECTIVE MULTINATIONAL NSCLC TRIAL (AP-QL TRIAL) WITH GOOD CROSS-CULTURAL RELIABILITY.
Sumitra Thongprasert, Thailand

P3.24-036: LUNG CANCER AWARENESS MONTHS IN SLOVAKIA - WHAT HAVE THEY CHANGED?
Peter Berzinec, Slovakia

P3.24-037: THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER
Natasha Leighl, Canada

P3.24-038: PERCEPTION OF LUNG CANCER AMONG THE GENERAL POPULATION AND COMPARISON WITH OTHER CANCERS.
Julien Mazieres, France
P3.24-039: NON SMALL CELLS LUNG CANCER STAGE IV: A RETROSPECTIVE STUDY OF 278 CASES
Farah Khedda, Algeria

P3.24-040: IODOP OVIDONE FOR PLEURODESIS IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION: A SAFE OPTION
Ricardo Terra, Brazil

P3.24-041: MALIGNANT PLEURAL MESOTHELIOMA: ACCUMULATED EXPERIENCE IN A BRAZILIAN TERTIARY HOSPITAL
Ricardo Terra, Brazil

P3.24-042: THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
Daisuke Noma, Japan

P3.24-043: DONOR-DERIVED METASTATIC LUNG CANCER IN A LIVER TRANSPLANT RECIPIENT
Harshita Paripati, USA

P3.24-044: EXPLICIT AND IMPLICIT ASSOCIATIONS TOWARD LUNG CANCER (LC) RELATIVE TO BREAST CANCER (BC)
Jennifer Mills, USA

P3.24-045: A FIRST ATTEMPT ON VIDEO-ASSISTED THORACIC SURGERY BRONCHIAL SLEEVE LOBECTOMY COMITANT WITH PULMONARY ARTERY RECONSTRUCTION (DOUBLE SLEEVE) FOR NON-SMALL CELL LUNG CANCER
Lunxu Liu, China

P3.24-046: FEASIBILITY AND SAFETY OF CHEMOTHERAPY ADMINISTRATION USING TELEONCOLOGY FOR RURAL LUNG CANCER PATIENTS IN NORTH QUEENSLAND.
Abhishek Joshi, Australia

P3.24-047: PULMONARY PAPILLARY ADENOMA LOCALIZED CENTRALLY
Turgut Isitmangil, Turkey

P3.24-048: PREVALENCE OF UNEXPECTED PULMONARY EMBOLISM AT CONTRAST-ENHANCED CT SCAN PERFORMED FOR CANCER STAGING IN PATIENTS WITH ADVANCED LUNG CANCER
Lucio Crino, Italy

P3.24-049: PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
Kavitha Ramchandran, USA

P3.24-050: MULTIPLE DISTANT METASTASES IN A CASE OF MALIGNANT PLEURAL MESOTELIOMA
Atila Akkoclu, Turkey

P3.24-051: PRIMARY THORACIC ANGIOSARCOMA: TREATMENT AND OUTCOMES OF 5 PATIENTS
Marina Scaranti, Brazil

P3.24-052: MYXOID MESENCHYMAL NEOPLASM PRESENTING AS MASSIVE ARM AND CHEST WALL EDEMA WITH PLEURAL EFFUSION
Konstantinos Arnaoutakis, USA

P3.24-053: CAUSE OF DEATH IN EARLY STAGE NON-SMALL CELL LUNG CANCER TREATED WITH CURATIVE INTENT
Katharine See, Australia

P3.24-054: ERLOTINIB IN NON-SMALL CELL LUNG CANCER: ANALYSIS OF TOXICITY AND EFFICACY IN CLINICAL PRACTICE
Maria Teresa Alexandre, Portugal

P3.25 Poster Session 3 Nurses

P3.25-001: INCREASING RESEARCH UTILISATION AND CAPACITY IN LUNG CANCER NURSING IN THE UK
Angela Tod, UK

P3.25-002: THE EFFECTS OF THE MOLECULAR TARGETED THERAPIES IN ADVANCED LUNG CANCER - FOCUS GROUP ANALYSIS
Lavinia Magee, UK

P3.25-003: EFFECTS OF ELECTRIC STIMULATION TO ACUPORTS ON GASTROINTESTINAL HORMONES AND MOTILITY AMONG OLD POSTOPERATIVE PATIENTS WITH LUNG TUMORS
Lili Hou, China
Meat Pie

The meat pie is considered iconic in Australia. It was described by former New South Wales Premier Bob Carr in 2003 as Australia’s “national dish”.

Australians consume an average of 12 meat pies each per year.

The meat pie is heavily associated with Australian rules football and Rugby League as one of the most popular consumed food items whilst watching a game.

It is estimated an Aussie Rules Final crowd in Melbourne would eat 90,000 pies in just a few hours. The amount of tomato sauce to go with those pies is also substantial!

Courtesy of wikipedia.org, travelwireasia.com
Author Index

Authors with presentations highlighted in bold = Presenting author for this presentation

A
Aagaard Inge .................. MC02.23
Aagaard Inge Marie ........ P2.07-045
Abul Heisein .................. B1.10-039
Abd Alla Hadi .................. P2.02-010
Abdott Alistair ................. P1.11-008
Abdi Allah Ahmed ............ P2.06-041
Abdeel-Hakim Zeinab .......... P1.08-018
Abdelrahman Abdelrahman ... P1.24-025
Abdelwahab Sherif ........... P1.09-018, P1.10-049
Abdiche M S .................. P2.10-013
Abdul Hamid M. a ............. MO03.09
Abdulkader Tahsin .......... P3.11-017, P3.11-019
Abe Masachi ................... P2.10-008
Abe Takashi .................... P2.10-045
Abell Fiona .................... P3.09-011
Abelina Denis .................. M517.3, MO11.04, D05.07
Abib Masoki ................... MO26.02, P12.003
Abiru Hajeem .................. P1.19-008
Abiru Aba ...................... P3.07-015
Aboulkaïss Fatma .......... P1.24-025
Abratt Raymond ................ MO25.05
Abu Hejithab Tahseb .......... P1.13-002
Abulatai Abulimiti .......... O12.07
Aburatani Hiroyuki .......... P3.02-002
Acura Isabel ..................... P1.10-033
Acharya Bickey ................ P1.21-003
Acharya Sandhya ............ P1.21-003
Acharya Hiroyuki ............. P3.11-007
Adachi Hirofumi ............. O13.03
Adachi Hiroyuki ............. P1.07-035, P2.07-010
Adam Judith .................. P2.09-013
Adam Juli .. O27.07, P3.18-018
Adams Mark ................... P1.09-008
Adanssen Lin .................. MO01.05
Adam Dwayne .................. P2.18-017
Adencia Ileana .............. P1.14-005
Adham Faisal .................. P2.04-004
Adile Ali ....................... MO524.0, MO12.12, P3.01-001
Adler Howard .................. P2.01-019
Adonis Mara .................. O18.01, P3.07-009
Adusumilli Prasad .......... MO04.01, MO11.02, MO12.01
Adveragaw Ayen ................ MO26.03, MO26.04, P08.02, O03.08, O09.01, O17.05, O17.06, O22.02, P18.019, P18.003
Aeros Joachim ................ MC04.08, P1.09-009
Aduong Ab ..................... P2.04-001, P3.01-001
Afonso Cálals ................ P2.23-001, P3.23-002
Afonso Francisco Javier .... P3.11-017, P3.11-019
Afonso Ana .................... P2.04-005
Afonso Gobbi Yashmin ........ P1.11-005
Agar Meera .................... MO26.07
Agarwala Jai Prakash .......... MO06.06
Agarwala Vandana .......... MO09.07
Agarwala Vikas ................ P3.03-002
Agasthian Thirumangam .... P3.09-015
Agatsu Hiroyuki ............. P2.19-005, P2.19-006
Agelko Sofia ................... MO13.04
Agelmas Idriss ................ P1.06-057
Aggarwal Ashutosh .......... P2.04-005
Aggourakis Despoina ....... P3.04-003
Agi Gliccario .................. P2.24-048, P1.06-048
Agorreeta Jackie ............. E09.01, MO05.09
Agrawal Anurag ............ P2.01-018
Aguado Alex .................. La Rosa Carolos 
Aguire M ....................... MO26.07, P2.08-15
Aguirres Francisco .......... P1.11-034
Aid Ahmed Motovu Malikya .... P3.11-001
Ahn Beomi ..................... P3.11-003
Ahn Dong-Seok ................ P3.11-003
Ahn Jeong-Suk .............. P3.11-003
Ahn Jihoon ..................... P3.11-003
Ahn Joon-Suck ............... P2.04-003
Ahn Inseok .................... P1.24-019
Ahn Jun-Sik .................. P1.10-017
Ahn Min-Kyu ................. P3.11-003
Ahn Seong-Kyu ................ P2.13-003
Ahn Sung-Ja .................. P2.18-012, P3.10-014
Ahn Won-Yong ................ P2.19-002
Akinbode-James ................ P3.20.004
Akinola Adebayo ............. P2.02-010
Akinlade Akinola ............ P2.09-002
Akin Mihail .................... P1.11-037
Akinci Ozyurek Beren ....... P3.24-015
Akita Hiroshi .................. P1.07-037, P2.21-003
Akira Yuzi .................... P3.11-004
Akita Akiko ................... P1.07-037
Akita Cimura .................. P1.18-009
Akley Wallence ............... P2.04-001
Akahiro Tatsuya ............ P2.10-005
Akira Yamada ................ P1.07-037
Akira Yuzi .................... P3.11-004
Akizuki Satomi ............. P1.07-037
Al-Dayel Fouad .............. P2.02-010, P3.18-008
Al-Hajeri Mucha ............ P2.02-010
Al-Mahmood Muhammad .... P2.02-010, P3.18-008
Al-Kuraya Khalwa ........... P3.11-025
Al-Khalaf Hania ............... P2.19-003
Al-Khalili Youssef .......... P1.03-002
Al-Saad Samer ............... P2.06-025, P3.06-014
Al-Shibi Khadeer ............. P2.06-025
Al-Azirouscter ................ P1.13-002
Al-Aziz Al-Saied .............. P1.13-002
Al-Aziz Badr ................. P1.13-002
Al-Aziz泡沫 .................. P1.13-002
Al-Aziz Pim ................... P1.13-002
Al-Aziz Badr .................. P1.13-002
Al-Aziz Badr .................. P1.13-002
Al-Aziz Badr .................. P1.13-002
Al-Aziz Badr .................. P1.13-002
Al-Aziz Badr .................. P1.13-002
Al-Aziz Badr .................. P1.13-002
AUTHOR INDEX
AUTHOR INDEX
<table>
<thead>
<tr>
<th>Name</th>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesser Martin</td>
<td>P3.24-035</td>
</tr>
<tr>
<td></td>
<td>P2.19-005, P3.24-030</td>
</tr>
<tr>
<td>Leroy Ladurie</td>
<td>MO22.08</td>
</tr>
<tr>
<td>Lenze Dido</td>
<td>P3.06-044</td>
</tr>
<tr>
<td>Lemoine Antoinette</td>
<td>P1.03-005, P1.24-001, P3.07-037</td>
</tr>
<tr>
<td>Lemoine Nick</td>
<td>P2.02-008</td>
</tr>
<tr>
<td>Leong Felicia May</td>
<td>P2.13-004</td>
</tr>
<tr>
<td>Leroux Delphine</td>
<td>P2.06-022</td>
</tr>
<tr>
<td>Leroy Ladurie Francois</td>
<td>P2.12-008</td>
</tr>
<tr>
<td>Lerpertasrule Nirushe</td>
<td>P2.11-005</td>
</tr>
<tr>
<td>Li Baosheng</td>
<td>P2.08-008</td>
</tr>
<tr>
<td>Li Bo</td>
<td>P2.06-008</td>
</tr>
<tr>
<td>Li Houwen</td>
<td>P1.07-013</td>
</tr>
<tr>
<td>Li Grace</td>
<td>P2.01-021</td>
</tr>
<tr>
<td>Li Feng</td>
<td>P3.01-008, P3.05-006</td>
</tr>
<tr>
<td>Li Jian</td>
<td>P2.05-013</td>
</tr>
<tr>
<td>Li Jun</td>
<td>P1.10-028, P1.22-005, P2.11-021</td>
</tr>
<tr>
<td>Li Jiayu--------------</td>
<td>P3.05-006, P3.06-025</td>
</tr>
<tr>
<td>Li Jiaqi--MO12.10, MO16.03, P2.06-014, P3.06-025</td>
<td></td>
</tr>
<tr>
<td>Li Meng---------------</td>
<td>P3.11-001</td>
</tr>
<tr>
<td>Li Ning---------------</td>
<td>P2.11-003, P3.07-013</td>
</tr>
<tr>
<td>Li Mengxi---MO24.04, P2.06-008</td>
<td></td>
</tr>
<tr>
<td>Li Mengyi---P1.03-005, P1.11-005</td>
<td></td>
</tr>
<tr>
<td>Li Mengyu---P1.03-005, P1.11-005, P2.06-014, P3.06-025</td>
<td></td>
</tr>
<tr>
<td>Li Min</td>
<td>P2.11-003</td>
</tr>
<tr>
<td>Li Min</td>
<td>P2.11-003, P3.07-013</td>
</tr>
<tr>
<td>Li Ning</td>
<td>P2.05-013</td>
</tr>
<tr>
<td>Li Qing</td>
<td>P1.03-001, P3.02-002</td>
</tr>
<tr>
<td>Li Ying</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Li Zhenxiang</td>
<td>P2.05-008, P2.06-014, P3.06-025</td>
</tr>
<tr>
<td>Li Yuan</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Li Zhi</td>
<td>P3.11-001</td>
</tr>
<tr>
<td>Li Zhi</td>
<td>P1.18-001</td>
</tr>
<tr>
<td>Li Zhi</td>
<td>P3.06-025</td>
</tr>
<tr>
<td>Li Zhi</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lim Jietao</td>
<td>P2.06-014</td>
</tr>
<tr>
<td>Lim Seung Pyung</td>
<td>P2.02-006, P1.19-003</td>
</tr>
<tr>
<td>Lim Wan-Teck</td>
<td>MO10.06, O03.03</td>
</tr>
<tr>
<td>Lim Weida</td>
<td>P2.12-001</td>
</tr>
<tr>
<td>Lim Weihong</td>
<td>P3.05-006</td>
</tr>
<tr>
<td>Lim Yiping</td>
<td>P2.05-013</td>
</tr>
<tr>
<td>Lim Yang</td>
<td>P2.07-005</td>
</tr>
<tr>
<td>Lim Zhong-Zhe</td>
<td>P1.12-005, P3.13-003</td>
</tr>
<tr>
<td>Liodori Helena</td>
<td>P2.20-005</td>
</tr>
<tr>
<td>Lind Michael</td>
<td>MO09.02, MO13.07, MO22.01</td>
</tr>
<tr>
<td>Lindner Daniel</td>
<td>O08.05</td>
</tr>
<tr>
<td>Lindsey</td>
<td>P3.05-006</td>
</tr>
<tr>
<td>Lin Alexiander</td>
<td>P2.04-004</td>
</tr>
<tr>
<td>Lin Emma</td>
<td>P2.04-014</td>
</tr>
<tr>
<td>Lin Kaito</td>
<td>P3.11-003, P3.12-002</td>
</tr>
<tr>
<td>Lin Kaito</td>
<td>P2.12-001</td>
</tr>
<tr>
<td>Lin Kaito</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P1.18-001</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.18-015</td>
</tr>
<tr>
<td>Lin Li</td>
<td>P3.12-009</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

A

Au, Roger

B

Baird, Andrew

C

Caradonna, Donald

D

Dallaporta, Steven

E

Davies, Ian

F

Fujita, Kenji

G

Gelber, Richard

H

Hiscox, Brian

I

Itano, Hiroshi

J

Jänne, Per

K

Kaneko, Akihiko

L

Lok, Chan Khoon

M

Montgomery, J. Anthony

N

Ng, Lai Seng

O

Oka, Minoru

P

Parker, Peter

R

Reynes, Francoise

S

Saito, Masahide

T

Taylor, Robert

U

Uemura, Tadao

Y

Yamada, Tatsuo

Z

Zhou, Yongning
Australian Rules Football

Australian rules football, is a sport played between two teams of eighteen players on the field of either an Australian football ground, a modified cricket field, or a similarly-sized sports venue. Frequent physical contests, spectacular marking, fast movement of both players and the ball and high scoring are the game’s main attributes.

Details of the game’s origins in Australia are obscure and still the subject of much debate. Australian football became organised in Melbourne in May 1859, when the first laws of the game were published by the Melbourne Football Club.

Australian football has the highest spectator attendance of all sports in Australia.

Courtesy of wikipedia.org
16th World Conference on Lung Cancer

Abstract Submission Open January 2015
Registration Open January 2015
Abstract Submission Deadline April 24, 2015
Abstract Notifications June 22, 2015
Early Registration Deadline June 26, 2015
Late Breaking Abstract Submission Deadline July 10, 2015
Regular Registration Deadline July 24, 2015

September 6–10, 2015
⇒ Denver, Colorado, USA
Cure for Lung Cancer
<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>TIME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>INAUGURAL COCHRANE WORKSHOP</td>
<td>07:30 – 12:00</td>
<td>BAYSIDE 204 A+B</td>
</tr>
<tr>
<td>CALC</td>
<td>CHINESE ALLIANCE AGAINST LUNG CANCER SESSION</td>
<td>07:30 – 12:00</td>
<td>PARKSIDE AUDITORIUM</td>
</tr>
<tr>
<td>Y</td>
<td>YOUNG INVESTIGATOR &amp; FIRST TIME ATTENDEE SESSION</td>
<td>08:00 – 11:30</td>
<td>PARKSIDE BALLROOM</td>
</tr>
<tr>
<td>GR</td>
<td>ADICTION INCORPORATED DOCUMENTARY SCREENING</td>
<td>10:00 – 12:00</td>
<td>BAYSIDE AUDITORIUM</td>
</tr>
<tr>
<td>HON</td>
<td>ABBOTT HANDS ON TRAINING SESSION: MOLECULAR DIAGNOSIS OF GENES FUSIONS BY FISH FOR TARGETED THERAPY</td>
<td>10:00 – 15:00</td>
<td>PARKSIDE 110 A+B</td>
</tr>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY BOHRINGER INGELHEIM: QUESTIONS IN THE TREATMENT OF NSCLC: TARGETING ANGIogenesis</td>
<td>12:00 – 13:30</td>
<td>BAYSIDE AUDITORIUM</td>
</tr>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY ASTRazeneca: FUTURE CONCEPTS IN EGFR MUTATION-POSITIVE ADVANCED NSCLC</td>
<td>14:00 – 15:30</td>
<td>PARKSIDE AUDITORIUM</td>
</tr>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY PFIZER: PREPARING FOR THE CLINICAL PROMISE OF COMBINED IMMUNOTHERAPIES</td>
<td>12:00 – 14:00</td>
<td>BAYSIDE GALLERY A</td>
</tr>
<tr>
<td>G01</td>
<td>PROGRESS IN LUNG CANCER: CELEBRATING 40 YEARS OF IASLC AND RESEARCH PROGRESS</td>
<td>17:30 – 18:30</td>
<td>PARKSIDE Ballroom A+B</td>
</tr>
<tr>
<td>PL01</td>
<td>OPENING PLENARY SESSION</td>
<td>18:45 – 20:15</td>
<td>PLENARY HALL</td>
</tr>
<tr>
<td>E</td>
<td>MEET THE EXPERT SESSION</td>
<td>20:15 – 21:30</td>
<td>EXHIBIT HALL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday, October 27, 2013</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>TIME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY CELGENE: TACKLING THE CHALLENGES OF SQUAMOUS CELL NSCLC PATIENTS</td>
<td>07:00 – 08:00</td>
<td>PARKSIDE BALLROOM A</td>
</tr>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY ABBOTT: PHARMACEUTICALS’ IMMUNE CHECKPOINTS IN THE TUMOR ENVIRONMENT: NOVEL TARGETS AND TRANSLATIONAL PROMISE OF COMBINED IMMUNOTHERAPIES</td>
<td>07:00 – 08:00</td>
<td>PARKSIDE BALLROOM B</td>
</tr>
<tr>
<td>MTE01</td>
<td>NCT01 – ADDITIONAL LESSONS AND FUTURE DIRECTIONS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE GALLERY B</td>
</tr>
<tr>
<td>MTE02</td>
<td>MOUSE MODELS OF ONCOGENIC DRIVERS IN NSCLC</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 104</td>
</tr>
<tr>
<td>MTE03</td>
<td>SUBMIT YOUR CHALLENGING CASES FOR DISCUSSION AND DEBATE</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 105</td>
</tr>
<tr>
<td>MTE04</td>
<td>NAVIGATION BRONCHOSCOPY</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 106</td>
</tr>
<tr>
<td>MTE05</td>
<td>MOLECULAR PATHOLOGY APPROACH FOR EARLY CLINICAL STAGE MESOTHELIOMA, CYTLOGICAL DIAGNOSIS, AND REACTIVE MESOTHELIAL HYPERPLASIA</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 107</td>
</tr>
<tr>
<td>MTE06</td>
<td>CHEST WALL RECON: MATERIALS, ARTIFICIAL RIBS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 108</td>
</tr>
<tr>
<td>MTE07</td>
<td>SMOKING CESSATION</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 109</td>
</tr>
<tr>
<td>MTE01</td>
<td>NLST – ADDITIONAL LESSONS AND FUTURE DIRECTIONS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 201 – 203</td>
</tr>
<tr>
<td>MTE02</td>
<td>MOUSE MODELS OF ONCOGENIC DRIVERS IN NSCLC</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE GALLERY B</td>
</tr>
<tr>
<td>MTE03</td>
<td>SUBMIT YOUR CHALLENGING CASES FOR DISCUSSION AND DEBATE</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 105</td>
</tr>
<tr>
<td>MTE04</td>
<td>NAVIGATION BRONCHOSCOPY</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 106</td>
</tr>
<tr>
<td>MTE05</td>
<td>MOLECULAR PATHOLOGY APPROACH FOR EARLY CLINICAL STAGE MESOTHELIOMA, CYTLOGICAL DIAGNOSIS, AND REACTIVE MESOTHELIAL HYPERPLASIA</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 107</td>
</tr>
<tr>
<td>MTE06</td>
<td>CHEST WALL RECON: MATERIALS, ARTIFICIAL RIBS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 108</td>
</tr>
<tr>
<td>MTE07</td>
<td>SMOKING CESSATION</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 109</td>
</tr>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY ROCHE: HITTING THE HIGH NOTES IN NSCLC THERAPY</td>
<td>08:00 – 09:30</td>
<td>PLENARY HALL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday, October 28, 2013</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>TIME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTE01</td>
<td>NCT01 – ADDITIONAL LESSONS AND FUTURE DIRECTIONS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE GALLERY B</td>
</tr>
<tr>
<td>MTE02</td>
<td>MOUSE MODELS OF ONCOGENIC DRIVERS IN NSCLC</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 104</td>
</tr>
<tr>
<td>MTE03</td>
<td>SUBMIT YOUR CHALLENGING CASES FOR DISCUSSION AND DEBATE</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 105</td>
</tr>
<tr>
<td>MTE04</td>
<td>NAVIGATION BRONCHOSCOPY</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 106</td>
</tr>
<tr>
<td>MTE05</td>
<td>MOLECULAR PATHOLOGY APPROACH FOR EARLY CLINICAL STAGE MESOTHELIOMA, CYTLOGICAL DIAGNOSIS, AND REACTIVE MESOTHELIAL HYPERPLASIA</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 107</td>
</tr>
<tr>
<td>MTE06</td>
<td>CHEST WALL RECON: MATERIALS, ARTIFICIAL RIBS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 108</td>
</tr>
<tr>
<td>MTE07</td>
<td>SMOKING CESSATION</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 109</td>
</tr>
<tr>
<td>MTE01</td>
<td>NLST – ADDITIONAL LESSONS AND FUTURE DIRECTIONS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 201 – 203</td>
</tr>
<tr>
<td>MTE02</td>
<td>MOUSE MODELS OF ONCOGENIC DRIVERS IN NSCLC</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE GALLERY B</td>
</tr>
<tr>
<td>MTE03</td>
<td>SUBMIT YOUR CHALLENGING CASES FOR DISCUSSION AND DEBATE</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 105</td>
</tr>
<tr>
<td>MTE04</td>
<td>NAVIGATION BRONCHOSCOPY</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 106</td>
</tr>
<tr>
<td>MTE05</td>
<td>MOLECULAR PATHOLOGY APPROACH FOR EARLY CLINICAL STAGE MESOTHELIOMA, CYTLOGICAL DIAGNOSIS, AND REACTIVE MESOTHELIAL HYPERPLASIA</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 107</td>
</tr>
<tr>
<td>MTE06</td>
<td>CHEST WALL RECON: MATERIALS, ARTIFICIAL RIBS</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 108</td>
</tr>
<tr>
<td>MTE07</td>
<td>SMOKING CESSATION</td>
<td>07:00 – 08:00</td>
<td>BAYSIDE 109</td>
</tr>
<tr>
<td>ISS</td>
<td>SYMPOSIUM SUPPORTED BY ROCHE: HITTING THE HIGH NOTES IN NSCLC THERAPY</td>
<td>08:00 – 09:30</td>
<td>PLENARY HALL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| E01 | LDCT SCREENING | 14:00 – 15:30 | BAYSIDE AUDITORIUM |
| E02 | RADIATION TOXICITY | 14:00 – 15:30 | BAYSIDE GALLERY A |
| E03 | CHEMOTHERAPY FOR NSCLC | 14:00 – 15:30 | BAYSIDE AUDITORIUM |
| E04 | LUNG CANCER PATHOLOGY CLASSIFICATION | 14:00 – 15:30 | BAYSIDE 105 – 109 |
| E05 | MANAGEMENT OF PLEURAL EFFUSION (MULTIPLE CASES) | 14:00 – 15:30 | BAYSIDE AUDITORIUM |
| E06 | ISSUES IN CURRENT MULTIDISCIPLINARY PRACTICE | 14:00 – 15:30 | BAYSIDE 204 A+B |
| E01 | LDCT SCREENING | 14:00 – 15:30 | BAYSIDE AUDITORIUM |
| E02 | RADIATION TOXICITY | 14:00 – 15:30 | BAYSIDE GALLERY A |
| E03 | CHEMOTHERAPY FOR NSCLC | 14:00 – 15:30 | BAYSIDE AUDITORIUM |
| E04 | LUNG CANCER PATHOLOGY CLASSIFICATION | 14:00 – 15:30 | BAYSIDE 105 – 109 |
| E05 | MANAGEMENT OF PLEURAL EFFUSION (MULTIPLE CASES) | 14:00 – 15:30 | BAYSIDE AUDITORIUM |
| E06 | ISSUES IN CURRENT MULTIDISCIPLINARY PRACTICE | 14:00 – 15:30 | BAYSIDE 204 A+B |

---

**Session Overview • Sunday, October 27, 2013**

**Session Overview • Monday, October 28, 2013**
7. Did you feel that any speakers were biased in their presentation?  
☐ Yes    ☐ No

If you marked “yes”, please check all of the categories you believe apply:
☐ Commercial Bias    ☐ Institutional Bias    ☐ Academic Bias
☐ Procedural Bias    ☐ Discipline Bias    ☐ Other Bias

Explain: ________________________________

8. Do you prefer the new compact 3 day format or the old 3.5 day format with a free afternoon?  
☐ New 3 day format    ☐ Old 3.5 day format with free afternoon    ☐ No preference

9. Rate the conference with respect to the following issues.  
Choose the response that best represents your level of satisfaction.

<table>
<thead>
<tr>
<th>Issues</th>
<th>EXCELLENT</th>
<th>GOOD</th>
<th>SATISFACTORY</th>
<th>NEEDS IMPROVEMENT</th>
<th>UNSATISFACTORY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall quality of the Conference</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall usefulness of the content provided</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Balance, evidence-basis, and scientific rigor of content presented in general</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall organization and schedule of the scientific sessions/ program</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10. Plenaries. How would you rate the Plenary Sessions?

<table>
<thead>
<tr>
<th>Plenary Sessions</th>
<th>EXCELLENT</th>
<th>VERY GOOD</th>
<th>GOOD</th>
<th>POOR</th>
<th>DID NOT ATTEND</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenary 1: Opening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary Session (Sunday)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary 2: Will Personalized Therapies Ever “Cure” Metastatic NSCLC? (Monday)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary 3: Presidential Symposium (Tuesday)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary 4: Curtailing Lung Cancer (Wednesday)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plenary 5: Genomics: From Research Tool To The Lung Cancer Clinic (Wednesday)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11. Please provide your feedback regarding the abstract sessions.  
(session formatting, presentation quality, etc.)

Oral Abstract Session


Mini Oral Abstract Session


Poster Session


12. Which of the following most impacts your decision to attend this meeting?  
(Check all that apply)

☐ Program Content  ☐ Speakers  ☐ Meeting Dates  ☐ CME Credits
☐ Registration Rates  ☐ Hotel Costs  ☐ Meeting Location  ☐ Networking Opportunities
☐ Other (please specify):

13. Please suggest any programs/topics you would like to have presented in the future:


14. Any specific comments about a speaker? Please give us their name and comment:


15. Conference Events. How would you rate the following?

<table>
<thead>
<tr>
<th>Conference Event</th>
<th>EXCELLENT</th>
<th>VERY GOOD</th>
<th>GOOD</th>
<th>POOR</th>
<th>DID NOT ATTEND</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gala Dinner</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

16. How did you first hear about the Conference?

☐ Conference Mailing  ☐ E-mail  ☐ Conference Website
☐ Word of Mouth  ☐ Previous Conference  ☐ Other ________________

17. How would you rate the Conference logistics?

<table>
<thead>
<tr>
<th>Logistics</th>
<th>EXCELLENT</th>
<th>VERY GOOD</th>
<th>GOOD</th>
<th>POOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Registration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Onsite Registration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Venue (Convention Centre)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Location (Sydney)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Exhibit Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Staff</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Signage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Website</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conference Onsite Materials</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Thank you again for taking the time to complete the Evaluation Form!
Trial sites around the world have signed up to enroll and randomize **1,100 patients** into the **ENSPIRIT Phase 3 clinical trial**.

**ENSPIRIT Primary Objective**
To evaluate if the combination regimen of custirsen and docetaxel improves the Overall Survival (OS) of patients with advanced or metastatic (Stage IV) **non-small cell lung cancer** (NSCLC) who have been previously treated with a first-line platinum-based chemotherapy.

**Why Advanced, Second-Line NSCLC?**
- Most patients with advanced NSCLC progress after first-line chemotherapy and long-term survival rates remain low.\(^1\) Despite efficacy of some targeted and non-targeted agents, there’s an urgency for novel ways to improve survival and quality of life.
- Custirsen is being studied in combination with docetaxel in patients with metastatic castrate resistant prostate cancer.

It is estimated that approximately 60% of first-line patients with NSCLC continue to receive second-line treatment.\(^2\) It is also estimated that in 2012 there were over 182,000 potential drug-treatable second-line patients with advanced NSCLC in the U.S., EU, and Japan.\(^3\)

To learn more about the trial, please visit [ClinicalTrials.gov](http://ClinicalTrials.gov), Identifier: NCT01630733.

---


---

Custirsen is an investigational agent and is not approved by FDA or any other regulatory agency for any indication.
A world of discovery awaits

Join Lilly Oncology as we gather with oncology professionals from all over the world to discuss our latest innovations.

Stop by our booth for the latest news and information on our drug discovery efforts.